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General introduction
Part of this chapter is based on:
“Vascular aspects of cognitive impairment and dementia.” Wiesmann M, 
Kiliaan AJ, and Claassen JAHR (2013). 
J Cereb Blood Flow Metab 33(11): 1696-1706. 
&
“Impact of Nutrition on Cerebral Circulation and Cognition in the 
Metabolic Syndrome.” Wiesmann M1, Mellendijk L1, and Kiliaan AJ (2015). 
Nutrients 7(11): 9416-9439.
1 The authors contributed equally to the present work.
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General introduction
The term dementia comprises several symptoms, for example a progressive loss 
of memory and behavioral changes, which together interfere with independent 
performance of tasks of daily life [1]. As a result of increasing life expectancy, 
dementia is developing into one of the major public health problems in our aging 
society. This is driven mostly by the increasing prevalence of Alzheimer´s disease 
(AD) with increasing age. AD and vascular dementia (VaD) are the number one 
and two disorders in terms of prevalence, and together they are responsible for 
most cases of dementia [2, 3]. These disorders are preceded by a stage in which 
the individual evidences cognitive decline but is still able to maintain independent 
functioning. In AD, this stage is referred to as mild cognitive impairment (MCI) due 
to AD, whereas in VaD this prodromal stage is termed vascular cognitive impairment 
(VCI). In this introduction the term AD will mostly reflect the continuum of MCI 
due to AD and dementia due to AD, and the term VaD will reflect the continuum 
of VCI and VaD.
Historically, AD and VaD have been considered as separate entities, and this 
separation remains driven by clinical classification criteria. Therefore, the inclusion 
of AD discussing vascular aspects of dementia may seem confusing. However, there 
is considerable overlap between these disorders, and the underlying interactions 
between VaD and AD will be explained and summarized in this introduction. 
Furthermore, two major risk factors for VaD and AD, hypertension and stroke, will 
be further discussed and investigated in this thesis. 
Studies involving LC-n3-FA supplementation and manipulation of the 
renin-angiotensin system (RAS) have shown that these novel therapeutic 
approaches have the potential to lower the effect of hypertension and stroke. 
Therefore, these new preventive strategies against two major risk factors for 
cognitive impairment and dementia will be discussed as well in this chapter and 
later in this thesis.
Vascular dementia (VaD), classification and etiology 
5-20% of dementia cases in the population are based on VaD,[4] which is a common 
disorder in the elderly but also prevalent among younger adults [5]. The concept 
of VaD consists of two main elements: the presence of a dementia syndrome 
and an underlying vascular cause [6]. To characterize VaD, criteria of State of 
California Alzheimer’s Disease Diagnostic and Treatment Centers and the National 
Institute for Neurological Disorders and Stroke-Association Internationale pour 
la Recherche et I’Enseignement en Neurosciences (NINDS-AIREN) are commonly 
used [4, 6, 7]. Dementia caused by ischemic or hemorrhagic cerebrovascular 
disease (CVD) or by ischemic-hypoxic brain lesions of cardiovascular origin is also 
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included in VaD [5, 8]. Among recurrent or first-ever stroke patients post-stroke 
dementia is a frequent sequel, ranging from 6 to 31,8% [9-11].
Definitions of VaD and VCI
The dementia stage of VaD can also be understood as the most severe form of 
vascular cognitive impairment (VCI) [4, 12]. VCI is a syndrome characterized by 
the presence of clinical stroke or vascular brain injury and cognitive impairment 
affecting more than one cognitive domain [13]. The VCI-VaD continuum can 
be divided into familial and sporadic forms [13]. The most frequent subtype of 
familial VaD, caused by genetic mutations, is the “cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy” (CADASIL) [13] 
caused by mutations in the Notch 3 gene [14]. Sporadic VaD has three major 
subtypes: multi infarct dementia, strategic infarct dementia, and subcortical 
vascular encephalopathy (synonymous with Binswanger’s disease) [13]. O’Brien 
et al. have published an alternative classification of the VaD subtypes [5, 15]: 
multi-infarct dementia (cortical VaD); small-vessel dementia (subcortical VaD); 
strategic infarct dementia; hypoperfusion dementia; hemorrhagic dementia; AD 
with CVD; and the familial variant of vascular dementia, CADASIL. 
Stroke and VaD
Many stroke patients show a gradual but continuous deterioration following a 
single stroke lesion [16]. This deterioration is characterized clinically by cognitive 
and behavioral dysfunction. Stroke research has traditionally focused on motor 
impairment (e.g. limb paresis), where a number of patients show partial recovery 
indicating the brain’s capacity for repair or compensation after injury [17]. 
However, this research has paid little attention to cognitive and behavioral deficits 
induced by stroke. After stroke, recovery from these deficits is often absent, and, 
as indicated, in many patients stroke leads to progressive deterioration even in 
the absence of new stroke lesions. Novel research indicates that stroke-induced 
lesions to brain networks are responsible for this absence of recovery or even 
for progressive disease, leading to an increased mortality rate [18]. However, 
it is still not fully understood how stroke, cognitive decline and dementia are 
interconnected. Stroke may predispose older adults to developing VaD.
AD, definition and etiology 
In 1906 Alois Alzheimer, mentioned already arteriosclerotic changes in cerebral 
blood vessels of the post mortem brain of his 55-year old patient Auguste D(eter) 
besides the neuropathological hallmarks amyloid plaques and neurofibrillary 
tangles [19, 20]. The production of Aβ peptides is increased in familial forms of 
AD and is thought to be the primary driving force in non-familial (sporadic) AD 
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pathogenesis [21]. This amyloid cascade hypothesis, is still the dominant theory 
for the pathogenesis of AD, but remains under debate as other researchers 
casted doubt that the Aβ plaques and the NFTs are really the main cause of the 
neurodegeneration in AD [22]. Experimental results showed that the density of 
senile Aβ plaques can be the same in patients affected by AD and non-affected 
patients [23, 24]. Recently, the focus of the research on amyloid-beta has shifted 
towards the oligomerization of Aβ since several studies showed that these 
oligomers and fibrils are in fact the toxic forms of Aβ-peptides [25].
Cerebral amyloid angiopathy and AD
The accumulation of Aβ in the walls of arteries and arterioles in the leptomeninges 
and cerebral cortex is called cerebral amyloid angiopathy (CAA) [26]. CAA has been 
linked to haemorrhages (microbleeds), most clearly shown in a mouse model for 
CAA [27]. Because CAA is found both in sporadic AD patients and also in cognitively 
normal individuals without prodromal AD, [28, 29] the exact relationship between 
AD and CAA remains uncertain.
Risk factors for VaD
The assumption has been made that risk factors for VCI and VaD would be the 
same as those for stroke [30]. The risk factors for stroke can be divided into three 
major classes, nonmodifiable (e.g. age, sex, genetic factors, etc); modifiable (e.g. 
hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, obesity, etc); 
and potentially modifiable (e.g. alcohol abuse, infection) [31]. 
Hypertension has been shown to be the most common modifiable risk factor 
for stroke worldwide [32, 33]. Large-scale, placebo-controlled clinical trials have 
shown an association between hypertension and stroke [34, 35] and a linear 
relationship between blood pressure and stroke mortality has been revealed [36]. 
More specifically, a rise of only 1 mm Hg in systolic blood pressure of treated 
hypertensive patients increased stroke deaths by 2% [36]. A community-based 
prospective cohort study revealed that incremental increases in blood pressure 
were linked to an increase in microinfarcts in initially non-demented persons 
(65-80 years of age), but not in the older age group [37].
A history of stroke leads to a twofold increase of the risk of dementia in the 
population older than 65 years [38, 39] and this effect was also confirmed in 
animal studies [40]. Combining confirmed AD pathology and cerebral infarcts 
after autopsy with the test results of cognitive function revealed that AD patients 
with cerebral infarcts showed more cognitive impairment than patients without 
cerebral lesions [41, 42]. In the population-based Rotterdam Scan Study, 1015 
participants underwent neuropsychological testing and cerebral MRI and were 
monitored for dementia during the study period [43]. In this study, silent brain 
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infarcts doubled the risk of dementia [43]. Furthermore, in subjects without 
dementia, presence of these infarcts increased the chances of a decline in global 
cognitive function [43]. Thus, an increased risk of incident stroke is associated 
with cognitive decline and dementia [44].
Even individuals who are stroke- and dementia-free, but have a higher risk to 
develop stroke, have more cognitive deficits than individuals with lower stroke 
risk [45]. As already mentioned for VaD, Stroke may also predispose older adults 
to developing AD. The mechanisms behind cognitive decline after the occurrence 
of a stroke could help us to develop new treatments to prevent the onset of 
dementia. Furthermore, new preventative treatments for stroke are needed to 
counteract both stroke and dementia. One possibility to reduce stroke would 
be to reduce the modifiable risk factors as lifestyle, hypertension, diabetes, 
hyperlipidemia, atrial fibrillation, smoking, obesity, etc.. 
Risk factors for AD
Several vascular risk factors for the development of AD have been demonstrated, 
e.g. hypertension, diabetes mellitus, atherosclerosis, atrial fibrillation, coronary 
artery disease, smoking, obesity, carrying apolipoprotein E ε4 allele (apoE4) and 
metabolic syndrome [46, 47]. Many studies have shown the association between 
increased blood pressure in mid-life and cognitive decline or AD in late-life, 
[48, 49] although conflicting studies are reported as well. The apolipoprotein E 
ε4 allele (apoE4) represents a strong genetic risk for AD as it is associated with 
increased cardiovascular risk factors [12, 50]. A recent review on apoE-related 
biomarker profiles in the early phase of AD further elucidates this relatively novel 
concept of the –ε4 to be considered more as a vulnerability factor rather than a 
pathogenic factor [51]. Moreover, apoE4 carriers are clearly more susceptible to 
vascular brain damage (eg. stroke, brain haemorrhage; [52-54] and they display 
aberrant functional connectivity [55]. Additionally, changes in brain diffusivity, 
as a biomarker for white and gray matter integrity, have been reported in 
human -ɛ4 carriers [56-59]. These structural modifications may be linked to the 
isoform-specific role of apoE in synaptic development, dendrite formation and 
axonal guidance, which in some extent may be impaired in apoE4 carriers [60]. 
However, among all vascular risk factors hypertension seems to be the most 
powerful risk factor for AD [61]. Furthermore, recent studies demonstrated that in 
the elderly a history of stroke can double the AD prevalence [62]. The combination 
of the latter results demonstrates the impact of these two risk factors for AD. 
The risk factors for AD are almost the same as for VaD. Therefore, in the next 
paragraph the overlap and interactions of VaD and AD, but also between their risk 
factors are discussed.
14
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Overlap and interactions of VaD and AD, and their risk factors
In the first instance, it may seem difficult to see the overlap between VaD and AD, 
as these entities are strictly separated in their clinical criteria. As a first illustration 
of why VaD and AD can no longer be strictly separated in this way, Biessels et 
al. have shown in their systematic review that diabetes as a risk factor may 
directly influence both vascular and neurodegenerative pathology [63]. Biessels 
et al. suggested from mechanistic studies that vascular disease and alterations in 
glucose, insulin, and amyloid metabolism were connected and may underlie the 
pathophysiology of both AD and VaD.
In line with this, several studies indeed indicate that Metabolic Syndrome (MetS) 
is a risk factor for lower cognitive function and dementia [64] and this association 
seems to be age-dependent [65-67]. MetS is characterized by the co-occurrence 
of several metabolic risk factors for cardiovascular disease (CVD), stroke, and/or 
type 2 diabetes mellitus (T2DM) [68, 69] and its increasing prevalence will drive 
the twin global epidemics for CVD and T2DM in the coming years [69]. The current 
epidemic of MetS in middle-age and the increasing prevalence of dementia with 
age, particularly AD, converge in findings that MetS occurring in middle-age is 
associated with an increased risk of cognitive decline and dementia later in life 
[70]. MCI can be considered as an intermediate stage of cognitive impairment 
wherein cognitive changes found in normal aging often proceed into those 
changes typically observed in dementia [71]. Indeed, one study described that 
MetS related risk for progression from MCI to dementia was increased significantly 
in a 3.5 year follow-up [72]. Other studies detected an association between MetS 
and AD [73, 74], neurodegenerative diseases [75], and VaD [76, 77]. Several 
factors of MetS have also been linked to cognitive impairment and dementia [78]. 
Obesity for instance, is recognized as a modifiable risk factor for dementia [79, 
80] and also hypertension, especially mid-life hypertension, and both diabetes 
and prediabetes, increase the risk of developing dementia [81, 82]. Possible 
explanations for these correlations might be found in an impaired vasculature 
and/or altered CBF due to MetS, which in turn leads to neuronal damage [70]. To 
maintain the structural and functional integrity of the brain, a well-regulated and 
continuous cerebral blood supply is crucial. For this reason it is not surprising that 
alterations in the cerebral vasculature, as seen in MetS, have a profound impact 
on cognitive function [83]. The structural and functional alterations in the blood 
vessels due to MetS can affect the brain by accelerating cerebral small vessel 
disease that may result in cerebral microbleeds, white matter lesions (WML), and 
brain atrophy [84]. Among MetS components, obesity and hypertriglyceridemia 
are associated with smaller brain volume, whereas hypertension is associated 
with an increased occurrence of white matter hyperintensities (WMH) and 
infarcts [85]. Unfortunately, the components of MetS have often been considered 
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in an independent manner, as if the syndrome consists of a sum of different 
disorders with neuronal damage as the end stage where all components’ effects 
assemble [86]. However, this view will be reductive to give an explanation for the 
global metabolic effects on cognitive decline and therefore it has been suggested 
to consider the metabolic alterations as a continuum leading to various degrees of 
cognitive disorders [86, 87].
There is now more and more awareness that vascular risk factors play a key role 
in the pathogenesis of AD [88]. In aged subjects a relation between vascular 
risk factors and AD has been found [89, 90]. In addition, other epidemiological 
and clinical studies identified that AD and VaD share common risk factors such 
as hypertension, diabetes mellitus, hyperlipidemia, and arrhythmia [91-96]. 
This overlap in major risk factors for these clinically and pathologically different 
conditions (VaD and AD) may seem confusing when it comes to understanding 
pathogenesis. A simple practical consequence however is, for example, that 
hypertension is a major risk factor for cognitive decline and dementia in the 
elderly, regardless of whether this is due to stroke, VaD or AD, or combinations 
of these disorders. Another overlap between VaD and AD is found in the 
neurovascular unit. The neurovascular unit is the collective term for neurons, glia, 
and perivascular and vascular cells [12]. This unit is responsible for the strong 
increase in cerebral blood flow following cognitive activation. In AD and VCI-VaD 
patients the neurovascular unit is disrupted, and this could lead to insufficient 
perfusion during cognitive activation, contributing to further neuronal dysfunction 
[97-101].
In addition, alterations in cerebral microvascular structure are related to AD and 
VCI [102, 103]. In animal models, hypertension, aging, and diabetes, the major 
risk factors for AD and VCI interfere with endothelium-dependent responses in 
the microcirculation and in the functional hemodynamic response of the brain 
[12, 98, 104, 105]. Furthermore, hypertension promotes atherosclerosis in 
cerebral arteries [99] and induces lipohyalinosis, affecting the blood supply for 
the white matter [99]. These changes can result in lacunar infarction or brain 
hemorrhage [99]. Notably, studies have shown that vascular lesions lead to a 
decrease in the threshold for the clinical manifestation of AD [12]. In demented 
and non-demented Japanese-American men Petrovitch et al. showed that 
cerebrovascular lesions increase dementia frequency in patients with low neuritic 
plaque frequency [106]. From this finding, they concluded that the preservation 
on late-life cognitive function is dependent on the prevention of cerebrovascular 
lesions [106]. To support the idea that vascular lesions or CVD lower the threshold 
for dementia due to AD and α-synucleinopathies, Toledo et al. demonstrated that 
CVD is commonly found in aged subjects with dementia, while it is even more 
common in AD patients, especially in younger patients [107]. Furthermore, Toledo 
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et al. found that the presence of CVD increases the risk of dementia in patients 
with α-synucleinopathies and also in those being affected by AD [107]. These 
latter studies clearly show the relation between cerebrovascular impairments and 
dementia, especially AD and VaD.
Hypertension – an overlapping risk factor for VaD and AD
Hypertension and AD
One of the most common cardiovascular risk factors, arterial hypertension, 
has been shown to increase the risk of both AD and VaD [49, 108-115]. Skoog 
et al. demonstrated a relationship between hypertension and amyloid plaques, 
neurofibrillary tangles, and brain atrophy.[114] Furthermore, Skoog and Gustafson 
showed that increased blood pressure appeared decades before the onset of AD, 
followed by a decrease in blood pressure years before the start of AD [114]. This 
phenomenon of hypertension followed by a gradual reduction in blood pressure 
may be caused by difficulties in maintaining blood pressure homeostasis due to a 
damaged central nervous system [114, 116]. Studies that link blood pressure with 
dementia may be complicated by this non-stationary course of blood pressure in 
the trajectory of dementia. 
Long-standing hypertension promotes atherosclerosis and vascular remodeling 
including increases in wall thickness. Arterial stiffness and severe atherosclerosis 
can lead to an increase in pulse pressure (the difference between systolic 
and diastolic blood pressure) [117]. In a community-based study, increased 
pulse pressure correlated with a higher risk of AD in older adults [117]. In the 
Rotterdam study the presence of atherosclerotic plaques or wall thickening has 
been associated with dementia and its two major subtypes AD and VaD [109]. 
Based on that study, arterial stiffening has been suggested to be a key player in 
the pathogenesis of dementia [118]. One hypothesis to explain how hypertension 
is a risk factor for dementia, which follows from these studies, is that hypertension 
could lead to atherosclerosis and arterial stiffness which in turn promotes the 
development of dementia (figure 1). 
Disentangling the possible causal relationships between hypertension, 
cerebrovascular disease and Alzheimer in human studies is complex, if not 
impossible, because vascular risk factors like hypertension may take years or 
decades to lead to marked cerebrovascular and cognitive symptoms, and because 
Alzheimer pathology is thought to be present years to decades before clinical 
symptoms appear. Therefore, animal models are needed to elucidate these 
mechanisms and translate them to preventive or therapeutic interventions. Poulet 
developed an animal model to resemble hypertension-related ‘Alzheimer-like 
pathology’ [119, 120]. These mice were subjected to high blood pressure, and 
this resulted in accumulation of amyloid aggregates [119, 120]. Hypertension 
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was induced via a coarctation of the aortic arch between the two carotid 
arteries, causing changes in the CBF, leakage of the blood-brain barrier and 
neurodegenerative changes [119, 120].
However, there may also be a reverse association between AD and hypertension. 
To investigate the impact of Aβ on blood pressure, in spontaneously hypotensive 
Sprague-Dawley rats (mean arterial blood pressure < 100 mmHg) the intra-arterial 
infusion of Aβ increased the mean arterial blood pressure compared to vehicle 
distilled water infusion [121]. This finding suggests that Aβ may be able to 
induce hypertension, possibly through direct systemic vascular effects, without 
parenchymal Aβ deposition and before dementia onset [121]. Taken together, 
animal studies suggest that Aβ may be responsible for high blood pressure as 
well as for cerebrovascular impairment. Furthermore, also neurodegeneration is 
due to energetic deficiency, and can be explained by Aβ-induced cerebrovascular 
impairment, by e.g. impairing glucose transport in hippocampal and cortical 
neurons.[122] Hypothetically, these blood pressure and vascular effects of Aβ, 
which predate cognitive effects, may interact with common vascular disease (e.g. 
essential hypertension), potentially further elevating blood pressure levels, and 
synergistically induce cerebrovascular lesions. 
Hypertension and VaD
Whereas the link between hypertension and VaD, through the well-established 
relationship between hypertension and stroke, may seem self-evident, it is often 
overlooked that in many cases of VaD there is no clear history of stroke. To be 
more precise, cortical stroke, which is often symptomatic and therefore more 
easily recognized, is not the most prevalent cause of VaD. VaD is most often 
caused by lacunar infarcts (e.g. multi-infarct dementia) and/or severe white 
matter disease, both related to small vessel disease, and these are frequently 
clinically unrecognized as acute stroke. As an illustration of this often clinically 
silent course, lacunar infarcts and white-matter disease are frequently found in 
studies in elderly subjects without known cognitive disorders [42, 123]. Depending 
on the location of these vascular lesions, their extent, and the patient’s cognitive 
reserve, these silent lesions can however have sufficient impact to cause VCI or 
VaD (figure 1). 
Can stroke cause VaD and AD?
To strengthen the overlap and the connections between AD and VaD, 
accumulation of amyloid precursor protein and Aβ 1-42, hallmarks of AD, has 
been demonstrated in patients with multi-infarct dementia, which is the most 
prevalent form of VaD [124-126]. Also, animal studies using models of cerebral 
ischemia indicated a relationship between the amyloid precursor protein and 
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cerebral ischemia [124, 125, 127]. A highly sensitive fluorescent RT-PCR assay 
revealed a significant increase in the peripheral blood expression of amyloid 
precursor protein mRNA levels among patients who suffered from recent stroke 
[128]. A correlation between the density of cortical microinfarcts (CMIs) and 
the degree of cerebral amyloid angiopathy (CAA) was found in a postmortem 
analysis of human brains [129]. Although CAA may occur unrelated to AD, this 
example serves to explain that AD patients with CAA may present with stroke and 
cerebrovascular comorbidity. 
Endothelin-induced ischemia mimicking small lacunar infarcts in the APP23 
AD mouse model mice increased AD-like pathology and inflammatory markers 
of AD in the cortex and hippocampus of these transgenic mice [40]. In another 
murine study Garcia-Alloza et al. demonstrated that stroke accelerates amyloid 
deposition via interference with amyloid clearance pathways [130]. Garcia-Alloza 
et al. examined this association by using a transgenic AD mouse model (APP/PS1) 
subjected to microstrokes in the middle cerebral artery territory, an experimental 
stroke model using Rose bengal dye [130]. A fast increase in amyloid plaque 
burden and CAA was measured in the region surrounding the infarction [130]. As 
discussed in that paper, these changes were transient –and this may explain why 
these authors did not find amyloid plaques in post-infarct brain tissue in humans 
in earlier work.
An association between cerebral hypoperfusion, caused by CAA, [131, 132] and 
CMIs was demonstrated by Okamoto et al. [129]. Chronic cerebral hypoperfusion 
due to bilateral common carotid artery stenosis in a CAA mouse model 
showed that the deposition of Aβ in leptomeningeal vessels was accelerated in 
combination with the development of microinfarcts [129]. Notably, in a rat model 
of AD and cerebral ischemia the accumulation of amyloid increased the infarct 
size, neuroinflammation and also cognitive deficits in these rats [133].
Hemodynamic changes in VaD and AD
A meta-analysis of transcranial Doppler studies has shown that both AD and 
VaD patients have evident changes in cerebrovascular hemodynamics (mostly 
reduced CBF and increased cerebrovascular resistance), albeit much more 
pronounced in VaD patients [134]. A study in transgenic mice overexpressing 
APP has demonstrated the impact of Aβ on cerebrovascular regulation [135]. 
Using quantitative autoradiography, resting CBF was shown to be reduced in the 
cerebral cortex and in the hippocampus [135]. These APP overexpressing mice also 
showed a disturbance in cerebrovascular autoregulation, as they were incapable 
to maintain a stable CBF during moderate hypotension or hypertension [136]. 
Whether this observation can be translated to human AD remains uncertain [137].
19
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Figure 1 Proposed connections between risk factors, dementia and possible therapies 
affecting the major vascular risk factors for Alzheimer’s disease (AD) and vascular 
dementia (VaD), hypertension and stroke. Hypertension and stroke are major risk factors 
for dementia in particular AD and VaD, while hypertension itself is also a risk factor for 
stroke. Despite all research and drug development efforts, no curative pharmacological 
therapies are available for dementia and also no definitive treatments are attainable 
for VaD. In human and animal studies long-chain omega-3 polyunsaturated fatty acids 
(LC-n3-FA) and the manipulation of factors involved in the renin-angiotensin system (RAS) 
have shown to be beneficial to lower the risk of developing dementia like AD and VaD.
Preventive strategies – long-chain omega-3 polyunsaturated fatty acids and 
Renin-angiotensin system
Despite all research and drug development efforts, no curative pharmacological 
therapy are available for dementia and also no definitive treatments are attainable 
for VaD [5]. Therefore, in order to reduce the huge burden of disease, development 
of preventive strategies is urgent. Considering that vascular disorders contribute 
importantly to dementia as described above, such preventive strategies could 
consist of pharmaceutical interventions aimed at vascular dysfunctions (for 
example, treatment of hypertension and hyperlipidemia). In addition, current 
studies focus more and more on lifestyle. As already mentioned above, there is 
growing awareness that lifestyle components, e.g. diet and exercise, can influence 
modifiable risk factors such as hypertension, type 2 diabetes, and obesity. These 
modifiable risk factors affect the vascular system, thereby influencing the risk for 
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dementia, including AD [49, 138-141]. Modifying these risk factors via a change 
in lifestyle may potentially delay the onset of dementia and lead to a decrease 
in prevalence and public health burden of dementia [44, 141]. Aarsland et al. 
demonstrated in a systematic review that physical exercise may prevent the 
development of VaD [142]. Ravaglia et al. found in a population-based cohort 
study that physical activity is associated with a lower risk of VaD but not of 
AD [143]. In the review of Dichgans et al. the lifestyle risk factors for VaD, AD, 
Dementia (unspecified) and cognitive impairment are nicely summarized [144]. 
Based on epidemiological studies, they show that VaD and AD share common 
lifestyle risk factors such as smoking, decreased physical activity and obesity 
[144]. Furthermore, they also state from the existing epidemiological studies 
that insufficient evidence for diet as a potential risk factor for VaD exists, while 
concerning AD an improved dietary behavior was associated with a lower risk of 
cognitive decline [144].
Of the many important lifestyle factors, in this review we focus on (the 
supplementation of) long-chain omega-3 polyunsaturated fatty acids (LC-n3-FA) 
and its impact on cognition and the development of dementia. In addition, we 
also concentrate on the impact of these LC-n3-FA on risk factors for VaD and 
AD as hypertension and stroke to show that diet could have an impact on the 
development of both VaD and AD.
In a randomized, double-blind, placebo-controlled trial van de Rest et al. 
no effect of supplementation with eicosapentaenoic acid (EPA) combined 
with docosahexaenoic acid (DHA) for 26 weeks on mental well-being in 
independently living older individuals could be detected [145]. In another 
randomized, double-blind, placebo-controlled clinical trial Freund-Levi et al. the 
administration of LC-n3-FA in patients with mild to moderate AD did not slow 
down cognitive decline [146]. However, in a small subgroup of patients with very 
mild AD this administration led to beneficial effects [146]. A twenty-four week 
supplementation with 900 mg/d DHA led to an improved learning and memory 
function in age-related cognitive decline [147].
Many of these clinical trials had a relatively short duration of supplementation 
of LC-n3-FA or focused only on moderate or advanced AD patients. A systematic 
review with a meta-analysis in animal models of AD focusing on the effects 
of long-term LC-n3-FA supplementation on cognitive impairment, amyloid-β 
pathology, and neuronal loss revealed reduced Aβ burden, improved cognitive 
function, and decreased neuronal loss [148]. A very recent, double-blind 
randomized interventional study has shown that the intake of LC-n3-FA in healthy 
older adults significantly increased executive functions [149]. Furthermore, Witte 
et al. demonstrated that this intake had also beneficial effects on microstructural 
integrity and gray matter volume in frontal, temporal, parietal, and limbic areas, 
and on carotid intima media thickness and diastolic blood pressure [149].
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Long-chain omega-3 polyunsaturated fatty acids and blood pressure
As already mentioned in the previous paragraph, Witte et al. were able to show 
that already in healthy older adults the LC-n3-FA supplementation led to a 
significant decrease in diastolic blood pressure [149]. In addition, a meta-analysis 
of 31 placebo-controlled trials in 1356 subjects revealed a dose-response effect 
of LC-n3-FA leading to a decrease of blood pressure [150]. This beneficial blood 
pressure lowering effect was even most prominent in hypertensive subjects 
and in patients with atherosclerosis or hypercholesterolemia [150]. This is in 
accordance with another study showing a reduction in blood pressure in untreated 
hypertensive patients with daily administration of LC-n3-FA [151]. However, the 
use of LC-n3-FA as antihypertensive treatment in humans needs to be analyzed in 
long-term studies. Long-term administration of DHA inhibits the development of 
hypertension in stroke-prone spontaneously hypertensive rats (SHRSP), a model 
for hypertension and stroke [152]. Notably, DHA also prolonged the life span of 
SHRSP [152]. But not only DHA may lower blood pressure. A meta-analysis of 25 
randomized controlled trials revealed that an increased intake of dietary fibers 
also reduces blood pressure in hypertensive patients [153]. Reducing dietary salt 
intake may also be beneficial, as high salt intake increased the mortality rate, 
raised blood pressure and increased the number of cerebral aneurysms in SHRSP 
[154]. Also in humans, evidence supports the idea that reducing dietary salt intake 
can reduce hypertension-related disease [155]
Long-chain omega-3 polyunsaturated fatty acids and stroke
As mentioned above, fish consumption is recommended to reduce the risk of 
cardiovascular diseases [156]. Therefore it is likely to reduce the risk of developing 
stroke as well. A meta-analysis performed by He et al. revealed that already a very 
low fish consumption protects against the incidence of ischemic stroke [157]. De 
Goede et al. demonstrated a relationship between higher EPA-DHA and a lower 
stroke risk for women, while for men, these associations were not statistically 
significant [158]. Intraperitoneal pretreatment with DHA helped to reduce brain 
infarctions in Sprague-Dawley rats [159]. Moreover, Ozen et al. demonstrated a 
protective effect against cerebral ischemia in rats fed with a standard diet plus 
LC-n3-FA - including EPA and DHA - : these rats had a reduced number of apoptotic 
neurons in the prefrontal cortex [160]. This effect of DHA may be mediated by 
neuroprotectin 1. DHA is the precursor of neuroprotectin 1 (NPD1) and aspirin 
activates the synthesis of aspirin-triggered NPD1 (AT-NPD1) [161]. After the 
occlusion of the middle cerebral artery in Sprague-Dawley rats, inducing an 
experimental stroke, the administration of synthetic AT-NPD1 attenuated cerebral 
ischemic injury [161]. In women, intake of LC-n3-FA was associated with a lowered 
risk of total stroke, while dietary cholesterol was positively associated with risk of 
total stroke and cerebral infarction [162]. Increased intake of Mediterranean-style 
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diet was associated with a lowered risk of ischemic stroke, myocardial infarction, 
and vascular death [163]. The reduction in cardiovascular morbidity was most 
prominent for stroke, and was attributed to high intake of olive oil or nuts. But 
not only this diet originating around the Mediterranean Sea seems to have an 
influence on stroke incidence. A population based case-control study performed 
in southern Sweden demonstrated that stroke risk decreased with fat fish intake 
and especially in women the consumption of lean fish increased the stroke risk 
[164]. Additionally, also a deficient intake of alpha-linolenic acid, the plant-derived 
LC-n3-FA, may be a risk factor for the development of stroke [165]. This is in line 
with a murine study on rapeseed oil-enriched diets (rapeseed oil is a rich source 
of alpha-linolenic acid). Following MCA occlusion, the rapeseed oil fed groups 
demonstrated a decreased mortality rate, lowered levels of lipid peroxidation, 
and a reduced infarct size [166]. A meta-analysis by Arab et al. showed that 
individuals consuming daily three cups of either green or black tea had a 21 % 
lower risk of stroke than those with a daily consumption of less than one cup of 
tea [167]. In summary, in human and animal studies LC-n3-FA have demonstrated 
to show beneficial effects on stroke and also on hypertension lowering the risk for 
dementia, see tables 1 and 2 and also figure 1. 
Manipulation of the renin-angiotensin system – another possible therapy
The renin-angiotensin system is not only important in the cardiovascular system 
but also in the central nervous system. Angiotensin II binds to two main receptors, 
type 1 (AT1) and type 2 (AT2). AT2 receptors are found in cerebral regions involved 
in control and learning of motor activity [168].
In Aβ injected mice the cognitive impairment was ameliorated by perindopril, 
a centrally active angiotensin-converting enzyme (ACE) inhibitor [169]. In these 
mice perindopril inhibited the cerebral, but not the peripheral ACE activity 
demonstrating a beneficial effect on AD as well as on hypertension [169]. In this 
animal study neither imidapril nor enalapril were able to reverse the cognitive 
impairment in spontaneous alteration and object recognition tests of the AD 
model mice [169]. In the SMART-MR study, patients treated with ARBs had less 
decline in CBF than patients treated with other hypertensive drugs (e.g. β-blockers, 
diuretics, calcium channel blockers, or ACE inhibitors) [170]. In line with this 
human study, in young AD transgenic mice models (APP23 mouse) treatment 
with the ARB olmesartan decreased oxidative stress in cerebral microvessels 
[171]. In the same study Takeda et al. used an acute mouse model induced by 
intracerebroventriculair administration of Aβ 1-40, where pretreatment with a low 
dose of olmesartan completely prevented Aβ-induced vascular dysregulation and 
also partially reduced the impairment of hippocampal synaptic plasticity [171]. 
This preventive effect on cognitive decline by treatment with ARBs in AD was 
also demonstrated by another animal study performed by Tsukuda et al., using 
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intracerebroventriculair injection of Aβ 1-40 in male ddY mice [172]. In these mice 
the ARB telmisartan decreased the cerebral Aβ 1-40 concentration and enhanced 
cerebral blood flow [172]. Furthermore, pretreatment with this ARB reduced the 
cognitive effects of Aβ 1-40 towards control level [172]. Using a similar model, 
Jing et al. demonstrated that the direct stimulation of the AT2 receptor by a newly 
generated AT2 receptor agonist, Compound 21 (C21), prevented cognitive decline 
[173]. In an observational study on cognitive function and systolic blood pressure 
reduction (OSCAR), in more than 60000 hypertensive patients, the specific use of 
the ARB eprosartan led to a reduction of blood pressure and also improved the 
cognitive function, revealing a positive correlation between cognitive decline or 
dementia and blood pressure levels [174].
ARBs do not only have the potential to reduce cognitive decline in animal and 
human studies (tables 1+2). In line with the described beneficial effect of ARBs on 
dementia, the Systolic Hypertension in the Elderly Program (SHEP) and the Systolic 
Hypertension in Europe (Syst-Eur) study demonstrated that antihypertensive 
treatment lowered the risk of developing stroke [34, 35]. In addition to the 
effect of an ARB in hypertension, an animal study showed a beneficial effect of 
ARBs on stroke [175]. After a MCA occlusion in apolipoprotein E-deficient mice 
– an atherosclerosis mouse model – treated with a cholesterol-high diet, the 
administration of the ARB telmisartan did not significantly decrease blood pressure, 
but decreased the ischemic area and also the atherosclerotic formation in the 
proximal aorta, and led to an improved cerebral blood flow in the penumbra of 
these treated mice [175]. In patients from the Kyoto heart study, who had coronary 
artery disease, the treatment with the ARB valsartan lowered the prevalence of 
stroke compared to the non-treated subjects [176]. Antihypertensive treatment 
with the ARB candesartan in elderly patients with isolated systolic hypertension, 
the relative risk of developing stroke was significantly reduced in comparison 
with other antihypertensive treatment, despite little difference in blood pressure 
reduction [177]. 
The potential mechanisms that could explain the link between hypertension 
and the development of AD need further investigation. Most human studies are 
epidemiological studies that show cross-sectional or longitudinal associations 
between hypertension and AD, but mechanistic studies or interventional studies 
are sparse (table 2). In animal studies, the focus of research has been mainly on 
the effect of low dosed blood pressure-lowering medication on Aβ accumulation 
and cognition. These preclinical studies indicate the possible potential for 
antihypertensive drugs against AD pathology and cognitive decline in AD patients 
[178]. Indeed, in a systematic review Shah et al. mentioned the need of large 
randomized clinical trials in order to explore the connection between blood 
pressure-lowering medications and dementia in humans [179].
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Table 1 Animal studies: Summary of intervention trials (long-chain omega-3 
polyunsaturated fatty acids, LC-n3-FA, and the manipulation of factors involved in the 
renin-angiotensin system, RAS). 
Used abbreviations: DHA=docosahexaenoic acid, EPA=eicosapentaenoic acid, AT-
NPD1=aspirin-triggered NPD1, ME=Methyl ester, SS=Sodium salt, RSO=Rapeseed oil, 
ACE=angiotensin-converting enzyme, ARB=angiotensin receptor blocker, CBF=cerebral 
blood flow
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Table 2 Human studies: Summary of intervention trials (long-chain omega-3 
polyunsaturated fatty acids, LC-n3-FA, and the manipulation of factors involved in the 
renin-angiotensin system, RAS). 
Used abbreviations: DHA=docosahexaenoic acid, EPA=eicosapentaenoic acid, MMSE= mini–
mental state examination, ARCD=Age-related cognitive decline, ALA=alpha-linolenic acid, 
pCBF=parenchymal cerebral blood flow, ARB=angiotensin receptor blocker, CAD=coronary 
artery disease
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Conclusions
Many studies showed that AD, VaD and stroke share hypertension as a common 
risk factor, while stroke in itself is also a risk factor for the development of AD 
or VaD (figure 1). Hypertension combined with aging decreases CBF results 
in changes in cerebrovascular structure and function [43, 44] leading to white 
matter changes, dysfunction of the blood-brain barrier, and to cognitive decline. 
Also MetS and its features induce structural and functional alterations in 
the cerebral vasculature, including resistance, stiffening, and remodeling. 
This seems to affect the brain in multiple ways. For instance, changes in the 
cerebral microcirculation can affect larger vessels and CBF. Changes in cerebral 
microcirculation also contribute to the development of cerebral small vessel 
disease possibly leading to WML, changes in gray matter microstructure, cerebral 
microbleeds, and brain cell (neuronal) atrophy. The affected brain tissue integrity 
might be a consequence of brain perfusion alterations, cerebral autoregulation 
disturbances, vascular reactivity abnormalities, or an altered production and 
secretion of peripheral adipokines being able to cross the BBB and to exert a wide 
range of effects on brain functioning. Eventually, all these factors together may 
lead to an increased risk of developing MCI, dementia, and stroke.
Notably, an increase in Aβ (regardless of the underlying cause) could lead to 
changes in cerebrovascular structure and function, and, if combined with for 
vascular disease could represent a vicious cycle of aggravated cerebrovascular 
disease, increasing Aβ pathology which in turn enhances vascular disease. As 
detailed, Aβ may increase blood pressure, decrease the amount of vascular 
endothelial cells, impair vascular function and decrease CBF, resulting in further 
neurodegeneration. Thus, elevated Aβ levels due to any cause could explain the 
association between hypertension, cerebrovascular disease and AD. Studying the 
causal relationships between hypertension, cerebrovascular disease and AD in 
humans is complex because of the long latency between pathological changes 
and clinical symptoms, which may span decades both in vascular disease and AD. 
Thus, properly designed animal studies that can be validly translated are needed 
to enlighten the underlying mechanisms and to translate them to preventive or 
therapeutic interventions. In murine studies, induced hypertension led to an 
increased accumulation of Aβ, neuroinflammation, changed CBF and disturbed 
BBB. Moreover, animal models for stroke showed also an increased AD-like 
pathology like enhanced amyloid deposition, neuroinflammation and cognitive 
deficits. If we consider hypertension and stroke as major risk factors for dementia, 
both for VaD and AD, there are two possible therapies for dementia. On the one 
hand, research has revealed that the supplementation with LC-n3-FA reduces 
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the risk of developing hypertension and stroke, thereby also lowering the risk of 
developing dementia (figure 1, tables 1+2). On the other hand, the manipulation 
of factors involved in the RAS like angiotensin II receptor blockers or ACE inhibitors 
showed beneficial effects in animal and human studies (figure 1, tables 1+2).
As a sequel, future research needs to focus more on the role of other (both 
medical and lifestyle) treatment strategies to lower the risk factors for dementia. 
Such research could elucidate the importance of reducing the rate of hypertension 
and stroke. Until now, studies on stroke have concentrated on motor impairment. 
Therefore, more research is needed aiming at the cognitive and behavioral 
deficits induced by stroke. This would also help to understand the connection 
between stroke, cognitive decline and dementia and to elucidate the differences 
and overlap between VaD and AD.
Thesis overview
The main aims of this thesis are:
- To elucidate the underlying pathological processes of major vascular risk 
factors hypertension, apoE4, and stroke during very early development of 
neurodegenerative processes in AD using several mice models.
- To investigate whether vascular risk factors have the potential to 
accelerate the course of neurodegenerative processes in AD.
- To investigate the possible capacity of antihypertensives and specific 
multi-nutrient diets to serve as preventive or treatment against AD-like 
symptoms and vascular risk factors for AD.
In chapter 2 we elucidated the underlying vascular origin of neurodegenerative 
processes in AD in a 16-18 months old double transgenic AβPPswe/PS1dE9 (AβPP/
PS1) mouse model for AD. Therefore, we investigated the relation between 
systolic blood pressure (SBP) cerebral blood flow (CBF) and vasoreactivity with 
brain structure and function in these aged AβPP/PS1 mice. These AβPP/PS1 mice 
are a murine model for familial very early-onset AD overexpressing Aβ. In familial 
forms of AD the production of Aβ peptides is also increased and is thought to be 
the primary driving force in non-familial (sporadic) AD pathogenesis [21]. Already 
the early stages of AD are characterized by the accumulation of Aβ affecting 
specific brain regions like the forebrain and medial temporal lobe structures like 
hippocampus, amygdala, and entorhinal cortex [23, 180, 181]. Almost all insoluble 
Aβ is accumulated within the neuritic plaques and cerebral vessel walls [182]. 
Using a multi-modal approach, including advanced MR neuroimaging tools, we 
investigated the relation between vascular parameters (systolic blood pressure 
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(SBP), cerebrovascular density, cerebral perfusion and vasoreactivity), brain tissue 
microstructure, neuroinflammation, neurogenesis, postsynaptic density, levels of 
fatty acids and sterols, and functional and structural connectivity, in relation to 
cognitive and behavioral alterations in this mouse model for the very early phase 
of AD.
The study presented in chapter 3 is directed on the impact of hypertension, the 
major vascular risk factor for AD, and its link with AD. The relation of hypertension 
with all (other) key markers of AD such as presence of Aβ plaques, neurofibrillary 
tangles, and brain atrophy, has been demonstrated [114]. Elevated angiotensin 
II (AngII) is an important cause of essential hypertension. AngII blocking agents 
can thus provide potential candidates to reduce AD risk factors in hypertensive 
patients. In this study, we studied the effect of 2 months AngII-infusion induced 
hypertension on SBP and CBF in 10 months-old wild-type (WT) C57bl/6j and 
AβPP/PS1 mice, and treatment with two different antihypertensives, eprosartan 
mesylate (EM) or hydrochlorotiazide, after 1 month of induced-hypertension. 
SBP was monitored each month via tail cuff plethysmography. CBF was measured 
with MR by flow-sensitive alternating inversion recovery. This study helps to 
gather more insight in the actions of hypertension and antihypertensives on brain 
processes and the vascular system, which may help to support the development 
of effective tailor-made blood pressure-lowering treatments for AD patients.
Since the research described in the previous chapter investigated the effect of 
AngII-induced hypertension on SBP and CBF in WT and AβPP/PS1 mice, chapter 4 
reveals more understanding into the link between midlife hypertension, decreased 
cerebral hemodynamics and connectivity, and concomitant cognition in an AD 
mouse model. In this study we investigated if AngII-induced hypertension is able 
to induce AD pathology in WT mice, and if this AngII-induced hypertension could 
aggravate the AD pathology in the AβPP/PS1 mice. Another aim of this study 
was to study the effects of EM, an AngII receptor blocker, on cerebrovascular, 
metabolic, connectivity and cognitive changes in AD and WT mice. To determine 
the impact of hypertension and antihypertensive on Aβ, vascular density, and 
neuroinflammation immunohistochemical stainings were performed for Aβ, 
glucose transporter type 1 (GLUT-1), and ionized calcium-binding adapter 
molecule 1 (IBA-1).
Using the same AD-like transgenic mouse model as in the two latter chapters, in 
chapter 5 we aimed to study the efficacy of a specific multi-nutrient combination 
dietary approach against AD progression. Due to a lack of effective pharmacological 
interventions against AD, recent research has shifted towards the use of dietary 
interventions for the treatment and prevention of AD. Therefore, we investigated 
the effects of the specific nutrient combination Fortasyn, containing the 
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dietary precursors and cofactors for membrane synthesis, viz. docosahexaenoic 
acid (DHA), eicosapentaenoic acid (EPA), UMP, choline, phospholipids, folic 
acid, vitamins B6, B12, C, E, and selenium, on spatial learning and memory in 
11-month-old male AβPP/PS1 mice and WT mice. To this end, we analyzed the 
different search strategies to find the hidden platform in the Morris water maze 
using a parameter-based algorithm to assess the qualitative aspects of learning 
[183-187]. Our study examined whether Fortasyn may improve spatial learning 
of transgenic mice by facilitating the use of hippocampus-dependent search 
strategies.
Representing another strong genetic risk for sporadic AD [188], the apoE4 
allele is associated with increased cardiovascular risk factors. Moreover, apoE4 
carriers are clearly more susceptible to vascular brain damage (eg. stroke, brain 
haemorrhage; [52-54] and they display aberrant functional connectivity [55]. 
ApoE4 has been related with increased toxicity, and loss of neuroprotective 
function in the pathogenesis of Alzheimer disease, dependent or independent 
from Aβ accumulation [29]. In chapter 6 another murine transgenic mouse 
model resembling this major vascular risk factor for AD, the ApoE4 mouse, was 
used to test if this aforementioned Fortasyn diet has the potential to reduce the 
occurrence of vulnerabilities for AD by simultaneously improving cerebrovascular 
health and enhancing neuroprotective mechanisms. To test this hypothesis, we 
evaluated the effect of the Fortasyn diet on cerebral and plasma levels of fatty 
acids and sterols, CBF, gray and white matter integrity, functional connectivity (FC) 
and post-synaptic density during aging in 12- and 18-month-old apoE4 mice.
Being another major risk factor for AD, ischemic strokes have been the target of 
many drug trials. Until now, thrombolysis and thrombectomy are the only used 
treatment options for ischemic stroke, but only a minority of patients benefit 
from these therapies due to the narrow therapeutic window and complexity of 
administration. Occlusion of the middle cerebral artery (MCAo) is among the 
most common causes of ischemic stroke in humans. Cerebral ischemia leads to 
brain lesions existing of an irreversibly injured core and an ischemic boundary 
zone, the penumbra, containing damaged but potentially salvageable tissue. As 
described in chapter 7, we applied transient occlusion (30 min) of the middle 
cerebral artery (tMCAo) in WT C57BL/6j mice in this cross-institutional study 
to investigate the neurorestorative efficacy of a dietary treatment (Fortasyn) 
as therapeutic approach counteracting neuroinflammation and impairment of 
cerebral (structural+functional) connectivity, CBF, and motor function. Male adult 
C57BL/6j mice were subjected to right tMCAo using the intraluminal filament 
model. At several time points after tMCAo, behavioral tests, and MRI and PET 
scanning were conducted to identify the impact of the multicomponent diet on 
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the elicited neuroinflammatory response, loss of cerebral connectivity, and the 
resulting impairment of motor function after experimental stroke. This study 
also integrates several multi-modal techniques revealing underlying pathological 
mechanisms of stroke revealing that multimodal neuroimaging combined with 
behavioral analysis is an excellent approach to assess brain function and motor 
function recovery after stroke.
All study findings presented in thesis are summarized and are discussed in chapter 
8 including suggestions for future studies.
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Abstract
Cardiovascular risk factors, especially hypertension, are also major risk factors 
for Alzheimer’s disease (AD). To elucidate the underlying vascular origin of 
neurodegenerative processes in AD, we investigated the relation between 
systolic blood pressure (SBP) cerebral blood flow (CBF) and vasoreactivity with 
brain structure and function in a 16-18 months old double transgenic AβPPswe/
PS1dE9 (AβPP/PS1) mouse model for AD. These aging AβPP/PS1 mice showed an 
increased SBP linked to a declined regional CBF. Furthermore, using advanced 
MRI techniques, decline of functional and structural connectivity was revealed 
in the AD-like mice coupled to impaired cognition, increased locomotor activity, 
and anxiety-related behavior. Post mortem analyses demonstrated also increased 
neuroinflammation, and both decreased synaptogenesis and neurogenesis in 
the AβPP/PS1 mice. Additionally, deviant levels of fatty acids and sterols were 
present in the brain tissue of the AβPP/PS1 mice indicating maladapted brain fatty 
acid metabolism. Our findings suggest a link between increased SBP, decreased 
cerebral hemodynamics and connectivity in an AD mouse model during aging, 
leading to behavioral and cognitive impairments. As these results mirror the 
complex clinical symptomatology in the prodromal phase of AD, we suggest that 
this AD-like murine model could be used to investigate prevention and treatment 
strategies for early AD patients. Moreover, this study helps to develop more 
efficient therapies and diagnostics for this very early stage of AD.
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Introduction
Dementia has become a public health problem in the aging world population 
[189, 190]. Alzheimer’s disease (AD) is responsible for most dementia cases 
followed by vascular dementia (VaD) [2, 3]. AD is characterized by brain atrophy 
and a gradual cognitive decline caused by neuronal death and loss of synapses 
in brain regions involved in learning and memory processes (e.g. temporal and 
frontal lobes) [182, 191]. Already the early stages of AD are characterized by the 
accumulation of Aβ affecting specific brain regions like the forebrain and medial 
temporal lobe structures like hippocampus, amygdala and entorhinal cortex [23, 
180, 181]. Almost all insoluble Aβ is accumulated within the neuritic plaques and 
cerebral vessel walls [182]. Epidemiological and clinical studies revealed that 
AD and VaD share common vascular related risk factors such as hypertension, 
diabetes, hyperlipidemia, cerebrovascular disease, and arrhythmia [91-93, 95, 96, 
192, 193]. Furthermore, it has been shown that vascular risk factors can influence 
the development of AD pathology (the vascular hypothesis) [194]. A recent study 
showed that hypertension affects the expression of tau as well as that of Aβ in an AD 
mouse model [195]. Further evidence supporting this link between hypertension 
and AD comes from clinical studies indicating that antihypertensives may reduce 
the development of AD [196, 197]. Other clinical studies suggested that resting 
cerebral blood flow (CBF) is decreased among hypertensive patients as opposed 
to that of normotensive subjects [198-202]. In elderly patients a decreased CBF 
has been shown to increase hippocampal and amygdalar atrophy [203, 204]. 
Therefore, an impaired or diminished cerebral perfusion may play a role in the 
development of AD via decreased delivery of oxygen in ischemia-sensitive brain 
regions like the hippocampus, inducing neurodegeneration and subsequent 
cognitive decline [205]. Notably, maladapted cerebral hemodynamics could lead 
to alteration in structural and functional connectivity in the brain represented 
by white matter lesions/hyperintensities. Impaired functional connectivity is also 
found in AD patients [206-208] and additionally, a link between the incidence 
of white matter lesions and the severity of the underlying AD pathology has 
been reported [209-211]. Many studies have shown the relationship between 
increased blood pressure in mid-life and cognitive decline or AD in late-life [48, 
49] indicating the relevance of proper blood pressure maintenance.
Therefore, to elucidate the underlying vascular origin of neurodegenerative 
processes in AD, we investigate the relation between vascular parameters 
(systolic blood pressure (SBP), cerebrovascular density, cerebral perfusion and 
vasoreactivity), functional and structural connectivity, and postmortem markers 
for neuroinflammation, neurogenesis, postsynaptic density, and levels of fatty 
acids and sterols and, in relation to cognition in the AβPPswe/PS1dE9 (AβPP/PS1) 
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mouse model for AD. To develop and evaluate potential therapeutic targets 
for early stages in AD it is necessary to understand underlying (neurovascular) 
pathological processes in AD by studying well characterized early stage AD animal 
models. 
Methods
Animals
The AβPPswe/PS1dE9 (AβPP/PS1) founder mice were originally obtained from John 
Hopkins University, Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. 
of Pathology) [212, 213] and a colony was first established at the University of 
Kuopio, Finland and thereafter a colony was bred at the Central Animal Facility at 
Radboud university medical center, The Netherlands. In short, mice were created 
by co-injection of chimeric mouse/human AβPPswe (mouse AβPP695 harbouring 
a human Aβ domain and mutations K595N and M596L linked to Swedish familial 
AD pedigrees) and human PS1-dE9 (deletion of exon 9) vectors controlled by 
independent mouse prion protein promoter elements. The two transfected 
genes co-integrate and co-segregate as a single locus [213]. This line was 
originally maintained on a hybrid background by backcrossing to C3HeJ×C57BL/6J 
F1 mice (so-called pseudo F2 stage). For the present work, the breeder mice 
were backcrossed to C57BL/6J for fourteen generations to obtain mice for the 
current study. Before the actual experiments, animals were housed socially with 
a maximum of six animals per cage, with room temperature at 21°C, and artificial 
12:12h light:dark cycle (lights on at 7 a.m.). Food and water were available ad 
libitum. The experiments were performed according to Dutch federal regulations 
for animal protection and were approved by the Veterinary Authority of Radboud 
university medical center, Nijmegen, The Netherlands, and the Animal Experiment 
Committee (called the Dierexperimentencommissie or DEC, RU-DEC 2011-058) of 
the Radboud university, Nijmegen, The Netherlands. The reporting of the animal 
experiments conforms with the ARRIVE guidelines [214].
For the present experiment, we used a total of 17 16-month-old months old male 
mice (ten WT littermates, and seven AβPP/PS1 mice); at eighteen months of age, 
all animals completed the experiments and were euthanized. All behavioural and 
MRI experiments were performed in the Preclinical Imaging Centre (PRIME) of the 
Radboud university medical center between 8 a.m. and 6 p.m..
Study design, randomization, blinding, and sample size
This was a single-institution, randomized, and double-blind controlled study 
(blinded for investigators and outcomes assessor) conducted at the preclinical 
imaging center (PRIME) of the Radboudumc (Nijmegen, the Netherlands). Per 
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experimental subgroup, the selection of animals was randomized. All animals 
completed the study, no animals were replaced. The sample size of minimal 6 
mice per experimental group was chosen based on formal calculation of power as 
described in the approved protocols (RU-DEC 2011-058; WP: 110149) and using 
results from our previous study [40]. At 16, 17, and 18 months of age systolic blood 
pressure measurements were performed. At 17 months of age (WT: 16,8±0,03; 
AβPP/PS1: 16,6±0,04) all animals underwent behavioural testing in the open 
field and Morris water maze (MWM) and subsequently MRI measurements at 18 
months of age (WT: 18.0±0,02; AβPP/PS1: 17,9±0,05). No animals were excluded 
from analysis. Post mortem immunohistochemical and biochemical procedures 
were performed on all brains.
Tail-cuff plethysmography
Mice were trained for two consecutive days in the warmed tail-cuff device (IITC Life 
Scientific Instruments, Woodland Hills, CA) to accustom them to the procedure. 
Starting from sixteen months of age and being repeated at seventeen and eighteen 
month of age, SBP was measured for two consecutive days monthly in trained, 
conscious and preheated mice using computerized tail-cuff plethysmography (IITC 
Life Scientific Instruments, Woodland Hills, CA), as previously described [41-44].
Behavioral analyses
The results of the behavioral analyses are placed in the supplementary material.
Morris water maze
The Morris water maze (MWM) is used to test spatial learning and memory 
in rodents. In short, at 17 months of age mice were placed in a circular pool, 
filled with opaque water, and were trained to find a submerged platform in the 
northeast (NE) quadrant of the pool by using distant visual cues. 
Acquisition (spatial learning): Mice were trained to find the location of the 
submerged escape platform in 4 acquisition trials (maximal swimming time 120 s; 
30 s on the platform; inter-trial interval 60 min) per day during 4 consecutive days. 
The latency time (s) to find the hidden platform was scored. Starting positions 
were south (S), north (N), east (E) and west (W). After the 2 min swim the mice 
were placed back in their home cage, and a paper towel was available inside the 
cage for additional drying.
Probe (spatial memory): At the start of the fifth day, mice performed a single probe 
trial (starting position: S), in which the platform was removed from the swimming 
pool. Mice were allowed to swim for 120 s and the time spent swimming and 
searching in the NE quadrant (where the platform had been located) was recorded.
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Open field
Locomotion and explorative behavior were evaluated for 30 minutes in the open 
field at 17 months of age, as previously described [40, 45, 46]. Using EthoVision 
XT10.1 (Noldus, Wageningen, The Netherlands), locomotion was automatically 
recorded. The floor of the arena was divided into center, periphery, and corners. 
The frequency of entering these zones was measured automatically. In addition, 
exploration was manually scored (walking, sitting, wall leaning, jumping, rearing, 
grooming) and analyzed as described previously [47, 48].
MRI protocol 
Following the behavioral examinations, at 18 months of age MRI measurements 
were performed on an 11.7 T BioSpec Avance III small animal MR system (Bruker 
BioSpin, Ettlingen, Germany) equipped with an actively shielded gradient set of 600 
mT/m and operating on the Paravision 5.1 software platform (Bruker, Karlsruhe, 
Germany). We used a circular polarised volume resonator for radiofrequency 
transmission and an actively decoupled mouse brain quadrature surface coil 
with integrated combiner and preamplifier for receive (Bruker BioSpin). For the 
imaging procedure, the animals were anesthetized with isoflurane (3.5% for fast 
induction and 1.8% for maintenance) in a 2:1 oxygen and N2O mixture (normal gas 
condition) or in a 3:0 oxygen and N2O mixture (vasoconstriction), and placed in 
a stereotactic holder to prevent unwanted movement during the scanning. Body 
temperature was monitored with a rectal temperature probe and maintained 
at 37˚C with heated airflow. Respiration of the animal was monitored using a 
pneumatic cushion respiratory monitoring system (Small Animal Instruments Inc, 
NY, USA). First gradient echo T2*-weighted images covering the entire mouse 
brain were acquired in three directions for anatomical reference using previously 
described acquisition parameters [49].
Cerebral blood flow
MR perfusion data were measured with flow-sensitive alternating inversion 
recovery (FAIR) MRI techniques; from a series of echo planar imaging (EPI)-images 
in three different regions of interest (ROI) were evaluated [50, 51] in the cerebral 
cortex (all cortical regions above corpus callosum), hippocampus, and thalamus 
according to the Franklin - Paxinos atlas [52]. Twelve images with increasing 
inversion times (TIs; 40–3000 ms) were obtained for the T1 calculations, accounting 
to a total scan time of 12 min. Inversion recovery data from the imaging slice 
were acquired after selective inversion interleaved with nonselective inversion. To 
evaluate vasoreactivity, a 2:1 oxygen and N2O mixture (normal gas condition) and 
a 3:0 oxygen and N2O mixture (vasoconstriction) were used. To calculate regional 
CBF we used the protocol that is described in [49].  
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Diffusion tensor imaging
Diffusion of water was imaged as described previously [40, 45, 53]. In short, 
22 axial slices covering the whole brain were acquired with a four-shot SE-EPI 
protocol. B0 shift compensation, navigator echoes and an automatic correction 
algorithm to limit the occurrence of ghosts and artefacts were implemented. 
Encoding b-factors of 0 s/mm2 (b0 images; 5×) and 1000 s/mm2 were used and 
diffusion-sensitizing gradients were applied along 30 non-collinear directions in 
three-dimensional space. 
The diffusion tensor was estimated for every voxel using the PATCH algorithm 
[54]; mean water diffusivity (MD) and fractional anisotropy (FA) were derived 
from the tensor estimation following a protocol as described elsewhere [45]. MD 
and FA values were measured in several white matter (WM) and grey matter (GM) 
areas, manually selected based on an anatomical atlas [52].
Resting state fMRI
Subsequently after the acquisition of the anatomical reference images, resting 
state fMRI (rsfMRI) datasets were acquired using a single-shot spin-echo 
sequence with echo-planar readout (SE-EPI) sequence. Six hundred repetitions 
with a repetition time (TR) of 1.8 s and echo time of 16.9 ms were recorded for 
a total acquisition time of 18 min. The rsfMRI datasets were first realigned using 
a least-squares method and rigid-body transformation with Statistical Parametric 
Mapping (SPM) mouse toolbox (SPM5, University College London; http://www.fil.
ion.ucl.ac.uk/spm/; Sawiak et al., 2009). Mean and maximum displacement across 
the six degrees of freedom (along the x-, y-, and z-axes and on three rotation 
parameters pitch, roll, and yaw) were measured in each mouse. The mean SE-EPI 
images for each mouse were then used to generate a study-specific template 
through linear affine and nonlinear diffeomorphic transformation (ANTs. v1.9; 
http://picsl.upenn.edu/ANTS/). Visual inspection of the normalised dataset was 
performed to screen for possible normalization biases. On the template, 12 areas 
were selected in left and right hemisphere. The selected regions were based on 
previous work concerning functional connectivity in mice [55], and included: left 
and right dorsal hippocampus, left and right ventral hippocampus, left and right 
auditory cortex, left and right motor cortex, left and right somatosensory cortex, 
and left and right visual cortex. All cortical ROIs were selected 1–2 voxels away 
from the edge of the cortex, to minimise the impact of susceptibility artefacts, 
which are more prominent in areas close to tissue interfaces (e.g., near the skull or 
near the ear canals). In-plane spatial smoothing (0.4 × 0.4 mm), linear detrending, 
and temporal high-pass filtering (cut-off at 0.01 Hz) were applied to compensate 
for small across-mouse misregistration and temporal low-frequency noise. FC 
group comparison between ROIs were calculated from the BOLD time series 
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using total and partial correlation analyses implemented in FSLNets (FSLNets v0.3; 
www.fmrib.ox.ac.uk/fsl). Pearson’s correlation values were Fisher transformed to 
Z-scores for group comparisons and statistical analysis.
Post mortem brain tissue preparation
Directly following the MR measurements at 18 months of age, anaesthetized mice 
were sacrificed by transcardial perfusion with 0.1M phosphate buffered saline 
(PBS) at room temperature. The perfused brains were cut mid-sagittally and the 
right hemispheres were snap frozen in liquid nitrogen and stored at -80°C, before 
further biochemical processing. The left hemispheres were immersion fixated for 
15h at 4°C in 4% paraformaldehyde fixative and thereafter stored in 0.1M PBS 
with 0.01% sodium azide at 4°C for immunohistochemical staining.
Immunohistochemistry
Eight series of 30 µm coronal sections were cut through the brain using a sliding 
microtome (Microm HM 440 E, Walldorf, Germany) equipped with an object table 
for freeze sectioning at -60°C. 
For every staining, one complete series with 240 µm distance between the sections 
was used. Immunohistochemistry was performed using standard free-floating 
labeling procedures, as described previously, and was carried out on a shaker 
table at room temperature. [40]. 
Postsynaptic density (PSD) was visualized with anti-PSD-95 antibody (1:2000; 
Abcam, catalog #ab18258, RRID:AB_444362) using one subseries of brain sections 
per animal. Donkey anti-rabbit biotin 1:1500 (Jackson ImmunoResearch, West 
Grove, PA, USA) was used as secondary antibody.
To visualize immature neurons we used an anti-doublecortin (DCX) antibody 
(1:4000; polyclonal goat anti-doublecortin (C18): sc-8066, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) with one subseries of brain sections 
per animal. Being a microtubule-associated protein, Doublecortin is exclusively 
found in somata and processes of migrating and differentiating neurons [56, 57]. 
Donkey-goat biotin 1:1500 (Jackson ImmunoResearch, West Grove, PA, USA) was 
used as secondary antibody.
To visualize and quantify the amount of macrophages and microglia, an anti-ionized 
calcium binding adapter molecule 1 (IBA-1) antibody (1:1500; polyclonal goat 
anti-IBA1 (C18); Abcam Inc., Cambridge, UK) was used with one subseries of brain 
sections per animal. Donkey-goat biotin 1:1500 (Jackson ImmunoResearch, West 
Grove, PA, USA) was used as secondary antibody.
The amount of glucose transporter type 1 (GLUT-1) was visualized using an 
anti-GLUT-1 antibody (1:2000; rabbit anti GLUT-1 transporter, Chemicon AB 1340, 
Chemicon International, Inc., Temecula, CA, USA). Donkey-rabbit biotin 1:1500 
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(Jackson ImmunoResearch, West Grove, PA, USA) was used as secondary antibody. 
Results of all immunohistochemical stainings for PSD-95, DCX, IBA-1, and GLUT-1 
can be found in the supplementary material.
Quantification – PSD-95
The stained sections were analyzed using a Zeiss Axioskop microscope equipped 
with hardware and software of Microbrightfield (Williston, VT, USA). Brain regions 
were based on the mouse brain atlas of Franklin & Paxinos [52] and quantified in 
five regions of the hippocampus: the inner molecular layer (IML), outer molecular 
layer (OML), cornu ammonis 1 (CA1), CA2 and CA3. Additionally, two regions in 
the cortex corresponding to the visual and somatosensory cortex were analyzed. 
The relevant regions were digitized at 100 times magnification with immersion oil 
using Stereo Investigator. The quantification of the photographs was performed 
using Image J (Image J, U. S. National Institutes of Health, and Bethesda, Maryland, 
USA). The contrast was manually enhanced, following the same procedure for 
all digitized images, and the amount of tissue stained was measured with a 
threshold-based approach.
Quantification – DCX, IBA-1 & GLUT-1
Brain sections between bregma -1.46 and -2.30 [52] were preselected for 
quantification. Quantification was done at a 5x magnification using an Axio Imager 
(A2, Zeiss Germany). ImageJ (National Institute of Health, Bethesda, MD, USA) was 
used to analyze the regions of interest: Cortex (IBA-1 & GLUT-1), hippocampus 
(DCX, IBA-1 & GLUT-1). 
Biochemical analyses
Serum and brain sterol levels were measured by gas-chromatography-mass-spec-
trometry-selected-ion-monitoring (GC-MS-SIM) as described in detail previously 
[58]. The cerebellum of the right hemisphere was homogenized and sterols 
were extracted overnight by chloroform/methanol trimethylsilylation prior to 
GC-MS-SIM analysis [58]. Brain fatty acid analyses were performed with a part 
of the brain homogenate (olfactory bulb and part of frontal cortex), as described 
previously [45].  
Statistics
For the statistical analysis, IBM SPSS 22 software (IBM Corporation, New York, NY, 
USA) was used. Multivariate ANOVA (Repeated measures ANOVA for the MWM and 
SBP data) with Bonferroni corrections was conducted with between-group-factors 
genotype to analyze possible differences in all the other parameters. Statistical 
significance was set at p ≤ 0.05, while a tendency was set at 0.05 < p < 0.08. All 
data are expressed as mean ± SEM. 
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Results
Body Weight
18-month-old AβPP/PS1 mice had the same body weight as their WT littermates 
before both MR scan sessions (Figure 1A, F(1,15)=2.7, p<0.124). 
Systolic blood pressure
Using tail-cuff plethysmography to measure systolic blood pressure (SBP), AβPP/
PS1 mice demonstrated an increased SBP compared to their WT littermates from 
16 to 18 months of age (Figure 1B, F(1,15)=5.6, p<0.032). Both AβPP/PS1 and WT 
mice exhibited a decrease in SBP over time from 16 to 18 months of age (Figure 
1B, F(2,30)=8.1, p<0.002).
Figure 1 Body weight (A) and systolic blood pressure (B, SBP) of AβPP/PS1 and wild-type 
(WT) mice.  (A) 18 month old AβPP/PS1 mice showed no difference in body weight 
compared to their WT littermates (p<0.124). (B) SBP was measured each experimental 
month for two consecutive days in trained, conscious and preheated mice using 
computerized tail-cuff plethysmography. Here, AβPP/PS1 mice had a higher SBP than their 
WT littermates from 16 to 18 months of age (p<0.032). SBP of both AβPP/PS1 and WT 
mice decreased over time from 16 to 18 months of age (p<0.002).
MR measurements
Cerebral blood flow and vasoreactivity
To study the effect of genotype differences on cerebrovascular health, CBF (Figure 
2A) and vasoreactivity (Figure 2B) were measured with FAIR ASL using normal (200 
O2 : 100 N2O mL/min) and vasoconstrictive (300 O2 : 0 N2O mL/min) gas conditions 
in three regions of interest (ROI): cortex, hippocampus and thalamus. Under 
normal gas condition a decreased CBF was observed in the cortex (F(1,14)=4.2, 
p<0.060) and thalamus (F(1,14)=10.5, p<0.007) of AβPP/PS1 mice compared to 
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their WT littermates. In addition, under vasoconstrictive condition our AD model 
mice had again a lower thalamic CBF (F(1,14)=5.1, p<0.040) than the WT mice. 
Both AβPP/PS1 and WT mice showed an intact vasoreactivity in the cortex (AβPP/
PS1, F(1,6)=6.2, p<0.048; WT, F(1,8)=13.7, p<0.006) and thalamus (AβPP/PS1, 
F(1,6)=13.2, p<0.011; WT, F(1,8)=35.4, p<0.001). In contrast, in the hippocampus 
only WT mice (F(1,8)=13.8, p<0.006) revealed an intact vasoreactivity, while 
AβPP/PS1 mice (F(1,6)=1.6, p<0.253) had an impaired vasoreactivity indicating an 
incapability to adapt to the vasoconstrictive gas condition.
Diffusion tensor imaging
Quantitative assessment of the diffusion tensor indices fractional anisotropy (FA); 
and mean diffusivity (MD) was performed for ROIs drawn in several white and 
gray matter regions to assess effects of AD-like pathology in 18-month-old AβPP/
PS1 and WT mice (Figure 2C+D). AβPP/PS1 mice showed impaired white matter 
integrity as indicated by a decrease in FA in the visual cortex, not being present 
in their WT littermates (Figure 2C, F(1,9)=24.5, p<0.001). No genotype effect was 
present for the MD (Figure 2D).
Resting state fMRI
To analyze the impact of AD-like pathology on the functional connectivity (FC) 
patterns at 18 months of age, rsfMRI data were statistically analyzed based on 
total correlation (Figure 3A) and partial correlation (Figure 3B).
Total correlation analyses
AβPP/PS1 mice showed no differences in FC, as analyzed with total correlations 
compared to their WT littermates (Figure 3A).
Partial correlation analyses
In comparison with the total correlation analysis, partial correlation analysis 
accentuates the direct connectivity between two ROI, while regressing the 
temporal BOLD signal from all other ROI. Resulting connectivity was thresholded 
at |Z| > 1.0. For the partial correlations we found significant genotype effects at 
18 months of age (Figure 3B). AβPP/PS1 mice showed a disturbed FC between 
several brain regions. While revealing an increased FC between the left motor 
cortex to left auditory cortex (F(1,12)=5.5, p<0.037), AβPP/PS1 mice compared to 
their WT littermates demonstrated a decreased FC between left auditory cortex 
to left ventral hippocampus (F(1,12)=5.7, p<0.034) and left somatosensory cortex 
to left visual cortex (F(1,12)=6.3, p<0.028).
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Figure 2 Genotype effects on the cortical, hippocampal and thalamic cerebral blood 
flow (A, CBF) and vasoreactivity (B) using normal (200 O2 : 100 N2O mL/min) and 
vasoconstrictive (300 O2 : 0 N2O mL/min) gas conditions in 18-month-old AβPP/
PS1 and wild-type (WT) mice. Quantitative assessment of diffusion tensor derived 
indices was performed for several ROI (AUC= Auditory cortex, CC=Corpus callosum, 
F=Fornix, HC=Hippocampus, MC=Motor cortex, OT=Optic tract, SSC=Somatosensory 
cortex, VC=Visual cortex) drawn in white and gray matter to assess effects of AD-like 
pathology in 18-Month-old AβPP/PS1 and WT mice on fractional anisotropy (C) and 
mean diffusivity (D). (A) CBF was measured with flow-sensitive alternating inversion 
recovery MRI technique; from a series of echo planar imaging images. Under normal 
gas condition, AβPP/PS1 mice had a lower cortical (p<0.060) and thalamic (p<0.007) CBF 
than their WT littermates. Under vasoconstrictive gas conditions, AβPP/PS1 mice showed 
again a lower thalamic CBF (p<0.040) than their WT littermates. (B) Both AβPP/PS1 and 
WT mice showed an intact vasoreactivity in the cortex (AβPP/PS1, p<0.048; WT, p<0.006) 
and thalamus (AβPP/PS1, p<0.011; WT, p<0.001). In contrast, in the hippocampus only 
WT mice (p<0.006) revealed an intact vasoreactivity, while AβPP/PS1 mice (p<0.253) 
had an impaired vasoreactivity indicating an incapability to adapt to the vasoconstrictive 
gas condition. (C) AβPP/PS1 mice had a lower FA in the VC than WT mice indicating an 
impaired white matter integrity (p<0.001). (D) No genotype effect was found for the MD 
in all measured ROI.
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Figure 3 Resting-state functional connectivity (FC) based on total (A) and partial (B) 
correlation analyses of 12 ROI in the brain of in 18-Month-old AβPP/PS1 and WT mice. 
(A) For the overall correlations no significant genotype effects were detected in the dorsal 
(DHC) and ventral hippocampus (VHC), and auditory (AUC), motor (MC), somatosensory 
(SSC), and visual cortices (VC). (B) AβPP/PS1 mice showed a disturbed FC between several 
brain regions. Between the left motor cortex to left auditory cortex (p<0.037) AβPP/PS1 
mice had a higher FC than their WT littermates, while showing a decreased FC between 
left auditory cortex to left ventral hippocampus (p<0.034) and left somatosensory cortex 
to left visual cortex (p<0.028).
Fatty acids in brain tissue 
Fatty acid content was determined in frontal cortex (Supplementary table 1).
No genotype effects were found for the brain fatty acids palmitic acid, stearic acid, 
saturated fatty acid, oleic acid, and mono-unsaturated fatty acid. However, AβPP/
PS1 mice showed increased arachidonic acid (F(1,15)=6.8, p<0.020), increased 
total omega-6 (F(1,15)=4.1, p<0.061), a decreased DHA (F(1,15)=9.6, p<0.008), 
a decreased overall omega-3 (F(1,15)=10.6, p<0.006), and a resulting decreased 
omega-3/omega-6 ratio (F(1,15)=8.6, p<0.011).  
Sterol levels 
Sterol levels were determined in the blood serum (Supplementary table 2) and in 
the cerebellum of the brain (Supplementary table 3).
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Blood serum
No genotype effects were found in levels of cholestanol, lathosterol, campesterol, 
campestanol, stigmasterol, sitosterol, sitostanol, avenasterol, brassicasterol, 
lanosterol, desmosterol, dihydro-lanosterol, 24OH-cholesterol, 7αOH-cholesterol, 
27OH-cholesterol, and global cholesterol.
Cerebellum
In brain tissue of 18-month-old AβPP/PS1 mice, levels of dihydro-lanosterol 
(F(1,15)=5.8, p<0.030) were higher than in the brain tissue of their WT littermates. 
No genotype effects were revealed for the sterol levels of cholestanol, lathosterol, 
campesterol, stigmasterin, sitosterol, lanosterol, desmosterol, 24OH-cholesterol, 
27OH-cholesterol, and global cholesterol.
Table 1. Summary of all significant results. 
Used abbreviations: AD (Alzheimer’s disease), SBP (systolic blood pressure), CBF (cerebral 
blood flow), DTI (diffusion tensor imaging), FA (fractional anisotropy), MD (mean diffusivity), 
rsfMRI (resting state functional MRI), MWM (Morris water maze), GLUT-1 (glucose 
transporter-1), IBA-1 (ionized calcium-binding adapter molecule 1), DCX (doublecortin), 
PSD-95 (postsynaptic density 95), CA1 (cornus ammonis 1), OML (outer molecular layer of 
the dentate gyrus), ARA (arachidonic acid), DHA (docosahexaenoic acid).
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Discussion
Hypertension is the most common cardiovascular risk factor [36, 59-65], and 
associated with all (other) key markers of AD such as presence of amyloid-β (Aβ) 
plaques, neurofibrillary tangles, and brain atrophy [64]. The increasing prevalence 
of hypertension due to the aging world population and growing prevalence of 
obesity could also increase the number of AD patients, since midlife hypertension 
almost doubles the risk of developing AD in later life [36, 66]. In agreement with 
this, the AβPP/PS1 AD-like model mice used in the present study, demonstrated 
an increased systolic blood pressure (SBP) and concomitant decreased regional 
CBF in the cortical and thalamic areas, decreased vasoreactivity of the circulation 
of the hippocampus, and impaired cognition. The WT and AβPP/PS1 mice showed 
a decrease in SBP over time, while the AβPP/PS1 mice always demonstrated a 
higher SBP than their WT littermates. This is in line with the AGES-Reykjavik study 
which has shown that midlife hypertension combined with a lower late-life BP is 
associated with a lowered total brain and gray matter volume [67]. Long-standing 
hypertension stimulates atherosclerosis and vascular remodeling leading to 
increases in wall thickness. Arterial stiffness and severe atherosclerosis can lead 
to an increase in pulse pressure [68]. An increased pulse pressure is correlated 
with a higher risk of AD in older adults [68]. In the Rotterdam study the presence 
of atherosclerotic plaques or wall thickening has been associated with dementia 
and its two major subtypes AD and vascular dementia [66]. In accordance 
to previous research, this AD-like mouse model suffers from early-impaired 
cerebrovascular autoregulation and CBF, but also shows abnormalities in the 
cortical microvasculature [69-72]. These results support the significant reduction 
in regional and global CBF as identified in studies on MCI and AD patients [73]. A 
lowered CBF is a common feature in the early phase of AD, which may possibly 
be caused by an accumulation of Aβ in the vessel walls or in close vicinity of 
the blood vessels [27, 74, 75]. Furthermore, the impaired vasoreactivity in our 
transgenic mice is also a clinical hallmark of AD [76]. Aβ has shown to directly 
enhance the vasoconstriction of the cerebral arteries and to stimulate selected 
constrictor responses, resulting in a reduced CBF [74]. In addition, deposition of 
Aβ in the cerebral microvessels promotes vascular pathology and dysfunction 
[77-79], as embodied by the impaired hippocampal vasoreactivity in the brains 
of the AβPP/PS1 mice. Hypertension may contribute to this remodeling through 
increase in smooth muscle tone and damage of endothelial cell function resulting 
in arterial wall thickening and microvascular rarefaction [80]. In line with our 
research, Toth et al. demonstrated that in aging mice hypertension could induce 
an impaired cerebrovascular autoregulation [81], cerebromicrovascular injury 
and neuroinflammation. In the present study we investigated brain diffusivity 
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with DTI as an imaging biomarker for white and gray matter integrity. FA is a 
marker of the degree of myelination and fiber density of white matter, while 
MD characterizes an inverse measure of the membrane density and is sensitive 
to cellularity, edema, and necrosis in grey matter (GM) [82-84]. In addition to 
an impaired cerebrovascular function, a reduced FA value of the visual cortex 
was found in our AD model mice indicating a subtle change in microstructural 
integrity. This impaired microstructural integrity could imply axonal degeneration 
or demyelination [84] in the visual cortex. Nevertheless, no genotype effects were 
found for MD, being considered to be more informative for grey matter regions 
like the visual cortex. In our previous research using DTI in 12-month-old WT and 
AβPP/PS1 mice as well, fiber tract volume reduction, loss of axonal neurofilaments, 
and myelin breakdown in axonal bundles of several white matter regions (i.e. 
body of the corpus callosum) were detected in AβPP/PS1 mice compared to WT 
[85]. In this recent study minor genotype effect on FA and no genotype effects 
on MD were found. One reason for these missing genotype effects could be that 
already in normal aging  significant white matter deterioration occurs due to 
myelin degeneration [86]. Therefore, myelin degeneration in our 18 months WT 
mice may mask partly the significant changes regarding structural connectivity 
in APP/PS1 mice. Nevertheless, in line with the loss of structural connectivity, 
a disturbed FC pattern in cortical and hippocampal brain regions was revealed 
in the 18-month-old AβPP/PS1 mice. In support, a mouse model for cerebral 
amyloidosis demonstrated a compromised FC affecting the sensory motor cortex 
already in pre-plaque stage [87]. Our latter results are in accordance with clinical 
studies, in which a decreased FC was also demonstrated in AD patients [29-31]. 
A limiting factor of the acquired FC results is that the rsfMRI measurements are 
acquired in isoflurane anesthetized mice. Fortunately, using rsfMRI a general 
structure of the functional networks transcending levels of consciousness was 
detected in both preclinical and clinical studies [88-90]. Notably, under isoflurane 
anaesthesia a bilateral cortical connectivity in several cortical regions was measured 
[91, 92]. Nevertheless, also contradictory results were detected in isoflurane 
anesthetized mice showing not the same level of bilateral connectivity [55, 93]. 
However, in our previous and recent studies using isoflurane as anaesthesia, we 
confirmed the presence of networks in several well defined cortical and subcortical 
brain regions in two different murine models for vascular risk factors for AD [94, 
95]. In our previous work we confirmed that both FC and CBF are dependent on 
isoflurane concentrations, and both FC and CBF decline with concentrations of 
isoflurane >2.2%, but do not further decline below a concentration of 2.2% 90. 
Therefore, using the low- dose isoflurane (~1.7%) in this recent experiment will 
preserve the resting-state networks and will not interfere with the outcome of 
this study, as all animals were kept under the same low isoflurane concentration.
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The combination of impaired cerebral hemodynamics, disturbed structural and 
functional connectivity, may underlie the impaired spatial learning capability 
found in the MWM. Here, the AβPP/PS1 mice needed more time to learn the 
position of the hidden platform. Moreover, these transgenic mice demonstrated 
a larger swim distance and higher swim velocity indicating an increased usage of 
non-spatial search strategies instead of hippocampus-dependent search strategies 
to find the hidden platform in the MWM [96, 97]. The behavior of the APP/PS1 
mouse has been well-characterized. Mirroring the cognitive impairment being 
present in early AD patients, this cognitive deficit is a well-known feature of this 
AD mouse model. While at 4 and 7 months of age no learning deficit could be 
determined in AβPP/PS1 mice [98, 99], these AD model mice tend to exhibit an 
impaired memory capacity at 8 months of age in our earlier studies [48] and a 
significantly impaired spatial memory at 12 months of age, as demonstrated in 
studies from Lalonde et al. [100]. In fear-conditioning tests Kilgore et al. showed 
at already six months of age an impaired contextual memory in the APP/PS1 
mouse model [101]. However, Webster et al. performed recently a comprehensive 
behavioral analysis of a knock-in AβPP/PS1 mouse model [102] using four different 
age groups (7, 11, 15, and 24 months) in which cognitive deficits in spatial 
reference memory (radial arm water maze) appeared from 11 months of age and 
becoming apparent as the disease progressed and recognition memory (novel 
object recognition) was demonstrated just from 15 months of age [102]. In line 
with previous results from our lab on younger (8-/12-/15-month-old) AβPP/PS1 
mice [40, 48], also our 18-month-old AβPP/PS1 mice exhibited an increased 
locomotor activity and anxiety-related behavior in the open field. Being linked to 
elevated anxiety levels, this heightened activity has been observed in many 
transgenic AD model mice [103-105]. This hyperactivity and anxiety-related 
behavior resembles restlessness and anxiety-related symptoms found in up to 
71% of AD patients [106, 107]. The increased anxiety of our mice could reveal a 
possible pathological mechanism for the elevation in SBP. This phenotype of 
anxiety is an expression of a stressful chronic condition. Therefore, it is well known 
that mental stress is able per se to provoke an increase in blood pressure in mice 
[108, 109]. The influence of the overexpression of AβPP and PS1 on cognition is 
well-characterized in several AD mouse models, while the non-cognitive behavior 
has not been considered as systematically [110]. Pugh et al. demonstrated 
reduced spontaneous motor activity, disinhibition, heightened frequency and 
duration of feeding bouts, decreased body weight and, by 10 months, increased 
activity over a 24h period in both female and male AβPP/PS1 mice [110]. In 
addition, male mice also expressed a heightened aggression relative to WT 
controls [110]. In the postmortem part of the study we revealed a decreased 
postsynaptic density and less DCX+ cells in the hippocampus of AβPP/PS1 mice 
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indicating respectively a lowered synaptogenesis and neurogenesis, which may 
be the cause of the profound cognitive impairment found in the MWM in this 
AD-like transgenic mouse model. Notably, in our earlier studies, AβPP/PS1 mice 
showed decreased neurogenesis combined with a lowered hippocampal CBF 
already at 12-month of age [40, 49]. Moreover, in these younger 12-month-old 
AβPP/PS1 mice Zerbi et al. also detected impaired structural connectivity in the 
corpus callosum, fimbria, and cortex measured also via DTI [49]. This decrease in 
hippocampal CBF was no longer observed in the 18-month-old AβPP/PS1 mice 
granting a possible pathological timeframe starting with an impaired hippocampal 
CBF provoking a decreased synapto- and neurogenesis resulting in an impaired 
cognition. In another study, Ermini et al. showed as well a decreased neurogenesis 
in younger (8 months of age) AβPP/PS1 and (5 months of age) AβPP23 mice [111]. 
In many transgenic mouse models of AD an increased neuroinflammation has 
been observed reporting modulation of cytokine levels, activation of microglia 
and in some cases an activation of the complement system [112]. In the early 
pre-plaque stages of transgenic AD mice and, to a much lesser extent, in old WT 
mice highly activated microglia have been found [113-117]. In addition, Aβ-plaques 
in AD are engulfed by activated microglia [117]. To measure neuroinflammation, 
we immunohistochemically stained the mouse brains with ionized calcium-binding 
adapter molecule 1 (IBA-1) being a marker for activated microglia [118-120]. 
Here, in our AD model mice more IBA+ cells were detected in cortical regions 
compared to their WT littermates. In accordance to the results of Minogue et al., 
in this mouse model after 14 months of age an age-associated dysregulation of 
microglial activation is coupled with an enhanced blood-brain barrier permeability 
[114]. Furthermore, Meadowcroft et al. demonstrated activated microglial cells 
surrounding Aβ plaques in the brain of AβPP/PS1 mice. In accordance to our 
previous study, 18-month-old AβPP/PS1 mice did not show any differences in 
hippocampal capillary density measured via immunohistochemical staining for 
GLUT-1 [121]. Notably, these mice exhibited the highest level of Aβ in combination 
with hippocampal atrophy [121]. While 8-month-old AβPP/PS1 mice demonstrated 
also an increased amount of Aβ deposition in the dentate gyrus, but did not show 
any differences in hippocampal atrophy [121]. Besides all other AD-like pathological 
changes in this AD mouse model, we also detected an increase in cerebral omega-6 
fatty (n6) acid content (especially arachidonic acid, ARA) combined with a decrease 
in cerebral omega-3 (n3) fatty acid content (in particular docosahexaenoic acid, 
DHA) resulting in a pronounced decreased n3/n6-ratio, which is thought to elevate 
the risk for AD [122, 123]. In accordance to our results, Dutch drug-naïve patients 
with mild AD (Mini-Mental State Examination (MMSE) = 25.0) showed a decreased 
relative content of n3 fatty acids (including DHA) and an increased relative content 
of ARA in erythrocyte membranes compared to a group of Dutch healthy controls 
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(MMSE = 29.0) [124]. In accordance, ARA is a mediator of inflammatory pathways, 
and its metabolites are involved in the production of Aβ and in the pathogenesis 
of AD [125]. In our previous research using the same transgenic mouse model, a 
multi-nutrient diet was able to induce a pronounced shift in n3/n6 ratio in favor 
of the n3 fatty acids as compared to the control diet [40]. Here, the reduction of 
the relative n6 content was mainly caused by a decrease in ARA, while the higher 
n3 content was mainly caused by an increase in DHA. Fabelo et al. revealed that 
AβPP/PS1 mice show a more rapid lipid raft aging compared to WT, which is 
related to an increased saturation of phospholipids (higher saturated fatty acids 
content and decreased content of the long chain unsaturated fatty acids ARA and 
DHA) and increased sphingomyelin levels rather than to alterations in cholesterol 
[126]. Moreover, Fabelo et al. demonstrated that both levels of ARA and DHA 
were gradually lowered with age in AβPP/PS1 mice, with its maximal reduction of 
approximately 50% at 14 months of age [126]. In our recent study the aged 
18-month-old AβPP/PS1 mice demonstrated a pronounced decreased n3/n6-ratio 
in the frontal cortices due to a decrease in DHA and increased ARA. This 
contradictory data on ARA levels may be explained by age and the brain area 
measured, as Fabelo et al. analyzed homogenized cortex of a total hemisphere. 
Notably, Perez et al. revealed that both male and female 6-month-old AβPP/PS1 
mice show neither a change in ARA nor a decrease in DHA brain fatty acid content 
[127] indicating the pathological role of aging in disturbing cerebral membrane 
composition. Notably, a novel finding is the increased level of dihydro-lanosterol 
in our AD-model mice, being an intermediate in the cholesterol synthesis. 
Nevertheless, no genotype effects on cholesterol levels in blood and brain tissue 
were found. Decreased brain cholesterol levels were measured in our previous 
research using 15-month-old AβPP/PS1 mice compared to their WT littermates 
[48]. In addition, mice fed a high cholesterol-containing typical western diet 
showed a significant decreased regional cerebral blood volume compared to mice 
fed a standard control chow diet [48]. Notably, Park et al. showed an increased Aβ 
synthesis and senile Aβ plaque deposition only in female AD model (Tg2576) mice 
when using lovastatin (a blood-brain barrier crossing inhibitor of the cholesterol 
biosynthesis pathway) [128]. Dysregulation of the cerebral cholesterol homeostasis 
has been increasingly associated with chronic neurodegenerative disorders, 
including AD, Huntington’s disease, and Parkinson’s disease [129]. Furthermore, 
the E4 isoform of apolipoprotein E, being a cholesterol-carrying protein, is linked 
to an increased risk of developing AD [129]. 
In conclusion, in this study we detected an increased SBP, impairments in cerebral 
hemodynamics resulting in an impaired cognition and structural and functional 
connectivity, increased locomotor activity, and anxiety-related behavior in an 
AD-like mouse model. In accordance, already in 4.5 months old AβPP/PS1 mice 
Cifuentes et al. indicated that hypertension is able to accelerate the development 
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of Alzheimer disease-related structural and functional alterations, partially 
through cerebral vasculature impairment and reduced nitric oxide production 
[130]. Future research should also consider gender differences in these AβPP/PS1 
mice. In detail, male mice develop Aβ plaques more rapidly than female mice, 
being saturated at nine months of age, while in female mice plaque accumulation 
does not reach its maximum in female mice until around 12 months of age [131]. 
Notably, using both male and female 4-, 12-, and 17-month-old AβPP/PS1 mice 
Wang et al. demonstrated that female AβPP/PS1 mice have a higher hippocampal 
Aβ40 and Aβ42 levels than male AβPP/PS1 mice at 4 months of age Aβ and female 
AβPP/PS1 mice had a heavier Aβ burden and higher plaque number compared to 
male mice of the same age, both at 12 and at 17 months of age [132]. Our results 
indicate that vascular impairment plays an important role in the very early stage of 
AD but whether it is a causative factor or just a contributor aggravating the disease 
progress, remains to be elucidated. Thus, future therapeutic approaches should 
focus on (cerebro)vascular impairment as a promising strategy for the prevention 
of AD. The present AD mouse model showing hypertension and cerebral circulation 
impairment could serve as translational tool for the development of treatments 
to inhibit neurodegenerative diseases like AD already in the prodromal phase of 
the disease.
Supplementary material
Results
Behavioural tests
Open field (OF)
We used the OF to measure the effect of the AD-like pathology on explorative 
and anxiety-related behavior. In the open field, locomotor activity (walk distance 
& walk velocity) and active exploration parameters (walking, sitting, wall leaning, 
rearing) and grooming were scored for 30 minutes. AβPP/PS1 mice seemed to 
be more active in the OF than their WT littermates. AβPP/PS1 mice walked more 
(Supplementary figure 1C, F(1,15)=4.0, p<0.063) and sat less (Supplementary 
figure 1C, F(1,15)=3.6, p<0.078) than their WT littermates. This resulted in a larger 
distance walked (Supplementary figure 1D, F(1,15)=3.5, p<0.080) and increased 
walk velocity (Supplementary figure 1F, F(1,15)=3.7, p<0.074) in our AD model mice 
than in their non-transgenic controls. AβPP/PS1 mice exhibited more explorative 
behaviour against the walls of the open field like wall leaning (Supplementary 
figure 1C, F(1,15)=5.5, p<0.033) than their WT littermates. Both AβPP/PS1 and WT 
mice spent more time in both corners (Supplementary figure 1E, F(1,30)=220.6, 
p<0.001) and periphery (Supplementary figure 1E, F(1,30)=285.0, p<0.001) than 
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in the center of the open field. Especially, the AβPP/PS1 mice (Supplementary 
figure 1E, F(1,12)=5.4, p<0.039) stayed longer in the corners than in the periphery 
indicating an increased anxiety in these transgenic mice.
Supplementary figure 1  Explorative and anxiety-related behavior, and locomotor activity 
(C-F) was measured in the open field (OF) in 17-month-old AβPP/PS1 and wild-type (WT) 
mice.  (A) In the OF AβPP/PS1 mice walked more (p<0.063) and sat less (p<0.078) than 
their WT littermates. AβPP/PS1 mice exhibited more wall leaning (p<0.033) than their 
WT littermates. (B+D) An increased walk distance (p<0.080) and walk velocity (p<0.074) 
was found in our AD model mice. (C) Both AβPP/PS1 and WT mice spent more time in 
both corners (p<0.001) and periphery (p<0.001) than in the center of the open field. 
Notably, only AβPP/PS1 mice (p<0.039) stayed longer in the corners than in the periphery 
indicating an increased anxiety in these transgenic mice.
Morris water maze (MWM)
We used the MWM to investigate the impact of the AD-like pathology on spatial 
learning abilities. During the acquisition phase AβPP/PS1 mice demonstrated 
a longer latency time to reach the hidden platform than their WT littermates 
(Supplementary figure 2A, F(1,15)=8.6, p<0.011). Moreover, these AD mice 
swam a larger distance than their WT littermates to find the hidden platform 
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during acquisition (Supplementary figure 2B, F(1,15)=5.5, p<0.033), while only at 
acquisition days 2 and 3 the AD model mice swam faster than their WT littermates 
(Supplementary figure 2C, Day 2: F(1,15)=3.6, p<0.078; Day 3: F(1,15)=7.1, 
p<0.018).
During the probe phase no significant genotype differences were found in the 
mean number of platform area crossings (Supplementary figure 2F, F(1,15)=1.1, 
p<0.310), the swim distance (Supplementary figure 2D, F(1,15)=0.2, p<0.677) and 
the swim velocity (Supplementary figure 2E, F(1,15)=0.2, p<0.684).
Supplementary figure 2 Morris water maze learning and memory in 18-month-old AβPP/
PS1 and wild-type (WT) mice. (A) Determining the latency to find a hidden platform in the 
North-East (NE) quadrant in a 4-day acquisition phase, spatial learning was measured. (A) 
During all four acquisition days, AβPP/PS1 mice reached the hidden platform slower than 
their WT littermates (p<0.011). (B) AβPP/PS1 mice showed a larger swim distance during 
all acquisition days compared to their WT littermates (p<0.033). (C) During the second 
(p<0.078) and third (p<0.018) acquisition day, all AβPP/PS1 mice swam faster than their 
WT littermates. (D+E+F) Spatial memory was tested in the probe phase measuring the 
frequency of crossing the former platform location. During the probe phase no significant 
genotype differences were found in the frequency crossing the platform area, the swim 
distance and swim velocity.
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Immunohistochemical procedures
PSD-95
Postsynaptic density (PSD) was stained with a polyclonal antibody against 
PSD-95 reflecting synaptic function. PSD was measured in the visual (V1) and 
somatosensory cortex (SSC), and in several hippocampal subregions: cornu 
ammonis (CA)2, stratum lucidum (SL) of CA3, stratum radiatum (SR) of CA1, outer 
molecular layer (OML) of the dentate gyrus (DG), and inner molecular layer (IML) 
of DG (Supplementary figure 3A+B). In the V1, SSC, CA2, SL of CA3, and IML of DG 
no genotype effects were found. In the SR of the CA1 (F(1,14)=5.1, p<0.041) and 
OML of the DG (F(1,14)=16.5, p<0.002), AβPP/PS1 mice had less PSD95+area than 
their WT littermates revealing a decreased PSD in these transgenic mice.
DCX
Immature neurons were visualized in all mice with a polyclonal antibody against 
doublecortin (DCX). As a measure for neurogenesis, DCX+ cells were counted in 
the subgranular zone of the dentate gyrus (Supplementary figure 3C+D). In the 
hippocampus of AβPP/PS1 mice less DCX+ neurons were counted than in the 
hippocampus of their WT littermates (F(1,15)=7.3, p<0.017) indicating a decreased 
neurogenesis in these AD model mice.
IBA-1
Brain sections of all mice were immunohistochemically stained against ionized 
calcium-binding adapter molecule 1 (IBA-1). IBA-1 is a marker for active and 
resting microglia, but also a marker for phagocytes in general (monocytes and 
macrophages). Here, we measured the relative area of the total section area being 
stained for IBA-1 (for results see the supplementary material) and the number 
of IBA-1+ cells in the cortex, hippocampus, and thalamus (Supplementary figure 
3E-G). Only for the number of IBA-1+ cells in the cortex a genotype effect was 
found. In detail, AβPP/PS1 mice had more IBA-1+-cells in the cortex (Supplementary 
figure 3F, F(1,15)=6.5, p<0.023) than their WT littermates revealing an increased 
inflammation in these transgenic mice. No results were detected for the relative 
area of the total section area being stained for IBA-1 (Supplementary figure 3G).
GLUT-1
All brains were processed for immunohistochemical staining with glucose 
transporter-1 (GLUT-1, Supplementary figure 3H-J) antibody as well. In order to 
reveal the changes in total amount of GLUT-1, we measured the relative area of 
the total section area being stained for GLUT-1 in the cortex, hippocampus, and 
thalamus (Supplementary figure 3J). Furthermore, we also measured vascular 
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density represented by the number of GLUT-1+ blood vessels (Supplementary 
figure 3I). For both amount of GLUT-1 and vascular density, no genotype effects 
were found.
Supplementary figure 3 Immunohistochemical stainings for Postsynaptic Density-95 
Protein (PSD-95, A+B), for doublecortin (DCX, C+D), for ionized calcium-binding adapter 
molecule 1 (IBA-1, E-G), and for glucose transporter-1 (GLUT-1, H-J) performed on brains 
of 18-Month-old AβPP/PS1 and wild-type (WT) mice. (A+B) PSD-95 was measured 
in the visual (V1, representative photo + magnified photo A, scale bar = 10µm) and 
somatosensory cortex (SSC), and in several hippocampal subregions: cornu ammonis 
(CA)2, stratum lucidum (SL) of CA3, stratum radiatum (SR) of CA1, outer molecular layer 
(OML) of the dentate gyrus (DG), and inner molecular layer (IML) of DG. In the SR of 
the CA1 (p<0.041) and OML of the DG (p<0.002), AβPP/PS1 mice had less PSD95+-area 
than their WT littermates revealing a decreased PSD in these transgenic mice. (C+D) In 
the hippocampus (DG, representative photo + magnified photo C, scale bar = 50µm), 
AβPP/PS1 mice had less DCX+ neurons than their WT littermates (p<0.017) indicating a 
decreased neurogenesis in these AD model mice. (E-G) IBA-1 is specifically expressed in 
activated microglia. Here, we measured the number of IBA-1+ cells (F) and the relative 
area of the total section area being stained for IBA-1 (G) in the cortex, hippocampus, 
and thalamus (representative photo + magnified photo E, scale bar = 200µm). AβPP/PS1 
mice had more IBA-1+-cells in the cortex (p<0.023) than their WT littermates revealing an 
increased inflammation in these transgenic mice. In contrast, for the relative area of the 
total section area being stained for IBA-1 no genotype effects were detected. (H-J) We 
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measured the vascular density via the number of GLUT-1+ blood vessels (I) and the total 
amount of GLUT-1 being stained for GLUT-1 (J) in the cortex, hippocampus, and thalamus 
(representative photo + magnified photo C, scale bar = 200µm). For both, amount of 
GLUT-1 and vascular density no genotype effects were found.
Table 1 Relative brain fatty acid content represented in average ± SEM for each 
experimental group. (Used abbreviations: PA=Palmitic acid; SA=Stearic acid; 
SFA=Saturated fatty acid; OA=Oleic acid; MUFA=Mono-unsaturated fatty acid; 
AA=Arachidonic acid; Ω-6=Omega-6; DHA=Docosahexaenoic acid; Ω-3=Omega-3; Ω 
3/6=Omega 3/6); # P = 0.05 - 0.08, * P ≤ 0.05, ** P ≤ 0.05
Table 2 Plasma sterol levels represented in average ± SEM for each experimental 
group. 
Table 3 Brain sterol levels represented in average ± SEM for each experimental group; 
* P ≤ 0.05
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Abstract
Hypertension, a risk factor for Alzheimer’s disease (AD), is a treatable condition, 
which offers possibilities for prevention of AD. Elevated angiotensin II (AngII) is 
an important cause of essential hypertension. AngII has deleterious effects on 
endothelial function and cerebral blood flow (CBF), which may contribute to 
AD. AngII blocking agents can thus provide potential candidates to reduce AD 
risk factors in hypertensive patients. We studied the effect of 2 months induced 
hypertension (AngII-infusion via osmotic micropumps) on systolic blood pressure 
(SBP) and CBF in 10 months-old wild-type (WT) C57bl/6j and AβPPswe/PS1dE9 (AβPP/
PS1) mice, and treatment with two different antihypertensives, 1) eprosartan 
mesylate (EM, 0.35mg/kg) or 2) hydrochlorotiazide (HCT, 7.5mg/kg), after 1 
month of induced-hypertension. SBP was monitored twice each month via tail 
cuff plethysmography. CBF was measured with MR by flow-sensitive alternating 
inversion recovery. Chronic AngII-infusion induced an increase in SBP in both 
AβPP/PS1 and WT mice accompanied by a decrease in hippocampal and thalamic 
CBF only in the AβPP/PS1 mice. An additional difference between the AβPP/
PS1 mice and WT mice was that SBP was much higher in AβPP/PS1 mice in both 
hypertensive and normotensive conditions. Moreover, both antihypertensives 
were less effective in reducing AngII-induced hypertension to normal levels 
in AβPP/PS1 mice, while being effective in WT mice. It can be concluded that 
AngII-induced elevated SBP results in impaired CBF and a decreased response 
to blood pressure lowering treatment in a transgenic model of AD. Our findings 
suggest a relation between midlife hypertension and decreased CBF in an AD 
mouse model, similar to the relation which has been found in AD patients. This 
translational mouse model could be used to investigate possible prevention and 
treatment strategies for AD.
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Introduction
Dementia has become a global public health problem as a result of the rapidly 
aging world population [189, 276]. Alzheimer’s disease (AD) is responsible for 
most dementia cases, followed by vascular dementia as second most cause (VaD) 
[2, 3].
In epidemiological and clinical studies it has been identified that AD and VaD 
share common risk factors like hypertension, diabetes mellitus, hyperlipidemia, 
cerebrovascular disease, and arrhythmia [91-96, 277]. Hypertension is the most 
common cardiovascular risk factor [49, 108-115], and its relation with all (other) 
key markers of AD such as presence of amyloid-β (Aβ) plaques, neurofibrillary 
tangles, and brain atrophy, has been demonstrated [114]. 
Further evidence supporting this link between hypertension and AD comes from 
preclinical and clinical studies in which it is argued that antihypertensives may 
reduce the development of AD [196, 197]. Angiotensin receptor blockers (ARBs) 
[278, 279] and the calcium antagonist nitrendipine [280] have been associated 
specifically with a reduced risk of AD. In the last decade many studies with 
contradictory results have been performed.
To illustrate this point: no significant effect of active treatment on the incidence 
of dementia [281, 282] was found compared to placebo as a result of two 
randomized, placebo-controlled studies. These two studies were conducted 
by ‘Study on Cognition and Prognosis in the Elderly’ (abbreviated to SCOPE; 
candesartan/ hydrochlorothiazide vs placebo) and ‘Systolic Hypertension in 
the Elderly Program’ (SHEP; chlorthalidone/ atenolol/ reserpine vs placebo). 
Contrarily to the example above, two other randomized, placebo-controlled 
studies named ‘Systolic Hypertension in Europe’ (Syst-Eur) and ‘Perindopril 
Protection Against Recurrent Stroke Study’ (PROGRESS), showed beneficial 
effects on the incidence of dementia and cognitive decline [280, 283, 284]. The 
Syst-Eur study revealed that active treatment with nitrendipine, enalapril, and/
or hydrochlorothiazide decreased the incidence of dementia [280, 283]. The 
PROGRESS study demonstrated a reduced cognitive decline, caused by treatment 
with angiotensin-converting enzyme inhibitors (ACEIs), resulting in a decrease in 
the incidence of stroke-related dementia. The use of diuretics did not have any 
impact [284].
It remains uncertain, however, which hypertension mechanisms increase the risk 
for AD and, on the other hand, which mechanisms of antihypertensive agents 
reduce the risk for AD. Elucidation of these mechanisms would provide much 
needed insight in the pathophysiology of AD and would boost the development 
of effective preventive strategies. 
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Long-standing hypertension promotes atherosclerosis, cerebrovascular 
remodeling, and increased cerebral vessel wall thickening. In a community-based 
study, increased wall thickness and associated increased pulse pressure were 
correlated with a higher risk of AD [117] and, moreover, in the Rotterdam study 
it was published that atherosclerotic plaques and vessel wall thickening were 
associated with dementia, including AD [109]. These findings suggest that 
cerebrovascular changes could be an important link between hypertension and 
AD. 
Angiotensin II (AngII), a component of the renin-angiotensin system (RAS), is a 
highly plausible candidate for this mechanistic link between hypertension and AD 
[285], due to its involvement in BP regulation [286]. AngII causes vasoconstriction 
and increases BP by means of binding to AT1 and AT2 receptors [225, 286, 287]. 
When present during mid-life, chronically elevated levels of AngII are an important 
cause of hypertension which induce cerebral vascular dysfunction by promoting 
vascular remodeling and inflammation [286, 288]. This causes malfunctioning 
of the neurovascular unit [289, 290] and promotes the expression of AβPP and 
Aβ production [290]. Decreased cerebral blood flow (CBF) is usually present in 
the early phase of AD, possibly caused by an accumulation of Aβ in the vessel 
walls or in close vicinity of the bloodvessels [204, 247, 248]. Preclinical data show 
that cerebrovascular dysfunction is partly caused by AngII, and not merely by an 
increased BP [217]. Recent clinical trials and studies in animal models suggest that 
manipulation of the renin-angiotensin-system (RAS) could reduce the pathologies 
of AD and VaD [169, 170, 172, 174].
We hypothesize that AngII affects the neurovascular function by impairing the 
cerebral blood flow (CBF) and also decreasing the response to antihypertensive 
treatment in a transgenic model of AD. To investigate this hypothesis, we 
designed a translational animal model to investigate the possible link between 
AngII and AD. We used wild-type littermate mice and an AD mouse model to 
investigate the hypothesis that AngII can initiate AD related cerebrovascular 
changes. To differentiate between the effect of AngII and elevated systolic 
blood pressure (SBP) per se, we also investigated the intervention by using two 
different blood pressure lowering agents: 1) diuretic hydrochlorothiazide (HCT) 
and 2) AngII receptor antagonist eprosartan mesylate (EM). With this study we 
aimed at increasing knowledge about antihypertensive actions on the cardio- and 
cerebrovascular system in AD, possibly supporting the development of effective, 
tailor-made blood pressure lowering treatments for AD patients.
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Materials and Methods
Animals
The AβPPswe/PS1dE9 (AβPP/PS1) founder mice were originally obtained from John 
Hopkins University, Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. of 
Pathology) [213, 291]. A colony was first established at the University of Kuopio, 
Finland, and, thereafter, a colony was bred at the Central Animal Facility of the 
Radboud University Medical Centre, The Netherlands. Mice were created by 
co-injection of chimeric mouse/human AβPPswe (mouse AβPP695 harboring a 
human Aβ domain and mutations K595N and M596L linked to Swedish familial 
AD pedigrees) and human PS1-dE9 (deletion of exon 9) vectors controlled by 
independent mouse prion protein promoter elements. The two transfected 
genes cointegrate and co-segregate as a single locus [213]. This line was originally 
maintained on a hybrid background by backcrossing to C3HeJ×C57BL/6J F1 mice 
(so-called pseudo F2 stage). Breeder mice were backcrossed to C57BL/6J for 14 
generations to obtain mice for the current study at the Central Animal Facility 
of the Radboud university medical center, Nijmegen, The Netherlands. Before 
experiments were carried out, animals were socially housed with a maximum of 
six animals per cage, at a room temperature of 21°C, with an artificial 12:12h 
light source: dark cycle (lights on at 7 a.m.). After the micro-osmotic pump 
implantation and throughout the experiments, the mice were housed separately 
(see below) to maintain a correct supplementation of drinking water or water 
mixed with medication (see below). Food and water were available ad libitum. 
Experiments were performed in compliance with Dutch federal regulations for 
animal protection and were approved by the Veterinary Authority of the Radboud 
University Medical Centre, Nijmegen, The Netherlands.
For the experiment, we used a total of 67 ten-months-old male mice (34 WT 
littermates, and 33 AβPP/PS1 mice). After completing the experiments for this 
study, all animals were euthanized, at twelve months of age.
Study overview
The AβPP/PS1 and WT mice were divided in two main groups: the first group 
received induced hypertension (AngII infusion delivered by subcutaneously 
implanted micro-osmotic pumps) and the second group consisted of controls and 
was given saline infusion. Table 1 provides an overview of the study and number of 
animals per group. After one month, both animal groups on AngII or saline infusion 
were further divided into 3 subgroups: treatment with EM (angiotensin receptor 
type 1 blocker, ARB), HCT (diuretic), and standard drinking water as control. SBP 
was measured in all mice at the age of eleven months. MRI measurements were 
performed at mice at the age of twelve months.
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Table 1 Summary of the study overview: both AβPP/PS1 and wild-type (WT) mice 
were divided into two main groups as soon as they reached the age of ten months: 
the first group was infused with angiotensin II (AngII), the second group with saline 
(Sal). This was applied by using implanted micro-osmotic pumps, containing a dose 
that was sufficient for 4 weeks. After one month (when mice were aged 11 months), 
a replacement micro-osmotic pump was implanted in all mice. Mice were then given 
eprosartan mesylate (EM), hydrochlorothiazide (HCT) simultaneously, or just plain 
water (CTR). Between the ages of 11 and 12 months, systolic blood pressure (SBP) was 
measured using computerized tail-cuff plethysmography. MRI measurements were 
performed on mice aged 12 months.
Implantation of Minipumps & Tail-cuff Plethysmography
Mice at 10 months of age received AngII (Sigma-Aldrich, Missouri, USA)or sterile 
saline (Sigma-Aldrich, Missouri, USA) for a period of 28 days via a newly implantated 
micro-osmotic pump (ALZET, CA, USA, model 1004). This period was followed 
by the implantation of a replacement micro-osmotic pump which delivered the 
same solution as the first pump for another 28 days. Micro-osmotic pumps were 
either filled with AngII or sterile saline. The micro-osmotic pumps were implanted 
subcutaneously under 2% of isoflurane anesthesia. Concentrations and delivery 
rates of AngII (500 ng·kg−1·min−1) were adjusted for each single mouse weight to 
produce comparable levels of SBP elevation. 
Mice were trained in the warmed tail-cuff plethysmography device (IITC Life 
Scientific Instruments, Woodland Hills, CA) for two consecutive days, in order to 
accustom them to the procedure. One week after the second micro-osmotic pump 
implantation, SBP was measured in trained, conscious and warmed mice. For this 
purpose, computerized tail-cuff plethysmography (IITC Life Scientific Instruments, 
Woodland Hills, CA), as previously described [216, 217, 292, 293], was used for 
two consecutive days.
Drug treatment
To avoid stress caused by repeated injections, drugs were administered orally via 
drinking water mimicking the human route of administration. Administration of 
these drugs was initiated immediately after the subcutaneous implantation of the 
second micro-osmotic pump.
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To investigate the effects of AngII receptor antagonists, mice received a supplement 
of ARB, EM (Sigma-Aldrich, Missouri, USA), dissolved in drinking water for four 
weeks (0.35 mg·kg−1·day−1). To investigate diuretic effects, mice received HCT 
(Sigma-Aldrich, Missouri, USA), dissolved in drinking water for four weeks (7.5 
mg·kg−1·day−1) (group-size: n = 4-8). EM was dissolved in a small amount of C2H6O, 
while HCT was dissolved in H2O.
Plain drinking water was used as a control for each condition. All drinking 
solutions were freshly prepared twice a week and kept at room temperature to 
block precipitation from solution.
MRI protocol 
MRI measurements were performed on a 11.7 T BioSpec Avance III small animal 
MR system (Bruker BioSpin, Ettlingen, Germany), equipped with an actively 
shielded gradient set of 600 mT/m and operating on Paravision 5.1 software 
platform (Bruker, Karlsruhe, Germany). We used a circular polarized volume 
resonator for signal transmission and an actively decoupled mouse brain 
quadrature surface coil with integrated combiner and preamplifier as receiver 
(Bruker BioSpin). As part of the imaging procedure, the mice were anaesthetized 
with isoflurane (3.5% for induction and 1.8% for maintenance) in a 2:1 oxygen and 
N2O mixture and placed in a stereotactic holder to prevent unwanted movement 
during scanning. Body temperature was monitored with a rectal temperature 
probe and maintained at 37˚C using heated airflow. Respiration of each animal 
was monitored using a pneumatic cushion respiratory monitoring system (Small 
Animal Instruments Inc, NY, USA). First gradient echo images were acquired using 
previously described image parameters [294]. MR perfusion data were acquired 
during resting conditions using established methods via flow-sensitive alternating 
inversion recovery (FAIR) technique [226, 295].
Regional perfusion was evaluated in the cerebral cortex (all cortical regions above 
the corpus callosum), hippocampus and thalamus, upon consultation of the 
mouse brain atlas of Franklin and Paxinos [296].
One representation of high-resolution voxel-wise analyzed CBF image is shown 
in Figure 2A. In order to calculate regional CBF, the same protocol was used as 
previously described [294]. 
Statistics
IBM SPSS Statistics 20 software was used (IBM Corporation, New York, NY, USA) 
for statistical analysis.
For the assessment of the effects of genotype, antihypertensive treatments, and 
interactions between genotype and treatment on SBP and cerebral perfusion, 
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SBP data for hypertensive and normotensive animals were analyzed separately. 
Univariate ANOVA was used for the SBP data and multivariate ANOVA for the CBF 
data (cortex, hippocampus and thalamus).
To unravel the impact of genotype, AngII-induced hypertension, and their 
interaction on SBP and CBF, SBP data were additionally analyzed separately 
for each single treatment (plain drinking water as control, EM and HCT) with 
univariate ANOVA for the SBP data and multivariate ANOVA for the CBF data 
(cortex, hippocampus and thalamus).
To demonstrate the meaning of AngII-induced hypertension, antihypertensive 
treatments and interrelations with SBP and CBF, SBP data were analyzed 
separately for transgenic and non-transgenic mice. Univariate ANOVA was used 
for the SBP data and multivariate ANOVA for the CBF data (cortex, hippocampus 
and thalamus).
Whenever statistical analysis revealed a significant effect in the antihypertensive 
treatments, we used the post-hoc Tukey`s HSD test to focus further on the 
separate groups. After overall analysis of SBP and CBF, data that showed significant 
interactions were divided into groups based on their specific interacting factors.
Statistical significance was set at p ≤ 0.05. All values used are expressed as mean 
± SEM. 
Results
Systolic blood pressure 
AngII and systolic blood pressure 
In both genotypes, infusion with AngII effectively increased SBP (AβPP/PS1: 
56.7±6.6 mmHg; WT: 48.9±7.4 mmHg), in comparison to mice that did not receive 
these antihypertensive drugs but merely plain drinking water (Figure 1: WT, 
F(1,9)=43.5, p=0.001; AβPP/PS1, F(1,7)=74.9, p=0.001).
Antihypertensive treatment and systolic blood pressure
In wild type animals, EM and HCT treatment lowered SBP under both normotensive 
(saline) (Figure 1: F(2,11)=12.4, p=0.002) and hypertensive (AngII) conditions 
(Figure 1: F(2,14)=19.3, p=0.001). Post hoc tests revealed that both EM (Figure 
1: Sal, p=0.001; AngII, p=0.0001) and HCT (Figure 1: Sal, p=0.017; AngII, p=0.001) 
decreased SBP in saline-infused and AngII-infused WT mice. In AngII-induced 
hypertension, SBP was reduced by EM and HCT to near-normal values in WT mice 
as well (Figure 1: EM, F(1,7)=4.8, p=0.064; HCT, F(1,9)=4.6, p=0.061). In contrast, 
EM and HCT lowered SBP only in hypertensive AβPP/PS1 mice only but not in 
normotensive AβPP/PS1 mice (Figure 1: F(2,11)=24.5, p=0.001). The post hoc 
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test showed here that EM (Figure 2C: AngII, p=0.000) and HCT (Figure 2C: AngII, 
p=0.000) lowered SBP in hypertensive AβPP/PS1 mice only. It is remarkable that 
EM and HTC decreased the AngII-induced hypertension less efficiently in AβPP/
PS1 mice, EM and HCT, whereas it decreased Angll-induced hypertension to 
normotensive values in their WT littermates that were only offered plain drinking 
water (Figure 1: EM, F(1,8)=7.8, p=0.023; HCT, F(1,7)=8.0, p=0.025). In addition, 
AβPP/PS1 mice on EM demonstrated an increased SBP (12.5±4.6 mmHg) in 
comparison to their WT littermates (F(1,15)=7.4, p=0.016). 
Overall, the hypertensive effect of AngII (significant increase in SBP; different in 
EM of 16.1±4.6 mmHg, a difference of HCT 20.6±6.0 mmHg) persisted in AβPP/
PS1 and WT mice despite treatment with antihypertensives: EM (F(1,15)=12.8, 
p=0.003) and HCT (F(1,16)=12.0, p=0.003).
Genotype and blood pressure
In the normotensive group (saline condition), AβPP/PS1 mice had a higher SBP 
(a difference of 7.3±2.9 mmHg) than their WT littermates (Figure 1: F(1,22)=6.5, 
p=0.018). This overall genotype effect was also observed in the hypertension 
group (AngII-infusion). SBP in AβPP/PS1 mice (a difference of 11.6±5.2 mmHg) 
was higher than the SBP of their WT littermates (Figure 1: F(1,25)=5.1, p=0.034).
In summary, sal-infused and AngII-infused AβPP/PS1 mice had a higher SBP than 
their WT littermates. Remarkably, AngII increased SBP in both transgenic and 
non-transgenic animals whereas both antihypertensive treatments (EM and HCT) 
lowered SBP in all experimental groups. However, these antihypertensives could 
not merely reduce AngII-induced increased SBP in AβPP/PS1 mice within the 
normal range. In addition, EM decreased SBP in a less efficient manner in AβPP/
PS1 mice than in their WT littermates. 
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Figure 1 Effect of angiotensin II(AngII)-infusion on systolic blood pressure (SBP) 
measurements of AβPP/PS1 and wild-type (WT) mice treated with two antihypertensives, 
eprosartan mesylate (EM) and hydrochlorothiazide (HCT), versus water as control. 
Without antihypertensive drugs, SBP was higher in AngII-infused AβPP/PS1 (j vs g) and WT 
(d vs a) mice than in saline (sal)-infused animals. In all AngII-infused animals, EM and HCT 
significantly lowered the SBP (WT: e/f vs d; AβPP/PS1:k/l vs j) while only WT mice under 
sal-infusion (b/c vs a) also demonstrated a decreased SBP after both antihypertensive 
treatments. In AβPP/PS1 mice, EM and HCT (EM: k vs h; HCT: l vs i) were not able to restore 
SBP to normal values, whereas in the WT littermates only a non-significant difference (EM: 
e vs b; HCT: f vs c) was detectable.
Cerebral blood flow
Neither AngII-induced hypertension nor antihypertensive treatment with EM and 
HCT had an effect on CBF in the cortex of both genotypes (Figure 2B).
In contrast, AngII-induced hypertensive AβPP/PS1 mice had a lower hippocampal 
CBF than their AngII-induced hypertensive WT littermates (Figure 2C: F(1,24)=4.4, 
p=0.046), while in normotensive animals this genotype effect was not visible.
Hypertensive AβPP/PS1 mice also showed a trend towards decreased CBF in 
the thalamus in comparison to their hypertensive WT littermates (Figure 2D: 
F(1,24)=4.0, p=0.057). 
In all ROI, no effects of antihypertensive treatment on CBF were found in WT and 
neither in AβPP/PS1 mice (Figures 2B-D).
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Figure 2 Cerebral blood flow (CBF) measurements of AβPP/PS1 and wild-type (WT) mice. 
CBF was measured by means of the flow-sensitive alternating inversion recovery (FAIR) 
MRI technique; from a series of echo planar imaging (EPI)-images. One representation of 
high-resolution voxel-wise analyzed CBF image is shown (A). The figure shows the cerebral 
perfusion data of AβPP/PS1 and WT mice infused with either saline (sal) or angiotensin 
II (AngII) and treated with either eprosartan mesylate (EM) or hydrochlorothiazide 
(HCT) compared to water as control. The CBF was measured in three different regions of 
interest (ROI): Cortex (B), hippocampus (C) and thalamus (D). No effect of AngII infusion 
or treatment with EM and HCT could be observed in the cortex (B). In contrast to controls 
(sal), under AngII infusion AβPP/PS1 mice had a lower hippocampal CBF than their WT 
littermates (C). Treatment with EM or HCT, however, did not influence hippocampal CBF 
either (C). On AngII, thalamic CBF was lowered in transgenic mice compared to their 
WT littermates, no decrease was present with sal infusion (D). This effect was only a 
statistical trend, however. In addition, no treatment effect on cerebral perfusion could be 
demonstrated in the thalamus in WT and AβPP/PS1 mice (D).
Discussion
This study assessed the relation between hypertension, antihypertensive treatment 
and cerebral blood flow (CBF) in a mouse model for Alzheimer’s disease (AD) and 
their wild-type littermates (WT), which were used as controls. We confirmed in 
part our hypothesis that AngII in interaction with Aβ negatively affects CBF by 
demonstrating a reduction in CBF and a decreased adaptive response to blood 
pressure lowering treatments in the hippocampus of the transgenic mouse model 
of AD compared to WT mice.
Several studies [95, 297] have demonstrated that midlife elevated BP compared 
to late-life elevated BP is associated with cognitive impairment and AD [298]. In 
this study, we showed that middle-aged 10 to 12 months old male AβPP/PS1 mice 
had a higher SBP compared to their WT littermates, both under control conditions 
(saline) and under AngII-infusion. This finding in our studies shows the same link 
between midlife hypertension and AD in mice as can be found in humans. Paris 
et al. showed that soluble Aβ peptides can enhance vasoconstriction induced by 
endothelin-1 (ET-1), which is an endogenous vasoconstrictor [299]. In contrast, 
Danielyan et al. reported that there was no genotype effect in 7-months old 
female AβPP/PS1 mice and WT mice [300]. In support of our hypothesis that AD 
pathology could contribute to higher blood pressure in our AD mouse model, 
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however, is the observation in spontaneously hypotensive Sprague-Dawley rats 
(mean arterial BP < 100 mmHg). In these rats, the intra-arterial infusion of Aβ 
increased the mean arterial BP as opposed to those rats who were given a vehicle 
distilled water infusion [121]. This finding suggests that Aβ may be able to increase 
SBP, possibly through direct systemic vascular effects, without parenchymal Aβ 
deposition and before dementia onset [121]. In addition, besides the parenchymal 
Aβ accumulation, this AβPP/PS1 mouse model has an early impairment in 
cerebrovascular autoregulation and CBF, but also in abnormalities in the cortical 
microvasculature [242-245]. A recent study showed that hypertension affects the 
expression of tau as well as that of Aβ in an AD mouse model (57). One limitation 
of our study is that all the features found in typical AD cannot be retrieved in 
AβPP/PS1 mice. These mice are characterized by early amyloid deposition in the 
brain parenchyma but not by neurofibrillary tangles and hyperphosphorylated 
tau. With this study we could therefore only look at the interaction between AngII 
and one feature found in AD. Hawkes et al. showed that particular regions of the 
brain demonstrate different vascular effects of perivascular Aβ [301], which could 
explain our findings that only the hippocampal and thalamic regions, and not the 
cortical regions, demonstrated a lowered CBF in hypertensive AD mice.
Furthermore, we assessed whether antihypertensive treatment is able to reduce 
the effects of AngII-induced hypertension in both WT and AβPP/PS1 mice. As 
shown before, AngII increased SBP in non-transgenic mice, and we have now also 
reported this effect in an AD mouse model. Both antihypertensives, i.e. EM and 
HCT, lowered the SBP. However, EM was less effective in lowering BP in AβPP/
PS1 mice than in their WT littermates. It can be suggested that this is a possible 
consequence of the vasotoxic effects of Aβ deposition, which is present in the 
cerebral vessel walls [302-304]. AD is associated with Aβ depositions in the wall of 
cerebral vessels or in close vicinity of the vasculature in the brain and was found 
in AβPP/PS1 mice as well [302, 304-306]. A study supporting this hypothesis 
was performed by Wang et al. showing that Valsartan treatment reduced AD 
neuropathology and attenuated the development of Aβ-mediated cognitive 
deterioration in Tg2576 mice, expressing double mutated human AβPP[307]. In 
accordance with the study of Wang et al., Danielyan and co-workers reported 
that intranasally administered ARB losartan, at a dosage below the systemic 
antihypertensive dose, decreased Aβ plaque burden in AβPP/PS1 mice [300]. In 
both studies, ARBs were used at sub-threshold dosages, being not effective for 
hypertension treatment in humans; and the mice were treated at least for two 
months with the ARB. In our study, a clinical dosage of EM was supplemented to 
the mice for one month only. It is possible that EM can also directly target Aβ by 
inhibiting its accumulation. Wang et al. have shown that another ARB, Valsartan, was 
capable of attenuating oligomerization of Aβ peptides into high-molecular-weight 
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oligomeric peptides [307]. Due to increased Aβ plaque production in AβPP/PS1 
mice, which was already known beforehand, EM molecules may be bound to Aβ 
peptides. As a consequence, less free EM molecules will be available to block 
AngII activity mediated by its receptor, and, therefore, less EM is able to bind 
to the AngII receptor blocking its antihypertensive effect. This mechanism may 
explain the genotype effect of EM in our study in which EM decreased SBP in 
AβPP/PS1 mice in a less effective manner than in their WT littermates. In this 
respect, Savaskan et al. have also shown that the staining intensity of the AngII 
type 1 receptor was increased in the parietal cortex of AD patients but not in their 
aged controls, suggesting an enhanced brain RAS system activity in the disease 
process [308]. Furthermore, our results correspond with the human SCOPE and 
PRoFESS studies in which AngII receptor blockers, candesartan and telmisartan, 
were less effective [309, 310]. As already mentioned above, HCT is also less 
efficient in decreasing SBP in AβPP/PS1 mice than in WT littermates. 
In this study we also found that Angll-infused AβPP/PS1 mice had a lower CBF in 
the hippocampus and thalamus than their Angll-infused control WT littermates. 
This may indicate that the combination of AngII-induced hypertension and 
presence of highly expressed Aβ in the AD mouse brain [291] has the potential 
to influence cerebral hemodynamics. No effect of AngII on CBF was found in the 
middle-aged healthy WT mice. Aβ may inhibit the neurogenic vascular control due 
to its toxicity to basal forebrain cholinergic neurons [311-313] and this blocking 
effect might be exacerbated by AngII. In addition, Meyer and colleagues already 
observed cerebrovascular changes in young transgenic mice overexpressing AβPP 
before the appearance of Aβ plaques [245]. In line with our results, other human 
studies suggested that resting CBF is decreased among hypertensive patients as 
opposed to that in normotensive subjects [198-202]. These results show that 
vascular diseases like hypertension may affect the development of AD already at 
middle-age. 
The second aim of this study was to investigate whether CBF is affected by specific 
AngII-increasing blood pressure mechanisms or other pathways. Therefore, we 
used the ARB, EM, to block AngII-receptor-interaction and also a diuretic, HCT, to 
lower SBP without influencing the actions of AngII. In our study neither of the two 
antihypertensives, EM and HCT, were able to restore the decrease in hippocampal 
and thalamic CBF in transgenic animals. In addition, no other treatment effects 
on CBF were found in this study. This indicates that AngII plays a crucial role in 
cerebral hemodynamics. Kume et al. showed that Telmisartan, another ARB like 
EM, was able to increase regional CBF in hypertensive patients, as opposed to 
those treated with amlodipine [314]. Recently, Toth et al. found an impaired 
cerebrovascular autoregulation in 24-month-old hypertensive mice [254]. We 
revealed that, after comparing the effect in both AD mice and WT littermates, the 
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cerebral perfusion is only impaired in hypertensive AD mice. Furthermore, the 
chronic infusion of AngII increased SBP but lowered CBF in these 12-month-old AD 
mice. An increased Aβ burden could possibly already disturb BP and CBF systems in 
younger mice, while Toth et al. showed that hypertension in aging mice could also 
impair cerebrovascular autoregulation [254]. Furthermore, Iadecola et al. have 
shown that Aβ acts directly on cerebral arteries to enhance vasoconstriction and 
to stimulate selected constrictor responses, resulting in a reduced CBF [247]. In our 
study, infusion of the vasoconstrictor AngII in Aβ overexpressing transgenic mice 
also decreased thalamic and hippocampal CBF, showing an exacerbating effect of 
AngII-induced hypertension on cerebral hemodynamics in Aβ expressing AD mice 
brains. In contrast, in AngII-infused WT mice no effect on CBF could be observed. 
Other studies demonstrated that hypertension also triggers neuroinflammation 
prior to Aβ deposition and that chronic hypertension could lead to an impaired 
blood-brain barrier permeability with deposition of Aβ in brain tissue [315, 316]. 
In conclusion, hypertension triggers different pathways to impair cerebrovascular 
function, also possibly resulting in cognitive impairment [317]. We showed that 
chronic infusion of AngII increased BP in both transgenic and WT mice, but only 
decreased the subsequent cerebral perfusion only in the hippocampus of the 
AD-like transgenic mouse model. This result supports the Honolulu Asia Aging 
Study which showed that untreated midlife blood pressure increases the risk 
for developing hippocampal atrophy indicating the hippocampal vulnerability to 
hypertension [318]. In addition, antihypertensive treatments acted differently in 
our AD-like transgenic mouse model resulting in a less effective blood-lowering 
response compared to that in WT animals. More specifically, the antihypertensives, 
EM and HCT, were not able to restore BP in AD mice in the same way as in their 
WT littermates. A scheme summarizing the potential effect of hypertension on 
neurovascular coupling and CBF in non-Alzheimer and Alzheimer mice is given 
in figure 3. Future studies should therefore include CBF response to stimulation, 
which could demonstrate the possible dysfunctional CBF regulation (neurovascular 
coupling) in hypertensive AβPP/PS1 transgenic mice. Gathering more insight in 
the actions of antihypertensives on brain processes and the vascular system could 
support the development of more efficient treatments for AD. Future studies are 
thus needed to elucidate the specific link between impaired cerebral perfusion 
and hypertension, in relation to functional and structural connectivity and 
cognitive impairment in AD.
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Figure 3   Schematic representation of the potential effect of hypertension on neurovascular 
coupling and cerebral blood flow (CBF) in non-Alzheimer versus Alzheimer mice. In 
non-Alzheimer mice, hypertension did not affect CBF. This is possibly due to a neurovascular 
coupling that is still intact. Furthermore, both Alzheimer and non-Alzheimer mice in this 
study were on antihypertensives: an angiotensin receptor type 1 blocker and a diuretic; 
both antihypertensives were less effective in Alzheimer mice. Inducing hypertension in our 
amyloid β (Aβ) overexpressing Alzheimer-like mice showed a higher increase in systolic 
blood pressure than that in non-Alzheimer mice. This induced hypertension may further 
stimulate aggregation of Aβ, which will affect the neurovasculature directly and increase 
hypertension even further, resulting in cerebrovascular impairment and a decreased 
hippocampal CBF. 
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Abstract
Elevated angiotensin II (AngII) causes hypertension and contributes to Alzheimer’s 
disease (AD) by affecting cerebral blood flow (CBF). AngII receptor blockers (ARB) 
may provide candidates to reduce (vascular) risk factors for AD.
We studied effects of 2 months AngII-induced hypertension on systolic blood 
pressure (SBP), and treatment with the ARB, eprosartan mesylate (EM), after 1 
month of induced-hypertension in wild-type (WT) C57bl/6j and AβPPswe/PS1dE9 
(AβPP/PS1 / AD) mice. AβPP/PS1 showed higher SBP than WT. Subsequent 
EM-treatment restored this elevated SBP in all mice. Functional connectivity 
(FC) was decreased in AngII-infused AD and WT mice, and only 12 months AD 
mice showed impaired CBF. Only AngII-infused AD mice exhibited decreased 
spatial learning in the Morris water maze. Altogether, AngII-induced hypertension 
exacerbated AD-like pathological changes such as impairment of CBF, FC, and 
cognition only in AD-model mice, but it also induced decreased FC in WT mice. 
However, we could not detect hypertension-induced overexpression of Aβ 
nor increased neuroinflammation. Our findings suggest a link between midlife 
hypertension, decreased cerebral hemodynamics and connectivity in an AD mouse 
model. EM treatment restored and beneficially affected CBF and connectivity. This 
model could be used to investigate prevention/ treatment strategies in early AD.
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Introduction
Dementia has become a public health problem in the aging world population 
[189, 190]. Alzheimer’s disease (AD) and vascular dementia (VaD) are the number 
one and two disorders, together responsible for most cases of dementia [2, 3]. 
Epidemiological and clinical studies revealed that AD and VaD share common 
vascular related risk factors such as hypertension, diabetes, hyperlipidemia, 
cerebrovascular disease, and arrhythmia [91-96, 192, 193]. Of these, hypertension 
is the most common cardiovascular risk factor for dementia. In coming years, 
the expected increase in the prevalence of hypertension due to the aging world 
population could also raise the number of AD patients, since midlife and late-life 
hypertension almost double the risk of developing AD in later life [239, 240]. 
Whether this association between hypertension and AD is causal – and if so, through 
which mechanism - remains unknown. Angiotensin II (AngII), a component of the 
renin-angiotensin system (RAS), is a candidate for the hypothesised mechanistic link 
between hypertension and AD [285]. AngII has a prominent role in blood pressure 
(BP) regulation [286], causing vasoconstriction and elevated BP by binding to the 
AngII-receptor type1 (AGTR1) and type2 (AGTR2) [286, 287] and is considered to 
be a key mediator of the clinical syndrome of essential hypertension [319], through 
chronically induced vasoconstriction, increased aldosterone secretion, increased 
sympathetic tone, and cardiac and vascular hypertrophy [320, 321]. How could 
AngII be linked mechanistically to AD? When initiated during mid-life, chronically 
elevated levels of AngII, in addition to causing hypertension, may induce cerebral 
vascular dysfunction by promoting vascular remodelling and inflammation [286, 
288], causing malfunctioning of the neurovascular unit [289, 290] and promoting 
expression of amyloid-β precursor protein (AβPP) and amyloid-β (Aβ) production 
[290]. Preclinical data show that cerebrovascular dysfunction is partly caused by 
AngII directly, and not via elevated BP alone [217]. A decreased cerebral blood 
flow (CBF) is an important and consistent early feature of AD, possibly as result 
of the accumulation of Aβ in or close to blood vessels [204, 247, 248]. Another 
hallmark of AD is a reduced glucose metabolism particularly in the temporal 
and parietal cortex [322, 323]. Being selectively highly expressed in the capillary 
endothelium of the brain, glucose transporter type 1 (GLUT-1) is responsible for 
transfer of glucose across the blood brain barrier [324]. A decreased hippocampal 
and cortical amount of GLUT-1 have been revealed in the brains of AD patients 
[325-327]. Another important component of AD pathology is neuroinflammation, 
manifested by activation of microglia [328-330]. Ionised calcium-binding adapter 
molecule 1 (IBA-1) is a marker for active and resting microglia [236-238]. GLUT-1 
and IBA-1 are used in this study as markers for changes in metabolism, vascular 
density, and neuroinflammation. Further support for this mechanistic link 
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between AngII and AD comes from recent clinical trials and studies in animal 
models showing that AD pathology can be reduced via RAS [169, 170, 172, 174]. 
Angiotensin receptor blockers (ARBs) specifically inhibit the activation of AGTR1 
and thus the actions of AngII [170]. Preclinical and clinical studies indicate that 
antihypertensives may reduce the development of AD [196, 197]. Specifically, 
ARBs have been associated with a reduced risk of AD [278, 279]. Findings from 
the Observational Study on Cognitive function And SBP Reduction (OSCAR) 
suggest that Eprosartan (ARB) is associated with preservation or improvement 
of cognitive performance [331]. A case control analysis showed that patients on 
ARBs and ACE-Is had a respectively 53% and 24% reduced risk of AD, compared to 
patients on other anti-hypertensives [278]. 
If indeed AngII is a causal factor linking hypertension to AD, we hypothesise 3 
potential mechanisms: 1) AngII initiates Aβ accumulation through increased 
production and/or reduced clearance, leading to AD pathology; 2) Aβ 
accumulation is initiated by other factors, but AngII contributes to AD by 
enhancing cerebrovascular toxicity and inflammatory potency of Aβ, and/or 
by contributing to enhanced Aβ production or reduced Aβ clearance; 3) AngII 
leads to neurovascular dysfunction causing cognitive decline independent of 
AD pathology, but adding to the cognitive effects of AD or even mimicking AD 
in absence of underlying AD pathology. To investigate these hypotheses, we 
developed a translational animal model to study the following mechanisms: 
1) Can AngII induce AD related pathology in wild-type (WT) mice; 2) Can AngII 
exacerbate AD pathology in the AβPP/PS1 mouse model for AD; 3) Can AngII 
induce cerebrovascular, metabolic/inflammatory and/or functional connectivity 
changes that mimic AD in WT animals or that add to the effects of AD pathology 
in AβPP/PS1 mice. In addition, to uncover the effects of AngII on AD, we aim to 
investigate whether treatment with the AngII receptor antagonist eprosartan 
mesylate (EM) is able to prevent or reduce AngII induced changes. The overall 
aim of this study is to elucidate the mechanisms through which hypertension and 
antihypertensive treatment influence AD. Translational characteristics of this study 
are the exposure to AngII at 10 months to simulate midlife hypertension, inclusion 
of WT animals in addition to transgenic animals to better translate to sporadic 
AD, and the use of MRI techniques with protocols similar to those used in clinical 
studies. We use flow-sensitive alternating inversion recovery arterial spin labeling 
(FAIR-ASL) to measure changes in CBF and DTI to reveal pathological adaptations 
in microstructural integrity of the white and grey matter. Several studies have 
revealed decreases in CBF in AD compared to healthy controls such as prefrontal 
cortex [332], temporo-occipital and parieto-occipital association cortices [333], 
and hippocampus [334]. Mean diffusivity (MD) is a measure of DTI which increases 
in presence of tissue damage [335]. Previous studies demonstrated an increased 
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MD in frontal [336, 337] and temporal lobes [336-341], but also in intercerebral 
tracts, including the superior superior longitudinal fasciculus [342] and the corpus 
callosum [337].
Materials and Methods
Animals
The AβPPswe/PS1dE9 (AβPP/PS1) founder mice were originally obtained from John 
Hopkins University, Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. 
of Pathology) [291, 343] and a colony is bred at the Central Animal Facility at 
Radboud university medical center, The Netherlands. This line was originally 
maintained on a hybrid background by backcrossing to C3HeJ×C57BL/6J F1 
mice and for the present work, the breeder mice were backcrossed to C57BL/6J 
for fifteen generations to obtain mice for the current study. Before the actual 
experiments, animals were housed socially with a maximum of six animals per 
cage, with room temperature at 21°C, and artificial 12:12h light:dark cycle (lights 
on at 7 a.m.). Throughout the experiments, the mice were housed separately 
after the micro-osmotic pump implantation to control intake of drinking water or 
water mixed with medication. Food and water were available ad libitum. 
We used fifty-one ten months old male mice (twenty-nine WT littermates, and 
twenty-two AβPP/PS1 mice); at twelve months of age, all animals completed the 
experiments and were euthanised. All experiments were performed between 8 
a.m. and 6 p.m..
Study design, randomization, and blinding
This was a randomised and controlled assessor-double-blind study. The experiments 
were performed according to the Dutch federal regulations for animal protection 
and approved (WP130084 + RU-DEC 2013-001) by the Veterinary Authority of 
Radboud university medical center, Nijmegen, The Netherlands, and the Animal 
Experiment Committee of the Radboud university, Nijmegen, The Netherlands. 
The reporting of the animal experiments are according to ARRIVE guidelines [214]. 
Per experimental subgroup, the selection of animals was randomised. There was 
no increased mortality (n=0) in this study. For the sample size calculation and 
ranked experimental outcomes per research question, see the supplementary 
materials. The AβPP/PS1 and WT mice were split in two main groups: 1) induced 
hypertension (using AngII infusion delivered by subcutaneously implanted 
micro-osmotic pumps) and 2) controls (saline infusion, further called Sal-infused 
animals/ mice). Supplemental table 1 provides an overview of the study design 
and number of animals per group. No animals were excluded from analysis. 
After one month, both animal groups on AngII or saline infusion were further 
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divided into 2 subgroups: treatment with EM (ARB) and standard drinking water 
as control. At age ten and eleven months, SBP was measured. Morris water maze 
(MWM) was exerted at eleven months. MRI measurements were performed at 
the age of twelve months. Post mortem immunohistochemical and biochemical 
procedures were performed.
Micropumps implantation & tail-cuff plethysmography
The implantation of the micro-osmotic pumps (ALZET, CA, USA, model 1004) to 
deliver either AngII (500 ng·kg−1·min−1, Sigma-Aldrich, Missouri, USA) or sterile 
saline (Sigma-Aldrich, Missouri, USA) and the tail-cuff plethysmography (IITC 
Life Scientific Instruments, Woodland Hills, CA) were performed, as previously 
described [344]. 
Drug treatment
To investigate the effects of an AngII receptor antagonist, mice were supplemented 
with EM (Sigma-Aldrich, Missouri, USA) dissolved in drinking water for four weeks 
(0.35 mg·kg−1·day−1), like previously described [344]. 
Morris water maze
Spatial learning and memory were tested in the MWM (for more detailed 
information, see [345]). 
MRI protocol 
MRI measurements were performed, as previously described [346]. For the 
imaging procedure, the animals were anesthetised with isoflurane (3.5% for fast 
induction and 1.7% for maintenance) in a 2:1 oxygen and N2O mixture (normal 
gas condition) or in a 3:0 oxygen and N2O mixture (vasoconstriction) with an air 
flow of 300 mL/min, and placed in a stereotactic holder to prevent movement 
during the scanning. Body temperature was monitored with a rectal temperature 
probe and maintained at 37˚C with heated airflow. Respiration of the animal 
was monitored using a pneumatic cushion respiratory monitoring system (Small 
Animal Instruments Inc, NY, USA). First gradient echo T2*-weighted images 
covering the entire mouse brain were acquired in three directions for anatomical 
reference using previously described image parameters [294].
Cerebral blood flow
MR perfusion data were measured with flow-sensitive alternating inversion 
recovery (FAIR) MRI techniques; from a series of echo planar imaging (EPI)-images 
in three different regions of interest (ROI) were evaluated [225, 226] in the cerebral 
cortex (all cortical regions above corpus callosum), hippocampus, thalamus 
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according to the Franklin - Paxinos atlas [227]. Regional CBF was calculated as 
described earlier [294]. 
Diffusion tensor imaging
Diffusion of water was imaged as described previously [229, 347]. Mean water 
diffusivity (MD) and fractional anisotropy (FA) were derived from the tensor 
estimation following a protocol as described elsewhere [229]. MD and FA values 
were measured in several white matter (WM) and grey matter (GM) areas, 
manually selected based on an anatomical atlas [227].
Resting state fMRI
Subsequently after the acquisition of the anatomical reference images, resting 
state fMRI (rsfMRI) datasets were acquired using a single-shot spin-echo sequence 
combined with echo-planar imaging (SE-EPI) sequence in anesthetised mice, as 
published previously [346]. FC group comparison between ROIs (left and right 
dorsal hippocampus, left and right ventral hippocampus, left and right auditory 
cortex, left and right motor cortex, left and right somatosensory cortex, and left 
and right visual cortex) were calculated from the BOLD time series using total 
correlation analyses implemented in FSLNets (FSLNets v0.3; www.fmrib.ox.ac.uk/
fsl), using previously published protocol [346]. Pearson’s correlation values were 
Fisher transformed to Z-scores for group comparisons and statistical analysis.
Immunohistochemical procedures
After scanning, the mice were sacrificed by transcardial perfusion using 0.1M 
phosphate-buffered saline (PBS). Details on tissue preparation and sectioning are 
described earlier [346].
A triple fluorescent staining for glucose transporter-1 (GLUT-1), ionised 
calcium-binding adapter molecule 1 (IBA-1), and amyloid-β (Aβ) was performed on 
free-floating brain sections on shaker tables at room temperature. Brain sections 
were first rinsed with 0.1 M PBS and pre-incubated in 0.5 ml 0.1M PBS-BT for 
30 minutes. After pre-incubation, primary antibodies (Aβ: Mouse anti-human-Aβ 
(1:10000; WO-2 antibody, mouse anti-human Aβ4-10, T Hartmann, Heidelberg, 
Germany), IBA-1: Goat anti-IBA-1 (1:750; Abcam, Cambridge, UK), GLUT-1: Rabbit 
anti-GLUT-1 (1:5000; Millipore, Billerica, MA, USA) were added for 16 hours. All 
sections were rinsed and the secondary antibodies (Aβ: Alexa647-conjugated 
donkey anti-mouse IgG, IBA-1: Cy3-conjugated donkey anti-goat IgG, GLUT-1: 
Alexa 488-conjugated donkey anti-Rabbit IgG; Jackson Immunoresearch Inc, 
Allentown, PA, USA) was added for 3 hours in the dark. After rinsing, mounting, 
and drying sections were enclosed with Fluorsave (Calbuichem, Canada).
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Quantification
Brain sections between bregma -1.46 and -2.30 [227] were preselected for 
quantification. Quantification was done at a 5x magnification using a Axio Imager 
(A2, Zeiss Germany). ImageJ (National Institute of Health, Bethesda, MD, USA) 
was used to analyse the regions of interest (cortex, hippocampus and thalamus). 
Statistics
For statistical analyses IBM SPSS Statistics 20 software was used (IBM Corporation, 
New York, NY, USA). 
We first analysed data gathered under untreated conditions (no EM). To unravel 
the impact of AngII-induced hypertension on all parameters and the possible 
genotype by AngII-induced hypertension interactions, data were analysed 
separately with univariate/ multivariate ANOVA with Bonferroni correction.
To assess effects of treatment (EM), data were analysed separately for AngII-infused 
and Sal-infused animals with univariate/ multivariate ANOVA with Bonferroni 
correction for multiple comparisons. After overall analysis, data were split into 
the specific interacting factors, when significantly different.
The repeated measures ANOVA with Bonferroni correction was only used for the 
acquisition phase of the MWM (with the repeated measure: acquisition days/ 
time). All values of the MWM acquisition are expressed as mean ± SEM for. All 
other results are shown in box plots with whiskers. The hinges of the boxes 
extend from the 25th to 75th percentiles of the data. The whiskers are drawn 
down to the 5th percentile and up to the 95th. For all statistical analyses there 
are significant comparisons between groups and treatments over all experimental 
outcome measures, and Type I error was consistently controlled and limited to p 
≤ 0.05 overall.
Results
Body weight was not influenced by genotype, AngII-infusion nor treatment with 
EM before (10-month), and during the experiment (11- and 12-month) (Figure 
1A).
At 11 months of age AngII-infused mice, both AβPP/PS1 and WT mice drank daily 
more water than Sal-infused mice (Figure 1B, F(1,22)=7.5, p=0.012). 
Systolic blood pressure 
Aging by genotype interactions on the relationship between AngII and SBP
Repeated measures ANOVA revealed a genotype by AngII interaction on SBP 
(p=0.032) over time (Figure 1C). 
AngII effectively increased SBP (11 months: 44.6±4.8 mmHg; 12 months: 45.5±4.9 
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mmHg) in all mice compared to littermates without AngII at 11 and 12 months of 
age (11 months, F(1,22)=85.0, p<0.001; 12 months, F(1,22)=85.6, p<0.001). 
At 12 months of age all AβPP/PS1 mice had a higher SBP than corresponding WT 
(11.4±4.9 mmHg; F(1,22)=5.4, p=0.030).
AngII, antihypertensive treatment with EM, and SBP
At 12 months of age, EM treatment lowered SBP (Figure 1D; -42.5±6.5 mmHg; 
F(1,22)=42.8, p<0.001) only in AngII-infused animals, and not in Sal-infused 
animals).
Figure 1 Effect of aging, angiotensin II (AngII)-infusion and treatment with eprosartan 
mesylate (EM) on body weight (A), drinking behaviour (B), systolic blood pressure (C+D, 
SBP) of AβPP/PS1 and wild-type (WT) mice treated with eprosartan mesylate (EM) 
versus water as control. (A) No significant genotype, AngII or EM effects were observed 
on body weight. (B) AngII-infusion increased water intake both in untreated AβPP/PS1 and 
WT (p=0.012) compared to their corresponding control Sal-infused (saline) littermates. 
This effect was not influenced by genotype or treatment with EM in AngII-infused 
and Sal-infused animals. (C) SBP was measured for two consecutive days in trained, 
conscious and preheated mice using computerised tail-cuff plethysmography. During both 
experimental months, infusion with AngII effectively increased SBP (11-Months: 44.6±4.8 
mmHg; 12-Months: 45.5±4.9 mmHg) in all mice compared to littermates without AngII 
(11-Months, p<0.001; 12-Months, p<0.001). At 12-months of age untreated (no EM) 
Sal-infused and AngII-infused AβPP/PS1 mice had a higher SBP than their corresponding 
WT mice (11.4±4.9 mmHg; p=0.030). (D) Only in AngII-infused animals, not in Sal-infused 
animals, treatment with EM lowered SBP (-42.5±6.5 mmHg; p<0.001).
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Cerebral blood flow
One representative high-resolution voxel-wise analysed CBF image is shown 
(Figure 2A). At 12 months of age, CBF was measured in the cortex (Figure 2B), 
hippocampus (Figure 2C) and thalamus (Figure 2D).
Furthermore, CBF was acquired in two standardised gas concentrations: normal 
(200 O2 : 100 N2O mL/min) and vasoconstriction (300 O2 : 0 N2O mL/min). For each 
ROI (cortex, hippocampus, thalamus) and each gas concentration (normal (200 
O2 : 100 N2O mL/min) and vasoconstriction (300 O2 : 0 N2O mL/min)) data were 
analysed on the one hand to detect genotype effects on the relationship between 
AngII and CBF, and on the other hand to investigate the relationship between 
AngII, antihypertensive treatment with EM, and CBF.
Cortex
Normal gas condition
AβPP/PS1 mice had a lower cortical CBF than WT littermates (-36.7±13.2 mL/100 
g/min; F(1,19)=7.7, p=0.012).
Gas condition inducing vasoconstriction
AβPP/PS1 mice had a decreased cortical CBF compared to corresponding WT 
littermates (-38.5±13.1 mL/100 g/min; F(1,19)=8.6, p=0.009).
Hippocampus
Normal gas condition
Treatment with EM increased hippocampal CBF both in AngII- (44.5±10.9 
mL/100 g/min; F(1,21)=16.5, p=0.001) and Sal-infused (25.5±9.0 mL/100 g/min; 
F(1,16)=8.0, p=0.012) animals compared with untreated (no EM) animals. 
Gas condition inducing vasoconstriction
No significant differences were found.
Thalamus
Normal gas condition
No significant differences were found.
Gas condition inducing vasoconstriction
No significant differences were found.
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Figure 2 Cerebral blood flow (CBF) measurements of the brains of 12-month-old 
saline-infused (Sal) and Angiotensin II-infused (AngII) AβPP/PS1 and wild-type (WT) 
mice, treated with eprosartan mesylate (EM) vs normal drinking water as control. CBF 
was measured with flow-sensitive alternating inversion recovery MRI technique; from 
a series of echo planar imaging images. One representative high-resolution voxel-wise 
analysed CBF image for each single animal group is shown (A). The figure shows the 
cerebral perfusion data of AβPP/PS1 and WT mice infused with either saline (sal) or 
angiotensin II (AngII) and treated with either eprosartan mesylate (EM) compared to water 
as control. The CBF was measured in three different regions of interest (ROI): Cortex (B), 
hippocampus (C) and thalamus (D). (B) Under normal gas concentration (normoxia=2:1 O2 
and N2O mixture) all untreated (no EM) AβPP/PS1 mice exhibited a decreased cortical CBF 
compared to their corresponding WT littermates (p=0.012). Again, under gas concentration 
inducing vasoconstriction (3: 02 and N2O mixture), all untreated (no EM) AβPP/PS1 mice 
demonstrated a decreased cortical CBF compared to their corresponding WT littermates 
(p=0.009). (C) No significant results were found in the hippocampal CBF. (D) No significant 
results were found in the thalamic CBF.
Diffusion tensor imaging
In this study brain diffusivity determined with DTI is a measure for white and grey 
matter integrity. One DTI measure is fractional anisotropy (FA) being a marker for 
myelination and fiber density of white matter (WM) and MD represents an inverse 
measure of membrane density, and sensitive measure for cellularity, edema, and 
necrosis in grey matter [348-350]. 
Quantitative assessment of diffusion tensor derived indices was performed for 
ROIs drawn in white and gray matter regions (Figure 3A) to assess effects of 
AngII-induced hypertension and genotype in 12-Month old AβPP/PS1 and WT 
mice (Figure 3B and C). Moreover, in AngII-infused and Sal-infused mice the 
impact of antihypertensive treatment with EM on microstructural integrity in 
white and grey matter regions was measured.
Fractional anisotropy
Treatment with EM led to higher hippocampal FA in all AngII-infused animals 
(transgenic and WT) (F(1,18)=5.0, p=0.039), also in the optic tract (F(1,17)=12.9, 
p=0.002) compared to animals without EM. 
Mean diffusivity
EM treatment decreased MD in the motor cortex of all Sal-infused mice (F(1,13)=8.0, 
p=0.014) compared to Sal-infused mice without EM. Only in AngII-infused animals 
a genotype by EM interaction was detected for MD in motor cortex (p=0.036) and 
optic tract (p=0.008). 
In detail, not EM treated AngII-infused AβPP/PS1 mice showed lower MD in the 
optic tract compared to WT (F(1,8)=7.4, p=0.026). 
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However, on EM treatment the MD in the motor cortex of AngII-infused AβPP/PS1 
mice was decreased compared to the non-treated mouse (F(1,9)=6.4, p=0.033). 
In AngII-infused EM treated WT a decreased MD in the optic tract was found 
compared to the non-treated mouse (F(1,8)=6.4, p=0.035).
Figure 3 Diffusion tensor imaging (DTI) measurements of the brains of 12-month-old 
saline-infused (Sal) and Angiotensin II-infused (AngII) AβPP/PS1 (Alzheimer’s disease, 
AD) and wild-type (WT) mice, treated with eprosartan mesylate (EM) vs normal 
drinking water as control. Quantitative assessment of diffusion tensor derived indices 
was performed for regions of interest (ROI; AUC= Auditory cortex, CC=Corpus callosum, 
F=Fornix, HC=Hippocampus, MC=Motor cortex, OT=Optic tract, SSC=Somatosensory 
cortex, VC=Visual cortex). (A) ROIs were drawn in white and gray matter to assess effects 
of AngII-infusion (induced hypertension) and antihypertensive treatment with EM in 
12-Month old AβPP/PS1 and WT mice on fractional anisotropy (B) and mean diffusivity 
(C). (B) Under AngII-infusion, hippocampal FA (p=0.039) and FA in the optic tract (p=0.002) 
were higher if animals were treated with EM compared with AngII without EM. (C) In all 
Sal-infused mice EM treatment decreased MD in the motor cortex (p=0.014). AngII-infused 
AβPP/PS1 mice (no EM) had a lower MD in the optic tract than their WT littermates 
(p=0.026). However, on EM treatment MD in the motor cortex of AngII-infused AβPP/
PS1 mice was decreased compared to their non-treated littermates (p=0.033). Under 
AngII-infusion, WT mice on EM had a decreased MD in the optic tract compared to their 
untreated littermates (no EM) (p=0.035).
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Resting state fMRI 
Resting state fMRI is based on the principle that during the resting state in 
functionally related brain regions spontaneous low-frequency fluctuations (SLFF) 
(<0.08 Hz) of the blood oxygen level dependent (BOLD) signals occur synchronously 
implying a possible neuronal functional connectivity (FC). Li et al. showed that 
AD patients have a different FC including alterations in the visual, sensory-motor, 
and visual networks [351]. Therefore, we also included these ROI (visual, motor, 
and somatosensory cortex) in our analysis. To compare FC patterns in 12 months 
old mice (Figure 4) rsfMRI data were analysed for genotype and AngII effects in 
untreated animals. In addition, in AngII-infused and Sal-infused mice the effect of 
antihypertensive treatment with EM on FC was investigated.
Figure 4 Resting-state functional connectivity (FC) based on total correlation analyses of 
12 ROI in the brain of 12-month-old Sal-infused (saline) and AngII-infused (Angiotensin 
II) AβPP/PS1 and wild-type (WT) mice, treated with eprosartan mesylate (EM) vs normal 
drinking water as control. In summary, for the overall correlations no significant genotype 
effects were detected in the dorsal and ventral hippocampus (hipp), and auditory, motor, 
somatosensory (SS) and visual cortex (ctx) of untreated animals (no EM). Notably, in all 
mice, AβPP/PS1 and WT mice, AngII-induced hypertension led to a decrease in FC between 
several brain regions, i.e. left dorsal hippocampus to right ventral hippocampus, left ventral 
hippocampus to left visual cortex, and right auditory ctx to right motor ctx. Investigating 
the effect of antihypertensive treatment with EM on FC in AngII-infused and Sal-infused 
animals revealed only negative effects of EM in normotensive animals and only positive 
effects on the FC in AngII-infused animals. A detailed description of the effects found in the 
total correlation analyses of the resting-state FC data is given in supplementary table 2.
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Total correlation analyses 
AβPP/PS1 showed no differences in FC compared to their WT littermates.
Notably, in both AβPP/PS1 and WT mice, AngII-induced hypertension led to a 
decreased FC between several brain regions, see supplementary table 2.
Investigating the effect of antihypertensive treatment with EM on FC in 
AngII-infused and Sal-infused animals revealed only negative effects of EM in 
Sal-infused animals and only positive effects on the FC in AngII-infused animals. 
More specifically, Sal-infused mice treated with EM had a lower FC between several 
brain regions than Sal-infused mice not treated with EM, see supplementary table 
2. In contrast, AngII-infused mice on EM showed a higher FC than non EM treated 
AngII-infused mice between many brain regions, see supplementary table 2.
Morris water maze
All mice were trained in the water maze task to assess spatial learning capacity 
at 11 months of age (Figure 5). During task acquisition, the latency to reach the 
platform was assessed (Figure 5A+B+C). Spatial memory was measured with 
the probe trial one hour after the last regular trial on the last day of the MWM 
experiment using the frequency of crossing the NE quadrant containing the 
platform position (Figure 5D). 
Acquisition
A genotype by AngII interaction was found for the latency to reach the platform 
in the acquisition phase (Figure 5A, p=0.009). Sal-infused AβPP/PS1 (F(3,9)=4.2, 
p=0.041) and WT mice (F(3,24)=5.4, p=0.006), and also AngII-infused WT mice 
(F(3,18)=5.9, p=0.005) were able to learn to find the platform from acquisition day 
1 to day 4, whereas AngII-infused AβPP/PS1 mice (F(3,15)=2.5, p=0.100) did not 
learn to find the platform from acquisition day 1 to day 4. Combining EM-treated 
with untreated mice revealed no effect or a genotype by antihypertensive 
treatment interaction (Figure 5B+C).
Probe
We detected no effects of genotype, AngII-infusion nor antihypertensive 
treatment with EM (Figure 5D). 
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Figure 5 Analysed data of the Morris water maze (MWM) performed by 11-month-old 
Sal-infused (saline) and AngII-infused (Angiotensin II) AβPP/PS1 (Alzheimer’s disease, 
AD) and wild-type (WT) mice, treated with eprosartan mesylate (EM) vs normal drinking 
water as control. While during task acquisition, all mice were trained in the MWM to assess 
spatial learning capabilities during 11-Month of age (A+B+C), during the probe phase the 
ability to remember the former platform location in the pool area was measured using 
the frequency of crossing NE quadrant of the pool area containing the platform location 
was measured as probe trial performance (D). (A) Task acquisition performance revealed 
that in untreated mice (no EM) almost all animal groups, Sal-infused WT mice (p=0.006), 
Sal-infused AβPP/PS1 mice (p=0.041), and AngII-infused WT mice (p=0.005), were able 
to learn to find the platform from acquisition day 1 to day 4, except of the AngII-infused 
AβPP/PS1 mice. This latter experimental group could not learn to find the platform from 
acquisition day 1 to day 4 (p=0.100). (B+C) Combining EM-treated with untreated mice 
revealed no effect nor a genotype by antihypertensive treatment interaction. (D) During 
the probe trial of the MWM the ability to cross NE quadrant of the pool area containing 
the platform location was measured as probe trial performance indicating spatial memory 
capacity. No effect on spatial memory was found.
Immunohistochemical procedures
To analyse effects of genotype and AngII in untreated animals, AngII-infused and 
Sal-infused mice and also the effect of an antihypertensive treatment with EM on 
metabolism, vascular density, neuroinflammation and amount of Aβ, all brains 
were stained for glucose transporter-1 (GLUT-1), against ionised calcium-binding 
adapter molecule 1 (IBA-1), and WO-2 antibody (mouse anti-human Aβ4–10) 
(Figure 6A).
GLUT-1 staining
All brains were processed for immunohistochemical staining with GLUT-1 
antibody. In order to reveal the changes in total amount of GLUT-1, we measured 
the relative area of the total section area being stained for GLUT-1 in the cortex, 
hippocampus, and thalamus (Figure 6B). While in the cortical and hippocampal 
regions no effect were detected, all AngII-infused animals displayed increased 
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GLUT-1 in the thalamus compared to their Sal-infused littermates (F(1,22)=3.4, 
p=0.039). Only in thalamic regions of all Sal-infused mice, EM-treatment increased 
amount of GLUT-1 (F(1,20)=5.3, p=0.032). We also measured vascular density via 
the number of GLUT-1+ bloodvessels, but no significant effects were found (data 
not shown).
IBA-1 staining
The brains of all mice were immunohistochemically stained for IBA-1. IBA-1 is 
specifically expressed in activated microglia. The typical example of the combined 
picture of figure 6A demonstrates clearly the colocalisation of IBA-1 with Aβ. We 
measured relative area of the total section area being stained for IBA-1 in the 
cortex, hippocampus, and thalamus as measure for amount of activated microglia 
(Figure 6C). No significant results were found for the amount of activated microglia.
Figure 6 Distribution of glucose transporter-1 (GLUT-1), ionised calcium-binding adapter 
molecule 1 (IBA-1), and amyloid-β (Aβ) in the cortex, hippocampus, and thalamus 
of 12-month-old Sal-infused (saline) and AngII-infused (Angiotensin II) AβPP/PS1 
(Alzheimer’s disease, AD) and wild-type (WT) mice, treated with eprosartan mesylate 
(EM) vs normal drinking water as control. A representative example of vessel density 
(GLUT-1), neuroinflammation (IBA-1), Aβ staining, and an overlay of all three staining in an 
AβPP/PS1 mouse is shown in (A). (B) The brains of all mice underwent immunohistochemical 
staining with GLUT-1 antibody representing amount of GLUT-1. While in the cortical and 
hippocampal regions no effect were detected, all AngII-infused animals displayed an 
increased amount of GLUT-1 in the thalamus compared to their Sal-infused littermates 
(p=0.039). Only in thalamic regions of all Sal-infused mice, EM-treatment increased 
amount of GLUT-1 (p=0.032). (C) The brains of all mice were immunohistochemically 
stained with an antibody against IBA-1 being specifically expressed in activated microglia. 
Notably, Aβ and microglia are colocalised as demonstrated in the combined picture. No 
significant differences were found for IBA-1. (D) The brains of all AβPP/PS1 mice were 
immunohistochemically stained with WO-2/Aβ antibody (mouse anti-human Aβ4–10). No 
significant AngII- or antihypertensive treatment effects were found.
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β-Amyloid staining
The brains of all AβPP/PS1 mice were immunohistochemically stained with WO-2 
antibody. As previously shown, brains of WT mice showed no immunoreactivity 
with this antibody [352], while Aβ deposits in transgenic mice were intensively 
stained. We measured the relative area of the total section area covered with Aβ 
depositions in the cortex, hippocampus, and thalamus (Figure 6D). No significant 
results were found for the area covered with Aβ depositions in the cortex, 
hippocampus, and thalamus.
A summary of all experimental results is given in table 1.
Table 1. Summary of all significant results. 
Used abbreviations: AngII (Angiotensin II), AD (Alzheimer’s disease), SBP (systolic blood 
pressure), EM (eprosartan mesylate), CBF (cerebral blood flow, DTI (diffusion tensor 
imaging), FA (fractional anisotropy), MD (mean diffusivity), Sal (saline), rsfMRI (resting 
state functional MRI), Total (total correlations), partial (partial correlations), MWM 
(Morris water maze), NE (North-East), GLUT-1 (glucose transporter-1), IBA-1 (ionised 
calcium-binding adapter molecule 1), Aβ (amyloid-β).
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Discussion
This study assessed the potential relationships between angiotensin-II induced 
hypertension and AD related cerebrovascular, metabolic, connectivity and 
cognitive changes in a mouse model for AD and wild-type controls. 
A summary of all significant results can be found in table 1.
We found that AngII-induced hypertension did not induce a total AD pathology 
in WT mice. One explanation for these results could be the use of relatively 
young mice. In accordance, Toth et al. showed that aging impairs autoregulatory 
protection in the brain, and this aggravates potentially cerebromicrovascular 
injury and neuroinflammation [353]. 
However, AngII led to a reduced functional connectivity (FC) in these WT 
mice, see supplementary table 2. In clinical studies a decreased FC was found 
in AD patients [206-208]. In support, a preclinical study using a mouse model 
for cerebral amyloidosis showed a compromised FC resulting in functional 
impairments affecting the sensory motor cortex already in pre-plaque stage [258]. 
In the current study we showed that in a hypertension model a reduction in FC 
could be introduced via AngII-induced hypertension, in absence of classical AD 
pathology (amyloidosis). A limitation of the acquired FC results is that the rsfMRI 
measurements are performed in isoflurane anesthetised mice. Fortunately, 
in both preclinical and clinical studies using rsfMRI a general structure of the 
functional networks transcending levels of consciousness was detected [354-356]. 
Liang et al. and Zhou et al. have confirmed the presence of a bilateral cortical 
connectivity in several cortical regions also under isoflurane anaesthesia [357, 
358]. Nevertheless, in isoflurane anesthetised mice Jonckers et al. and Guilfoyle 
et al. did not find the same level of bilateral connectivity [231, 359]. However, in 
our previous and recent studies using isoflurane as anaesthesia, we confirmed the 
presence of networks in several well defined cortical and subcortical brain regions 
in two different murine models for vascular risk factors for AD [346, 360]. In our 
previous work we confirmed that both FC and CBF are dependent on isoflurane 
concentrations, and both FC and CBF decline with concentrations of isoflurane 
>2.2%, but do not further decline below a concentration of 2.2% 90. Therefore, 
using the low- dose isoflurane (~1.7%) in this recent experiment will preserve the 
resting-state networks and will not interfere with the outcome of this study, as all 
animals were kept under the same low isoflurane concentration.
Second, we used an AD mouse model to study the influence of AngII-induced 
hypertension on AD pathology. As expected, in all mice (AD and WT), AngII 
increased SBP. This result is in line with other studies showing that AngII causes 
vasoconstriction and increased BP by binding to AT1 and AT2 receptors [225, 
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286, 287]. However, at 12 months of age, our AD mice had a higher SBP than 
their WT littermates, confirming recent findings [344]. Our results revealed a 
relationship between aging, AngII-induced hypertension and Alzheimer-like 
(Aβ-overexpression) pathology leading to an increased SBP. A possible explanation 
for this finding is that Aβ enhances the vasoconstrictive effect of AngII, or causes 
vasoconstriction independent of AngII. Niwa et al. have shown that Aβ acts 
directly on cerebral arteries to enhance vasoconstriction and to stimulate selected 
constrictor responses, resulting in a reduced CBF [247]. In accordance, we showed 
that our AD mice showed also an impaired CBF, similar to our earlier study in 
the same AD mouse model [294]. Studies in MCI and AD patients also identified 
a significant reduction in regional and global CBF [246]. Whether this reduction 
is due to reduced metabolic demand or due to vascular pathology is difficult to 
disentangle in human studies. Contrarily to our expectations we could not detect 
hypertension-induced overexpression of Aβ in the cortex, hippocampus nor 
thalamus in the brains of the AD-like mice, while these mice do show impaired 
cortical CBF. Sun et al. induced hypoxia, a direct consequence of hypoperfusion, 
in another Aβ overexpressing mouse model at eight months of age and revealed 
both an increased Aβ deposition and neuritic plaque formation [361], whereas in 
our study hypertension was induced by AngII-infusion for only two months starting 
from 10 months of age. A limitation of this study is the usage of a relatively high 
dosage (500 ng·kg−1·min−1) of AngII being infused via osmotic minipumps for 
two months starting from ten months of age. Using this hypertension model we 
wanted to simulate hypertension during mid-life via chronically elevated levels 
of AngII for only two months. Therefore, we needed a slightly higher dosage of 
AngII increasing SBP already after a short period of time to induce AngII-induced 
hypertension and the consequent pathological changes resembling the human 
situation. For example, the Honolulu Asia Aging Study revealed that untreated 
hypertension during midlife can increase the risk for late age dementia in men 
[95]. Dosages of 200 ng·kg−1·min−1 and 400 ng·kg−1·min−1 using the same slow 
pressor model have proven not to elevate SBP within the first six days after the 
implantation of the osmotic minipumps, while a dosage of 1.000 ng·kg−1·min−1 
heightened SBP already at three days after the implantation [362]. However, Qi 
et al. also infused 6 weeks old mice via osmotic minipumps with even a higher 
dosage of AngII (1.500 ng·kg−1·min−1) for 7 days increasing SBP already at 4 days 
post operation [363]. Nevertheless, Edgley et al. have proven that intravenous 
infusions of AngII into the systemic circulation requires much lower dosages of 
AngII [364].
In summary, our AD mice exhibited an increased SBP and a decreased cortical CBF. 
In addition, AD mice on AngII showed a decreased FC like their WT littermates, 
but only in these AngII-infused AD mice did this lead to a lowered spatial learning 
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capacity. RsfMRI has developed into a method for the analysis of spontaneous 
neural activity through the blood-oxygen-level-dependent (BOLD) signal change 
[365] representing FC. Our findings indicating an impaired FC in AngII-infused 
mice are in line with a recent study that found reduced connectivity in cortex 
regions of older hypertensive AD patients relative to older non-hypertensive 
AD patients [366]. We found no cognitive effects of AngII induced hypertension 
in WT animals. Haley et al. demonstrated even in healthy young adults that a 
family history of hypertension was associated with subtle changes in visuospatial 
attention combined with a lowered task-related activation in several brain regions 
during this visuospatial working memory task [367]. This result is in accordance 
with a study revealing an impaired memory and learning in hypertensive rats [368]. 
Hypertensive patients had deficits in the white matter and functional connectivity 
in frontal and parietal lobes, associated with cognitive decline [369]. However only 
our AngII-infused AD model mice exhibited a decreased spatial learning capacity 
during the MWM, which could be due to the functional connective impairments 
combined with the loss of cortical CBF being only present in this experimental 
group.
We could not observe genotype or AngII effects on structural connectivity. In 
this study AngII-infusion was administrated only for two months starting from 
10 months of age. This short duration of AngII-infusion could be one reason 
we found no changes in structural connectivity measured via DTI. Another 
explanation could be the increased amount of GLUT-1 measured in the thalamus 
of AngII-infused mice as a compensatory mechanism. GLUT-1 is responsible 
for the transfer of glucose across the blood brain barrier and being selectively 
expressed at high levels in the capillary endothelium of the brain [324]. GLUT-1 
is a marker for vascular endothelial cells and cerebral metabolism. In several 
animal studies, myocardial ischemia increased the synthesis of GLUT-1 mRNA and 
protein levels in both ischemic and also nonischemic cardiac regions indicating 
also a potential rescue mechanism for myocardial ischemia [370, 371]. Notably, 
McCall et al. reported an overexpression of GLUT-1 in microvessels after the onset 
of global cerebral ischemia in the rat brain [372]. Moreover, Gerhart et al. and 
Urabe et al. also showed also an overexpression of GLUT-1 in the cerebral cortex 
in two ischemia and reperfusion animal models [373, 374]. However, no effects of 
genotype or AngII-infusion were found on vascular density. 
In summary, regarding our second aim of this study, AD model mice had an increased 
SBP and an impaired CBF. Furthermore, AngII-induced hypertension exacerbated 
several AD-like pathological changes such as impaired CBF, impaired functional 
connectivity, and cognitive impairment. These results are in accordance with the 
recent study of Cifuentes et al. demonstrating that hypertension advances the 
development of AD-like structural and functional alterations, partially through 
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cerebral vasculature impairment and reduced nitric oxide production [375]. This 
result of Cifuentes et al. is in line with our results of the immunohistochemical 
data of IBA-1, a marker for activated microglia [236-238]. Here, no differences 
in amount of IBA-1+ cells nor immunohistochemically stained surface in the 
AngII-infused and AD model mice could be observed.
Another aim of this study was to investigate the effect of an ARB such as EM on 
possible (neuro)pathological changes induced by hypertension and to indicate a 
relationship between the AD-like pathology, AngII, and its receptors.
In all AngII-infused experimental mice, treatment with the angiotensin-receptor 
blocker EM restored SBP, in line with previous work [376]. Treatment of 
hypertension with EM enhanced hippocampal CBF. This beneficial effect was 
shown in all mice, and was not restricted to transgenic animals only, indicating 
that either blood pressure lowering or blocking effects of endogenous AngII may 
be beneficial for brain perfusion. In accordance, Tryambake et al. demonstrated 
that blood pressure lowering treatments increased CBF in older subjects with 
hypertension as well [377].
A beneficial effect of EM was detected in all AngII-infused mice regarding the 
structural connectivity. Here, FA in the hippocampus and optic tract was increased 
in EM-treated AngII-infused mice indicating an improved microstructural integrity, 
while after EM-treatment MD of the motor cortex of Sal-infused mice and of 
AngII-infused AD mice, and MD of the optic tract of AngII-infused WT mice was 
lowered. In accordance, Gons et al. showed that increased blood pressure is 
associated with a decrease in FA respectively an increase in MD [378]. De Leeuw 
et al. also demonstrated that long-standing hypertension increases the risk of 
developing white matter lesions [379]. Notably, a novel finding is the negative 
effect of EM on FC in all Sal-infused mice, but not in AngII-infused mice, see 
supplementary table 2 for a detailed description of the significant results. While 
all Sal-infused EM-treated mice showed a decreased FC compared with untreated 
mice, all AngII-infused EM-treated mice showed an increased FC compared with 
untreated mice. In addition, Füchtemeier et al. showed that Compound 21, an 
AngII receptor type 2 agonist, had opposing effects on spatial reference memory in 
hypoperfused and sham mice [380]. These effects need to be further investigated 
in future studies, but suggest that blockade of the angiotensin II receptors in 
absence of elevated AngII levels may have harmful effects on structural connectivity 
and cognition. Moreover, Henriksen et al. also showed in insulin resistant obese 
Zucker rats that irbesartan, another AngII receptor antagonist, improved insulin 
sensitivity and glucose tolerance in the skeletal muscle by increasing the protein 
expression of glucose transporter type 4, indicating the importance of measuring 
insulin and glucose blood levels [381] and the relationship with AngII in future 
studies. Furthermore, it will be interesting to investigate the possible role of 
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phosphorylated tau (pTau) in follow-up studies, because of the emerging role of 
pTau in pathology and behavior for both AD [382]. Glodzik et al. revealed that only 
in hypertensive subjects a longitudinal decrease in mean arterial pressure was 
related to memory decline and an increase in phosphorylated tau [383]. Another 
interesting aspect to investigate in future studies is how hypertension affects 
heart hypertrophy, and whether cognitive decline and decreased connectivity are 
indirect effects of heart diseases. In a systematic review Vogels et al. confirmed 
that heart failure is associated with a pattern of generalised cognitive impairment 
that includes primarily memory, attention, mental flexibility and global cognitive 
deficits [384].
In conclusion, we showed that chronic infusion of AngII increased SBP in 
both transgenic and WT mice, which could be reversed by EM-treatment. In 
addition, aging combined with AD pathology exacerbated the increase in SBP. 
Correspondingly cerebral perfusion was impaired in the AD mouse model. 
Furthermore, EM-treatment improved the white matter integrity combined 
with increased CBF and improved FC. AngII-induced hypertension impaired the 
functional connectivity in AD and WT mice comparably, indicating a negative role 
of hypertension on functional connectivity irrespective of AD pathology. 
Our results suggest that elevated levels of AngII may indeed represent a 
mechanistic link between the risk factor hypertension and the clinical development 
of AD, however, AngII may not to be a causal factor for sporadic AD as it did 
not initiate amyloid pathology in this study. Rather, it may progress the clinical 
development of AD in people with amyloid accumulation through its negative 
effects on cerebral blood flow, functional connectivity and cognition. Recent 
human studies on sporadic AD indicate that amyloid accumulation increases with 
age to as much as 30- 50 % of the normal population over the age of 70, but can 
remain asymptomatic for decades [385-387]. We speculate that elevated levels 
of AngII (essential hypertension) may be a factor promoting the development 
of symptomatic disease. In addition, our study suggests that elevated AngII may 
also lead to abnormalities that may mimic AD (reduced functional connectivity 
leading to cognitive decline) which could imply that hypertension may lead to 
dementia that has similarity with AD and may be clinically diagnosed as such. In 
both scenarios however, counteracting the negative effects of elevated AngII will 
have a beneficial effect in reducing the prevalence of dementia. Gathering more 
insight in the actions of antihypertensive treatments on brain processes and the 
vascular system could support the development of effective tailor-made blood 
pressure-lowering treatments for AD patients. 
98
Angiotensin II, hypertension, and angiotensin II receptor antagonismChapter 4
Supplementary material
Supplementary material can be found here:  
http://journals.sagepub.com/doi/full/10.1177/0271678X16667364#_i47


5
Improved spatial learning strategy and 
memory in aged Alzheimer AβPPswe/
PS1
dE9
 mice on a multi-nutrient diet
Wiesmann M, Jansen D, Zerbi V, Broersen LM, Garthe A, and Kiliaan AJ 
(2013). J Alzheimers Dis 37(1): 233-245.
102
Improved spatial learning strategy and memory in aged Alzheimer AβPPswe/PS1dE9 miceChapter 5
Abstract
There is accumulating evidence showing that lifestyle factors like diet may influence 
the onset and progression of Alzheimer’s disease (AD). Our previous studies 
suggest that a multi-nutrient diet, Fortasyn, containing nutritional precursors and 
cofactors for membrane synthesis, viz. docosahexaenoic acid, eicosapentaenoic 
acid, uridine-mono-phosphate, choline, phospholipids, folic acid, vitamins B6, 
B12, C, E, and selenium, has an ameliorating effect on cognitive deficits in an AD 
mouse model. In the present study we analyzed learning strategies and memory of 
11-month-old AβPPswe/PS1dE9 (AβPP/PS1) mice in the Morris water maze (MWM) 
task performed after nine months of dietary intervention with a control diet or 
a Fortasyn diet to characterize diet-induced changes in cognitive performance. 
The Fortasyn diet had no significant effect on MWM task acquisition. To assess 
hippocampus-dependent learning, the strategies that the mice used to find the 
hidden platform in the MWM were analyzed using the swim path data. While on 
control diet during the fourth day of the MWM AβPP/PS1 mice used more often 
the non-spatial random search strategy, on Fortasyn diet the transgenic animals 
exhibited more chaining strategy than their wild-type littermates. During the 
probe trial, AβPP/PS1 mice displayed no clear preference for the target quadrant. 
Notably, in both transgenic and nontransgenic mice on Fortasyn diet the latency 
to reach the former platform position was decreased compared to the mice on 
control diet. In conclusion, this specific nutrient combination showed a tendency 
to improve searching behavior in AβPP/PS1 mice by increasing the use of a more 
efficient search strategy and improving their swim efficiency by decreasing the 
latency to reach the former platform position.
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Introduction
The most common form of dementia is Alzheimer`s disease (AD). AD is characterized 
by brain atrophy and a gradual cognitive decline caused by neuronal death and 
loss of synapses in brain regions involved in learning and memory processes (e.g. 
temporal and frontal lobes) [182, 191]. During the course of AD, pathological 
hallmarks are the deposition of amyloid-β (Aβ) plaques into parenchymal and 
cerebrovascular tissue, the production of intracellular neurofibrillary tangles 
consisting of hyperphosphorylated tau protein (NFT), and neuronal cell loss 
[388-390]. Already the early stages of AD are characterized by the accumulation 
of Aβ affecting specific brain regions like the forebrain and medial temporal lobe 
structures like hippocampus, amygdala and entorhinal cortex [180, 181, 391]. 
Almost all insoluble Aβ is accumulated within the neuritic plaques and cerebral 
vessel walls [182]. There are many theories proposing the cause of AD, and one 
of the most well-known ones is the amyloid cascade hypothesis. According to the 
amyloid cascade hypothesis, Aβ plaques are the leading cause of the neuronal cell 
death and the cognitive decline in AD [390, 392]. This hypothesis is under debate 
because Aβ plaques do not correlate well with the severity of the disease [194]. No 
correlation between neuronal, metabolic or synaptic loss with amount of amyloid 
plaques could be found [194, 393]. However, the amyloid theory still stands firm 
by recent findings suggesting that the soluble oligomers and not the Aβ plaques 
are the toxic forms of Aβ [394, 395]. Many large epidemiological studies have 
indicated that vascular disorders are risk factors for AD [396-398]. Furthermore, 
it has been shown that vascular risk factors can influence the development of 
AD pathology, and this led to the vascular hypothesis [194]. In elderly patients 
a decreased CBF was related to increased hippocampal and amygdalar atrophy 
[203, 399]. Therefore an impaired or reduced cerebral perfusion may play a role 
in the development of AD via decreased delivery of oxygen in energy-sensitive 
brain regions like the hippocampus, inducing neurodegeneration and subsequent 
cognitive decline [205]. Up to now, no effective treatment for AD is available. This 
calls for new approaches for treatment and prevention of AD. There is growing 
knowledge about lifestyle factors such as nutrition having an impact on the onset 
and development of AD in late life [400, 401]. Many studies have shown that 
Mediterranean diets may not only have a positive effect on vascular health, but 
also on cognitive symptoms in AD [402, 403]. Epidemiological studies indicate 
that intake of omega-3 fatty acids is correlated to a reduced risk of AD [404-406]. 
Docosahexaenoic acid (DHA) is a polyunsaturated fatty acid of the omega-3 family 
(n3-PUFA) and an important component of neuronal phospholipid membranes 
via which membrane fluidity may be affected [407]. Animal studies show that 
the combined supplementation of dietary membrane precursors like DHA, EPA, 
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UMP, and choline, stimulates the synthesis of neuronal and synaptic membranes 
through the production of phospholipids via the Kennedy cycle [408-410]. 
In addition, the dietary interventions were found to increase dendritic spine 
density, and to improve learning and memory [410-412]. The combined intake of 
nutritional precursors and cofactors in neuronal membrane synthesis known as 
Fortasyn Connect® was recently shown to improve memory performance in early 
AD [413, 414]. The findings are in line with observations that brains of AD patients 
show decreased concentrations of choline, phospholipids, and polyunsaturated 
fatty acids like DHA [415-417]. Notably, epidemiological studies have shown that 
the plasma levels of DHA, folic acid, vitamin B12, vitamin E, and vitamin C are also 
lower in AD patients compared to age-matched controls [418-420], suggesting that 
the dietary intake of these nutrients may be relatively insufficient. In behavioural 
neuroscience the Morris water maze (MWM) navigation task is used to study 
spatial memory and learning [421]. Cognition of mice can be studied with the 
common MWM test, but the qualitative aspects of learning cannot be assessed. 
Originally, Wolfer and Lipp have shown that different behavioral strategies are 
available in the context of spatial learning [184, 185, 187, 422]. So the analysis of 
the different behavioral search strategies to find the hidden platform in the Morris 
water enables the identification of the actual hippocampal search strategies. 
In the current study, we investigated the effects of the specific nutrient combination 
Fortasyn, containing the dietary precursors and cofactors for membrane 
synthesis, viz. DHA, eicosapentaenoic acid (EPA), UMP, choline, phospholipids, 
folic acid, vitamins B6, B12, C, E, and selenium, on spatial learning and memory 
in 11-month-old male AβPPswe/PS1dE9 [AβPP/PS1] mice [423] and wild-type 
C57BL/6J littermates mice. To this end, we analyzed the different search strategies 
to find the hidden platform in the Morris water maze. A parameter-based 
algorithm was used to assess the qualitative aspects of learning [183-187]. Our 
study investigated whether Fortasyn may improve spatial learning of transgenic 
mice by facilitating the use of hippocampus-dependent search strategies. 
Materials and Methods
Animals & diets
The AβPPswe/PS1dE9 founder mice were obtained from John Hopkins University, 
Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. of Pathology) [423, 
424] and a colony was first established at the University of Kuopio, Finland 
and thereafter a colony was bred at the Central Animal Facility at the Radboud 
University Nijmegen Medical Centre, The Netherlands. In short, mice were created 
by co-injection of chimeric mouse/human AβPPswe (mouse AβPP695 harboring 
a human Aβ domain and mutations K595N and M596L linked to Swedish familial 
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AD pedigrees) and human PS1-dE9 (deletion of exon 9) vectors controlled by 
independent mouse prion protein promoter elements. The two transfected 
genes cointegrate and co-segregate as a single locus [423]. This line was originally 
maintained on a hybrid background by backcrossing to C3HeJ×C57BL/6J F1 
mice (so-called pseudo F2 stage). For the present work, the breeder mice were 
backcrossed to C57BL/6J for 13 generations to obtain mice for the current study 
at the Central Animal Facility of the Radboud University Nijmegen Medical Centre, 
The Netherlands. Throughout the experiments, the animals were housed socially 
with a maximum of six animals per cage, in a controlled environment, with room 
temperature at 21°C, and an artificial 12:12h light:dark cycle (lights on at 7 a.m.). 
Food and water were available ad libitum. The experiments were performed 
according to Dutch federal regulations for animal protection and were approved 
by the Veterinary Authority of the Radboud University Nijmegen Medical Centre.
For the present experiment, we used a total of 58 male mice, of which 36 wild-type 
littermates, and 22 AβPP/PS1 mice. From two months of age, all wild-type and 
transgenic littermates were separated into distinct groups and fed either a 
control diet, similar to normal rodent chow, or a specific Fortasyn diet containing 
precursors and cofactors in membrane synthesis, such as EPA, DHA, phospholipids, 
UMP, choline, vitamins B6, B9, B12, C and E, folic acid and selenium for 9 months 
(Table S1). Both diets were isoenergetic, based on AIN93M [425], pelleted and 
kept at -20°C until use.
Morris water maze
From 11 months of age, all mice were trained in the water maze task to assess 
spatial learning capabilities. Mice were tested in a circular pool (104 cm diameter) 
filled with water (21-22 °C; made opaque by the addition of milk powder). During 
the task mice had to learn to find a hidden platform in the North-East (NE) 
quadrant of the pool starting from four different positions defined by the four 
cardinal points (South, North, East and West). Four colored shapes on the room 
walls were presented as distant visual cues. 
Task acquisition 
Mice performed four acquisition trials (maximal swimming time 120 seconds, 30 
seconds on the platform and an inter-trial interval of 60 minutes) per day for four 
days. After each trial mice were placed on a paper towel for additional drying and 
then put back into their home cages.
Probe trial 
At the end of the fourth day, the platform was removed from the pool and the 
mice had to perform a single probe trial (swimming time 120 seconds; starting 
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point: South) to test the short-term visuospatial memory. Swim paths, total 
swim distance, swim velocity, relative time spent in each quadrant, and platform 
crossings were recorded and analyzed using EthoVision (EthoVision XT 7.0, Noldus 
Information Technology, Wageningen, The Netherlands).
Data analysis of the MWM
During task acquisition general spatial learning was assessed using classical 
water maze parameters like latency to reach the platform, swim path length and 
swimming velocity. The measured velocity in the acquisition was monitored by 
EthoVision (EthoVision XT 7.0, Noldus Information Technology, Wageningen, The 
Netherlands). This measured velocity represents the averaged velocity during 
swimming throughout a trial, and not the velocity averaged over the total length 
over the trial. Furthermore, relative time spent in each pool quadrant and platform 
area crossings were calculated. For heatmaps the pool was divided into 10x10 cm 
wide sectors allowing the presence probability of a mouse in each sector to be 
represented as heatmap-like occupancy plots [183].
Classification and Qualitative Analysis of Search strategies
Wolfer and Lipp have shown that there are different behavioral strategies in 
the context of spatial learning in the water maze [184, 185, 187, 422]. During 
subsequent trials mice proceed towards hippocampus-dependent and thus 
increasingly directed and precise search strategies (Figure 1A), indicating both 
effective selection of stable visual cues as well as organizing these cues into a 
coherent cognitive map. To differentiate between hippocampus-dependent and 
independent search strategies, swim paths were analyzed using a parameter-based 
classification of search strategies developed by Garthe et al. [183]. In summary, 
swim path data recorded with an Ethovision video tracking system (Ethovision 
XT 7.0, Noldus Information Technology, Wageningen, Netherlands) were used to 
record the time-tagged xy-coordinates of the animals. The coordinates were then 
analyzed using an algorithm implemented in Matlab. In summary, due to stress by 
a novel environment and situation, the mice first show a persistent swim along the 
wall of the pool including possible sporadic swims toward the center of the pool, 
called thigmotaxis (wall-hugging swim). The next strategy of the animals is the 
random search pattern. Here, the animals could swim in straight swims (zig-zag 
pattern) through the total pool, or in wide circular swims. During the next strategy 
the mice scan their environment for landmarks, known as the scanning strategy. 
The next search behavior is called chaining. Here, the mice use circular swimming 
(in anticlockwise or clockwise direction) at a fixed distance from the wall being 
equal to the distance between platform and wall of the pool. During chaining the 
mice use the visual cues or the height of the wall of the pool to determine the 
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distance of the platform from the wall. Chaining is considered as a non-spatial 
strategy, because here the mice do not really make use of information stored in 
their hippocampus. Chaining is a successor of the scanning technique and helps 
the mice to find the platform more effectively than using the non-spatially precise 
search strategies as random search and scanning. Thereafter, by making increasing 
use of the visual cues, the animals develop a precise and place-specific preference 
for the goal platform by using search strategies as directed search, focal search 
and direct swimming being more spatially precise search strategies. For a brief 
overview see table 1 and for a detailed description of search patterns recognized 
and the parameters used for classification, see Garthe et al. [183].
Table 1 Short descriptions of the search strategies. 
Statistics
For the statistical analysis, SPSS 20.0 software (SPSS Inc., Chicago, IL, USA) for 
Windows was used. Repeated-measures ANOVA for the total task acquisition 
phase using genotype and diet fixed factors was used to analyze swim path length, 
velocity and latency time to reach the hidden platform. Moreover, to evaluate 
different aspects of spatial learning we analyzed the swim patterns for each trial 
and also performance per day. Due to the high trial-to-trial variation we divided the 
task into mean performances per separate day and used the days as within-subject 
factor for repeated measures ANOVA. First an overall repeated-measures ANOVA 
was performed using genotype, diet and search strategy as between-subject 
factors and the days as within-subject factor to elucidate the effects of the 
between subject factors across the acquisition time. When this statistical test 
reveals an interaction between search strategies, genotypes and diets across 
days, subsequent splitting of the data was performed. Furthermore, the Morris 
water maze data were analysed for each separate day of the acquisition phase 
using univariate ANOVA to detect differences in genotype- and diet-interactions 
in the use of the different search strategies during each single day. Probe trial 
performance was assessed using univariate ANOVA with the genotype and diet as 
between-subject factors to evaluate the differences in the latencies to reach the 
platform, swim distance and velocity, as well as time spent in each pool quadrant. 
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All ANOVAs were performed with the Bonferroni correction. In all cases, when 
overall statistical analysis showed a significant difference, we used the post-hoc 
Tukey`s HSD test to analyze the separate groups. The statistical significance 
was set at p ≤ 0.05. Furthermore, also an univariate ANOVA to show eventual 
genotype-diet interactions on the body weight was performed. To determine the 
relationship between genotypes, diets or body weight between the swimming 
distance during the total probe phase, a bivariate correlation with a Pearson 
correlation coefficient (r) was used.
Results
Body weight 
Only genotype (F(1,50)=22.3, p<0.000) and not diet (F(1,50)=0.4, p<0.528) affected 
the overall body weight of the animals, but a genotype-diet interaction was 
measured (F(1,50)=4.3, p<0.043). The AβPP/PS1 mice on Fortasyn diet showed 
increased body weight compared to their wild-type littermates on Fortasyn (AβPP/
PS1-Fortasyn: 41.4g±4.1g; WT-Fortasyn: 33.8g±3.4g) (F(1,23)=24.6, p<0.001), 
while in comparison with the transgenic animals on control diet the AβPP/
PS1 mice on Fortasyn exhibited only a non-significant increase in body weight 
(AβPP/PS1-Fortasyn: 41.4g±4.1g; AβPP/PS1-control: 39.8g±4.2g) (F(1,27)=3.5, 
p<0.074). Furthermore, AβPP/PS1 mice on control diet also had a slightly 
higher body weight than the wild-type mice on control diet (AβPP/PS1-control: 
39.8g±4.2g; WT-control: 36.9g±4.2g) (F(1,27)=3.5, p<0.074), although it did not 
reach statistical significance. The wild-type mice on Fortasyn showed a decreased 
body weight compared to the wild-type group on control diet (WT-Fortasyn: 
33.8g±3.4g; WT-control: 36.9g±4.2g) (F(1,31)=5.1, p<0.030). A summary of the 
significant differences can be found in table 2. 
Additionally, also bivariate relationships between weight, genotypes, diets and 
swimming distance during the total time of the probe phase were performed by 
using Pearson correlation coefficients. An overall relationship analysis showed 
that no statistical significant correlations existed between weight (r=-0.122; 
p<0.393), genotypes (r=-0.117; p<0.410) nor diets (r=-0.241; p<0.085) compared 
with swimming distance. 
Morris water maze – Qualitative aspects of spatial learning
Acquisition
Spatial learning and memory was assessed with the MWM. AβPP/PS1 mice needed 
significantly more time to reach the platform compared to wildtype mice during all 
days as shown by overall ANOVA for repeated measures (WT: 38.0s±1.8s; AβPP/PS1: 
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47.7±2.2) (F(1,55)=11.8, p<0.001), although both genotypes successfully learned 
to navigate to the hidden platform during the MWM. During the acquisition phase 
AβPP/PS1 mice exhibited an increased swim distance and swim velocity to reach 
the target platform compared to their wild-type littermates (Distance: Figure 1A: 
F(1,55)=14.7, p<0.000; Velocity: Figure 1B: F(1,55)=10.4, p<0.002). No diet effects 
or genotype-diet interactions were observed (Figure 1A+B).
Figure 1 Analyzed data of the MWM performed by 11-month-old AβPP/PS1 (TG) and 
C57BL/6J wild-type mice on Fortasyn and Control diets. (A) During the first thirty seconds 
AβPP/PS1 mice on Fortasyn showed a decreased swim distance compared to their wild-type 
littermates on the same diet and also compared to APP/PS1 mice on control diet. (B) These 
same effects were also shown during the total probe phase. 
Search strategy
To evaluate different aspects of spatial learning we analyzed the swim patterns 
for each trial (Figure 2B+C), but also performed further analysis on each single 
day performance (Figure 2D+E). The parameter-based classification of search 
strategies revealed that both wildtype and transgenic mice, irrespective of the 
specific diet used, showed the full range of search strategies to find the hidden 
platform. Due to the high trial-to-trial variation we divided the task into average 
single day performances and used the days as within-subject factor for repeated 
measures ANOVA. Repeated-measures ANOVA applied to the acquisition phase 
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task revealed an interaction between days, different search strategies, genotypes 
and diets across time (Figure 2D+E: F(1,24)=2.0, p<0.003). This allowed us to 
perform single day analysis on each single search strategy performance by ANOVA 
with genotype and diet as between-subject factors. Therefore, we were allowed 
to split our dataset into genotypes and diets to analyze each corresponding 
between-subject factor. As it can be seen clearly in figure 2D+E each animal group 
exhibit substantial day-to-day variation. 
1st day of MWM
Genotype-effects
During the first day of the MWM AβPP/PS1 mice on control diet used more 
random search than wild-type mice on control diet (Figure 2D: F(1,31)=9.7, 
p<0.004). In agreement, the use of the directed search strategy was decreased 
in transgenic mice on control diet compared to their wild-type littermates (Figure 
2D: F(1,31)=4.5, p<0.043). 
Diet-effects
The supplementation with the Fortasyn diet led to an increase of the use of 
random search in wild-type mice compared to the wild-type mice on control 
diet (Figure 2D+E: F(1,34)=8.4, p<0.006). At the same time, wild-type mice on 
Fortasyn exhibited a tendency to use less directed search than their control diet 
fed littermates (Figure 2D+E: F(1,34)=3.5, p<0.070).
2nd day of MWM
Genotype-effects
During the second day of the acquisition phase AβPP/PS1 mice on Fortasyn used 
more thigmotaxis than their wild-type littermates on the same diet (Figure 2E: 
F(1,23)=8.943, p<0.007). On Fortasyn AβPP/PS1 mice showed a tendency to 
use the directed search strategy less than their wild-type littermates (Figure 2E: 
F(1,23)=3.7, p<0.068).
Diet-effects
No diet-effects were found on this acquisition day.
3rd day of MWM
Genotype-effects
On the third day of the acquisition phase, AβPP/PS1 mice on control diet used 
more thigmotaxis than their nontransgenic littermates on the same diet (Figure 
2D: F(1,31)=4.6, p<0.024). In addition, AβPP/PS1 on control diet mice showed a 
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decreased preference for directed search compared to their wild-type littermates 
on this diet (Figure 2D: F(1,31)=12.7, p<0.001). AβPP/PS1 mice on Fortasyn 
demonstrated a tendency to use less directed search (Figure 2E: F(1,23)=4.2, 
p<0.052), and they also displayed more thigmotaxis (Figure 2E: F(1,23)=6.6, 
p<0.017) than their wild-type littermates fed with this diet.
Diet-effects
Throughout the third day, the transgenic animals on Fortasyn used tendentiously 
less scanning search strategy (Figure 2D+E: F(1,20)=3.8, p<0.065) than their 
transgenic littermates on control diet.
4th day of MWM
Genotype-effects
During the fourth day AβPP/PS1 mice on control diet used more random search 
than wild-type animals (Figure 2D: F(1,31)=8.4, p<0.007). Only on the fourth day 
the transgenic mice on control diet tended to use the chaining strategy more 
often than the wild-type mice on the same diet (Figure 2D: F(1,31)=3.9, p<0.059). 
The directed search strategy was used significantly less by the transgenic mice 
on Fortasyn than by their wild-type littermates fed with the same diet (Figure 2E: 
F(1,23)=15.9, p<0.001). Notably, the AβPP/PS1 mice on a Fortasyn diet performed 
the chaining strategy more often than their wild-type littermates on Fortasyn 
(Figure 2E: F(1,23)=10.5, p<0.004).
Diet-effects
During the fourth day the AβPP/PS1 mice fed with Fortasyn used tendentiously 
more chaining than their transgenic littermates on control diet (Figure 2E: 
F(1,20)=4.1, p<0.057). Moreover, during the last MWM day the AβPP/PS1-Fortasyn 
group showed less directed search than their transgenic littermates on control 
diet (Figure 2E: F(1,20)=4.7, p<0.042).
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Figure 2 Qualitative analysis of spatial learning in 11-month-old AβPP/PS1 (TG) and 
C57BL/6J wild-type mice on Fortasyn and Control diets. (A) Examples of search strategies 
detected with the classification algorithm used. (B) In the wild-type animals on Control 
diet a clear progression towards increasingly spatially precise strategies was measured 
from day 1 to day 4, while the transgenic mice on Control diet did not. (C) Both groups of 
mice (AβPP/PS1 and C57BL/6J wild-type) on Fortasyn showed a changed pattern of used 
search strategies compared to the corresponding group. (D+E) Also the averaged daily 
pattern of the relative time engaged in specific search strategies to solve the MWM task 
are shown to reduce the enormous trial to trial variation in the prevalence of the different 
behavioral strategies.
Morris water maze – Reference memory in AβPP/PS1 mice
Probe
The ability to remember the platform location in the pool area was measured as 
probe trial performance one hour after the last regular trial on the last day of the 
MWM experiment. 
The overall univariate ANOVA revealed a significant genotype-diet interaction 
in swim distance during the first thirty seconds and also during the total probe 
phase (1st thirty seconds: F(3,55)=6.6, p<0.013; Total time: F(3,52)=4.4, p<0.040). 
During the total probe and in the first thirty seconds of the probe trial significant 
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genotype differences in mice on Fortasyn were found regarding the swim distance 
(Figure 3A+B: 1st thirty seconds: F(1,24)=9.9, p<0.004; Total time: F(1,22)=4.5, 
p<0.045). More specifically, AβPP/PS1 mice on the Fortasyn diet swam less than 
their wild-type littermates (Figure 3A+B). In addition, during the total probe trial 
and also in the first thirty seconds of the probe trial diet effects were found in 
transgenic animals (Figure 3A+B: 1st thirty seconds: F(1,21)=6.8, p<0.016; Total 
time: F(1,19)=7.0, p<0.016). In detail, Fortasyn fed AβPP/PS1 mice swam less than 
AβPP/PS1 mice on control diet (Figure 3A+B).
Figure 3 Probe phase of the MWM - decreased swim distance in AβPP/PS1 mice (TG) 
on Fortasyn. (A) Analyzing the first thirty seconds of the MWM probe data revealed that 
the AβPP/PS1-Fortasyn group exhibited a decreased swim distance compared to their 
wild-type littermates on the same diet but also compared to their transgenic littermates 
on control diet. (B) This effect was also detected during the total MWM probe. 
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In the probe trial AβPP/PS1 animals needed more time to reach the platform 
position for the first time than their wild-type littermates demonstrating an 
overall genotype effect (Figure 4A: F(1,47)=8.1, p<0.007). An overall diet effect 
was found in both groups of animals. In detail, latency to reach the platform for 
the first time was lower in all animals on a Fortasyn diet compared to control diet 
(Figure 4B: F(1,47)=5.2, p<0.027). 
Figure 4 Probe phase of the MWM - enhancing effect of the treatment with Fortasyn diet 
on spatial memory of 11-month-old AβPP/PS1 and C57BL/6J wild type mice. (A) After 
removing the platform in the probe trial on the last day of the MWM, the transgenic mice 
needed more time to reach the former platform position than their wild type littermates. 
(B) All animals fed Fortasyn showed a decrease in the latency time to reach the platform 
position. In conclusion, Fortasyn was able to improve spatial memory in wild type and 
transgenic mice.
The statistical analysis for the first thirty seconds revealed overall genotype-effects 
for the time spent in the North-East (NE) target quadrant. In detail, transgenic 
animals spent less time in the NE target quadrant than their wild-type littermates 
(Figure 5D: F(1,54)=6.1, p<0.017). 
In addition, during the total time the same genotype-effects as during the 
first thirty seconds of the probe were found. Wildtype-animals still showed a 
preference for the NE target quadrant compared to their transgenic littermates 
(Figure 5E: F(1,50)=19.5, p<0.000). 
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Figure 5 Probe phase of the MWM - Spatial memory measured in 11-month-old AβPP/
PS1 (TG) and C57BL/6J wild-type mice, on control & Fortasyn diet. The occupancy plots, 
respectively heatmaps, reveal the presence probability of each experimental group during 
the first thirty seconds (A) and also the total time (B) of the MWM probe trial. Analyzing 
the first thirty seconds and also the total MWM probe trial revealed that the wild-type 
mice spent more time in the NE target quadrant than transgenic mice, indicating successful 
spatial learning of the position of the platform by the wild-type animals (D+E).
A summary of the significant differences is given in table 2.
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Table 2 Summary of the significant differences. A=WT-control, B=WT-Fortasyn, C=AβPP/
PS1-control & D=AβPP/PS1-Fortasyn
Discussion
Several studies revealed the use of diverse search strategies in rats and AD 
transgenic mice [185, 187, 422, 426-429]. However, until now no studies 
demonstrated dietary influences on the use of search strategies in wild-type and 
transgenic mice, making the present study unique in this field. In this study we 
hypothesized that the identification of the search strategies used in the MWM 
may help to study the effects of dietary intake on spatial memory and learning 
abilities in mice.
In the present study the influence of a specific nutrient combination registered 
as Fortasyn® Connect, and comprising DHA, EPA, phospholipids, choline, UMP, 
vitamin B12, B6, and folate, vitamins C and E and selenium, was studied on 
cognitive decline in the AβPP/PS1 mouse model. Our results suggest that Fortasyn 
induced beneficial effects on learning and memory in both AβPP/PS1 mice and 
wild-type animals. During the acquisition phase of the MWM, AβPP/PS1 mice on 
Fortasyn focused more on the chaining strategy than their transgenic littermates 
on control diet, this effect was even more visible during the last acquisition day. 
Furthermore, AβPP/PS1 mice and also their wild-type littermates on Fortasyn 
showed a decreased latency to swim to the former platform position during the 
probe trials compared to their control groups indicating an improved memory. 
Fortasyn stimulated the transgenic mice to use the chaining strategy thereby 
developing a highly efficient way to reach the platform that is not dependent 
on an intact hippocampus [430]. While chaining is usually considered as a coping 
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strategy, it seems to help to compensate for the cognitive decline in AβPP/PS1 mice. 
Referring to the least-effort principle, for searching a hidden goal in a comparatively 
small pool chaining can become highly effective. Therefore, Fortasyn improved 
the search behavior of these AβPP/PS1 mice by facilitating the use of a chaining 
strategy. For the given experimental conditions this affects the overall efficiency 
of these animals to find the hidden goal. In accordance to our results, another 
study showed that the supplementation with long chain polyunsaturated fatty 
acids and extra additives enhanced the performance of the cerebral hypoperfused 
animals in MWM tests [431]. Notably, our results are also not at variance with 
other studies showing that fish oil containing diets improve spatial memory in 
AβPP/PS1 mice and ameliorate performance in hippocampus dependent spatial 
memory tests like the MWM [432-434]. 
During the probe trial of the Morris water maze in the present study, transgenic 
mice showed no clear preference for the target quadrant neither during the first 
thirty seconds nor the total time of the probe. While wild-type mice exhibited 
a clear goal preference during the first thirty seconds and also the total time of 
the probe. One possible explanation could be that the chaining search pattern 
during the fourth day of the MWM was the dominant search strategy of both 
transgenic groups. Moreover, the AβPP/PS1-Fortasyn group used this strategy 
even more often than their transgenic littermates on control diet. Again, chaining 
is considered as circular swimming at a fixed distance from the wall equally to 
the distance between platform and wall of the pool [422]. During the probe trial, 
the platform is removed from the pool and these aforementioned transgenic 
mice used the chaining strategy to find the platform resulting in serial visits and 
circular swimming. This searching behavior resulted in equal search times in all 
quadrants of the MWM pool during the probe trial in both transgenic groups and 
explains our findings that no clear preference for any quadrant could be found. 
Chaining is a normal part of the strategy pattern, which is increased in AD mice 
after the supplementation with Fortasyn resulting in zero quadrant preference, as 
observed in the probe trial, when the platform is removed.
The analysis of the probe phase of the MWM showed that all transgenic mice took 
more time to reach the platform position for the first time than their wild-type 
littermates indicating impaired memory. This supports the AD-like pathology of 
the AβPP/PS1 mice presenting cognitive decline and impaired memory [435]. 
Notably, all mice on Fortasyn diet showed a shorter latency to reach the former 
platform position in the probe trial than mice on control diet. In addition, during 
the probe phase AβPP/PS1 mice on Fortasyn swam also less compared to almost 
all other animal groups indicating an improvement of their swim efficiency. 
This specific nutrient combination was able to improve memory performance 
in transgenic and also nontransgenic mice on Fortasyn diet. From this latter 
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result we conclude that Fortasyn diet is beneficial irrespective of genotype due 
to an improvement in the latency time to reach the platform for the first time 
in both wild-type and transgenic mice. In a double-blind, placebo-Controlled 
human study using functional near IR spectroscopy (NIRS) to measure cerebral 
hemodynamics, the supplementation of a DHA-rich diet increased the cerebral 
blood flow in response to cognitive tasks [436], showing already that this results 
and ours are in line with each other. In AD, cerebral phospholipids [415, 416] 
and synaptic connections are reduced [437, 438] being thought to contribute 
also to the loss of cognitive functioning. In a randomized, double-blind human 
study a twelve weeks long supplementation with the medical food Souvenaid, 
containing Fortasyn® Connect, improved memory (delayed verbal recall) in mild 
AD patients [413]. Recently, Scheltens et al. demonstrated again that Souvenaid 
is well tolerated and improves memory performance in drug-naïve patients 
with mild AD [414]. Their EEG outcomes suggested also that Souvenaid had an 
effect on brain functional connectivity [414]. Our previous mouse studies have 
shown that feeding AβPP/PS1 mice specific nutrient-enriched diets can diminish 
the AD-like pathology [439, 440]. We now show that, in 15-month-old AD mice 
on the Fortasyn diet the amount of Aβ was decreased, the relative cerebral 
blood volume was slightly increased and the spatial memory of these mice was 
improved being again in accordance with our results. Other experiments have 
also shown that the membrane phospholipid synthesis is stimulated, the dendritic 
spine density is increased, and also learning and memory are improved, when the 
two synergistically acting components, DHA and UMP, are enriched in the diet 
[410-412]. 
In our present study we observed a decreased swim distance in the AβPP/PS1 
mice on Fortasyn diet compared to their transgenic littermates on control diet 
and also to the wild-type mice on Fortasyn. Previous studies have shown that 
AβPP/PS1 mice were more active than wild-type mice in the open field test [434, 
435]. In general hyperactivity seems to be a specific characteristic of many AβPP 
transgenic mice [441-443]and this effect may be related to elevated levels of 
anxiety in these animals [443, 444]. However, in the present study we did not 
find higher activity levels in the AβPP/PS1 mice, not even in the ones on control 
diet, rendering the possibility unlikely that this characteristic was of influence on 
the present observations. However, in the present study both AβPP/PS1 groups 
had higher body weights than the wild-type control groups, while the change 
in swimming distance was only observed in the AβPP/PS1 mice on Fortasyn 
diet. Despite their reduced swimming distance, the AβPP/PS1 mice on Fortasyn 
do show an improved task performance. It is possible that the adopted search 
strategy in these animals may have contributed to both observations. 
In summary, our present results show that Fortasyn improved spatial learning and 
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memory in mice as evidenced by a reduced latency to find the hidden platform in 
the MWM. Importantly, AβPP/PS1 mice on Fortasyn diet showed a tendency to 
use more chaining than controls to master the task, albeit without relying on the 
hippocampus. Whether this adapted cognitive performance is due to a reduced 
AD pathology or to an improved ability to cope with such pathology needs further 
investigation. 
Supplementary material
Supplementary material can be found here: 
http://dx.doi.org/10.3233/JAD-130179
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Abstract
APOE ε4 (apoE4) polymorphism is the main genetic determinant of sporadic 
Alzheimer’s disease (AD). A dietary approach (Fortasyn) including docosahexaenoic 
acid, eicosapentaenoic acid, uridine, choline, phospholipids, folic acid, vitamins 
B12, B6, C, and E, and selenium has been proposed for dietary management of 
AD. We hypothesize that the diet could inhibit AD-like pathologies in apoE4 mice, 
specifically cerebrovascular and connectivity impairment. Moreover, we evaluated 
the diet effect on cerebral blood flow (CBF), functional connectivity (FC), gray/
white matter integrity and post-synaptic density in aging apoE4 mice. At 10-12 
months, apoE4 mice did not display prominent pathological differences compared 
to wild-type (WT) mice. However, 16-18 month-old apoE4 mice revealed reduced 
CBF and accelerated synaptic loss. The diet increased cortical CBF, amount of 
synapses, and improved white matter integrity and FC in both aging apoE4 and 
WT mice. We demonstrated that protective mechanisms on vascular and synapse 
health are enhanced by Fortasyn, independent from apoE genotype. We further 
showed the efficacy of a multi-modal translational approach, including advanced 
MR neuroimaging to study dietary intervention on brain structure and function 
in aging.
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Introduction
Extensive research has been pursued in search for an effective therapy for 
Alzheimer’s disease (AD). However, no treatment is yet available nor seems 
near. Preventive approaches have therefore consistently emerged as key policy 
priorities in recently formulated dementia strategies. These approaches include 
modification of health-compromising behavior such as lifestyle and dietary intake 
that may lead to AD. For example, the Mediterranean diet (high consumption 
of fruit, vegetables and legumes, moderate consumption of fish, nuts and olive 
oil as the main source of fats), has been associated with a reduced risk of AD 
[445, 446] and with a lower mortality [447, 448]. The mechanisms via which diet 
influences the onset and progression of AD pathology are still under investigation. 
One possible mode of action is the beneficial effect of nutrients, such as omega-3 
long-chain polyunsaturated fatty acids (n3-LCPUFAs) on the vascular system [448, 
449].
Herewith n3-LCPUFAs will target the very early, asymptomatic phase of the 
disease, in which (cerebro)vascular impairment is the strongest contributor to 
the onset and progression of neurodegenerative traits of typical AD and dementia 
in general [450]. N3-LCPUFAs may diminish severity of vascular risk factors, 
like atherosclerosis [451], high blood pressure [452] and other cardiovascular 
diseases [451, 453-455], which are risk factors for AD as well. Other nutrients 
may instead directly protect synaptic integrity. For instance, the formation of 
phosphatidylcholine, the most common phosphatide in the brain and a major 
component of the synaptic membrane, is enhanced due to presence of its precursors 
in the diet [456, 457]. Several preclinical studies confirmed these findings, showing 
that animals supplemented with the combination of these membrane precursors 
showed increased levels of brain phospholipids, dendritic spines and neurite 
outgrowth, with beneficial effects on cognition [260, 458-461]. Based on these 
findings, a novel multi-nutrient supplementation diet called Fortasyn, comprising 
n3-LCPUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), 
besides other precursors and cofactors for membrane synthesis, such as uridine, 
choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium, has 
been proposed for the dietary management of AD [462]. To date, two randomized 
controlled clinical trials have shown improvements in the delayed verbal recall 
task and better cognitive performance in mild AD patients supplemented with this 
nutrient combination [463-465]. Although it has been recognized that Fortasyn 
addresses specific nutritional needs in early AD and that it improves functional 
connectivity as assessed by EEG [466], other processes by which Fortasyn may 
influence the pathophysiology of AD need to be further elucidated, and more 
studies are required to confirm its efficacy.
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Some studies suggested an interaction of the cholesterol transporter 
apolipoprotein (apoE) with lipid-based dietary intervention [467-469]. ApoE is a 
34-kDa glycoprotein that exists in three isoforms: apoE -ε2, -ε3 and -ε4, which 
differ by one or two amino acid residues 112 and 158 [470]. This small difference 
strongly affects the conformation and the structure of apoE and influences its 
ability to bind lipids, receptors and amyloid-β (Aβ) [471]. ApoE polymorphic alleles 
have been identified as the main genetic determinants of AD risk; specifically, 
apoE-ε4 has been associated with increased toxicity, and loss of neuroprotective 
function in the pathogenesis of Alzheimer disease, dependent or independent 
from Aβ accumulation [53]. Importantly, some of these processes are directly or 
indirectly linked to an impaired vascular system [472-474]. The development of 
an appropriate animal model, targeting the murine APOE gene for replacement 
with the human APOE-ε4 (apoE-ε4/apoE4 mouse) [475], opened a window 
for new possibilities to characterize the apoE-ε4 phenotype and to study the 
effects of very early AD-like pathology development in relation with lipid-based 
treatment. ApoE4 carrier mice exhibit an altered lipid profile, with increased 
risk of atherosclerosis plaques formation [475]. Altered behavior and cognitive 
deficits have also been reported [476]. A previous study from our group showed 
that a long-term dietary intervention with the Fortasyn diet was able to reduce 
anxiety behavior in 10-month-old apoE4 mice [477]. Transgenic AD mice on the 
same diet showed restored cortical cerebral blood flow (CBF) and brain structural 
integrity compared to wild-type mice [461].
Following these promising findings, we hypothesize that a nutritional intervention 
with Fortasyn may be able to rescue or prevent the occurrence of early AD-like 
pathologies in apoE4 mice, such as cerebrovascular impairment and concomitant 
brain connectivity loss. To test this hypothesis, we evaluated the effect of the 
Fortasyn diet on cerebral and plasma levels of fatty acids and sterols, cerebral 
blood flow (CBF), gray and white matter integrity, functional connectivity (FC) and 
post-synaptic density during aging in 12- and 18-month-old apoE4 mice.
Materials and Methods
Animals
The apoE-ε4 founder mice were originally obtained from Taconic Transgenic 
Models (Hudson, NY, USA) and a colony was established at the Radboud university 
medical center (Radboudumc). ApoE4 mice were created by targeting the murine 
apoE gene for replacement with the human apoE-ε4 alleles cultured in E14TG2a 
embryonic stem (ES) cells as described previously [478]. Resulting chimeras were 
backcrossed to C57BL/6J mice for 8 generations. The line was derived by embryo 
transfer and is maintained by inbreeding homozygous mice. For the present study, 
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male and female apoE4 breeder mice were used to generate homozygous apoE4 
offspring (3rd generation).
C57BL/6J wild-type mice (WT), obtained from our colony at the Radboudumc 
were used as controls. Throughout the experiment animals were housed in groups 
of 2-7 mice per cage in a controlled environment, homogenously illuminated by 
normal fluorescent room light at 60 lux, with room temperature at 21ºC, and 
an artificial 12:12h light:dark cycle (lights on at 7 a.m.). Food and water were 
available ad libitum. 
The experiments were performed according to Dutch federal regulations for 
animal protection. The Veterinary Authority of the Radboudumc, the Netherlands, 
approved all the protocols within this study (RU-DEC 2011-058). 
Diets and timeline of experimental design
Starting at 2 months of age, mice were randomly divided in two groups; animals 
were fed either with control diet or Fortasyn diet that differed with respect to the 
presence of a specific combination of dietary precursors and cofactors, i.e. uridine, 
docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, 
vitamins B12, B6, C, and E, and selenium (Table 1). Both diets were isocaloric 
and based on AIN-93M [479] with 5% fat. The control diet contained 1.9% soy 
oil, 0.9% coconut oil and 2.2% corn oil; the Fortasyn diet contained 0.1% coconut 
oil, 1.9% corn oil and 3.0% fish oil. The Fortasyn-based diet contains a specific 
multi-nutrient composition comprising nucleotides, omega-3 PUFAs, choline, B 
vitamins, phospholipids and antioxidants (Table 1). Diets were manufactured and 
pelleted by Ssniff (Soest, Germany) and stored at −20°C until use. The first group 
of mice underwent MR imaging at 11 (average age: 10.6 ± 0.1 months) to 12 
months of age (average age: 12.3 ± 0.1 months) and was sacrificed immediately 
thereafter. The second group was scanned at 16 months of age (average age: 16.2 
± 0.1 months) and sacrificed at 18 months of age (average age: 17.9 ± 0.1 months). 
The time line of the experimental design is illustrated in figure 1. The sample size 
of minimal 6 mice (12-Month: WT-control n=9, WT-Fortasyn n=9, apoE4-control 
n=8, apoE4-Fortasyn n=10; 18-Month: WT-control n=10, WT-Fortasyn n=10, 
apoE4-control n=10, apoE4-Fortasyn n=6) per group was chosen based on formal 
calculation of power as described in the approved protocols (RU-DEC 2011-058). 
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Table 1. Compositions of the experimental diets used, based on AIN-93M [479] with 
minor revisions
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Figure 1: Timeline of experimental design. Starting from 2 months of age, mice were 
randomly divided in two groups; animals were fed either with control diet or Fortasyn 
diet. The first group of mice underwent MR imaging (MRI) at 11 to 12 months of age and 
were sacrificed (†) immediately thereafter. The second group was sacrificed after MRI at 
18 months of age.
MR imaging
MRI measurements were performed on an 11.7 T BioSpec Avance III small animal 
MR system (Bruker BioSpin, Ettlingen, Germany) equipped with an actively shielded 
gradient set of 600 mT/m and operated by Paravision 5.1 software between 8 am 
and 8 pm. We used a circular polarized volume resonator for signal transmission 
and an actively decoupled mouse brain quadrature surface coil for signal reception 
(Bruker BioSpin). During the MR experiments, low-dose isoflurane was used 
(3.5% for induction and ~1.5% for maintenance), slightly adjusted throughout the 
experiment to maintain a fast and stable breathing frequency (>130 bpm). The 
mice were placed in a stereotactic device in order to immobilize the head. Body 
temperature was measured with a rectal thermometer and maintained at 37°-C 
by a heated air flow device.
After standard adjustments and shimming, gradient echo (GE) T2
*-weighted 
images covering the entire mouse brain were acquired for anatomical reference.
To study brain perfusion under resting conditions, we used a flow-sensitive 
alternating inversion recovery arterial spin labelling (FAIR ASL) technique [461, 
480]. Briefly, fifteen images with increasing inversion times (TIs) (40 ms - 3000 
ms) were obtained for the T1 calculations, amounting to a total scan time of 12 
minutes. Inversion recovery data from the imaging slice were acquired after 
selective inversion interleaved with non-selective inversion. Relative cerebral 
blood flow (CBF) was measured in the cortex, in the hippocampus and in the 
thalamus based on [461]. 
Diffusion of water was imaged as described previously [228, 477]. In short, 
22 axial slices covering the whole brain were acquired with a four-shot SE-EPI 
protocol. B0 shift compensation, navigator echoes and an automatic correction 
algorithm to limit the occurrence of ghosts and artefacts were implemented. 
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Encoding b-factors of 0 s/mm2 (b0 images; 5×) and 1000 s/mm2 were used and 
diffusion-sensitizing gradients were applied along 30 non-collinear directions in 
three-dimensional space. 
The diffusion tensor was estimated for every voxel using the PATCH algorithm 
[230]; mean water diffusivity (MD) and fractional anisotropy (FA) were derived 
from the tensor estimation following a protocol as described elsewhere [477]. 
MD and FA values were measured in several white matter (WM) and grey matter 
(GM) areas, which were manually selected based on an anatomical atlas [481].
The resting state fMRI (rsfMRI) datasets were first realigned using a least-squares 
method and rigid-body transformation with Statistical Parametric Mapping (SPM) 
mouse toolbox (SPM5, University College London; http://www.fil.ion.ucl.ac.uk/
spm/; Sawiak et al., 2009). Mean and maximum displacement across the six 
degrees of freedom (along the x-, y-, and z-axes and on three rotation parameters 
pitch, roll, and yaw) were measured in each mouse. The mean SE-EPI images of 
each mouse were then used to generate a study-specific template through linear 
affine and nonlinear diffeomorphic transformation (ANTs. v1.9; http://picsl.
upenn.edu/ANTS/). Visual inspection of the normalized dataset was performed to 
screen for possible normalization biases. On the template, 15 areas were selected 
in left and right hemisphere. The selected regions were based on previous 
work in functional connectivity in mice [231], and included: left and right dorsal 
hippocampus, left and right ventral hippocampus, left and right auditory cortex, 
left and right motor cortex, left and right somatosensory cortex, and left and right 
visual cortex. All cortical ROI were selected 1–2 voxels away from the edge of the 
cortex, to minimize the impact of susceptibility-weighted artifacts, which are more 
prominent in areas of different tissues interface (e.g., near the skull or near the ear 
canals). After motion regression, in-plane spatial smoothing (0.4 × 0.4 mm), linear 
detrending, and temporal high-pass filtering (cutoff at 0.01 Hz) were applied to 
compensate for small across-mouse misregistration and temporal low-frequency 
noise. FC group comparison between ROIs were calculated from the BOLD time 
series using total correlation and partial correlation analyses implemented in 
FSLNets (FSLNets v0.3; www.fmrib.ox.ac.uk/fsl). Pearson’s correlation values were 
Fisher transformed to Z-scores for group comparisons and statistical analysis.
Brain tissue preparation
Directly following the MR measurements at 12 and 18 months of age, anaesthetised 
mice were sacrificed by transcardial perfusion with 0.1M phosphate buffered 
saline (PBS). The perfused brains were cut sagittally and the right hemispheres 
were snap frozen in liquid nitrogen and stored at -80°C, before further biochemical 
processing. The left hemispheres were immersion fixated for 15h at 4°C in 4% 
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paraformaldehyde fixative and thereafter stored in 0.1M PBS with 0.01% sodium 
azide at 4°C for immunohistochemical staining.
Immunohistochemistry - PSD95 
Eight series of 30 µm coronal sections were cut through the brain using a sliding 
microtome (Microm HM 440 E, Walldorf, Germany) equipped with an object 
table for freeze sectioning at -60°C. The tissue was stained for postsynaptic 
density with Polyclonal rabbit anti-PSD95 antibody (1:2000; Abcam Cat# 
ab18258, RRID:AB_444362) using one complete series of brain sections. 
Immunohistochemistry was performed using standard free-floating labelling 
procedures, as described previously. 
Quantification
The stained sections were analysed using a Zeiss Axioskop microscope equipped 
with hardware and software of Microbrightfield (Williston, VT, USA). Brain regions 
were based on the mouse brain atlas of Franklin & Paxinos (third edition, 2008) 
and quantified in five regions of the hippocampus: the inner molecular layer (IML), 
outer molecular layer (OML), cornus ammonis 1 (CA1), CA2 and CA3. Additionally, 
two regions in the cortex corresponding to the visual and somatosensory cortex 
were analysed. The relevant regions were digitized at 100 times magnification with 
immersion oil using Stereo Investigator. The quantification of the photographs 
was performed using Image J (Image J, U. S. National Institutes of Health, and 
Bethesda, Maryland, USA). The contrast was manually enhanced, following the 
same procedure for all digitized images, and the amount of tissue stained was 
measured with a threshold-based approach. 
Biochemical analyses
Serum and brain sterol levels were measured by gas-chromatography-mass-spec-
trometry-selected-ion-monitoring (GC-MS-SIM) as described in detail previously 
[234]. The cerebellum of the right hemisphere was homogenized and sterols 
were extracted overnight by chloroform/methanol trimethylsilylation prior to 
GC-MS-SIM analysis [234]. Brain fatty acid analyses were performed with a part 
of the brain homogenate (olfactory bulb and part of frontal cortex), as described 
previously [477]. 
Statistics
For the statistical analysis, IBM SPSS 20 software (IBM Corporation, New York, NY, 
USA) was used. Since the setup of the current study was designed to determine 
the effects of diet supply at two stages in which apoE4 mice may develop different 
neuropathological traits of AD, statistical analyses were performed separately for 
the two age-points. 
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Multivariate ANOVA (MANOVA) with Bonferroni corrections, using body weight 
as covariate when necessary, was conducted with between-group-factors 
genotype and diet to analyze possible differences in all the other parameters. If 
the Bonferroni post hoc test indicated a significant interaction between genotype 
and diet, the data were split for the concerning factor and thereafter analyzed 
again with the MANOVA. Statistical significance was set at p ≤ 0.05. All data are 
expressed as mean ± SEM. 
Results
Mortality rate in the apoE4 mice was normal until age 18 months (<8% total 
mortality rate) in both diet groups. None of the WT animals died during the 
experiment.
Body weight
10-12 month-old mice
Body weight was measured at 10 and 12 months of age (figure 2A). Statistical 
analysis revealed a significant genotype x diet interaction (p=0.050). ApoE4 
and WT mice fed the Fortasyn diet were significantly heavier than animals on 
control diet (ApoE4: F(1,18)=46.6, p<0.001; WT: F(1,17)=31.2, p<0.001). ApoE4 
mice on Fortasyn were significantly heavier compared to WT mice on Fortasyn 
(F(1,17)=7.3, p=0.015).
At the start of the MRI measurements a significant genotype x diet interaction on 
bodyweight was found (p=0.018). Again, all animals on Fortasyn diet showed an 
increased body weight compared to animals on control diet (ApoE4: F(1,18)=50.1, 
p<0.001; Wild-type: F(1,17)=6.7, p=0.019). ApoE4 mice on Fortasyn were heavier 
than wild-type mice on the same diet (F(1,17)=7.6, p=0.013). 
16-18 month old mice
Body weight was measured at 16 and 18 months of age (figure 2B). In both 
measurements, ApoE4 mice weighed significantly less than WT mice (16 months: 
F(1,33)=10.3, p=0.003; 18 months: F(1,33)=9.0, p=0.005). Both at 16 and 18 
months of age, all animals on Fortasyn were heavier than animals on control diet 
(16 months: F(1,33)=5.6, p=0.024; 18 months: F(1,33)=4.5, p=0.042). 
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Figure 2: Body weight was measured in 10-12 month old (A) and 16-18 month old ApoE4 
and wild-type mice (WT). (A) At 10 months of age, ApoE4 and also wild-type mice on 
Fortasyn were significantly heavier than on control diet (ApoE4: p<0.001; Wild-type: 
p<0.001). Only on Fortasyn diet a genotype effect was found showing a higher weight 
of ApoE4 mice compared with wild-type mice (p=0.015). Again at 12 months of age, all 
animals on Fortasyn diet showed an increased body weight compared to animals on 
control diet (ApoE4: p<0.001; Wild-type: p=0.019). ApoE4 mice on Fortasyn were heavier 
than wild-type mice on the same diet (p=0.013). (B) At 16 and also 18 months of age, 
ApoE4 mice were significantly lighter than wild-type mice (16-Month: p=0.003; 18-Month: 
p=0.005). Furthermore, all animals on Fortasyn were heavier than animals on control diet 
(16-Month: p=0.024; 18-Month: p=0.042).
 
Magnetic Resonance Imaging
Cerebral blood flow
To study group-related differences on cerebrovascular health, we measured 
cerebral blood flow (CBF) with a flow-sensitive MRI technique (FAIR ASL). Three 
regions of interest (ROI) on the left and right brain hemispheres were analysed: 
cortex, hippocampus and thalamus. Since no intra-individual differences in CBF 
between right and left hemispheres were detected between mice groups (data 
not shown), values from both sides were averaged. In all measures, CBF was not 
significantly influenced by body weight.
In the 12-month-old mice, we detected a genotype×diet interaction in the 
thalamus (p=0.045). In detail, Fortasyn diet increased thalamic CBF (F(1,16)=5.0, 
p=0.040) more strongly in WT mice than in the apoE4 littermates (figure 3A). 
In the 18-month-old mice (figure 3B), CBF was decreased in the cortex (F(1,31)=4.4, 
p=0.044) and in the thalamus (F(1,31)=5.7, p=0.023) of apoE4 mice as compared 
to WT mice. Cortical CBF was increased by the Fortasyn diet in both WT and apoE4 
mice (F(1,31)=4.7, p=0.038).
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Figure 3: Cerebral blood flow (CBF) as measured with a flow-sensitive MRI technique 
(FAIR ASL) at 12 months and 18 months of age in C57BL/6J wild-type control mice and 
ApoE4 transgenic mice on control diet or Fortasyn diet. Three regions of interest (ROI) on 
the left and right brain hemispheres were analysed: cortex, hippocampus and thalamus. 
(A) In the 12-month-old mice we detected a genotype×diet interaction in the thalamus 
(p=0.045). Fortasyn diet increased thalamic CBF (p=0.040) more strongly in wild-type mice 
than in the apoE4 littermates. (B) In the 18-month-old mice, CBF was decreased in the 
cortex (p=0.044) and in the thalamus (p=0.023) of apoE4 mice as compared to wild-type 
mice. Cortical CBF was increased by the Fortasyn diet in both wild-type and apoE4 mice 
(p=0.038).
Diffusion Tensor Imaging
Quantitative assessment of diffusion tensor derived indices was performed for 
ROIs drawn in white and gray matter regions to assess genotype and diet effects 
in apoE4 and non-transgenic WT mice (figure 4A). 
Fractional anisotropy
In the 12-month-old mice, we did not detect any significant differences in white 
matter FA between the groups of mice (figure 4B).
At 18 months of age (figure 4C), Fortasyn fed mice showed a lower FA at -0.7mm 
in the corpus callosum compared to control fed mice (F(1,31)=4.7, p=0.008).
Mean diffusivity
In the 12-month-old mice, the MANOVA revealed a genotype×diet interaction for 
MD in the motor cortex (p=0.024, figure 4B). 
In detail, WT mice on Fortasyn diet had higher MD in the motor cortex than 
wild-type mice on control diet (F(1,14)=9.2, p=0.009). Furthermore apoE4 mice 
on Fortasyn diet had a lower MD in the motor cortex than WT mice on Fortasyn 
(F(1,17)=5.2, p=0.036). Fortasyn diet decreased MD in the auditory cortex 
(F(1,29)=4.9, p=0.034), and in the somatosensory cortex (F(1,29)=7.9, p=0.009) 
compared to control diet, irrespective of genotype.
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At 18 months of age (figure 4c), apoE4 mice displayed an increased MD in the 
auditory cortex (F(1,29)=5.6, p=0.025) compared to WT mice.
Figure 4: Quantitatively assessed diffusion tensor derived indices at 12 months and 
18 months of age in C57BL/6J wild-type control mice and ApoE4 transgenic mice on 
control diet or Fortasyn diet. (A) Fractional anisotropy (FA) and mean diffusivity (MD) 
were measured for ROIs drawn in white and gray matter regions, respectively. (B) In 
12-month-old mice, no differences in FA were observed. In the 12-month-old mice, the 
wild-type mice on Fortasyn diet had higher MD in the motor cortex than wild-type mice 
on control diet (p=0.009). Furthermore apoE4 mice on Fortasyn diet had a lower MD in 
the motor cortex than wild-type mice on Fortasyn (p=0.036). Fortasyn diet decreased MD 
in the auditory cortex (p=0.034), and in the somatosensory cortex (p=0.009) compared to 
control diet, irrespective of genotype. (C) At 18 months of age, Fortasyn fed mice had a 
lower FA at -0.7mm in the corpus callosum than Control fed mice (p=0.008). At 18 months 
of age, apoE4 mice displayed an increased MD in the auditory cortex (p=0.025).
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rsfMRI
Total correlation analyses
To compare the FC patterns between different genotypes and diets, rsfMRI 
data were statistically analyzed based on total correlation (figure 5) and partial 
correlation (figure 6). 
At 12 months of age, multivariate ANOVA (MANOVA) revealed some significant 
genotype but no diet effects in apoE4 compared to WT mice. More specifically, 
apoE4 mice showed reduced FC between the right auditory cortex and the left 
dorsal hippocampus (F(1,24)=5.1, p=0.033), and also between the left visual 
cortex and the right auditory cortex (F(1,24)=5.5, p=0.028).
At 18 months of age, the MANOVA demonstrated several significant genotype 
and diet effects. In detail, apoE4 mice had significant lower FC between cortical 
and hippocampal regions, but also between cortical regions themselves. Notably, 
Fortasyn was able to increase the hippocampal FC, and also FC between the visual 
and retrosplenial cortex to the hippocampus. 
The MANOVA revealed genotype×diet interactions in the left auditory cortex to 
retrosplenial cortex (p=0.011), in the right auditory cortex to right somatosensory 
cortex, (p=0.05), and in the left somatosensory cortex to retrosplenial cortex 
(p=0.025). ApoE4 mice on control diet showed a reduced FC between left auditory 
cortex and retrosplenial cortex (F(1,15)=17.9, p=0.001), right auditory cortex and 
right somatosensory cortex (F(1,15)=4.9, p=0.042), and left somatosensory cortex 
to retrosplenial cortex (F(1,15)=18.2, p=0.001), which were not observed in ApoE4 
mice on Fortasyn diet.
Moreover, compared to their transgenic littermates on control diet only apoE4 
mice on Fortasyn displayed an increased FC between left auditory cortex to 
retrosplenial cortex (F(1,11)=13.0, p=0.004), right auditory cortex to right 
somatosensory cortex (F(1,11)=9.9, p=0.009), and left somatosensory cortex to 
retrosplenial cortex (F(1,11)=10.2, p=0.009).
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Figure 5: Resting-state functional connectivity (FC) based on total correlation analyses 
of 15 regions of interest (ROI) in the mouse brain. Total correlation matrices of wild-type 
and apoE4 at 12 and 18 months of age, both on Fortasyn and control diets. At 12 months 
of age, multivariate ANOVA (MANOVA) revealed some significant genotype but no diet 
effects in apoE4 compared to wild-type mice, (figure 5B). More specifically, apoE4 mice 
showed reduced FC between the right auditory cortex and the left dorsal hippocampus 
(p=0.033), and also between the left visual cortex and the right auditory cortex (p=0.028). At 
18 months of age, apoE4 mice had significant lower FC between cortical and hippocampal 
regions, but also between cortical regions themselves. Notably, Fortasyn was able to 
increase the hippocampal FC, and also FC between the visual and retrosplenial cortices to 
the hippocampus. 
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Partial correlation analyses
At 12 months of age, significant genotype and diet effects were shown using 
MANOVA (figure 6). In detail, apoE4 mice showed a reduced FC between left 
dorsal and ventral hippocampus (F(1,24)=4.7, p=0.040). Additionally, animals on 
Fortasyn diet showed an increased partial correlation in the interhemispheric 
connection between left and right ventral hippocampus (F(1,24)=7.3, p=0.012). 
At 18 months of age, the MANOVA showed several significant genotype and diet 
effects (figure 6). ApoE4 mice had a reduced FC between the right auditory cortex 
and the right motor cortex (F(1,26)=16.4, p<0.001). The Fortasyn diet increased FC 
between left and right motor cortices (F(1,26)=7.1, p=0.013), but slightly reduced 
FC between left and right dorsal hippocampus (F(1,26)=4.4, p=0.045).
MANOVA also revealed a genotype×diet interaction between right auditory 
cortex to right somatosensory cortex, p=0.010. Fortasyn diet increased partial 
correlation in apoE4 mice compared to WT between right auditory cortex to right 
somatosensory cortex, (F(1,12)=8.1, p=0.015). 
Postsynaptic density protein-95 (PSD-95)
Density of postsynaptic densities were visualised and quantified 
immunohistochemically in various cortical and hippocampal areas with polyclonal 
rabbit anti-PSD-95. At 12 months, we did not observe significant differences 
between groups (figure 7). At 18 months, reduced PSD-95 levels were seen in 
the sensory cortex of apoE4 mice compared to WT mice (F(1,33)=5.8, p<0.021). 
Fortasyn diet increased levels of PSD-95 in the sensory cortex (F(1,33)=6.7, 
p<0.014), CA3 area (F(1,31)=9.9, p<0.004), and IML (F(1,31)=9.9, p<0.004), 
irrespective of genotype. No genotype × diet interactions were observed.
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Figure 6: Resting-state functional connectivity (FC) based on partial correlation analyses 
of 15 regions of interest (ROI) in the mouse brain. (A) Total correlation matrices of 
wild-type and apoE4 at 12 and 18 months of age, both on Fortasyn and control diets. 
At 12 months of age, apoE4 mice showed a reduced FC pattern between left dorsal and 
ventral hippocampus (p=0.040). Additionally, animals on Fortasyn compared to control 
diet showed an increased partial correlation in the interhemespheric connection between 
left and right ventral hippocampus (p=0.012). (C) At 18 months of age, ApoE4 mice on 
both diets had a reduced FC between the right auditory cortex and the right motor cortex 
(p<0.001). The Fortasyn diet caused contrasting effects: a higher FC was found between 
left to right motor cortices (p=0.013), but a slightly FC reduction was revealed between 
left to right dorsal hippocampus (p=0.045). Fortasyn diet increased partial correlation in 
apoE4 mice compared to their wild-type littermates between left to right auditory cortex 
(p=0.015), and between right auditory cortex to right somatosensory cortex, (p=0.015). In 
wild-type mice FC between left somatosensory cortex to left auditory cortex (p=0.041) was 
higher in Fortasyn fed animals compared to control fed animals.
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Figure 7: Levels of postsynaptic density-95 (PSD-95) in various brain areas in wild-type 
mice and apoE4 mice on either control diet or Fortasyn diet. (A) At 12 months, we did not 
find significant differences between groups. (B) At 18 months, reduced PSD-95 levels were 
seen in the sensory cortex of apoE4 mice compared to wild-type mice (p=0.021). Fortasyn 
diet increased levels of PSD-95 in the sensory cortex (p=0.014), CA3 area (p=0.004), and 
IML (p=0.004), irrespective of genotype. No genotype × diet interactions were observed.
Fatty acids  
Fatty acid content was analysed in the brains of apoE4 and WT mice (supplementary 
material + supplementary table 1). At both 12 and 18 months of age, increased 
relative levels of omega-3 fatty acids (p=0.000), and an increased ratio of omega 
3/6 were found in Fortasyn fed mice compared to their littermates on Control 
diet (p=0.000). At 18 months of age, ApoE4 mice displayed significantly increased 
relative arachidonic acid (p=0.022) and relative omega-6 content (p=0.038) 
compared to wild-type mice. For a detailed overview see the fatty acid section in 
the supplementary material and supplementary table 1.
Sterol levels
Sterol levels were determined in the blood plasma (serum) and in the cerebellum 
of the brain. The main findings are described below, for all detailed results see 
supplementary material and supplementary table 2 respectively 3.
Blood serum
At 12 months of age, apoE4 mice displayed increased level of the cholesterol 
precursor, dihydro-lanosterol, (p=0.000) compared to WT mice. At 12 months of 
age, apoE4 mice on control diet had higher levels of lathosterol (p=0.002) and 
lanosterol (p=0.003) compared to WT mice on control diet. 
At 18 months of age, apoE4 and WT mice on control diet displayed increased levels 
of campesterol (p=0.000), sitosterol (p=0.016), lanosterol (p=0.010), desmosterol 
(p=0.000), 24OH-cholesterol (p=0.002) and cholesterol (p=0.033) compared to 
apoE4 and WT mice on Fortasyn diet.
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Cerebellum
At 12 months of age, apoE4 and WT mice on control diet demonstrated increased 
levels of lathosterol (p=0.003), campesterol (p<0.000), and lanosterol (p=0.001) 
in the cerebellum.
At 18 months of age, cerebellar cholesterol levels were unchanged in ApoE4 mice 
compared to WT mice (p=0.614). In control fed mice levels of campesterol and 
precursors of cholesterol, lathosterol and lanosterol, were higher than in Fortasyn 
fed mice (Campesterol, p<0.000; Lathosterol, p<0.000; Lanosterol, p=0.011).
Discussion
ApoE4 mice as model for the early asymptomatic phase in AD
In this study, we investigated the extent to which apoE4 mice display 
cerebrovascular flaws, synaptic loss and connectivity during aging. The ε4 allele 
of the apoE gene is strongly associated with sporadic AD [188]. Among several 
proposed mechanisms by which apoE4 promotes AD, there are indications that 
apoE4 is less effective in synaptic repair and remodelling processes compared to 
other isoforms [482, 483]. Moreover, apoE4 carriers are clearly more susceptible 
to vascular brain damage (eg. stroke, brain haemorrhage; [52-54] and they display 
aberrant functional connectivity [55].
Similarly, the apoE4 mouse line exhibits increased risk of developing vascular 
disorders and neuronal deficits due to altered cholesterol metabolism, especially 
when challenged with a high-fat diet [475]. Recently we also described spontaneous 
functional connectivity deficits in these mice, possibly associated with cerebral 
blood flow reduction [484]. Because these deficits seem to aggravate with aging 
we investigated this mouse line at two different ages. 
At 10-12 months of age, apoE4 mice did not display many differences compared 
to WT animals. Despite some slight alterations in the sterol levels of 12-month-old 
apoE4 mice, all other measured parameters including cerebral blood flow and 
number of post-synapses were unaffected compared to WT animals. Previously, 
we have shown that at this age also cerebral blood volume, amount of 
pre-synaptic boutons and neurogenesis did not differ from WT mice [477]. The 
lack of cerebrovascular alterations like a reduced CBF at this age may explain the 
absence of pathologies. 
However at 16-18 months of age, apoE4 mice revealed reduced CBF and 
accelerated neurodegeneration, which are typical features of prodromal AD 
[485-488]. Specifically, we detected reduced thalamic and cortical perfusion, 
reduced cortical post-synaptic density, increased cortical mean diffusivity (MD) 
and reduced fractional anisotropy (FA) in white matter tracts. Similar changes in 
brain diffusivity, as a biomarker for white and gray matter integrity, have been 
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reported in human -ɛ4 carriers [57], [56, 58, 59]. These structural modifications 
may be linked to the isoform-specific role of apoE in synaptic development, 
dendrite formation and axonal guidance, which in some extent may be impaired 
in apoE4 carriers [60]. Nevertheless, these results were not consistent across 
different ages, suggesting that changes in WM/GM microstructure properties 
may not directly reflect an associated AD-like pathology [489]. Moreover, at this 
age we measured a widespread reduction in functional connectivity at rest, which 
was previously reported [360]. 
Overall, in line with other studies in this mouse model [476], these findings 
suggest that the apoE4 mice spontaneously develop age- and apoE4-dependent 
accelerated brain pathology. This is in agreement with human studies on apoE4 
carriers showing a faster decline of CBF during aging [490, 491], and reduced 
connectivity between cortical regions at old age [492-494]. However, the apoE4 
mice exhibited relatively small genotype effects like CBF decline and reduced 
connectivity just at 18 months of age, and not at 12 months of age. Therefore, one 
could argue that an 18-month-old apoE4 mouse is at most similar to a 65-year-old 
still healthy, possibly only mildly impaired human apoE4 carrier, showing no 
signs of dementia yet and carrying no multiple risk factors and co morbidities. 
It has been found namely, that human apoE4 carriers often carry multiple risk 
factors (genetic modifiers, co-morbidities and lifestyle factors) that contribute 
significantly to synaptic integrity. The only risk factor included in our mice was 
age, combined with apoE4 genotype causing mild pathology. 
A recent review on apoE-related biomarker profiles in the early phase of AD 
further elucidates this relatively novel concept of the –ε4 to be considered more 
as a vulnerability factor rather than a pathogenic factor [51]. Based on this idea, it 
is the interaction between these vulnerabilities and the age-related pathological 
events that may trigger synaptic loss, contributing to the development of AD. In 
our study, this aging-dependency of apoE4 seemed confirmed, as most of the 
biomarkers for brain deficits were identified only in the 18-month-old apoE4 
group; representing an early stage of the disease, when complete early AD-like 
pathology is still not fully developed. Holding this hypothesis, the model becomes 
extremely attractive to study the effects of nutritional intervention as a preventive 
strategy against early AD-like pathology.
Dietary intervention 
In the current experiment we fed the mice a specific multi-nutrient supplementation 
diet designed to ameliorate synapse loss and to reduce membrane-related 
pathology in AD by providing nutritional precursors and cofactors to support 
neuronal membrane formation and function [495]. This nutrient combination, 
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called Fortasyn, comprises uridine, docosahexaenoic acid, eicosapentaenoic acid, 
choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium. Some 
of the components in these diets, such as omega-3 long-chain polyunsaturated 
fatty acids (n-3 LCPUFAs), have also been shown to improve vascular health 
[449, 496-499]. The results confirmed our initial hypothesis, that the Fortasyn 
diet has the potential to reduce the occurrence of vulnerabilities for AD by 
simultaneously improving cerebrovascular health and enhancing neuroprotective 
mechanisms. However it is also possible that the capacity of the diet to support 
membrane phospholipid synthesis could underlie both the synapse formation/ 
functional connectivity and the effects on cerebrovascular functioning. Besides, 
the combination of phosphatide precursors like n3-LCPUFAs, uridine, and choline, 
has proven to synergistically increase the synthesis of synaptic proteins and 
phospholipids in the brain [458-460]. 
These findings confirm novel important mechanisms by which these diets may 
affect AD onset and development, similar to earlier findings in a transgenic AD 
mouse model [461]. Particularly, among the different parameters analyzed, 
the strongest and most consistent dietary effect in these studies involve the 
improvement of cerebrovascular health and functional connectivity. Several 
epidemiological studies and controlled trials showed a correlation between 
B-vitamins, n3-LCPUFAs and MUFA (like oleic acid from olive oil and nuts) 
and improvements in autonomic function, lowered blood pressure, reduced 
atherosclerosis, reduced total homocysteine and enhanced microvascular 
endothelium-dependent vasodilation processes [448, 500, 501].
All these factors may contribute to an improved functionality of the brain 
vasculature, with a beneficial effect particularly in apoE4 mice, in which these 
pathologies are aggravated. Interestingly, increased cortical CBF and levels of 
post-synaptic markers were found in both apoE4 and WT animals on Fortasyn 
diet; these findings suggest that the diet had a similar effect in both genotypes 
and its contribution is not determined by the apoE genotype. We have also 
shown that the Fortasyn diet affected brain fatty acid profiles in both genotypes 
(supplementary material, table 1), by decreasing the relative concentration of n6 
fatty (notably arachidonic acid), which is significantly increased in the 18-month-old 
apoE4 mice compared to WT, and by increasing the relative concentration of n3 
fatty acids (notably DHA) and monounsaturated fatty acids, especially oleic acid. 
These supplementary results indicate a replacement of n6 fatty acids from cell 
membranes in favour of n3-LCPUFAs, (reflected by the increased n3/n6 ratio) 
which has beneficial effects on membrane fluidity, and neuronal transmission 
and signalling [502-504]. Furthermore, we have shown that the Fortasyn diet 
similarly affected serum (supplementary material, table 2) and brain sterol level 
(supplementary material, table 3). In detail, in the plasma of aged animals on 
142
A dietary treatment improves cerebral blood flow and brain connectivity in aging apoE4 miceChapter 6
Fortasyn we found decreased levels of cholesterol, but also of precursors like 
lanosterol and derivates of cholesterol like 24OH-cholesterol. Notably, in the 
cerebellum of aged animals on Fortasyn we detected a decreased concentration 
of the cholesterol-precursor lanosterol and increased level of a derivate of 
cholesterol, 24S-hydroxycholesterol. In the brain, the enzyme, cholesterol 
24S-hydroxylase, converts cholesterol to 24S-hydroxycholesterol. This mechanism 
is the most important pathway for the elimination of brain cholesterol and the 
maintenance of brain cholesterol homeostasis [505-508]. These results are also 
in line with our previous study using another AD mouse model overexpressing 
Aβ. Here, another cholesterol precursor, lathosterol, was decreased in the brain 
of Fortasyn fed AD and WT mice, while again an increased cerebral level of the 
derivate of cholesterol, 24S-hydroxycholesterol, was measured in Fortasyn fed AD 
and WT mice [215]. Our data indicate a higher elimination rate of brain cholesterol 
in Fortasyn fed mice.
This may also explain the improved white matter integrity and preserved 
functional connectivity in both WT and AD mice fed with Fortasyn. In support of 
this hypothesis, it has been demonstrated that animals fed with a diet containing 
uridine monophosphate (UMP), n3-LCPUFAs and choline, showed increased levels 
of brain phospholipids, dendritic spines and neurite outgrowth [458-460]. 
Conclusions
Overall, the study presented here further proved that two simultaneous protective 
mechanisms on vascular and synapse health are both enhanced by the specific 
Fortasyn diet and may strengthen each other synergistically, independent from 
the apoE genotype. The beneficial effect of these diets is suggested to be caused 
by increased production of phospholipids to sustain synaptic genesis and repair 
processes [458, 509]. In this and other recent experiments, we showed that a 
strong effect of these diets also involves the amelioration of cerebrovascular 
health. Although decreased cerebral perfusion has been recognized as an early 
and important contributor to AD pathology and cognitive decline [510], we believe 
that this aspect is not sufficiently considered in human nutritional intervention 
studies. In our mice, we have detected most of the pathological effects of apoE4 
just at 18 months of age, and therefore, most of the beneficial effects of the diet 
were just present at 18 months of age. It is important to stress that our apoE4 
mouse model only represents susceptibility to cognitive impairment and just like 
in human apoE4 carriers multiple risk factors are required in combination with 
apoE4 to precipitate disease pathology. For future research it would therefore 
be interesting to study the effect of the Fortasyn diet in older (24 months of age) 
apoE4 mice, in apoE4 mice with induced apoE4 co-morbities like hypertension, 
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stroke, or in apoE4 mice on high fat diet or in female apoE4 mice, resembling 
more closely the human susceptibility to AD. For example, in clinical studies on 
brain atrophy and clinical decline among cognitively normal older individuals and 
individuals with mild cognitive impairment and Alzheimer disease it has been 
shown that the presence of apoE4 significantly accelerated rates of decline, and 
women in all cohorts had higher rates of decline than men [511]. Additionally, a 
preclinical study revealed that expression of human apoE4 renders aged mice fed 
with a western-type diet more susceptible to sensorimotor deficits upon stroke 
indicating an altered functional outcome following stroke in apoE4 carriers [512]. 
Furthermore, this study demonstrated the value of a multi-modal approach, 
including advanced MR neuroimaging tools, for detecting changes in brain 
structure and function with respect to dietary intervention.
Supplementary material
Supplementary material can be found here:  
https://www.hindawi.com/journals/np/2016/6846721/sup

7
A specific dietary intervention to restore 
brain structure and function after 
ischemic stroke
Wiesmann M1, Zinnhardt B1, Reinhardt D, Eligehausen S, Wachsmuth L, 
Hermann S, Dederen PJ, Hellwich M, Kuhlmann M, Broersen LM, 
Heerschap A, Jacobs AH, and Kiliaan AJ (2017). Theranostics 7(2): 493-512.
1 The authors contributed equally to the present work.
146
A specific dietary intervention to restore brain structure and functionChapter 7
Abstract
Occlusion of the middle cerebral artery (MCAo) is among the most common 
causes of ischemic stroke in humans. Cerebral ischemia leads to brain lesions 
existing of an irreversibly injured core and an ischemic boundary zone, the 
penumbra, containing damaged but potentially salvageable tissue. Using a 
transient occlusion (30 min) of the middle cerebral artery (tMCAo) mouse model 
in this cross-institutional study we investigated the neurorestorative efficacy of a 
dietary approach (Fortasyn) comprising docosahexaenoic acid, eicosapentaenoic 
acid, uridine, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, 
and selenium as therapeutic approach to counteract neuroinflammation and 
impairments of cerebral (structural+functional) connectivity, cerebral blood flow 
(CBF), and motor function. Male adult C57BL/6j mice were subjected to right 
tMCAo using the intraluminal filament model. Following tMCAo, animals were 
either maintained on Control diet or switched to the multicomponent Fortasyn 
diet. At several time points after tMCAo, behavioral tests, and MRI and PET 
scanning were conducted to identify the impact of the multicomponent diet 
on the elicited neuroinflammatory response, loss of cerebral connectivity, and 
the resulting impairment of motor function after experimental stroke. Mice on 
the multicomponent diet showed decreased neuroinflammation, improved 
functional and structural connectivity, beneficial effect on CBF, and also improved 
motor function after tMCAo. Our present data show that this specific dietary 
intervention may have beneficial effects on structural and functional recovery and 
therefore therapeutic potential after ischemic stroke. 
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Introduction
Stroke is the second leading cause of morbidity and mortality [513], and the most 
common cause of serious adult long-term disability in the United States [514, 
515]. Ischemic strokes have been the target of many failed drug trials [516] and 
only few treatment options are available, but many patients still show significant 
poststroke disabilities [517-519]. Until now, thrombolysis and thrombectomy 
are the common treatments for ischemic stroke, but not many patients benefit 
from these therapies due to the narrow therapeutic window and complexity of 
administration [515, 520]. 
There is therefore an urge for restorative interventions supporting better recovery 
and improving quality of life. Damaged brain networks have been shown to be 
responsible for absence of recovery or even for progressive disease, leading to 
increased mortality [18]. Furthermore, 87% of all strokes are ischemic [521], 
indicating that specific treatments should aim to improve impairments in cerebral 
blood flow (CBF) [516]. Therefore, stroke studies are needed investigating 
the effects of stroke and its interaction with a novel treatment on parameters 
being alternated after a stroke CBF, structural and functional connectivity, 
neuroinflammation, neuro- and synaptogenesis, vascular density, cognition, and 
behavioral parameters (motor coordination, activity etc.). Novel approaches 
targeting CBF, neuroinflammation, and brain networks may provide new avenues 
for stroke treatment [522]. In particular, dietary approaches could facilitate 
recovery after stroke [523, 524] because it has been shown that increased 
adherence to a Mediterranean-style diet is associated with a lowered risk of 
ischemic stroke and myocardial infarction [163]. Following MCA occlusion, mice 
fed a rapeseed oil-enriched diet revealed a decreased mortality rate, lowered levels 
of lipid peroxidation, and a reduced infarct size [166]. Also low fish consumption 
may already decrease the incidence of ischemic stroke [157]. In women, intake 
of omega-3 long-chain polyunsaturated fatty acids (n3-LCPUFA) is associated 
with a lowered risk of total stroke, while dietary cholesterol has been found to 
be positively associated with risk of total stroke and cerebral infarction [162]. 
In several other studies n3-LCPUFA have shown to diminish severity of vascular 
risk factors, like atherosclerosis [451], high blood pressure [525], and other 
cardiovascular diseases [451, 526-528]. Ozen et al. demonstrated a protective 
effect of n3-LCPUFA against cerebral ischemia in rats, showing a reduced number 
of apoptotic neurons in the prefrontal cortex when fed a standard diet combining 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [160]. Moreover, 
combined administration of DHA and UMP improved learning abilities in rats 
[529] and combined administration of DHA and EPA improves (cerebral) vascular 
health in human [530, 531]. Supplementation of DHA and choline to normal adult 
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gerbils also enhanced performance on several maze tests, being even further 
enhanced by coadministering UMP [532]. Additionally, in several studies a specific 
combination of nutrients called Fortasyn, comprising precursors and cofactors for 
membranes (DHA, EPA, uridine monophosphate (UMP), choline, phospholipids, 
folic acid, vitamins B12, B6, C, and E, and selenium), has been shown to support 
synergistically neuronal membrane synthesis [533, 534], increasing levels of 
brain phospholipids, dendritic spines and neurite outgrowth, cerebral blood 
flow, and to beneficially affect cognition [260, 294, 459, 535, 536]. Recently, we 
showed that this latter Fortasyn diet increased cortical CBF and synaptic density, 
and improved white matter integrity and functional connectivity (FC) in aging 
apoE4 mouse. Furthermore, we demonstrated that protective mechanisms on 
vascular and synapse health are enhanced by Fortasyn, independent of apoE 
genotype [346]. In another AD murine model, we showed that this multi-nutrient 
supplementation diet improved cerebrovascular health and protected against 
neuronal degeneration [224]. This neurorestorative potential of Fortasyn has 
recently been obtained in a rodent model of spinal cord injury as well [537].Thus, 
in present experiment we wanted to investigate the possible efficacy of this 
multicomponent diet as therapeutic intervention after transient ischemic stroke 
on both structural and functional parameters. Using state-of-the-art imaging 
techniques, we measured CBF, and the neuroinflammatory response after 
ischemia. Notably, upon activation during the neuroninflammatory response, 
microglial cells express the translocator protein (TSPO) [538, 539]. In vivo positron 
emission tomography (PET) for imaging of microglial activation has focused on 
a variety of radiolabeled compounds binding to TSPO. In particular, the second 
generation TSPO tracer N,N-diethyl-2-(2-(4-(2-[18F]fluoroethoxy)phenyl)-5,7-di-
methylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide ([18F]DPA-714) has been assessed 
for temporal and spatial evaluation of inflammatory alterations in models of 
cerebral ischemia, experimental autoimmune encephalomyelitis and cancer 
[540]. 
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Material and methods
Animals and diets (Nijmegen, The Netherlands; Münster, Germany)
In total 48 3–4 months old C57BL/6J mice (Nijmegen, 24 mice: Harlan Laboratories 
Inc., Horst, the Netherlands; Münster, 24 mice 3–4 months old in-house bred 
C57BL/6J mice) were used for this cross-institutional, randomized, and double-blind 
controlled study (blinded for investigators and outcomes assessor) conducted 
at the preclinical imaging center (PRIME) of the Radboudumc (Nijmegen, the 
Netherlands) and the European Institute for Molecular Imaging (EIMI, Münster, 
Germany). Before tMCAo, the animals were housed socially with a maximum of six 
animals per cage, with room temperature at 21°C, and artificial 12:12h light: dark 
cycle (lights on at 7 a.m.). After stroke induction, the mice were housed separately 
to control the food intake of the experimental diets (see below). Food and water 
were available ad libitum. Samples sizes were determined by power analysis 
during the animal ethics dossier application. The experiments (Nijmegen) were 
performed according to Dutch federal regulations for animal protection and were 
approved by the Veterinary Authority of the Radboud university medical center, 
Nijmegen, The Netherlands. Experiments (Germany) were in accordance with the 
German Law on the Care and Use of Laboratory Animals and approved by the 
Landesamt für Natur, Umwelt und Verbraucherschutz of North Rhine-Westphalia. 
All experiments (Nijmegen & Münster) of this international multicenter preclinical 
study were exerted in accordance to the ARRIVE [214] and the (updated) STAIR 
guidelines [541-543]. All applicable international, national, and institutional 
guidelines for the care and use of animals were followed.
Before tMCAo all mice were fed a standard Control diet (Ssniff rm/h V1534-000, 
Bio Services, Uden, The Netherlands). Starting right after tMCAo, mice were 
randomly divided in two groups; animals were fed either Control or Fortasyn diet 
that differed with respect to their fatty acid composition and some additional 
nutrients. All diets were isocaloric and based on AIN-93M [425] with 5% fat. 
The Control diet contained 1.9% soy oil, 0.9% coconut oil and 2.2% corn oil. The 
Fortasyn diet contained 0.1% coconut oil, 1.9% corn oil and 3.0% fish oil. The 
Fortasyn diet contains a specific multi-nutrient composition comprising uridine, 
omega-3 PUFAs, choline, B vitamins, phospholipids and antioxidants as specified 
in Table 1. To assure intercenter-comparability and accordance to the ARRIVE 
and (updated) STAIR guidelines in this study, all experiments were performed 
in line with the following predefined experimental rules. In this experiment we 
used a study design with pre-set endpoints for all participating centers (Münster 
& Nijmegen). Both diets were manufactured and pelleted by Ssniff (Soest, 
Germany) and stored at −20°C until use. All mice underwent behavioral tests 
before and after tMCAo. 35 days poststroke, MRI measurements were performed 
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and all animals were euthanized after completion of the study. Post mortem 
immunohistochemical procedures were performed on all brains. The time line of 
the experimental design is illustrated in figure 1. No potential disparities in verum/ 
control group allocation are given. The random allocation of each mouse into its 
test group was performed by a blinded researcher. To insure intercenter-compara-
bility, all surgeries were performed by the same experienced researcher (D. R.) in 
Münster, Germany, and in Nijmegen, the Netherlands. For all surgeries, the same 
type of filaments (70SPRePK5, Doccol Corp., Sharon, MA, USA) for the occlusion 
of the MCA was used in Münster, Germany, and in Nijmegen, the Netherlands and 
the same batch of diets were tested in both centers. Furthermore, in Nijmegen, 
the Netherlands, all imaging and behavioral procedures were performed by the 
same researchers. In accordance, in Münster, Germany, all imaging procedures 
were performed by the same investigator. Moreover, all analyses of behavioral, 
imaging, and immunohistochemical data were performed by blinded researchers.
Figure 1. Study design. Behavioral and MRI studies were performed in Nijmegen, the 
Netherlands. After a transient occlusion of the middle cerebral artery (tMCAo) for 30 min, 
mice were divided into two dietary groups (Control or Fortasyn). At 7 and 14 days post 
tMCAo all mice underwent MRI. In between, all mice were tested on motor and cognitive 
impairments via several behavioral tests, like the Open field, Rotarod, Pole test, Prepulse 
inhibition (Ppi), grip strength test, and novel object recognition test (ORT). After MRI, all 
brains were processed for immunohistochemical stainings. PET imaging studies were 
conducted in parallel in Münster, Germany. [18F]DPA-714 PET was conducted 7, 14 and 
35 d after tMCAo in two dietary groups (Control or Fortasyn). T2w MRI for anatomical 
localization of stroke was conducted 14 d post tMCAo. The group sizes at the start and 
at the end of the experiments performed in Nijmegen, the Netherlands, and in Münster, 
Germany, are given. The group sizes shown in brackets indicates the number of mice used 
for the behavioral or imaging procedures and quantification. The dashed line indicates the 
period of time of exclusion of mice due to i.e. surgical problems, human endpoint.
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Transient Middle Cerebral Artery Occlusion Surgery (Nijmegen, The Netherlands; 
Münster, Germany)
3 months old, male C57BL/6J mice underwent right tMCAo (30 minutes), using an 
intraluminal occlusion model as described elsewhere with minor modifications 
[544, 545]. This stroke model of transient occlusion of the MCA mimics one of 
the most common types of ischemic stroke in patients [544, 546]. The MCA 
was transiently occluded for 30 min. This ischemia time leads to moderate 
pathological changes within the infarct core, perilesional and remote regions 
[547-549]. In accordance with human stroke this reperfusion model involves a 
substantial degree of reperfusion via collateralization through the circle of Willis 
and leptomeningeal collaterals, and via early clot lysis [550]. In summary, mice 
were anesthetized with 1.5% isoflurane (Abbott Animal Health, Abbott Park, IL, 
USA) in a 2:1 air and oxygen mixture. After preparing the right common carotid 
artery, a 7-0 monofilament (tip diameter 190 to 200 μm, coating length 2 to 3 
mm, 70SPRePK5, Doccol Corp., Sharon, MA, USA), was inserted in the common 
carotid artery and positioned at the point where the MCA branches out. Successful 
occlusion was maintained for 30 minutes before retracting the filament allowing 
reperfusion. Reduction in blood flow was monitored intraoperatively via a Laser 
Doppler probe (Nijmegen, moorVMS-LDF2, Moor Instruments, UK; Münster, 
Periflux 5000, Perimed Instruments, Järfälla, Sweden) attached to the skull of the 
mouse. Using the Laser Doppler Flow measurement, we considered an induction 
of ischemia as valid, when during the occlusion a decrease in regional CBF of more 
than 80% of baseline values at filament insertion is reached (inclusion criterion). 
Mice were kept under 1.5% isoflurane anesthesia in a 2:1 air and oxygen mixture 
throughout the procedure. Body temperature was maintained at physiological 
levels with a custom built heating pad. Exclusion criteria were: a decreased motor 
activity (<50% of the baseline measurements combined from the baseline values 
of each behavioral test) or extreme weight loss (>20% within three consecutive 
days). Using a T2-weighted RARE sequence to measure lesion size, all animals 
showed a comparable lesion size and no dietary effect on lesion size (data not 
shown). In all animals N=3 Control animals and n=4 animal on Fortasyn diet died 
during first week poststroke in Nijmegen, the Netherlands. N=2 Control animals 
and n=1 animal on Fortasyn diet died during the experiments in Münster, Germany.
Behavioral and cognitive tests (Nijmegen, The Netherlands)
Open field
Locomotion and explorative behavior were evaluated for 10 minutes in the 
open field prior to the tMCAo, and also 3 and 23 days poststroke as previously 
described [215, 224, 345, 551]. Using EthoVision XT10.1 (Noldus, Wageningen, 
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The Netherlands), locomotion was automatically recorded. The floor of the 
arena was divided into center, periphery, and corners. The frequency of entering 
these zones was measured automatically. In addition, exploration was manually 
scored (walking, sitting, wall leaning, jumping, rearing, grooming) and analyzed as 
described previously [305, 552].
Grip strength test
Grip strength test was performed at 14 days poststroke using a grip strength 
meter (Grip-Strength Meter, 47200, Ugo Basile, Italy) to determine forelimb and 
also total limb (fore- and hindlimbs combined) muscle strength. Each mouse was 
trained prior to tMCAo to perform this test. The grip strength meter was arranged 
horizontally on the table. While holding the tails, the mice were lowered towards 
the grip strength meter to enable to grasp the grip trapeze with the forepaws or 
the grid with both their fore- and hindpaws. After grasping the trapeze or the grid, 
the mice were pulled backwards till the grasp was released. The test was repeated 
five consecutive times first with the trapeze and one hour later with the grasping 
grid. For each session the average value of the peak force (in gf) was calculated 
from the last three trials [553] and the first two trials were used as acclimatization. 
Additionally, trials were only analyzed, in which the mouse grasped with either 
two forepaws (trapeze) or all four paws (grid).
Pole test
The pole test was performed at day 15 poststroke, as previously described [554]. 
The mice were placed head upward just below the top of a vertical rough-surfaced 
pole (diameter 2.5 cm; height 60 cm) and then allowed to descend. This 
procedure was repeated five times. Each mouse was trained prior to tMCAo to 
perform this behavioral test. The time taken to turn completely downward and 
the rotation direction were measured manually, while the time to reach the floor 
was determined in EthoVision XT10.1 (Noldus, Wageningen, The Netherlands) to 
measure downward velocity (cm/s). Laterality index is determined by the averaged 
turn direction of each mouse (0= left/ contralateral turn, 1= right/ ipsilateral 
turn). A laterality index of 0.5 indicates that no lateralization is present, while a 
laterality index of 0.0 respectively 1.0 suggests a laterality of more contralateral 
respectively ipsilateral turns. Results for downward velocity and rotation time are 
displayed as the mean of minimal three successful trials. The first acquisition trial 
was excluded from the statistical analysis and used as acclimatization trial.
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MRI protocol (Nijmegen, The Netherlands)
MRI measurements were performed at 7 and 35 days poststroke on a 11.7 T 
BioSpec Avance III small animal MR system (Bruker BioSpin, Ettlingen, Germany) 
equipped with an actively shielded gradient set of 600 mT/m and operating on 
Paravision 5.1 software platform (Bruker, Karlsruhe, Germany). We used a circular 
polarized volume resonator for signal transmission and an actively decoupled 
mouse brain quadrature surface coil with integrated combiner and preamplifier 
for receiving (Bruker BioSpin). For the imaging procedure, the animals were 
anesthetized with isoflurane (3.5% for induction and 1.8% for maintenance) in 
a 2:1 oxygen and N2O mixture, and placed in a stereotactic holder to prevent 
unwanted movement during the scanning. Body temperature was monitored 
with a rectal probe and maintained at 37˚C with heated airflow. Respiration of the 
animal was monitored using a pneumatic cushion respiratory monitoring system 
(Small Animal Instruments Inc, NY, USA). First gradient echo images were acquired 
using previously described image parameters [224]. 
Cerebral blood flow
MR perfusion data were acquired under resting conditions using established 
methods with a flow-sensitive alternating inversion recovery (FAIR) technique 
[226, 295].
Regional perfusion was evaluated in the cerebral cortex (all cortical regions 
above corpus callosum), hippocampus, thalamus [224] accordingly to the atlas of 
Franklin and Paxinos [227]. To calculate regional CBF we used the same protocol 
as previously described [224]. 
Diffusion tensor imaging
Diffusion of water was imaged as described previously [347, 555]. In short, 
22 axial slices covering the whole brain were acquired with a four-shot SE-EPI 
protocol. B0 shift compensation, navigator echoes and an automatic correction 
algorithm to limit the occurrence of ghosts and artefacts were implemented. 
Encoding b-factors of 0 s/mm2 (b0 images; 5×) and 1000 s/mm2 were used and 
diffusion-sensitizing gradients were applied along 30 non-collinear directions in 
three-dimensional space. 
The diffusion tensor was estimated for every voxel using the PATCH algorithm 
[230]; mean water diffusivity (MD) and fractional anisotropy (FA) were derived 
from the tensor estimation following a protocol as described elsewhere [555]. 
MD and FA values were measured in several white matter (WM) and grey matter 
(GM) areas, manually selected based on an anatomical atlas [227], as described 
previously in [346].
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Resting state fMRI
The resting state fMRI (rsfMRI) datasets were first realigned using a least-squares 
method and rigid-body transformation with Statistical Parametric Mapping 
(SPM) mouse toolbox (SPM5, University College London; http://www.fil.ion.ucl.
ac.uk/spm/; [556]). Mean and maximum displacement across the six degrees 
of freedom (along the x-, y-, and z-axes and on three rotation parameters pitch, 
roll, and yaw) were measured in each mouse. The mean SE-EPI images of each 
mouse were then used to generate a study-specific template through linear affine 
and nonlinear diffeomorphic transformation (ANTs. v1.9; http://picsl.upenn.edu/
ANTS/). Visual inspection of the normalized dataset was performed to screen for 
possible normalization biases. On the template, 14 areas were selected in left and 
right hemisphere. The selected regions were based on previous work in functional 
connectivity in mice [231], and includes: left and right dorsal hippocampus, left 
and right ventral hippocampus, left and right auditory cortex, left and right motor 
cortex, left and right somatosensory cortex, and left and right visual cortex. All 
cortical ROI were selected 1–2 voxels away from the edge of the cortex, to minimize 
the impact of susceptibility-weighted artefacts, which are more prominent in 
areas of different tissues interface (e.g., near the skull or near the ear canals). After 
motion regression, in-plane spatial smoothing (0.4 × 0.4 mm), linear detrending, 
and temporal high-pass filtering (cut-off at 0.01 Hz) were applied to compensate 
for small across-mouse misregistration and temporal low-frequency noise. FC 
group comparisons between ROI were calculated from the BOLD time series 
using total correlation and partial correlation analyses implemented in FSLNets 
(FSLNets v0.3; www.fmrib.ox.ac.uk/fsl). Pearson’s correlation values were Fisher 
transformed to Z-scores for group comparisons and statistical analysis.
[18F]DPA-714 Positron Emission Tomography (PET, Münster)
During image acquisition, mice were anesthetized with 1.5% isoflurane (Abbott 
Animal Health) in pure oxygen. For tracer application, the lateral tail vein was 
cannulated using a 26 Ga catheter (Vasculon Plus, BD, Heidelberg, Germany) 
connected to a 15-cm polyethylene tubing (27 Ga, Smith Medical, Kent, UK). 
[18F]DPA-714 was prepared following the procedure described previously with a 
radioactive purity of 99% and a decay corrected yield (rcy) of 25.1 ± 4.9% [557].
Mice were injected with 15.7 ± 1.5 MBq of [18F]DPA-714 and imaged consecutively 
7 (n=5/group), 14 (n=8/group), and 35 (n=8/group) days poststroke. Only animals 
with complete imaging set (n=5 group) could be taken into consideration 
for repeated measurement ANOVA analysis. N=2 animals per group without 
measureable infarction and DPA-714 PET changes were excluded from the 
analysis. PET data were acquired 45-55 min p.i. on a high-resolution small animal 
PET scanner (32 module quadHIDAC, Oxford Positron Systems Ltd., Oxford, UK) 
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with uniform spatial resolution (1 mm FWHM (full-width at halfmaximum)) 
over a large cylindrical field-of-view (165 mm diameter, 280 mm axial length). 
Images were reconstructed with a one-pass list mode expectation maximization 
algorithm with resolution recovery. CT images were acquired on a small animal 
CT scanner (Inveon, Siemens Medical Solutions, Knoxville, TN, USA) with a 
spatial resolution of 80 μm. For data analysis, CT images were coregistered to 
PET, followed by co-registration to MRI data using a landmark-based approach as 
described previously [545]. Magnetic Resonance Imaging studies were performed 
with a 9.4-T small animal MR scanner with 20 cm bore size (Bios-Spec 94/20; 
BrukerBioSpin MRI GmbH, Ettlingen, Germany). The system was operated using 
the software ParaVision 5.1. (BrukerBioSpin MRI GmbH). Anatomic T2w RARE 
brain images were obtained in three imaging planes (28 planes, slice thickness 
0.5 mm, in-plane resolution 78 μm (repetition time 3,000 to 5,500 ms, echo time 
50 ms, rare factor 16, 6 averages, 14 to 28 contiguous slices, slice thickness 0.5 
mm, field of view 20 mm2, 256 matrix, in-plane resolution 78 μm2, scan time 5 to 
9 minutes, respectively). Image analysis was conducted with the VINCI software 
(Version: 4.19.0; http://www.nf.mpg.de/vinci3/) [558] by drawing a volume 
of interest (VOI) over the infarcted area depicted by T2w MRI. A duplicate VOI 
was mirrored to the contralateral hemisphere and served as control. Mean and 
maximum lesion-to-background (Lmean/Bmean and Lmax/Bmean) ratios were 
calculated.
Immunohistochemical procedures (Nijmegen, The Netherlands; Münster, 
Germany)
After the last scanning session, the mice were sacrificed by transcardial perfusion 
using 0.1M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde 
in 0.1M PBS. The brains were harvested and stored separately. The brains were 
postfixed overnight in 4% paraformaldehyde at 4°C and transferred to 0.1M PBS 
containing 0.01% sodium azide the next day. One part of the brain (Bregma: -0.7 
to -4.36) was cut in 30 μm frontal sections using a sliding microtome (Microm 
HC 440, Walldorf, Germany) equipped with an object table for freeze-sectioning 
at -60°C. 24 Hours before cutting, the brains were transferred in 30% sucrose in 
0.1M phosphate buffer. 8 Series were cut and stored in 0.1M PBS with 0.01% 
sodium azide so multiple immunohistochemical stainings could be performed.
All sections were stained in one session to minimize differences in staining 
intensity.
In total three stainings were performed for vascular integrity measured via 
glucose transporter-1 (GLUT-1), for activated microglia via ionized calcium-binding 
adapter molecule 1 (IBA-1) as indicator for neuroinflammation, and for immature 
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neurons (measure for neurogenesis) with antibodies against doublecortin (DCX) 
on free-floating brain sections on shaker tables at room temperature.
Immunohistochemistry was performed using standard free-floating labelling 
procedures, using previously described protocols [559].
The GLUT-1 amount was visualized using polyclonal rabbit anti-GLUT-1 antibody 
(1:40.000,Chemicon AB 1340, Chemicon International, Inc., Temecula, CA, 
USA) and as secondary antibody donkey anti-rabbit biotin (1:1500 Jackson 
ImmunoResearch, West Grove,PA, USA).
For IBA-1, as primary antibody against IBA-1 polyclonal goat anti-IBA-1 (1:3000; 
Abcam) and for DCX, polyclonal goat anti-DCX (1:8000; Santa Cruz Biotechnology 
Inc., SantaCruz, CA, USA) was used as a primary antibody to assess neurogenesis. 
For both as secondary antibody donkey anti-goat biotin (1:1500; Jackson 
ImmunoResearch, West Grove, PA, USA) was used.
From a more frontal part of the brain tissue (Bregma: -0.10 to 0.98) was fixed 
in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) and embedded in 
paraffin according to a standard protocol.
Synaptophysin (SYN; measure for synaptic plasticity) immuno reactive presynaptic 
boutons with antibodies against synaptophysin and postsynaptic density (measure 
for synaptic plasticity) with antibodies against postsynaptic density protein 95 
(PSD-95) were demonstrated immunohistochemically on 5 μm thin paraffin 
sections.
We used monoclonal rabbit anti-synaptophysin clone EP1098Y (1:500; Abcam Inc., 
Cambridge, UK) as a primary antibody to visualize synaptophysin in presynaptic 
boutons. For PSD-95, polyclonal rabbit anti-PSD95 (1:800; Abcam Inc.) was used 
as a primary antibody to reveal the postsynaptic density. After washing 3 times 
with 0.1M PBS, for both the synaptophysin and PSD-95 staining, the secondary 
antibody used was donkey anti-rabbit biotin (1:200; Jackson ImmunoResearch), 
followed again by 3 washes, Vector ABC-Elite (1:50) and the above mentioned 
DAB-Ni incubation.
Immunohistochemistry for TSPO (1:250, NBP1-95674, Novus Biologicals, 
Cambridge, UK) and GFAP (1:1000; Abcam Inc., Cambridge, UK) was performed 
on paraffin embedded slices. The slides were boiled in citrate buffer for antigen 
retrieval (pH 6; 30 minutes), before being treated with blocking solution for 30 
minutes (1%BSA and 0.5% Triton-X in PBS), Primary antibodies were subsequently 
incubated with the primary antibodies (4°C, overnight). TSPO immunoreactivity was 
visualized through a multi-step process, including incubation with a biotinylated 
goat anti-rabbit (1:800, 45 minutes, B21078, Life Technologies, Darmstadt, 
Germany), followed by HRP-Streptavidin incubation (20 minutes, K1016, DAKO, 
Hamburg, Germany) and 3,3-Diaminobenzidine (D-5637, 5 min, Sigma, Hamburg, 
Germany). Sections were counterstained with hematoxylin, dehydrated, cleared 
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with xylol and mounted using Entellan (Merck, Darmstadt, Germany). For double 
immunohistochemistry slides were incubated with Alexa Fluor 488-conjugated 
anti-rabbit secondary antibody (1:800, A-21206, Life Technologies, Carlsbad, CA, 
USA), or Alexa Fluor 555 conjugated anti-goat (1:800, A-21432, Life Technologies, 
Carlsbad, CA, USA). Slides were mounted in DAPI containing mounting medium 
(Vectashield, H-1500, Vector Laboratories, Burlingame, CA, USA). Images were 
acquired with a combined fluorescence-light microscope (Nikon Eclipse NI-E, 
Nikon, Tokyo, Japan).
Quantification (SYN and PSD-95)
The stained sections (Bregma: 0.02 to 0.62) were analyzed using a Zeiss Axioskop 
microscope equipped with hardware and software of Microbrightfield. Brain 
regions were based on the mouse brain atlas of Paxinos and Franklin [227] and 
quantified in four regions of the hippocampus: left cortex, right cortex, left caudate 
putamen, and right caudate putamen. The relevant regions were digitized with a 
40x objective and using Stereo Investigator software for finding the right location 
for the image. The quantification of the images was performed using ImageJ 
(National Institute of Health, Bethesda, MD, USA).
Quantification (GLUT-1, IBA-1 and DCX)
Brain sections (Bregma: -1.46 to -2.30) were preselected for quantification 
accordingly to the atlas of Franklin and Paxinos [227]. Quantification was done on 
images at a 5x objective using an Axio Imager A2 (Zeiss Germany). ImageJ (National 
Institute of Health, Bethesda, MD, USA) was used to analyze the regions of interest 
(GLUT-1+IBA-1: Cortex, hippocampus and thalamus; DCX: Hippocampus, and the 
subventricular zone, called SVZ). 
Statistics
For the statistical analysis, IBM SPSS 22 software (IBM Corporation, New York, NY, 
USA) was used. Multivariate ANOVA or univariate ANOVA both with Bonferroni 
corrections (using Repeated measures ANOVA, when necessary, for example 
open field and PET data) was conducted with between-group-factor diet and if 
necessary also time to analyze possible differences in all the other parameters.
Statistical significance was set at p ≤ 0.05: #, 0.05 < p < 0.08 (tendency); *, p ≤ 
0.05; **, p ≤ 0.01; ***, p ≤ 0.001. Degrees of freedoms, f-values and p-values are 
given for each statistical analysis. All data are expressed as mean ± SD. 
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Results 
A summary of all experimental results is given in table 1.
Table 1. Summary of all significant results. Used abbreviations: CBF (cerebral blood flow), 
DTI (diffusion tensor imaging), FA (fractional anisotropy), MD (mean diffusivity), rsfMRI 
(resting state functional MRI), Total (total correlations), Partial (partial correlations), IHC 
(Immunohistochemistry), GLUT-1 (glucose transporter-1), IBA-1 (ionized calcium-binding adapter 
molecule 1), DCX (doublecortin), SYN (synaptophysin), PSD-95 (postsynaptic density protein 95).
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Food intake and body weight (Nijmegen, The Netherlands)
Body weight of both dietary groups decreased poststroke, while it increased 
significantly over time, comparing the first with the second to fifth week poststroke 
in all mice, for further details see supplemental material and supplemental figure 
1A. 
The daily food intake increased over time on both diets in all mice. Fortasyn diet 
tended to increase food intake compared to Control diet, for further details see 
supplemental material and supplemental figure 1B.
Behavioral and cognitive tests (Nijmegen, The Netherlands)
Open field
Open field was performed for 10 minutes to measure locomotion (total walking 
distance, velocity), frequency of zone enters (corners, center, periphery), 
exploration frequency (walking, wall leaning, rearing, sitting) and grooming, prior 
to tMCAo (baseline), 3 and 23 days after tMCAo.
Both diet groups exhibited a decreased total distance walked (Figure 2A; 
F(1,12)=87.8, p<.001) and velocity (Figure 2B; F(1,12)=84.2, p<.001) three days 
poststroke compared to baseline.
The frequency of entering the three zones of the open field (Figure 2C), corners 
(F(1,12)=61.5, p<.001), periphery (F(1,12)=55.9, p<.001), and center (F(1,12)=35.3, 
p<.001) were also decreased in both diet groups comparing before and three 
days poststroke. From three to 23 days poststroke, both diet groups increased 
their frequency of entering the center (F(1,13)=81.9, p<.001) and periphery 
(F(1,13)=4.1, p<.065) again.
Measured via manual scoring (Figure 2D), frequencies of walking (F(1,12)=39.4, 
p<.001), wall leaning (F(1,12)=28.2, p<.001), and rearing (F(1,12)=17.4, p<.002) 
were decreased, and frequency of grooming (F(1,12)=3.7, p<.079) was increased 
in both diet groups comparing before with three days after tMCAo. In contrast, 
from 3 to 23 days poststroke, mice showed an increase in frequency of sitting 
(F(1,13)=5.1, p<.042), and decrease in frequency of grooming (F(1,13)=11.1, 
p<.006). 
Notably, a diet effect was shown over time on frequency of walking (F(1,13)=8.1, 
p<.014). Only mice on Fortasyn diet walked more often overtime (F(1,13)=10.2, 
p<.019). 23 days poststroke, Fortasyn fed mice walked more frequently than 
Control fed mice (F(1,13)=4.6, p<.052, trend).
Grip strength test
The grip strength test was performed to quantify muscle strength (of forepaws 
respectively of fore- hindlimbs combined) at 14 days poststroke.
160
A specific dietary intervention to restore brain structure and functionChapter 7
No diet effects in muscle strength of the forepaws was found (Figure 2E). The 
grasping grid revealed that mice on Fortasyn diet tended to have higher muscle 
strength than mice on Control diet (F(1,13)=4.5, p<.057).
Figure 2 Effects of Fortasyn on: locomotion (A+B), time spent in different zones (C), and 
exploration in open field measured prior to tMCAo (PO), and 3 and 23 days poststroke 
(E) grip strength test 14 days poststroke g-f ;gram-force (F-H) motor coordination 
determined via pole test 15 days poststroke . Values represent mean±SD). (A+B) Both 
diets exhibited decreased total distance walked (p<.001) and velocity (p<.001) comparing 
before, and three days poststroke. (C) Frequency of entering corners (p<.001), periphery 
(p<.001), and the center (p<.001) were decreased in both diet groups comparing before, 
with three days poststroke. From three to 23 days after tMCAo, both diet groups increased 
frequency of entering center (p<.001) and periphery (p<.065). (D) Frequencies of walking 
(p<.001), wall leaning (p<.001), and rearing (p<.002) were decreased. All mice showed 
increased frequency of sitting (p<.042), and decreased frequency of grooming (p<.006) 
poststroke. Mice on Fortasyn walked more at 23 days compared to 3 days poststroke 
(p<.019). At 23 days poststroke, Fortasyn fed mice tended to walk more frequently than 
Control fed mice (p<.052). (E) No diet effect was found in muscle strength of the forepaws 
(trapeze). Measuring total limb strength (grasping grid), revealed higher muscle strength 
on Fortasyn tended (p<.057). (F) No diet effects were observed concerning velocity to 
descend along the pole. (G) Control fed mice needed a longer turning time than Fortasyn 
fed mice when placed head-upwards on top of the pole (p<.010). (H) Mice fed Control diet 
displayed an ipsilateral bias to fully turn head-down (p<.058, trend).
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Pole test
Motor coordination was measured with the pole test: turning time, rotation 
direction, and the downwards walking velocity. No differences were detected 
between the dietary groups concerning velocity to descend along the pole 
(Figure 2F, F(1,14)=0.2, p<.909). Mice on Control diet needed more time to turn 
than mice on Fortasyn diet when being placed head-upwards on top of the pole 
(Figure 2G, F(1,14)=9.0, p<.010). The turning phase requires fine-tuned and 
coordinated movements demanding on the potential motor coordination [554]. 
Notably, mice fed Control diet tended to turn more frequently to the right to fully 
turn head-down than mice fed Fortasyn diet indicating reduced laterality in the 
Fortasyn fed mice (Figure 2H, F(1,14)=4.3, p<.058).
Cerebral blood flow (Nijmegen, The Netherlands)
CBF was measured with flow-sensitive alternating inversion recovery (FAIR) MRI; 
from a series of echo planar imaging (EPI)-images in three different regions of 
interest (ROI): Cortex, hippocampus and thalamus. Each ROI was drawn double 
blind. One representative high-resolution voxel-wise analyzed CBF image for each 
dietary group at 7 and 35 after tMCAo is shown (Figure 3B). CBF was analyzed 
for each ROI in the unaffected (contralateral/ left) and affected (ipsilateral/ right) 
hemisphere separately for each dietary group at 7 and 35 poststroke (Figure 3A). 
Furthermore, loss of CBF in the affected ROI was calculated as the difference 
in CBF between right and left hemispheric ROI relative to left hemispheric ROI 
(Figure 3C).
7 days poststroke CBF in the right cortex (Control, F(1,12)=46.9, p<.001; Fortasyn, 
F(1,12)=38.8, p<.001), right hippocampus (Control, F(1,12)=148.2, p<.001; 
Fortasyn, F(1,12)=34.6, p<.001), and right thalamus (Control, F(1,12)=12.3, p<.005; 
Fortasyn, F(1,12)=60.7, p<.001) were lower than corresponding left ROI in mice 
for both diets. At this time point, mice on Fortasyn demonstrated higher CBF in 
the right affected cortex than mice on Control diet (Fortasyn, F(1,12)=7.7, p<.017). 
35 days poststroke only mice on Control diet demonstrated lower CBF in right 
cortex (F(1,12)=5.2, p<.043), right hippocampus (F(1,12)=9.4, p<.010), and in right 
thalamus (F(1,12)=8.1, p<.015) compared to corresponding left ROI. Contrarily, 
mice on Fortasyn showed only a decreased CBF in right thalamus compared to left 
thalamus (F(1,10)=17.3, p<.002). Moreover, Fortasyn mice had a higher CBF than 
Control mice in left cortex (F(1,11)=5.4, p<.040), right hippocampus (F(1,11)=5.2, 
p<.045), and also the left thalamus (F(1,11)=7.4, p<.020) over time.
We also investigated CBF over time from 7 days to 35 days poststroke. While 
animals on Control diet showed only a decreased CBF in left cortex (F(1,12)=17.7, 
p<.002) and in left hippocampus (F(1,12)=3.7, p<.079) over time, animals on 
Fortasyn diet did not show these decreases (left cortex, F(1,11)=1.4, p<.256; 
left hippocampus, F(1,11)=.0, p<.886), and had an increased CBF in the right 
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hippocampus (F(1,11)=7.6, p<.019) and right thalamus (F(1,11)=6.1, p<.032) over 
time. At 7 days poststroke, Fortasyn mice exhibited a lower decrease in cortical 
CBF than Control mice (F(1,12)=7.7, p<.017). This beneficial effect was also seen 
at 35 days poststroke in the hippocampus of Fortasyn fed mice compared with 
Control diet fed mice (F(1,11)=5.5, p<.040). From 7 to 35 days poststroke both 
dietary groups showed a less impaired CBF in cortex (Control, F(1,12)=10.9, 
p<.007; Fortasyn, F(1,11)=5.5, p<.040) and hippocampus (Control, F(1,12)=6.7, 
p<.024; Fortasyn, F(1,11)=10.1, p<.009), while this improvement was also revealed 
in the thalamus of Fortasyn mice only (Control, F(1,12)=2.4, p<.147; Fortasyn, 
F(1,11)=7.9, p<.018).
Figure 3. Cerebral blood flow (CBF) determined with flow-sensitive alternating inversion 
recovery (FAIR) MRI 7 and 35 days after tMCAo in cortex, hippocampus and thalamus 
of mice on Fortasyn or Control diet. Values represent mean±SD. (B) Representative 
high-resolution voxel-wise analyzed CBF image at 7 and 35 poststroke. (A) 7 days poststroke 
CBF in right cortex (Control, p<.001; Fortasyn, p<.001), right hippocampus (Control, p<.001; 
Fortasyn, p<.001), and in right thalamus (Control, p<.005; Fortasyn, p<.001) were lower 
than corresponding left ROI for both diets. Mice on Fortasyn showed increased CBF in right 
affected cortex (p<.017). 35 days poststroke, Control mice demonstrated lower CBF in right 
cortex (p<.043), right hippocampus (p<.010), and right thalamus (p<.015) compared to 
left ROI, while Fortasyn mice demonstrated decreased right thalamic CBF (p<.002) and a 
higher CBF than control mice in left cortex (p<.040), right hippocampus (p<.045), and also 
left thalamus (p<.020) at day 35. Control mice showed a decreased left cortical (p<.002) 
and left hippocampal (p<.079) CBF over time, Fortasyn fed animals showed increased CBF 
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in right hippocampus (p<.019) and right thalamus (p<.032) over time. (C) Fortasyn mice 
exhibited a less diminished cortical CBF at 7 days poststroke (p<.017) and in hippocampal 
CBF at 35 days poststroke (p<.040). CBF recovery was shown in cortex (Control, p<.007; 
Fortasyn, p<.040) and hippocampus (Control, p<.024; Fortasyn, p<.009), and thalamus 
(Fortasyn, p<.018).
Diffusion tensor imaging (Nijmegen, The Netherlands)
Quantitative assessment of diffusion tensor derived indices (fractional anisotropy, 
FA, Figure 4B; and mean diffusivity, MD, Figure 4C) was performed for ROI drawn 
in white and gray matter regions to assess diet and time effects 7 and 35 days 
poststroke.
Fractional anisotropy
Fortasyn mice showed a trend of an increased FA in the right Motor Cortex (MC) 
compared to Control (F(1,22)=4.2, p<.053) at 7 and 35 days poststroke. Notably, a 
diet effect was found over time in the ROI containing the right Caudate, Putamen 
and Globus Pallidus (Cpu+GP, F(1,22)=3.8, p<.065). More specifically, only mice 
on Fortasyn showed an increase in FA in the right Cpu+GP over time (F(1,11)=1.2, 
p<.044), while mice on Control diet did not show this increase.
All mice, showed increased FA over time poststroke in the left Corpus Callosum 
(CC, F(1,22)=3.8, p<.065), left Hippocampus (HC, F(1,22)=5.6, p<.028), right HC 
(F(1,22)=9.0, p<.007), and left optic tract (F(1,22)=4.1, p<.055).
7 days poststroke in both dietary groups a lower FA was measured in the right 
caudate CPu+GP compared with CPu+GP in the left hemisphere (Control, 
F(1,12)=6.4, p<.027; Fortasyn, F(1,12)=9.1, p<.011). 
While Fortasyn mice showed no significant decrease of FA in the right ROI 
compared with the corresponding left ROI at 35 days poststroke, Control mice 
showed a lower FA in the right visual cortex (VC, F(1,10)=6.5, p<.030) compared 
to left VC. 
Mean diffusivity
Again, at 7 and 35 days poststroke Fortasyn mice had a lower MD in the right MC 
than Control mice (F(1,22)=4.0, p<.059, trend). Notably, a diet effect was found 
over time in the left Cpu+GP (F(1,22)=3.4, p<.078): only mice on Control diet 
showed a non-significant decreased MD in the left Cpu+GP over time (F(1,11)=4.2, 
p<.066). In all mice, MD tended to decrease over time in the Fornix (F(1,22)=3.8, 
p<.065).
While Fortasyn mice showed no MD increase in the right hemisphere ROI compared 
with the corresponding left hemisphere ROI at 35 days poststroke, Control mice 
showed a higher MD in the right Cpu+GP (F(1,10)=9.9, p<.030) compared to left 
Cpu+GP. 
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Figure 4. Quantitatively assessed diffusion tensor derived indices at 7 + 35 days poststroke 
in mice fed Fortasyn or Control diet. Fractional anisotropy (FA) and mean diffusivity 
(MD) were measured for ROI drawn in white and gray matter regions (AUC=auditory 
cortex, CC=corpus callosum, F=fornix, HC=hippocampus, MC=motor cortex, OT=optic 
tract, SSC=somatosensory cortex, VC=visual cortex, Cpu+GP= caudate putamen+globus 
pallidus). Values represent mean±SD. (A) Representative high-resolution set of three 
(Bregma: 0.38, -1.34, -2.92) FA images is shown for each dietary group 7 and 35 days 
poststroke. (B) Fortasyn mice showed a higher FA in the right MC than Control mice 
(p<.053) 7 and 35 days poststroke. Only mice on Fortasyn showed an increased FA in right 
Cpu+GP over time (p<.044). In all mice, FA increased from day 7 to day 35 poststroke in left 
CC (p<.065), left HC (p<.028), right HC (p<.007), and left OT (p<.055). Both dietary groups 
demonstrated a lower FA in right Cpu+GP compared to left Cpu+GP (Control, p<.027; 
Fortasyn, p<.011) 7 days poststroke. Control mice showed a lower FA in right VC (p<.030) 
compared to left VC. (C) Fortasyn mice showed a lower MD in the right MC than Control 
mice overtime (p<.059, trend). Only Control fed mice showed a non-significant decrease in 
MD in left Cpu+GP over time (p<.066). In all mice, MD seemed to decrease again from day 
7 to day 35 poststroke in the F (p<.065). Only Control mice showed a higher MD in right 
Cpu+GP (p<.030) than in left Cpu+GP.
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Resting state fMRI (Nijmegen, The Netherlands)
To compare functional connectivity (FC) patterns at 7 and 35 days poststroke 
and on different diets, rsfMRI data were statistically analyzed based on total 
(Supplemental figure 2A-C) and partial correlation (Figure 5A-C) in twelve 
ROI including: left and right dorsal hippocampus (DH), left and right ventral 
hippocampus (VH), left and right auditory cortex (AU), left and right motor cortex 
(M1), left and right somatosensory cortex (S1), and left and right visual cortex 
(V1).
Total correlation analyses 
With total correlations no significant diet effects nor time effects (Supplemental 
figure 2B,C) were measured.
Partial correlation analyses 
Partial correlation analysis accentuates the direct connectivity between two ROI, 
while regressing the temporal BOLD signal from all other ROI. For the partial 
correlations we found significant diet effects at 7 and 35 days poststroke (Figure 
5B). 
At 7 days after tMCAo Fortasyn mice showed a decreased FC between left and 
right DH (F(1,8)=11.2, p<.011), and between right DH and left AU (F(1,8)=5.4, 
p<.050). In contrast, already at 7 days poststroke Fortasyn exhibited an increased 
FC between right AU and right V1 (F(1,8)=6.2, p<.038). 
At 35 days poststroke Fortasyn mice showed only a decreased FC between left DH 
and left V1 (F(1,8)=5.7, p<.044), while FC between right VH and left AU (F(1,8)=5.5, 
p<.048), and between right AU and left M1 (F(1,8)=6.8, p<.032) was increased in 
mice fed the Fortasyn diet.
For the partial correlations we found significant time effects in mice on both diets 
(Figure 5C). Main findings were less negative effects over time in animals fed 
Fortasyn than animals fed the Control diet. Furthermore, a beneficial effect on FC 
between left and right M1 was revealed only in Fortasyn mice.
On Control diet, FC was lowered between left DH and right S1 (F(1,8)=11.6, 
p<.010), between left VH and right AU (F(1,8)=6.2, p<.038), between right VH 
and left AU (F(1,8)=22.9, p<.002), and between right AU and left M1 (F(1,8)=6.5, 
p<.035), while FC was heightened between right DH and left VH (F(1,8)=5.9, 
p<.041), between right AU and left DH (F(1,8)=13.9, p<.006), and between left V1 
and left M1 (F(1,8)=5.9, p<.041).
On Fortasyn diet, FC was decreased only between left DH to left VH (F(1,8)=5.3, 
p<.050) and right AU to left V1 (F(1,8)=9.1, p<.017). Notably, mice on Fortasyn had 
a higher FC between left and right M1 over time (F(1,8)=6.8, p<.032).
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Figure 5. Resting-state functional connectivity (FC) based on partial correlation analyses 
(A) in the brains of mice fed Fortasyn or Control diet 7 and 35 days poststroke. FC was 
measured between 12 ROI: dorsal hippocampus (DH), ventral hippocampus (VH), 
auditory cortex (AU), motor cortex (M1), somatosensory cortex (S1), and visual cortex 
(V1). (B) 7 days poststroke Fortasyn mice showed decreased FC between DH and right 
DH p<.011), and between right DH and left AU (p<.050). Fortasyn mice exhibited an 
increased FC between right AU and right V1 (p<.038) 7 days poststroke. At 35 days after 
tMCAo Fortasyn mice showed decreased FC between left DH and left V1 (p<.044), while 
FC between right VH and left AU (p<.048), and between right AU and left M1 (p<.032) was 
increased in Fortasyn mice. (C) On Control diet, FC was lowered over time between several 
ROI, e.g. left DH and right S1 (p<.010), while FC was increased between left V1 and left 
M1 (p<.041). On Fortasyn diet, FC was decreased between left DH to left VH (p<.050) and 
right AU to left V1 (p<.017). Fortasyn fed mice had a higher FC between left and right M1 
over time (p<.032).
PET results (Münster, Germany)
N=24 mice underwent tMCAo surgery and were intra-individually followed 7d, 14 
d, and 35 d poststroke by PET using the TSPO ligand [18F]DPA-714. [18F]DPA-714 
signal appeared within and around the infarct as determined by T2w-MRI (Figure 
6A). In accordance, immunohistochemical data showed good spatial agreement 
as well as reduced TSPO levels in the Fortasyn group (Figure 6B). Double staining 
immunohistochemistry for TSPO and GFAP indicates astrocytes as source of TSPO 
at late time points after stroke (Figure 6C).
Investigation of diet effects over time revealed that [18F]DPA-714 mean uptake ratios 
(Figure 6D) were significantly reduced from 7 to 35 d poststroke in the Fortasyn 
group (Lmean/Cmean: 1.43+/-0.16; n=5) when compared to Control animals 
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(Lmean/Cmean: 1.58+/-0.16; n=5; F(1,8)=7.1, p<.029). Similarly, comparison of 
the maximum [18F]DPA-714 radio uptake ratios (Figure 6E) highlighted reduced 
[18F]DPA-714 uptake in the Fortasyn diet group from 7 to 35 d poststroke (Lmax/
Cmean: 1.57+/-0.23; n=5) as compared to the Control diet group (Lmax/Cmean: 
2.21+/-0.20; n=5; (F(1,8)=9.4, p<.016).
Immunohistochemical procedures 
In the supplemental material (supplemental figures 3-7) for each 
immunohistochemical staining a set of photos is given showing photos of each 
animal group in each ROI.
GLUT-1 staining (Nijmegen, The Netherlands)
All brains were processed for immunohistochemical staining with GLUT-1 antibody 
(glucose transporter-1). In order to reveal the changes in total GLUT-1 amount 
as well as in capillary density, we measured relative GLUT-1+ area and counted 
manually the amount of GLUT-1+ blood vessels in the cortex, hippocampus, and 
thalamus (Figure 7A-C). In the supplemental material
No diet effects were found for total GLUT-1 amount in the cortex, hippocampus, 
and thalamus (Figure 7B). Notably, Fortasyn mice had more GLUT-1 positive blood 
vessels in the cortex than Control mice (Figure 7C, F(1,13)=5.8, p<.024), especially 
in the right cortex (F(1,13)=5.6, p<.034) indicating a higher vascular density.
IBA-1 staining (Nijmegen, The Netherlands)
The brains of all mice were immunohistochemically stained with an antibody 
against ionized calcium-binding adapter molecule 1 (IBA-1, Figure 7D). IBA-1 
is expressed by microglia, but also by phagocytes in general (monocytes and 
macrophages). We measured relative IBA-1+ area and the amount of IBA-1+ cells 
in the cortex, hippocampus, and thalamus (Figure 7D-F). 
Compared to the left thalamus, the right thalamus revealed an increased relative 
IBA-1+ area (Figure 7E, F(1,26)=12.2, p<.002) and also an increased amount of 
IBA-1+ cells (Figure 7F, F(1,26)=21.8, p<.001) in mice on both diets. While mice 
on Fortasyn seemed to have a decreased relative IBA-1+ area in the cortex 
(F(1,28)=4.0, p<.057) and the hippocampus (F(1,24)=4.1, p<.054) compared with 
mice on Control diet, a non-significant increased relative IBA-1+ area was seen in 
the thalamus of Fortasyn mice (F(1,26)=3.5, p<.074). In addition, mice on Control 
diet had more IBA-1+ cells in their right hippocampus than mice on Fortasyn 
(Figure 7F, F(1,12)=5.5, p<.037), and also all mice on Fortasyn showed less IBA1+ 
cells in the total hippocampus than mice on Control diet. (Figure 7F, F(1,24)=4.8, 
p<.039). 
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Figure 6. Positron Emission Tomography (PET) of microglial activation. (A) Representative 
intra-individual MR images and fusion images over time with PET of mice fed with the 
Control diet (left) versus mice fed with the Fortasyn diet (right). Fortasyn fed mice showed 
a reduced uptake of [18F]DPA-714 in the infarction after 35 days. (B) Comparison of [18F]
DPA-714 with TSPO immunohistochemistry reveals reduced TSPO staining in Fortasyn 
animals (Scale bar: 1000µm and 50µm). (C) Irrespective of the dietary intervention, TSPO 
(red) is also expressed by astrocytes (green) 35d after tMCAo (Scale bar: 100µm. (D) Values 
represent mean+SD. [18F]DPA-714 mean uptake ratios were significantly reduced from 7 to 
35 d after tMCAo in the Fortasyn group when compared to Control animals (p<.029). (E) 
Comparison of the max [18F]DPA-714 radio uptake ratios highlighted reduced [18F]DPA-714 
uptake in the Fortasyn diet group from 7 to 35 d (p<.016).
DCX staining (Nijmegen, The Netherlands)
Immature neurons were visualized in all mice with a polyclonal antibody against 
doublecortin (DCX). As a measure for neurogenesis, DCX+ cells were counted 
in the subgranular zone of the hippocampus (Figure 7G+H) and DCX+ area was 
measured also in the subventricular zone (SVZ, Figure 7I+J).
No diet effects were found in the hippocampus. In the right SVZ Fortasyn fed mice 
had more DCX+ area than in their left SVZ (Figure 7J, F(1,12)=4.9, p<.047), and 
than Control fed mice in the same ROI (Figure 7J, F(1,12)=5.4, p<.039). 
SYN and PSD-95 staining (Nijmegen, The Netherlands)
The amount of presynaptic boutons was visualized with a monoclonal antibody 
against synaptophysin (SYN). Whereas, postsynaptic density was stained with a 
polyclonal antibody against postsynaptic density protein 95 (PSD-95) reflecting 
synaptic function. Both pre- (Figure 7K-M) and postsynaptic (Figure 7N-P) density 
were measured in the cortex and caudate putamen (Cpu).
No diet effects were found in the cortex and Cpu for both the relative SYN+ and 
PSD-95+ area. All mice showed a decreased relative SYN+ area in the right Cpu 
(Figure 7M, F(1,25)=9.2, p<.006) compared to corresponding left ROI.
All mice had a lowered PSD-95+ area in the right cortex (Figure 7O, F(1,26)=11.3, 
p<.003) and also in the right Cpu (Figure 7P, F(1,24)=35.5, p<.001) compared to 
corresponding left ROI.
TSPO immunohistochemistry (Münster, Germany)
Spatial comparison of [18F]DPA-714 with immunohistochemistry for TSPO at 
35 days after stroke revealed good spatial agreement. However, reduced TSPO 
immunohistochemistry was observed in Fortasyn treated animals (Figure 6B). 
Interestingly, 35 d after stroke astrocytes (GFAP) also expressed TSPO. (Figure 6C).
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Figure 7. Immunohistochemical stainings for glucose transporter-1 (GLUT-1, A-C), ionized 
calcium-binding adapter molecule 1 (IBA-1, D-F), doublecortin (DCX, G-J), synaptophysin 
(SYN, K-L) and Postsynaptic Density-95 Protein (PSD-95, N-P) on brains of Fortasyn and 
Control fed mice 35 days after tMCAo. Values represent mean±SD. (C) Fortasyn mice had 
more GLUT-1+blood vessels in the cortex than Control fed mice (p<.024), especially in the 
right cortex (p<.034) indicating a higher vascular density. (E) Mice on Fortasyn seemed to 
have a decreased relative IBA-1+ in cortex (p<.057) and hippocampus (p<.054) compared 
to Control fed mice. (E+F) The right thalamus showed a larger IBA-1+ area (p<.002) and 
more IBA-1+ cells (p<.001) than the left thalamus in mice on both diets. (F) Control fed 
mice had more IBA-1+ cells in the right hippocampus than Fortasyn fed mice (p<.037), 
whereas Fortasyn mice showed less IBA1+ cells in total hippocampus compared to Control 
(p<.039). (G-J) DCX+ cells were counted in the subgranular zone of the hippocampus (G+H) 
and in the subventricular zone (SVZ) (I+J). (J) Fortasyn fed mice had more DCX+ area in 
the right SVZ than in left SVZ (p<.047), and in the same ROI of Control fed mice (p<.039). 
(M) All mice showed a decreased relative SYN+ area in the right caudate putamen (Cpu, 
p<.006) compared to the left Cpu. (O+P) All mice had a lowered PSD-95+ area in the right 
cortex (p<.003) and in the right Cpu (p<.001) compared to the corresponding left ROI.
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Discussion 
The present data show that the specific nutrient combination Fortasyn may 
enhance recovery from ischemic stroke in mice, as evidenced by improved 
cerebral blood flow, reduced loss of functional connectivity, and improved motor 
performance. Relevant processes for recovery after stroke, such as neurogenesis, 
angiogenesis, and neuroinflammation, were positively affected by the Fortasyn 
diet. 
Cerebral hemodynamics
CBF was increased already at seven and also at 35 days poststroke in mice on 
Fortasyn diet. Notably, CBF dropped over time in several brain regions in Control 
mice from 7 to 35 days poststroke, while this decrease was not seen in Fortasyn 
mice. These results are in accordance with our previous research showing that 
this nutrient combination is able to improve cerebral perfusion in mice models 
of (vascular risk factors for) Alzheimer’s disease (AD) [224, 346]. In addition, 
improved vascular density due to an increased angiogenesis was found in the 
cortex of Fortasyn fed mice. This improved vascular health may explain the 
beneficial effects of Fortasyn on cerebral hemodynamics after the ischemic event.
DTI and rsfMRI
In the present study we investigated brain diffusivity with DTI as an imaging 
biomarker for white and gray matter integrity. FA is a marker of the degree of 
myelination and fiber density of white matter (WM), while MD characterizes an 
inverse measure of the membrane density and is sensitive to cellularity, edema, 
and necrosis in grey matter (GM) [348-350]. Here, we revealed an impaired 
WM microstructure at seven days poststroke in regions containing the Caudate 
Putamen and Globus Pallidus of both dietary groups. Notably, microstructural 
integrity of WM was restored in Fortasyn mice over time in affected regions 
containing Caudate Putamen and Globus Pallidus of the affected hemisphere. 
Moreover, at 7 and 35 days poststroke a slight beneficial effect on WM 
microstructure of the right Motor cortex was also seen only in Fortasyn mice. Also 
an improved GM microstructure in the right Motor cortex of Fortasyn animals at 
seven and 35 days, and an impaired GM integrity (an increase in MD) in regions 
containing the right Caudate Putamen and Globus Pallidus of only mice on Control 
diet was measured. Thus, Fortasyn may limit the damage to existing structures 
and may also support the regeneration of lost connectivity. Comparable results 
were found in other studies showing that intracerebral injection of EPA is able 
to stimulate the expression of myelin proteins in rat pup brain [560]. Partial 
correlations of functional connectivity data revealed several beneficial diet effects 
172
A specific dietary intervention to restore brain structure and functionChapter 7
already at 7 and also at 35 days poststroke. Fortasyn diet increased FC between 
several brain regions, and over time Fortasyn limited loss of FC compared to 
Control diet. Notably, Fortasyn mice showed an improved interhemispheric 
FC between the motor cortices supporting the therapeutic value of Fortasyn 
already after 35 days. The importance of dietary composition for developing 
and maintaining distributed brain systems was shown in another preclinical 
rsfMRI study showing that n3-LCPUFA are crucial for functional connectivity and 
large-scale system organization in rhesus macaque brains [561]. Additionally, in 
a 24-week randomized, controlled, double-blind, parallel-group, multi-country 
study de Waal et al. explored the effect of a nutritional intervention with Fortasyn 
on brain activity-based networks. They showed that the nutritional intervention 
preserved the organization of brain networks in patients with mild AD within 24 
weeks potentially via counteracting the progressive network disruption over time 
in AD [562]. In addition, in a recent study Fortasyn ameliorated deficits in FC in a 
mouse model for asymptomatic AD [346]. Notably, in a longitudinal observational 
clinical study acquiring rsfMRI data 4 times over a period of 6 months Park et al. 
demonstrated that FC of the ipsilesional M1 with the contralesional thalamus, 
supplementary motor area, and middle frontal gyrus at onset was positively 
correlated with motor recovery at 6 months after stroke [563]. 
Molecular alterations
The combination of phosphatide precursors like n3-LCPUFA, uridine, and choline, 
has proven to synergistically increase the synthesis of synaptic proteins and 
phospholipids in the brain [459, 535, 536]. In our study, a decreased amount 
of pre- and postsynaptic markers in the ipsilateral cortex and caudate putamen 
was observed indicating a significant negative effect of experimental stroke on 
synthesis and maintenance of synaptic proteins. Kawakita et al. demonstrated that 
DHA effectively promotes neurogenesis both in vitro and in vivo [564]. Notably, 
even in an experimental murine stroke model our specific nutrient combination 
was able to increase neurogenesis. Here, we measured via DCX a significant 
enhanced neurogenesis in the right (affected) border zones of the lateral ventricle 
in Fortasyn fed animals indicating accelerated (neuronal) membrane synthesis. 
Neuroinflammation
[18F]DPA-714 is a ligand for the 18 kDa translocatorprotein (TSPO), which is highly 
expressed by microglial cells upon neuroinflammatory stimuli. Previous studies 
have shown that the majority of PET signal is due to increased expression of TSPO 
by microglia [545, 565]. Therefore, [18F]DPA-714 has now already been used in 
a variety of clinical studies in neurological diseases [566]. However, due to the 
lack of specific markers and antibodies reliably distinguishing microglia and 
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macrophages it cannot be excluded that macrophages contribute to the signal. 
We and others have shown that under rather chronic conditions astrocytes faintly 
express TSPO (see Figure 7C and [567]), whereas at early-intermediate time points 
(24h-14 days) after stroke astrocytes seem not play an important role [545]. A 
decreased neuroinflammation/ microglial activation was observed with Fortasyn 
for up to 35 days post stroke by PET imaging. The beneficial function of Fortasyn 
was likely mediated by a reduction of IBA-1 positive cells. IBA-1, which is expressed 
in activated microglia and macrophages, was reduced at 35 days post stroke in the 
cortex and the hippocampus of Fortasyn mice. Notably, Harvey et al. could not 
show an effect of single administration of DHA on IBA-1 at three, 7, and 21 days 
after TBI on neuroinflammation in post-traumatic brain injury (TBI) in Sprague 
Dawley rats, indicating that a combination of factors may enhance diet function. 
However, they also showed that DHA may be able to facilitate the polarization 
of microglia or macrophages into an anti-inflammatory and reparative microglia 
phenotype [568]. The reduced neuroinflammatory response might also explain 
the beneficial effects on functional and structural connectivity. Several recent 
studies indicated that microglia are crucially involved in processes of synaptic 
remodeling and plasticity in the healthy brain [569-571]. In future preclinical 
stroke research the impact of Fortasyn on glial cells needs to be studied, since 
DHA as single component by itself is already able to modulate glial cell activity 
by regulating gene expression and release of inflammatory mediators, as well as 
serving as substrate for specialized pro-resolving mediators [572-574].
Motor function
Fortasyn mice tended to have more grip strength with all four limbs compared 
to control mice. This effect could partly be due to the beneficial effects of the 
Fortasyn diet on cerebral regions involved in motor functions. During the turning 
phase of the pole test set of fine-tuned and coordinated movements are required 
[554]. In the current study mice on Control diet needed more time to turn on 
the pole than mice on Fortasyn diet. In addition, Control mice showed a lateral 
bias at 15 days poststroke which was not present in Fortasyn mice. These latter 
results are in accordance to the recent study of Bourourou et al. Here, the dietary 
supplementation with the omega-3 precursor, alpha-linolenic acid, was more 
effective in improving motor coordination in a mouse model of ischemic stroke 
than intravenous treatment [575]. Notably, at 23 days poststroke all Fortasyn 
mice walked more often than the Control mice and also more often than at three 
days poststroke indicating an improved locomotion. These latter results are in line 
with other studies demonstrating that DHA treatment has beneficial effects on 
locomotor activity [18, 346]. While Cao et al. focused only on the preventive effect 
of DHA treatment and Hong et al. on the acute phase after stroke, in our study we 
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now finally get one step further towards effective acute treatment for recovery after 
stroke which is still lacking for many stroke patients. The pole and grip test were 
not performed at multiple time points after tMCAo like the Rotarod or open field. 
Future studies should repeat these motor tests at multiple time points to obtain 
additional indications of the long-term effects of Fortasyn on motor performance 
at later time points poststroke. Particularly, rodents are well known to be able to 
compensate functional differences rather than presenting true recovery after an 
experimental stroke [576]. Notably, an example of functional compensation in our 
study is the improved functional connectivity over time in our control mice. Here, 
control mice also showed an improved functional connectivity between several 
brain regions, being not present in animals on Fortasyn diet. Here, we were able 
to demonstrate beneficial dietary effects already at 7 and also at 35 days post 
experimental stroke. Future studies should also focus on more severe stroke 
models to study the beneficial effects of multi-nutrient interventions.
We showed improvement of long-term outcome using a specific combination 
of nutrients. Notably, in the current experiments no effect on body weight was 
detected, but all Fortasyn mice seemed to have a higher food intake during all 35 
days after an experimental stroke. 
We did not find diet effects on cognition in the novel object recognition test (ORT) 
measured from 22 to 24 days poststroke. This absent effect is in line with previous 
research of Wang et al. who demonstrated a significantly reduced preference 
at 7 and 14 days following stroke, but normal values between 21 and 28 days 
post-stroke, within the ORT [577]. Therefore in future research, the ORT should be 
performed earlier after the induction of the experimental stroke to reveal subtle 
dietary effects. 
Summary and conclusions 
This international, multicenter preclinical study was exerted according to ARRIVE 
and STAIR guidelines [214, 541-543] revealing that multimodal neuroimaging 
combined with behavioral analysis is an excellent approach to assess brain 
and motor function recovery after stroke. In addition, this experimental setup 
shows the beneficial effects of an academic-industry collaboration and an 
industry-relevant translational research covering many aspects and complexities 
of a multicenter multimodal paradigm [578, 579]. In conclusion, our data indicate 
that a post-stroke intervention with the specific nutrient combination of Fortasyn 
is able to support recovery after ischemic stroke, by improving cerebral circulation 
due to an improved vascularization and increased angiogenesis, protecting 
white and gray matter integrity, restoring functional connectivity, increasing 
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neurogenesis, decreasing the neuroinflammatory response, and improving motor 
skills and muscle strength. No therapeutic intervention is available for stroke yet, 
but the broad range of structural and functional therapeutic benefits observed in 
the present study indicates clear therapeutic potential of the Fortasyn nutrient 
combination to support functional recovery after ischemic stroke. This recent study 
investigating a specific dietary approach which has been tested in several mouse 
models of (risk factors) AD, is the first step in the development of tailor-based 
dietary treatments against stroke. Increased adherence to a Mediterranean-style 
diet lowers the risk of ischemic stroke [163], and future studies should therefore 
start to focus on optimization of multicomponent combinations targeting dietary 
components of the Mediterranean diet to improve clinical outcome after a stroke.
Supplementary material
Supplementary material can be found here:  
http://www.thno.org/v07/p0493/thnov07p0493s1.pdf
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Summarizing discussion 
Due to the increasing life expectancy, dementia is developing into one of 
the major public health problems in the aging world population [189, 190]. 
Alzheimer’s disease (AD) and vascular dementia (VaD) are responsible for most 
cases of dementia [2, 3]. The production of Aβ peptides – deposited in plaques - is 
increased in familial forms of AD and is thought to be the primary driving force 
in non-familial (sporadic) AD pathogenesis [21]. Although this amyloid cascade 
hypothesis is still the dominant theory for the pathogenesis of AD, it is under 
debate for years whether the Aβ plaques and the NFTs are the main cause of 
neurodegeneration in AD [22]. To underline this, studies revealed that the density 
of senile Aβ plaques in brains of non-affected patients may resemble the large 
amount of Aβ found in brains of AD patients [23, 24]. Epidemiological and clinical 
studies demonstrated that AD and VaD share common vascular related risk factors 
such as hypertension, diabetes, hyperlipidemia, cerebrovascular disease, and 
arrhythmia [91-96, 192, 193]. Furthermore, it has been shown that vascular risk 
factors can influence the development of AD pathology (the vascular hypothesis) 
[194]. AD, VaD, and stroke share hypertension as a common risk factor, while 
stroke in itself is also a risk factor for the development of AD and VaD. The risk 
of incident dementia is elevated in patients with ischemic stroke [580], but even 
mild dementia and cognitive impairment are related to an increased incidence 
of stroke among subjects age 75 years old and over [581]. The apolipoprotein E 
ε4 allele (apoE4) represents another strong genetic (vascular) risk factor for AD 
as it is associated with increased cardiovascular risk factors [12, 50]. Recently, 
research is focusing on the very early, asymptomatic phase of the disease, in which 
(cerebro)vascular impairment may be the strongest contributor to the onset and 
progression of neurodegenerative traits of typical AD and dementia in general 
[450]. Preventive approaches have therefore consistently emerged as key policy 
priorities in recently formulated dementia strategies. These approaches include 
modification of health-compromising behavior such as lifestyle and dietary intake 
that may lead to AD. Contrarily, the Mediterranean diet (MD; high consumption 
of fruit, vegetables and legumes, moderate consumption of fish, nuts and olive 
oil as the main source of fats), has been associated with a reduced risk of AD 
[445, 446] and with a lower mortality [447, 448]. Notably, in the Doetinchem 
Cohort Study high intake of some subgroups of fruits and vegetables (i.e. nuts, 
cabbage and root vegetables) was associated with better cognitive function at 
baseline and/or smaller decline in in middle-aged individuals [582]. Moreover, a 
meta-analysis showed that interventions aiming at adopting a MD dietary pattern 
for at least 1 year reduced both the systolic blood pressure (BP) and diastolic BP 
levels in individuals with normal BP or mild hypertension [583]. Among persons 
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at high cardiovascular risk, a MD supplemented with extra-virgin olive oil or 
nuts reduced the incidence of major cardiovascular events [584]. Moreover, this 
latter MD supplemented with nuts was able to exert a beneficial effect on the 
risk of depression in patients with type 2 diabetes [585]. In accordance with the 
beneficial effect on hypertension, another meta-analysis revealed that even only a 
very moderate fish consumption protects against the incidence of ischemic stroke 
[157]. Docosahexaenoic acid (DHA), one of the main components in fish oil besides 
eicosaepentanoic acid (EPA), both being omega-3 long-chain polyunsaturated 
fatty acids (n3-LCPUFAs), has proven its benefits as therapeutic approach for 
focal ischemic stroke [517, 586]. Other dietary nutrients may instead directly 
protect synaptic integrity. For instance, the formation of phosphatidylcholine, 
the most common phosphatide in the brain and a major component of the 
neuronal membrane, is promoted due to presence of its precursors in the diet 
[456, 457]. Several preclinical studies confirmed these findings, showing that 
animals supplemented with the combination of these membrane precursors 
showed heightened levels of brain phospholipids, dendritic spines and neurite 
outgrowth, with beneficial effects on cognition [260, 458-461]. Therefore, a 
novel multi-nutrient supplementation diet called Fortasyn (Fortasyn®Connect, 
medical name Souvenaid), containing DHA and EPA, besides other precursors and 
cofactors for membrane synthesis, such as uridine, choline, phospholipids, folic 
acid, vitamins B12, B6, C, and E, and selenium, has been proposed for the dietary 
management of AD [462]. Although it has been demonstrated that this nutritional 
supplement addresses specific nutritional deficiencies in early AD and that it may 
improve functional connectivity as assessed by EEG [466] and MRI [461], other 
processes by which it may have an impact on the pathophysiology of AD need to 
be further investigated, and more studies are required to confirm its efficacy.
This thesis aimed to elucidate the underlying pathological processes of major 
vascular risk factors hypertension, apoE4 and stroke during very early development 
of neurodegenerative processes in AD using several mice models. Another aim 
of this thesis was to investigate whether vascular risk factors have the potential 
to accelerate the course of neurodegenerative processes in AD. In addition, this 
thesis also intended to investigate the possible capacity of antihypertensives and 
specific multi-nutrient diets to serve as preventive or treatment against AD-like 
symptoms and vascular risk factors in the very early stage of AD.
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Familiar Alzheimer’s Disease/ Genetic Risk Factors
Aβ
As mentioned above, the excessive production of Aβ proteins and the consecutive 
formation of Aβ plaques is a pathological hallmark of the familial forms of AD. 
During the course of AD, pathological hallmarks are not only the deposition of Aβ 
plaques into parenchymal and cerebrovascular walls, but also the production of 
intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein 
(NFT), and neuronal cell loss [388-390]. Already during the early stages of AD, the 
accumulation of Aβ affects specific brain regions like the forebrain and medial 
temporal lobe structures like hippocampus, amygdala and entorhinal cortex [180, 
181, 391]. This increased Aβ production might also lead to cerebral amyloid 
angiopathy (CAA) which exacerbates cerebrovascular degeneration [587-589]. 
Studies on MCI and AD patients [246] revealed an impaired cerebral blood flow 
(CBF) in the early phase of AD, which may possibly be caused by an accumulation 
of Aβ in the vessel walls or in close vicinity of the blood vessels [204, 247, 248]. 
The pathophysiological process of AD can be divided into several stages, including 
the very early phase showing no pathology being followed by the preclinical phase 
wherein the Aβ accumulation, the synaptic dysfunction, and tau-mediated 
neuronal injury is promoted [590]. The next pathological stage of AD is the MCI 
stage involving impairment of brain structures accompanied by cognitive decline 
[590]. These stages indicate that increased vascular and parenchymal Aβ 
deposition is accompanied by a diminished CBF leading to impaired cognition. 
Furthermore, the impaired vasoreactivity observed in our transgenic mice is also 
a clinical hallmark of AD [249]. Aβ is able to directly enhance the vasoconstriction 
of the cerebral arteries and to stimulate selected constrictor responses, resulting 
in a reduced CBF [247]. In addition, deposition of Aβ in the cerebral microvessels 
promotes vascular pathology and dysfunction [250-252]. In this thesis we also 
used an Aβ-overexpressing AD-like mouse model, the double transgenic AβPP/
PS1 mouse [213, 291]. This AD-like mouse model tested in studies described in 
chapter 2 to chapter 5 of this thesis resembles a mouse model for cerebral 
amyloidosis and familial early-onset AD [212, 213]. In chapter 2 we aimed to 
elucidate the underlying vascular origin of the very early phase of neurodegenerative 
processes in AD, therefore we investigated the relation between vascular 
parameters (systolic blood pressure (SBP), cerebrovascular density, cerebral 
perfusion and vasoreactivity), functional and structural connectivity, and 
postmortem markers for neuroinflammation, neurogenesis, postsynaptic density, 
and levels of fatty acids and sterols, and their relationship with cognition in the 
AβPP/PS1 mouse model. This study aimed to reveal how vascular parameters like 
SBP are involved in the AD pathology of aging AβPP/PS1 mice. These aging 16 to 
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18-month-old AβPP/PS1 mice showed an increased SBP linked to a declined 
regional CBF. Furthermore, using advanced MRI techniques, decline of functional 
and structural connectivity was revealed in the AD-like mice in relation to impaired 
cognition, increased locomotor activity and anxiety-related behavior. In 
accordance, also in chapter 3, we investigated cerebral hemodynamics in younger 
12-month old, normotensive and hypertensive AβPP/PS1 mice, and showed that 
the hypertensive AD-model mice had an impaired CBF in the hippocampus (and a 
slightly reduced CBF in the thalamus). Hypertension as a major vascular risk factor 
is able to induce AD-like symptoms like an impaired CBF. Aging and AD genotype 
lead to more AD-like symptoms due to declining CBF and possibly related energy 
metabolism of the aging brain. In aging rats, structural abnormalities of cerebral 
microvessels [591-593] like microvascular fibrosis, and basement membrane 
thickening were observed [592, 594]. Notably, these age-related, degenerative 
capillary changes can be accelerated by chronic hypertension [595]. These 
pathological microvascular alterations combined with a lowered cerebral 
perfusion can block nutrient transport to and consequent metabolic activity of 
the brain [596] contributing to impaired cognition [597], as seen in our aged AD 
mice. In accordance, this AD-like mouse model suffers from early-impaired CBF, 
but also shows abnormalities in the cortical microvasculature [242-245], 
additionally presenting cognitive decline and impaired memory [435]. All 
untreated (normotensive and hypertensive) 12-month old AβPP/PS1 mice 
demonstrated impaired cerebrovascular circulation (chapter 4). Notably, in 
chapter 4 we investigated whether AngII-induced hypertension causes 
neurovascular dysfunction leading to cognitive decline independent of AD 
pathology. Moreover, we also tested if AngII-induced hypertension adds to the 
cognitive effects of AD or even is able to mimic AD in absence of underlying AD 
pathology in 12-month old normotensive and hypertensive AβPP/PS1 mice 
compared to their age-matched WT littermates. Here, we found again that 
transgenic AD-model mice had an impaired cerebral blood flow. Paris et al. 
showed that soluble Aβ peptides can enhance vasoconstriction induced by 
endothelin-1 (ET-1), which is an endogenous vasoconstrictor [299]. Moreover, in 
WT and AD model mice cerebral autoregulation remained intact resembling the 
human AD situation [598]. The severity of disturbances in cerebral hemodynamics 
is significantly lower in AD compared to VaD [599]. Notably, cerebral vasomotor 
reactivity to hypercapnia is reduced in AD [600]. In chapter 4 we now further 
investigated the effect of AngII-induced hypertension in our 12-month-old AD-like 
model mice using advanced MRI techniques, the Morris water maze (MWM), and 
immunohistochemical stainings. In particular, at 12 months of age, SBP of AD 
mice was increased compared to WT littermates. In addition, these hypertensive 
12-month-old AD mice presented an impaired functional connectivity (FC) 
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comparable to the FC at 18 months of age indicating the impact of hypertension 
on FC in AD-model mice. With resting-state fMRI (RsfMRI) spontaneous neural 
activity through the blood-oxygen-level-dependent (BOLD) signal change [601] 
representing FC can be analyzed. Impaired FC is a clinical symptom found in AD 
patients as well [206-208] and additionally, a link between the incidence of white 
matter lesions and the severity of the underlying AD pathology like cognitive 
impairment has also been reported [209-211]. In accordance, a lowered 
connectivity between cortical regions was detected in older hypertensive AD 
patients relative to older non-hypertensive AD patients [602]. Furthermore, the 
aforementioned hyperactivity present in our aged 18-month-old AβPP/PS1 mice 
seems to be a specific characteristic of many AβPP transgenic mice [441-443] 
including the AβPP/PS1 mouse, being potentially related to elevated levels of 
anxiety in these animals [443, 444]. Anxiety is also a clinical symptom of dementia 
[603]. Post mortem analyses demonstrated also an enhanced neuroinflammation, 
and both lowered synaptogenesis and neurogenesis in these aged 18-month-old 
AβPP/PS1 mice (chapter 2). Aβ-plaques in AD are engulfed by activated microglia 
[271]. In accordance to the study of Minogue et al., an age-associated dysregulation 
of microglial activation is coupled to an enhanced blood-brain barrier permeability 
in this mouse model after 14 months of age [268]. In the early pre-plaque stages 
of transgenic AD mice and, to a much lesser extent, in old WT mice highly activated 
microglia have been found [267-271]. As mentioned above, all these pathological 
changes in the AβPP/PS1 mouse model lead to an impaired cognition as found in 
18-month-old transgenic mice (chapter 2). In accordance, induced hypertension 
in 12-month-old AβPP/PS1 mice, was followed by a decreased spatial learning 
capacity during the MWM indicating a diminished cognitive function like in aged 
transgenic AD model mice. Additionally, we analyzed the different search 
strategies to find the hidden platform in the MWM using a parameter-based 
algorithm to assess the qualitative aspects of learning (chapter 5) [183-187]. In 
behavioural neuroscience the MWM navigation task is used to examine spatial 
memory and learning [421]. Cognition of mice can be studied with the common 
MWM test, but the qualitative aspects of learning cannot be assessed. In our 
study described in chapter 5 we investigated the use of spatial learning of 
transgenic mice by analyzing the hippocampus-dependent search strategies. 
Here, we demonstrated that AβPP/PS1 mice used the ‘’chaining’’ search pattern 
during the fourth day of the MWM as their dominant search strategy. During the 
‘’chaining’’ strategy, the mice use circular swimming at a fixed distance from the 
wall being equal to the distance between platform and wall of the pool. Therefore, 
they utilize the visual cues or the height of the wall of the pool to determine the 
distance of the platform from the wall. Several studies revealed the use of diverse 
search strategies in rats and AD transgenic mice [185, 187, 422, 426-429]. In 
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accordance to our results, impairment in spatial working memory was 
demonstrated in a six-arm radial water maze in another transgenic mouse model 
for AD however showing a retained plasticity to choose alternative search 
strategies like the chaining search strategy [604]. In addition, our transgenic 
AD-like mice did not show clear preference for the target quadrant, indicating an 
impaired spatial memory. This supports the AD-like pathology of the AβPP/PS1 
mice presenting cognitive decline and impaired memory [435]. The present AβPP/
PS1 mouse model used in the studies described in chapter 2 to chapter 5 showed 
that an increased SBP is present already in younger, 10- to 12-month-old, 
transgenic mice, but that induced hypertension promotes a cerebrovascular 
dysfunction accompanied by an impaired FC and cognition. In contrast, in aged 
animals increased SBP, impaired cognition, increased locomotor activity, and an 
anxiety-related behavior was concomitant with impairments in cerebral 
hemodynamics, and loss of structural and functional connectivity. Therefore, this 
AD murine model could serve as translational tool for the development of 
treatments to inhibit neurodegenerative diseases like AD already in the prodromal 
phase of the disease, also because of its vulnerability to a vascular risk factor like 
hypertension already at younger age.
ApoE4
As mentioned above, familial early-onset AD (< 1% of all AD cases [388, 605]) is 
primarily caused by the overproduction of Aβ due to mutations in either the Aβ 
precursor protein (AβPP) and/ or in genes encoding presenilin 1 or presenilin 2 
being crucial components of the γ-secretase complexes responsible for cleavage 
and release of Aβ [606]. The apolipoprotein E ε4 allele (apoE4) represents 
another strong genetic (vascular) risk factor for sporadic AD [188]. ApoE is a 
34-kDa glycoprotein existing in three isoforms: apoE -ε2, -ε3 and -ε4; differing 
by one or two amino acid residues 112 and 158 [470]. In detail, apoE, produced 
mainly by astrocytes, plays a crucial role in cholesterol transport and clearance 
of Aβ [606]. This small difference of the three isoforms affects the conformation 
and structure of apoE which changes its potential to bind lipids, receptors and 
Aβ [471]. Specifically, apoE4 is related with increased neurotoxicity accompanied 
by a loss of neuroprotective function in the pathogenesis of Alzheimer disease, 
dependent or independent from Aβ accumulation [606]. Replacement of the 
murine APOE gene with the human APOE-ε4 (apoE-ε4/apoE4 mouse) [475], 
creates a novel appropriate animal model to examine the apoE4 phenotype and 
to measure the effects of very early AD-like pathology development. ApoE4 carrier 
mice have an altered lipid profile, with increased risk of atherosclerosis plaques 
formation [475], accompanied by an altered behavior and an impaired cognition 
[476]. Especially when challenged with a high-fat diet, these transgenic apoE4 
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mice demonstrate an altered cholesterol metabolism combined with heightened 
risk of developing vascular disorders and neuronal deficits [475]. The translational 
character of the apoE4 mouse makes it an extremely attractive model to study the 
effects of apoE4 on CBF, synaptogenesis and connectivity during aging (chapter 6). 
No genotype effects on cerebral blood volume, amount of presynaptic boutons, 
nor neurogenesis were observed in younger 12-month-old apoE4 mice compared 
to their age-matched WT littermates, while these transgenic mice exhibited an 
impaired spatial memory at that age [235]. These latter results are in line with 
the results described in chapter 6 using age-matched apoE4 and WT mice. Here, 
no effects of apoE4 were detected on all measured parameters including cerebral 
blood flow and number of post-synapses, despite some slight alterations in the 
sterol levels and an impaired FC. However, in aged 16- to 18-month-old apoE4 
mice an impaired cerebrovascular circulation, a reduced cortical post-synaptic 
density, and a disturbed white and gray matter integrity in white matter tracts 
was found. Additionally, these apoE4 mice had a significant lower FC between 
cortical and hippocampal regions, but also between cortical regions themselves. 
Recently, we also showed spontaneous functional connectivity impairments in 
these mice, possibly associated with cerebral blood flow reduction [484]. In a 
recent study of Luo et al. a decreased interhemispheric FC in apoE4 versus apoE3 
carriers was observed [607]. In accordance, in young, middle-aged, and elderly 
human apoE4 carriers an impaired CBF and cerebral glucose metabolism has 
been found in cerebral regions being affected during the pathological changes 
in AD [490]. Furthermore, during aging, apoE4 carriers show a faster decline in 
CBF than apoE3 carriers, which demonstrates that APOE genotype differentially 
impacts cerebrovascular function across the lifespan and that it may modify the 
relationship between CBF and cognition indicating a potential mechanism in the 
development of AD [608]. In 9 months old apoE4 mice we could not detect impact 
of genotype on spatial learning and memory [235], but as mentioned above 
these apoE4 mice exhibited an impaired cerebral hemodynamics at 18 months 
of age [484]. These latter results elucidate that the apoE4 mice is mirroring the 
asymptomatic/ preclinical phase of AD [590]. These human and our mouse data 
show the relationship between the apoE4-genotype and aging accelerating 
the course of neurodegenerative processes in AD like impaired structural and 
functional connectivity, CBF, and cognition. Therefore, this transgenic apoE4 
mouse model demonstrates also several clinical symptoms of AD during aging, 
making it a suitable animal model to study neurodegenerative diseases already 
in the prodromal phase of the disease. With our study we could show that apoE4 
is not only a strong genetic risk factor for AD. Notably, apoE4 represents also an 
association with increased cardiovascular risk factors [12, 50] like the impaired 
CBF in our aged apoE4 model mice indicating that apoE4 is also a major vascular 
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risk factor for AD. Contributing to an increased risk of AD, the apoE4 genotype 
is synergistically linked to atherosclerosis, peripheral vascular disease, or type 2 
diabetes [606, 609, 610], being by itself already vascular risk factors for AD.
Vascular Risk Factors
Hypertension
Hypertension is considered to be one of the leading causes of morbidity and 
mortality worldwide [611, 612]. Among all vascular related risk factors, 
hypertension is the most common cardiovascular risk factor [49, 108-115], being 
associated with all (other) key markers of AD such as of Aβ deposition, 
neurofibrillary tangles, and brain atrophy [114]. In several studies [95, 297] an 
association between midlife elevated BP compared to late-life elevated BP is 
found with cognitive impairment and AD [298]. Further evidence supporting this 
link between hypertension and AD comes from preclinical and clinical studies in 
which it is argued that antihypertensives may reduce the development of AD 
[196, 197]. A recent study showed that hypertension negatively affects the 
expression of tau in an animal for tauopathies as well as that of Aβ in an AD 
mouse model [195]. Other studies demonstrated that hypertension also triggers 
neuroinflammation prior to Aβ deposition and that chronic hypertension could 
lead to an impaired blood-brain barrier permeability with deposition of Aβ in 
brain tissue [315, 316]. Hypertension via promoting the development of 
atherosclerotic plaques, is able to alter the cerebral blood vessel structure and 
function [613]. Being a component of the renin-angiotensin system (RAS), 
Angiotensin II (AngII) is a candidate for the hypothesized mechanistic link between 
hypertension and AD [285]. AngII plays a crucial role in BP regulation [286], 
causing vasoconstriction and elevated BP by binding to the AngII-receptor type1 
(AGTR1) and AngII-receptor type2 (AGTR2) [286, 287]. It is thought to be a key 
mediator of the clinical syndrome of essential hypertension [319], through 
chronically induced vasoconstriction, increased aldosterone secretion, increased 
sympathetic tone, and cardiac and vascular hypertrophy [320, 614]. To examine 
the effect of hypertension on WT and AD mice, we used the so called slow pressor 
model of hypertension because of its similarities to some forms of AngII–
dependent hypertension in humans (chapters 3 and 4) [615-617]. In both studies, 
AD and their WT littermates received systemically a chronic infusion of either 
AngII (hypertension) or saline (normotension) delivered by subcutaneously 
implanted micro-osmotic pumps [217] starting from 10 months of age till 12 
months of age. In chapter 3 chronic AngII-infusion elevated systolic BP (SBP) in 
both AβPP/PS1 and WT mice. Notably, in both hypertensive and normotensive 
conditions AβPP/PS1 mice had a higher SBP than their WT littermates. Another 
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aim of this study was to determine the relation between AngII-induced 
hypertension and cerebral circulation. Hypertensive AD mice exhibited an 
impaired CBF in the hippocampus and thalamus. Using the same hypertension 
and AD model, chapter 4 focuses more on the pathological changes during AD 
accompanied with hypertension and vice versa. We chronically infused WT mice 
with AngII to investigate if AngII can initiate AD pathology, or whether AngII 
promotes AD-like changes in absence of AD pathology. Therefore, we investigated 
post-mortem brain pathology and metabolic changes, and in vivo cerebrovascular, 
FC, and cognitive changes in WT mice. We detected that AngII-induced 
hypertension did not induce all aspects of AD pathology in WT mice. However, 
AngII-induced hypertension caused an impaired FC in these WT mice. In 
accordance, hypertensive patients show deficits in the white matter and functional 
connectivity in frontal and parietal lobes, associated with cognitive decline [618]. 
Moreover, in clinical studies a decreased FC is detected in AD patients [207, 208, 
619]. In healthy young adults a family history of hypertension was related to 
subtle changes in visuospatial attention combined with a lowered task-related 
activation in several brain regions during this visuospatial working memory task 
without the accumulation of Aβ [620]. The second aim of the study was to 
determine whether AngII-induced hypertension can exacerbate AD pathology, 
and to study possible negative interactions between AngII and AD pathology 
(chapter 4). Notably, confirming the findings of chapter 3, AD mice showed a 
higher SBP at 12 months of age. At 12 months of age, only hypertensive AβPP/PS1 
mice exhibited an impaired FC accompanied by lowered spatial learning capacity. 
Our results demonstrate impaired FC in AngII-infused mice. In agreement with a 
recent study, a reduced connectivity between cortical regions was found in older 
hypertensive AD patients relative to older non-hypertensive AD patients [602]. 
Furthermore, this diminished cognition present in our hypertensive AD model 
mice is in line with another study in a rat model of hypertension revealing an 
impaired memory and learning [368]. No effects of the AngII-induced hypertension 
was found on structural connectivity using DTI and its related parameters, 
fractional anisotropy (FA) and mean diffusivity (MD). In contrast, increased blood 
pressure has been associated with a decrease in FA respectively an increase in MD 
[378] indicating impaired white and grey matter integrity. Moreover, de Leeuw et 
al. also demonstrated that long-standing hypertension increases the risk of 
developing white matter lesions [379]. Nevertheless, in our study, AngII was 
infused only for two months starting from 10 months of age. This short duration 
of AngII-infusion can be a reason for the unaffected structural connectivity 
measured via DTI, but many changes in functional parameters like FC and 
cognition. Another explanation could be the increased amount of GLUT-1 
measured in the thalamus of AngII-infused mice as a compensatory mechanism 
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leading to this unaffected structural connectivity. GLUT-1 is a marker for vascular 
endothelial cells and cerebral metabolism [324]. In several animal studies, 
myocardial ischemia increased the synthesis of GLUT-1 mRNA and protein levels 
in both ischemic and also non-ischemic cardiac regions indicating also a potential 
rescue mechanism for myocardial ischemia [370, 371]. Notably, McCall et al. 
revealed an overexpression of GLUT-1 in microvessels after the onset of global 
cerebral ischemia in the rat brain [372]. Moreover, Gerhart et al. and Urabe et al. 
also showed also an overexpression of GLUT-1 in the cerebral cortex in two 
ischemia and reperfusion animal models [373, 374]. Notably, without inducing 
experimental hypertension, AβPP/PS1 mice exhibited an increased SBP 
accompanied by a decreased cortical and thalamic CBF, an impaired hippocampal 
vasoreactivity, and a diminished cognition as described in chapter 3. Long-standing 
hypertension stimulates atherosclerosis and vascular remodeling leading to 
increases in wall thickness. Arterial stiffness and severe atherosclerosis can lead 
to an increase in pulse pressure [117]. An increased pulse pressure is correlated 
with a higher risk of AD in older adults [117]. In the Rotterdam study the presence 
of atherosclerotic plaques or wall thickening has been associated with AD and 
vascular dementia [109]. In line with our research, Toth et al. demonstrated that 
hypertension could induce an impaired cerebrovascular autoregulation [254], 
cerebromicrovascular injury and neuroinflammation in aging mice. Hypertension 
itself worsens vascular dysfunctions and aggravates pathological processes, like 
endothelial dysfunction, vascular remodeling, inflammation, and arterial stiffness. 
All these pathological processes are crucial players in the development of 
hypertension itself [621]. Moreover, Cifuentes et al. revealed that hypertension 
advances the development of AD-like structural and functional alterations, 
partially through cerebral vascular impairment and reduced nitric oxide production 
[375]. With this thesis we wanted to unravel the impact of hypertension as a 
major vascular risk factor of AD on the development of neurodegenerative 
processes in AD. The second aim was, whether hypertension is able to accelerate 
the course of neurodegenerative processes in AD. In chapter 4 we showed for the 
first time that a reduction in FC could be introduced in mice via AngII-induced 
hypertension, also even in the absence of a classical AD pathology (amyloidosis). 
Using an experimental hypertension mouse model measuring the SBP (chapters 3 
and 4), helped us to demonstrate that hypertension promotes and exacerbates 
pathological processes like cerebrovascular impairments, a diminished FC, and an 
impaired cognition, without affecting and stimulating Aβ deposition already in 
younger animals. Our results (chapters 3 and 4) indicate that heightened levels of 
AngII may indeed represent a mechanistic link between the risk factor hypertension 
and the clinical development of AD. However, AngII may not be a causal factor for 
sporadic AD as it did not initiate amyloid pathology in this study. Rather, it may is 
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involved in the clinical development of AD in people with amyloid accumulation 
through its negative effects on CBF, FC and cognition. Notably, also in aged AD 
model mice (chapter 2) we detected an elevated SBP, deteriorations in cerebral 
hemodynamics resulting in an impaired cognition and structural and functional 
connectivity, increased locomotor activity, and anxiety-related behaviour being all 
symptoms of clinical AD. These latter results elucidate that hypertension and 
vascular impairment play important roles in the very early stage of AD but whether 
these are causative factors or just a contributors aggravating the disease progress, 
remains to be investigated.
Stroke
Another vascular risk factor for dementia is stroke. Global stroke incidence was 
calculated at 16 million cases in 2005, and is projected at 23 million by 2030 [622]. 
Stroke is the second leading cause of morbidity and mortality [513]. Many stroke 
patients show a gradual but continuous deterioration following a single stroke 
lesion [16] being characterized clinically by cognitive and behavioral dysfunction. 
87% of all strokes are ischemic [521], indicating that specific treatments should 
target CBF impairments [516]. Stroke is a major vascular risk factor for dementia 
[623]. The accumulation of AβPP and Aβ 1-42 demonstrated in patients with 
multi-infarct dementia emphasizes the overlap and relationship between AD and 
VaD [124-126]. In animal models of cerebral ischemia a relationship between 
the AβPP and cerebral ischemia was demonstrated [124, 125, 127]. Notably, in a 
combined AD and cerebral ischemia rat model the presence of Aβ increased the 
infarct size, neuroinflammation and also cognitive deficits [133]. A highly sensitive 
fluorescent RT-PCR assay revealed a significant increase in the peripheral blood 
expression of AβPP mRNA levels among patients who suffered from recent stroke 
[128]. A correlation between the density of cortical microinfarcts (CMIs) and the 
degree of cerebral amyloid angiopathy (CAA) was found in a postmortem analysis 
of human brains [129]. After subjecting AβPP/PS1 to microstrokes, Garcia-Alloza 
et al. showed that also vice versa stroke is able to accelerate Aβ deposition 
via interference with amyloid clearance pathways revealing a fast increase in 
Aβ plaque burden and CAA in the region surrounding the infarction [130]. As 
mentioned above, the risk of incident dementia is high among patients with 
ischemic stroke [580], but also already mild dementia and cognitive impairment 
are associated with an increased incidence of stroke among subjects age 75 years 
old and over [581]. Ischemic strokes have been the target of many failed drug 
trials [516] and only few treatment options are available, and therefore the a large 
amount of patients suffers from significant poststroke disabilities [517-519]. There 
is therefore an urge for restorative interventions supporting better recovery and 
improving quality of life. In chapter 7 we used a transient middle cerebral artery 
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occlusion model as mouse model for stroke. Here, 3 months old, male C57BL/6J 
mice underwent right tMCAo (30 minutes), using an intraluminal occlusion model 
[544, 545]. This stroke model of transient occlusion of the MCA mimics one of the 
most common types of ischemic stroke in patients [544, 546], as mentioned above 
accounting for 87% of all stroke cases [521]. The MCA was transiently occluded 
for 30 min. This ischemia time leads to moderate pathological changes within 
the infarct core, perilesional and remote regions [547-549]. In accordance with 
human stroke, this reperfusion model reveals a substantial degree of reperfusion 
via collateralization through the Willis’ circle and leptomeningeal collaterals, and 
via early clot lysis [550]. Here (chapter 7), after an induced experimental stroke, 
mice demonstrated a decrease in body weight. Moreover, after the experimental 
stroke these mice walked less and slower, leaned and reared less, and showed 
a decreased explorative respectively an increased anxious phenotype in the 
open field. Using advanced imaging techniques, these stroke mice exhibited 
7 days after stroke increased neuroinflammation, impaired cerebrovascular 
function accompanied by a diminished structural and functional connectivity 
in the tMCAo affected cerebral hemisphere, being all clinical hallmarks and risk 
factors for dementia [624]. Notably, in the stroke control mice CBF dropped over 
time in several brain regions in 7 to 35 days poststroke indicating the impact of 
aging on clinical outcome after stroke. In detail, we revealed an impaired WM 
microstructure at seven days poststroke in regions containing the Caudate 
Putamen and Globus Pallidus. In accordance to our results, Firbank et al. found in 
human studies, that the poststroke dementia group has more vascular pathology 
indicated by white matter hyperintensities (WMH) volumes and lower cortical 
perfusion than the poststroke no dementia group [625]. In contrast, in the AD 
group a reduced cerebral perfusion specifically in the parietal and prefrontal 
area, consistent with previous studies [626], but no increase in WMH volumes 
was found [625]. Revealing enhanced neuroinflammatory response in the stroke 
affected hemisphere, our results are in line with current research showing that 
inflammation is a crucial key player in the pathogenesis of ischemic stroke and 
other forms of ischemic brain injury [625]. In our research the tMCAo mouse model 
(chapter 7) has shown several AD-like symptoms making it a highly translational 
model to study the interaction of stroke and AD. In our thesis we aimed to 
reveal the underlying vascular origin of stroke during very early development of 
neurodegenerative processes in AD using several mice models. Here (chapter 
7), we showed that in our tMCAo mouse model an impaired cerebral blood flow 
is accompanied by a worsened structural and functional connectivity, and an 
enhanced neuroinflammatory response indicating the influence of stroke on the 
development of AD-like symptoms.
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Treatments
Antihypertensives 
With this thesis we aimed to increase the knowledge of antihypertensive 
actions on the cerebrovascular system in AD and on AD-like symptoms, herewith 
possibly supporting the development of effective, tailor-made blood pressure 
lowering treatments for AD patients. Preclinical and clinical studies reveal that 
antihypertensives may reduce the development of AD [196, 197]. Specifically, 
AngII receptor blockers (ARBs) have been associated with a lowered risk of AD 
[278, 279]. In the last decade many studies with contradictory results have been 
performed. To illustrate this point: no significant effects of active treatment on 
the incidence of dementia [281, 282] were found compared to placebo as shown 
in two randomized, placebo-controlled studies, the ‘Study on Cognition and 
Prognosis in the Elderly’ (SCOPE; candesartan/ hydrochlorothiazide vs placebo) 
and the ‘Systolic Hypertension in the Elderly Program’ (SHEP; chlorthalidone/ 
atenolol/ reserpine vs placebo). Contrarily to the examples above, two other 
randomized, placebo-controlled studies named ‘Systolic Hypertension in 
Europe’ (Syst-Eur) and ‘Perindopril Protection Against Recurrent Stroke Study’ 
(PROGRESS), showed beneficial effects on the incidence of dementia and cognitive 
decline [280, 283, 284]. The Syst-Eur study revealed that active treatment with 
nitrendipine, enalapril, and/or hydrochlorothiazide lowered the incidence of 
dementia [280, 283]. Results from the ‘Observational Study on Cognitive function 
And SBP Reduction’ (OSCAR) revealed that Eprosartan (ARB) is associated with 
preservation or improvement of cognitive performance [627]. A case control 
analysis within the UK showed that patients on ARBs and angiotensin converting 
enzyme inhibitors (ACE-Is) had a respectively 53% and 24% reduced risk of AD, 
compared to patients on other anti-hypertensive medications [278]. To analyze 
the impact of antihypertensives on hypertension and to differentiate between 
the effect of AngII and elevated SBP per se (chapter 3), we also investigated 
the intervention by using two different antihypertensives: 1) the diuretic 
hydrochlorothiazide (HCT) and 2) the ARB eprosartan mesylate (EM). Both EM 
and HCT were able to lower the SBP in saline-infused and AngII-infused mice. 
Notably, AngII-induced hypertension was reduced by EM and HCT to near-normal 
values only in WT mice, and not in AβPP/PS1 mice. EM and HCT were not effective 
in lowering SBP and were not able to restore the decrease in hippocampal and 
thalamic CBF in our (hypertensive) AD-model mice, possibly by the vasotoxic 
effects of the present Aβ. EM was even less effective in reducing SBP than HCT. 
In contrast, Kume et al. revealed that Telmisartan, another ARB like EM, was able 
to elevate regional CBF in hypertensive patients, as opposed to those treated 
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with amlodipine [314]. In our study, after one month of untreated hypertension 
a clinical dosage of EM was supplemented to the mice only for one month 
indicating that the duration of treatment was probably too short. This is similar 
to results of h a clinical trial, in which normotensive mean values were reached 
in 75,5% hypertensive stroke patients just after three months of treatment with 
EM, [628]. Another possible explanation for the decreased impact of EM on SBP 
and CBF could be that EM directly targets Aβ by inhibiting its accumulation. It has 
been shown that another ARB, Valsartan, was able to attenuate oligomerization 
of Aβ peptides into high-molecular-weight oligomeric peptides [307]. Due to 
increased Aβ production in AβPP/PS1 mice, EM molecules may be bound to 
Aβ peptides. Therefore, less EM molecules will be free and able to inhibit AngII 
activity mediated by its receptor, and, therefore, less EM is able to bind to the 
AngII receptor blocking its antihypertensive effect. This mechanism may explain 
the genotype effect of EM in our study in which EM decreased SBP in AβPP/PS1 
mice in a less effective manner than in their WT littermates. As described in the 
previous chapter, SBP was also lowered in animals treated with EM. Treatment 
of hypertension with EM enhanced hippocampal CBF. This beneficial effect was 
shown in all mice, and was not restricted to transgenic animals only, indicating that 
either blood pressure lowering or blocking effects of endogenous AngII may be 
beneficial for brain perfusion. In accordance, blood pressure lowering treatments 
heightened CBF in older subjects with hypertension as well [377]. Furthermore, 
after EM-treatment we also detected an improved microstructural integrity 
measured via DTI in sal-infused mice and AngII-infused AD mice. Notably, a novel 
finding is the negative effect of EM on FC in all Sal-infused mice, but the beneficial 
effect in AngII-infused mice. While all saline-infused EM-treated mice had an 
impaired FC compared with untreated mice, all AngII-infused EM-treated mice 
showed an improved FC compared with untreated mice. This reveals the positive 
effect of EM as antihypertensive treatment on CBF, microstructural integrity of 
white and grey matter, and concomitant FC. In accordance to our results, the 
secondary longitudinal data analysis of the Ginkgo Evaluation of Memory Study 
demonstrated that diuretics, ARBs, and ACE-Is in addition to and/or independently 
of mean SBP, were associated with a lowered risk of AD dementia in participants 
with normal cognition, while only diuretics were associated with reduced risk in 
participants with MCI [629]. Nevertheless, not all AD-like pathological changes like 
an impaired cognition or CBF could be ameliorated by EM. These results are in line 
with the SCOPE and SHEP studies showing also no effect of antihypertensives on 
the incidence of dementia [281, 282]. Our results indicate the necessity to gather 
more insight in the actions of antihypertensive treatments on brain processes 
and the vascular system being involved in pathological processes of AD leading 
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to a better development of more effective tailor-made blood pressure-lowering 
treatments for early stage AD patients. In addition, our data also elucidate that 
the usage of only antihypertensives is not leading to a reduction of all AD-like 
symptoms.
Diet (preventive/ therapeutic approach)
Extensive research has been pursued in search for effective therapies for AD. Till 
now, no effective treatment is available nor seems near. Preventive approaches 
have therefore consistently emerged as key policy priorities in recently formulated 
dementia strategies including modification of health-compromising behavior 
such as sedentary lifestyle and high fat, high caloric dietary intake leading 
potentially to AD. Lately the Mediterranean diet has been associated with a 
reduced risk of AD [445, 446] and with a lower mortality [447, 448]. The 
mechanisms via which diet influences the onset and progression of AD pathology 
are still under investigation. One possible mode of action is the beneficial effect of 
nutrients, such as omega-3 long-chain polyunsaturated fatty acids (n3-LCPUFAs) 
on the vascular system [448, 449]. Several epidemiological studies and controlled 
trials showed a correlation between B-vitamins, n3-LCPUFAs and monounsaturated 
fatty acids and improvements in autonomic function, reduced blood pressure, 
decreased atherosclerosis, lowered total homocysteine and enhanced 
microvascular endothelium-dependent vasodilation processes [448, 500, 501]. 
Atherosclerosis [451], high blood pressure [452] and other cardiovascular diseases 
are risk factors for cardiovascular disease and AD and are diminished by 
n3-LCPUFAs [451, 453-455]. Based on these findings, a novel multi-nutrient 
supplementation diet called Fortasyn, comprising n3-LCPUFAs, DHA and 
eicosapentaenoic acid (EPA), besides other precursors and cofactors for membrane 
synthesis, such as uridine monophosphate (UMP), choline, phospholipids, folic 
acid, vitamins B12, B6, C, and E, and selenium, has been proposed for the dietary 
management of very early stages of MCI and AD [462, 562]. To investigate the 
possible capacity of such a specific multi-nutrient diet to serve as preventive or 
treatment against AD-like symptoms and vascular risk factors for AD, we studied 
the effect of this specific multi-nutrient supplementation diet in chapter 6. This 
diet is designed to ameliorate synaptic loss and to reduce membrane-related 
pathology in AD by providing nutritional precursors and cofactors to support 
neuronal membrane formation and function [495] in younger and aged apoE4 
model mice. These mice resemble patients in the prodromal phase of AD. Here, 
we hypothesized that this nutritional intervention with Fortasyn may be able to 
inhibit or prevent the occurrence of early AD-like pathologies such as 
cerebrovascular impairment and concomitant brain connectivity loss. In apoE4 
mice, particularly, the strongest and most consistent dietary effect in these studies 
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involve the improvement of cerebrovascular health and FC indicated by an 
increased cortical CBF and levels of post-synaptic markers in both apoE4 and WT 
animals on Fortasyn diet. Concomitant with the preserved FC in both WT and AD 
mice fed with Fortasyn, we also observed an improved white matter integrity. In 
support with our findings, it has been demonstrated that animals fed with a diet 
containing a part of the diet composition, UMP, n3-LCPUFAs and choline, showed 
increased levels of brain phospholipids, dendritic spines and neurite outgrowth 
[458-460]. Our results show that this Fortasyn diet is a preventive multi-targeting 
approach against impairments in the cerebral vasculature, connectivity and 
underlying pathological mechanisms like neurogenesis and neuroinflammation. 
In addition, in the study described in chapter 5, we investigated the impact of 
Fortasyn on spatial learning and memory in 11-month-old male AβPP/PS1 mice 
and WT littermates. To this end, we analyzed the different search strategies to 
find the hidden platform in the Morris water maze to assess the qualitative aspects 
of learning using a parameter-based algorithm [183-187]. We investigated 
whether Fortasyn may improve spatial learning of transgenic mice by facilitating 
the use of hippocampus-dependent search strategies. Here, Fortasyn induced 
beneficial effects on learning and memory in both AβPP/PS1 mice and wild-type 
animals. During the MWM acquisition, Fortasyn promoted the AD model mice to 
use the chaining strategy thereby developing a highly efficient way to find the 
platform being independent of an intact hippocampus [430]. While chaining is 
considered to be a coping strategy, it seems to help to compensate for the 
cognitive decline in these AβPP/PS1 mice. In accordance, our results are 
concordant with other studies showing that fish oil containing diets improve 
spatial memory in AβPP/PS1 mice and ameliorate performance in hippocampus 
dependent spatial memory tests like the MWM [432-434]. In these AβPP/PS1 
mice we also measured the effect of Fortasyn on behavior, neurogenesis [630], 
cerebrovascular health, and other neuroprotective mechanisms [461]. Fortasyn 
had an anxiolytic effect, restored neurogenesis to normal WT values, enhanced 
cerebral perfusion, and protected against neurodegenerative processes in both 
grey and white matter improving also spatial learning capacity (chapter 5) in these 
AD mice. Till now, only two randomized controlled clinical trials have revealed 
improvements in the delayed verbal recall task and better cognitive performance 
in mild AD patients supplemented with this nutrient combination [463-465]. In 
contrast, a double-blind randomized controlled trial in patients with 
mild-to-moderate AD demonstrated that 24-week use of Souvenaid 
(Fortasyn®Connect) did not slow cognitive decline in these patients [631]. In 
addition, in a recent exploratory 24-week, double-blind, randomized, controlled 
electro- and magnetoencephalography study also no interventional effects of 
Souvenaid on brain activity could be detected in mild AD patients [632]. This 
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Fortasyn diet contains besides DHA and EPA, other precursors and cofactors for 
membrane synthesis [462]. DHA, alone or combined with EPA, contribute to 
improved memory function in older adults with mild memory complaints [633]. 
Combinations of EPA and DHA (EPA ≥ 60%) were effective against primary 
depression [634]. Notably, supplementation with EPA and/or DHA improved 
verbal fluency and attention in patients who had only very mild dementia or AD 
or presented apoE4 negative genotype [635]. But in AD patients, EPA and/or DHA 
supplementations did not reduce cognitive decline rates [635]. Some observational 
studies demonstrated that higher dietary intake or heightened serum levels of 
folate and fish/fatty acids accompanied with low serum levels of homocysteine 
were associated with a reduced risk of incident AD and dementia, while other 
studies showed no association [500]. Besides, the combination of phosphatide 
precursors like n3-LCPUFAs, uridine, and choline, has proven to synergistically 
increase the synthesis of synaptic proteins and phospholipids in the brain 
[458-460]. In addition, a meta-analysis of randomized controlled trials has proven, 
that the addition of EPA+DHA reduces SBP [636]. All the results of single 
component diets are inconsistent. Although it has been recognized that Fortasyn 
addresses specific nutritional needs in early AD and that it improves functional 
connectivity as assessed by EEG [466], other processes by which Fortasyn may 
influence the pathophysiology of AD need to be further elucidated, and more 
studies are required to confirm its efficacy. Therefore, the combination of our 
results from a multi-nutrient dietary approach and epidemiological data of dietary 
patterns on risk reduction of AD [637] indicates a greater opportunity of 
intervention in the very early phase of AD. This has been proven in our two mouse 
models of the early AD phase showing several beneficial effects. The data 
presented in this thesis regarding the impact of such a multicomponent diet on 
AD is encouraging for planning and exerting future clinical studies. Future studies 
developing multicomponent diets against AD should focus on the cerebral vascular 
impairment in the latent phase of AD, thereby protecting functional and structural 
connectivity, combined with improved cognition to develop tailor-based and 
personalized preventive treatments against the progression of AD, already during 
the very early phase of this disease. Therefore, these studies should further 
elucidate the impact and efficacy of Fortasyn and Mediterranean type dietary 
compositions on the pathophysiology of AD.
In both studies described in chapters 5 and 6 we investigated the effect of such 
a specific nutrient combination diet as a preventive approach on pathological 
processes in AβPP/PS1 and apoE4 mouse models representing both mouse models 
of (vascular) risk factors for AD. For each study, male transgenic mice and their WT 
littermates were assigned to the different diet groups from 2 months of age, until 
the end of the experiment. Nevertheless, ischemic strokes have been the target 
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of many failed drug trials [516] and only few treatment options are available, but 
many patients still show significant poststroke disabilities [517-519]. Until now, 
thrombolysis and thrombectomy are the common treatments for ischemic stroke, 
but not many patients benefit from these therapies due to the narrow therapeutic 
window and complexity of administration [515, 520]. There is therefore an urge for 
restorative therapeutic interventions supporting better recovery and improving 
quality of life. Novel approaches targeting several early underlying processes 
like CBF, neuroinflammation, and brain networks may provide new avenues for 
stroke treatment [522]. In particular, dietary approaches could facilitate recovery 
after stroke [523, 524] because it has been shown that increased adherence to 
a Mediterranean-style diet is associated with a lowered risk of ischemic stroke 
and myocardial infarction [163]. Among persons at high cardiovascular risk, 
a MD supplemented with extra-virgin olive oil or nuts reduced the incidence 
of major cardiovascular events [584]. Moreover, this latter MD supplemented 
with nuts had a beneficial effect on the risk of depression in patients with type 
2 diabetes [585]. Therefore, in chapter 7 we elucidated the possible efficacy of 
this multicomponent diet as therapeutic intervention after transient ischemic 
stroke, another major vascular risk factor of AD on both structural and functional 
parameters. Using state-of-the-art imaging techniques, we measured CBF, and 
the neuroinflammatory response after ischemia. Our data described in chapter 7 
indicate that a post-stroke intervention with the specific nutrient combination of 
Fortasyn is able to support recovery after ischemic stroke, by improving cerebral 
circulation due to an improved vascularization and increased angiogenesis, 
protecting white and gray matter integrity, restoring functional connectivity, 
increasing neurogenesis, decreasing the neuroinflammatory response, and 
improving motor skills and muscle strength. The present data show that the specific 
nutrient combination Fortasyn may enhance recovery from ischemic stroke in 
mice, as evidenced by improved cerebral blood flow, reduced loss of functional 
connectivity, and improved motor performance. Relevant processes for recovery 
after stroke, such as neurogenesis, angiogenesis, and neuroinflammation, were 
positively affected by the Fortasyn diet. In accordance, this neurorestorative 
potential of Fortasyn has recently been obtained in a rodent model of spinal 
cord injury as well [537]. Comparable results regarding structural and functional 
connectivity were found in other studies showing that intracerebral injection of 
EPA is able to stimulate the expression of myelin proteins in rat pup brain [560] 
and that n3-LCPUFA are crucial for functional connectivity and large-scale system 
organization in rhesus macaque brains [561]. Additionally, Fortasyn preserved 
the organization of brain networks in patients with mild AD within 24 weeks 
potentially via counteracting the progressive network disruption over time in 
AD [562]. This specific multi-nutrient approach has proven to counteract several 
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pathological alterations in several mouse models of (vascular) risk factors of 
AD as either a preventive or a therapeutic dietary approach (Chapters 5 to 7). 
Nevertheless, even low fish consumption may already decrease the incidence of 
ischemic stroke [157]. In women, intake of n3-LCPUFAs is related to a lowered 
risk of total stroke, while dietary cholesterol has been found to be positively 
associated with risk of total stroke and cerebral infarction [162]. As mentioned 
above, n3-LCPUFAs have shown to diminish severity of vascular risk factors, like 
atherosclerosis [451], high blood pressure [525], and other cardiovascular diseases 
[451, 526-528]. N3-LCPUFAs have a protective effect against cerebral ischemia in 
rats, presented by a reduced number of apoptotic neurons in the prefrontal cortex 
when fed a standard diet combining EPA and DHA [160]. Moreover, combined 
administration of DHA and UMP improved learning abilities in rats [529] and 
combined administration of DHA and EPA improves (cerebral) vascular health 
in human [530, 531]. These studies described in chapters 5 to 7 investigating a 
specific dietary approach which has been tested in several mouse models of (risk 
factors) AD, is the first step in the development of tailor-based dietary treatments 
against dementia. Future studies should therefore start to focus on optimization 
of multicomponent combinations targeting simultaneously several underlying 
processes of the early pathological processes in dementia and its (vascular) 
risk factors to develop effective preventive or therapeutic approaches. These 
future studies should evolve personalized approaches adapted to the individual 
pathological problems like an increased neuroinflammatory response etc..
Concluding remarks
The elucidation of the underlying source of major vascular risk factors 
like hypertension, apoE4 and stroke during very early development of 
neurodegenerative processes in AD using several mice models was the first aim 
of this thesis. Hypertension has proven to be associated with cerebrovascular 
impairment already at young age in AD model mice leading to reductions in 
structural and functional connectivity accompanied by an impaired cognition. 
Notably, aged AD mice developed an increased SBP concomitant with several 
AD-like pathological changes, like impairment in cerebral hemodynamics 
resulting in an impaired cognition, structural and functional connectivity, 
increased locomotor activity, and anxiety-related behavior without 
ANGII-induced hypertension. Notably, also in aged transgenic apoE4 mice an 
impaired cerebrovascular circulation, reduced cortical post-synaptic density, 
disturbed white and gray matter integrity in white matter tracts, and a lowered 
FC were detected. In conclusion, the (vascular) risk factors being present and/
or induced in our mouse models have proven to be involved in the very early 
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development of neurodegenerative processes in AD. Therefore, all mouse models 
used for this thesis are animal models for the asymptomatic phase of AD, but 
possessing the potential to be challenged by (vascular) risk factors to develop 
and to accelerate the course of neurodegenerative processes in AD. Another 
aim of this thesis was to reveal the possible capacity of antihypertensives and 
specific multi-nutrient diets to serve as preventive or treatment against AD-like 
symptoms and vascular risk factors for AD. Despite their blood-lowering actions, 
we showed that antihypertensives like EM have beneficial effects on pathological 
processes of AD like counteracting the impaired CBF, and the reduced structural 
and functional connectivity. Therefore, it is important to improve development of 
more effective tailor-made blood pressure-lowering treatments for AD patients 
and to increase awareness for hypertension as a risk factor for AD. Furthermore, 
we demonstrated the value of a multi-modal approach, including advanced MR 
neuroimaging tools, for detecting changes in brain structure and function with 
respect to dietary intervention. The investigated multicomponent diet showed 
several beneficial effects as a preventive but also as a therapeutic approach on 
pathological alterations in mouse models for (vascular) risk factors for AD. Future 
studies should therefore focus on optimization of multicomponent combinations 
comprising dietary components of the Mediterranean diet to improve clinical 
outcome after a stroke to lower the incidence of stroke accompanied by a 
reduction of the incidence of dementia. Moreover, all tests were performed in 
relative young animals. Therefore, future studies should repeat all studies in older 
mice. In accordance, Toth et al. demonstrated that hypertension in aging mice 
could induce an impaired cerebrovascular autoregulation, cerebromicrovascular 
injury and neuroinflammation [254]. Also in our stroke study we used relatively 
young mice to evaluate our specific dietary approach against pathological changes 
of the experimental ischemic stroke. It has been confirmed that aged animals 
react differently to an induction of an experimental stroke [638]. Furthermore, 
for apoE4 [511, 639], hypertension [640], and also for stroke [641] sex differences 
have been revealed. Therefore, it is of utmost importance to study gender 
differences regarding to all of these risk factors of AD by testing also female 
mice during lifespan. All in all, vascular risk factors for AD have several negative 
effects on the very early development of neurodegenerative processes involved 
in AD, but these risk factors can be challenged and blocked by an effective 
tailor-based preventive or therapeutic approach lowering the incidence of AD. 
As our experimental results and epidemiological data have shown that treatment 
with only antihypertensives or single-component diets is not sufficient to fully 
counteract underlying processes of the early pathological processes in dementia. 
Therefore, future research should focus on preventive/ therapeutic approaches 
using personalized multinutrient dietary approaches targeting pathological 
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processes like neuroinflammation, impaired CBF, cognitive impairments, and other 
clinical symptoms of dementia. Future studies should evaluate a mixed preventive 
approach containing cognitive and physical exercise [642, 643], in combination 
with a personalized multicomponent diet during the very early phases of AD. 
Moreover, these mixed preventive approaches need to be personalized for each 
individual dementia patient to develop an optimal prevention and to cover each 
individual genetic make-up.
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Wereldwijd vormt dementie een groot gezondheidsprobleem mede door de 
hogere levensverwachting van mensen [189, 190]. De ziekte van Alzheimer (AD) 
en vasculaire dementie (VaD) zijn de twee meest voorkomende vormen van 
dementie bij ouderen [2, 3]. In de familiaire variant van AD is de productie van 
het amyloid-β (Aβ) eiwit verhoogd door een genetische afwijking, dit resulteert 
in de karakteristieke Aβ eiwit ophopingen in het brein. Ook in de niet-familiaire 
(sporadische) variant van AD worden de Aβ overproductie en ophopingen daarvan 
als drijvende kracht gezien [21]. De Aβ cascade hypothese is nog steeds de meest 
dominante theorie voor de pathogenese van AD, echter staat ter discussie of de 
Aβ ophopingen en de kluwen van draadvormige eiwitten (neurofibrillaire tangles) 
in de hersencellen de hoofdoorzaak van de neurodegeneratie in AD zijn [22]. 
Zo hebben bijvoorbeeld verschillende studies laten zien dat de hoeveelheid Aβ 
ophopingen in de hersenen van niet-Alzheimer patiënten net zo hoog kan zijn als 
in de hersenen van AD patiënten [23, 24]. Verder hebben epidemiologische en 
klinische studies aangetoond dat AD en VaD gemeenschappelijke vasculaire risico 
factoren hebben, zoals een hoge bloeddruk (hypertensie), diabetes, hyperlipidemie 
zoals verhoogd cholesterol waarden in je bloed, cerebrovasculaire aandoeningen, 
en hartritmestoornissen [91-96, 192, 193]. Dus vasculaire risicofactoren kunnen 
invloed hebben op het ontwikkelen van de AD pathologie [194]. Verder hebben 
AD, VaD en beroerte, hypertensie als een gemeenschappelijke risicofactor, en is 
het krijgen van een beroerte ook een risicofactor voor het ontwikkelen van AD en 
VaD [582].
Het apolipoproteine E4 gen (apoE4) levert een grote genetische (mede via het 
vasculair systeem) bijdrage aan de ontwikkeling van AD. Dit gen is betrokken bij 
het cholesterol metabolisme [12, 50]. Het AD onderzoek richt zich steeds meer 
op de vroege, asymptomatische fase van de ziekte, waarin (cerebro)vasculaire 
aandoeningen zich manifesteren [449]. Vanuit de wetenschappelijke gemeenschap 
is er met toenemende mate belangstelling voor het ontwikkelen van preventieve 
benaderingen om AD te bestrijden. Deze strategieën hebben als doel om het 
aantal AD incidenten te verlagen door onder andere aanpassingen op het gebied 
van voeding en levensstijl. Een Mediterraan dieet (MD), wat een hoge consumptie 
van fruit, groenten en peulvruchten, matige consumptie van vis, noten en olijfolie 
in houdt, wordt in verband gebracht met een verlaagd risico op AD [444, 445] 
en met een lagere mortaliteit [446, 447]. In de Doetinchem Cohort Studie werd 
bijvoorbeeld aangetoond dat een verhoogde inname van groenten en fruit (o. a. 
noten, koolsoorten en knolgewassen) is geassocieerd met een betere cognitieve 
functie [584]. Een meta-analyse toonde aan dat interventies met een MD voor 
ten minste 1 jaar zowel de systolische als de diastolische bloeddruk kunnen 
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verlagen bij mensen met normale bloeddruk of milde hypertensie [585]. Ook 
vermindert een MD het ontstaan van ernstige cardiovasculaire gebeurtenissen 
bij mensen met een hoog cardiovasculair risico [586]. Naast het gunstig effect op 
de bloeddruk, werd in een andere studie gevonden dat een matige visconsumptie 
beschermt tegen het ontwikkelen van herseninfarcten [157].
Doxosahexaeenzuur (DHA) en eicosapentaeenzuur (EPA) behoren tot de omega-3 
meervoudig onverzadigde vetzuren (n3-LCPUFAs) en zijn hoofdcomponenten van 
visolie. Verschillende studies hebben aangetoond dat DHA een positief effect kan 
hebben bij het herstel van herseninfarcten [516, 588]. Andere voedingsstoffen zoals 
bijvoorbeeld fosfatiden kunnen direct de synaptische integriteit beschermen. De 
aanwezigheid van fosfatiden kan de vorming van fosfatidylcholine stimuleren, wat 
de meest voorkomende fosfatide in de hersenen is en een belangrijke component 
vormt voor de neuronale membranen [455, 456]. Deze bevindingen werden door 
verschillende preklinische studies bevestigd. Als reactie op deze bevindingen werd 
er een specifiek dieet, Fortasyn ontwikkeld speciaal voor AD patiënten. Dit dieet 
is verrijkt met DHA en EPA, naast andere voorlopers en cofactoren betrokken bij 
de membraansynthese zoals uridine, choline, fosfolipiden, foliumzuur, vitamines 
B12, B6, C en E en selenium [461]. Verschillende studies hebben aangetoond dat 
Fortasyn de verlaagde concentraties van specifieke voedingscomponenten kan 
aanvullen in beginnende AD en ook dat het de functionele connectiviteit kan 
worden verbeterd zoals gemeten met EEG [465] en MRI [460]. 
Dit proefschrift heeft als focus om met behulp van verschillende muismodellen 
de onderliggende pathologische processen van vasculaire risicofactoren zoals 
hypertensie, apoE4 en beroerte te onderzoeken tijdens de zeer vroege ontwikkeling 
van neurodegeneratieve processen binnen AD. De vasculaire risicofactoren voor 
AD worden bediscussieerd in hoofdstuk 1. Een ander doel van dit proefschrift 
was om te ontrafelen of vasculaire risicofactoren, zoals hypertensie of een 
herseninfarct, de potentie hebben om het verloop van neurodegeneratieve 
processen in AD te versnellen.
Daarnaast is deze thesis bedoeld om te onderzoeken of bloeddrukverlagende 
middelen en specifieke multinutriënt diëten als preventieve of therapeutische 
middelen tegen vasculaire risicofactoren en AD symptomen in het vroege stadium 
een positief effect kunnen hebben.
Om de vasculaire oorsprong van neurodegeneratieve processen in AD te kunnen 
ontrafelen, hebben wij in hoofdstuk 2 onderzoek gedaan naar de relatie tussen 
de systolische bloeddruk (SBP), cerebrale doorbloeding (CBF), vasoreactiviteit, 
hersenstructuur en -functie in 16-18 maanden oude AD-muismodellen (AβPPswe/
PS1dE9 (AβPP/PS1)). Deze oude AβPP/PS1 muizen hadden een verhoogd SBP 
gekoppeld aan een verlaagd CBF. Met behulp van geavanceerde MRI-technieken 
werd de achteruitgang van de functionele en structurele connectiviteit in het brein 
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onthuld in deze AD muismodellen. Daarbij hadden deze muizen een verminderde 
cognitie, verhoogde bewegingsactiviteit en angst-gerelateerd gedrag. Post 
mortem analyses toonden ook aan dat de neuroinflammatie was verhoogd, terwijl 
de synaptogenese en de neurogenese in deze AβPP/PS1 muizen was gedaald. Ook 
werden afwijkende concentraties van vetzuren en sterolen in het hersenweefsel 
van de AβPP/PS1 muizen gevonden, waardoor men kan concluderen dat deze 
transgene muizen een slecht aangepast cerebrale vetzuurmetabolisme hebben. 
Onze bevindingen suggereren een verband tussen verhoogde SBP, verminderde 
cerebrale hemodynamiek en connectiviteit in een AD muismodel gedurende het 
verouderingsproces. Dit zorgt uiteindelijk voor afwijkingen in gedrag en cognitie. 
Deze resultaten weerspiegelen de complexe klinische symptomatologie in de 
preklinische fase van AD en daarom stellen wij voor dat dit AD muismodel kan 
worden gebruikt voor het onderzoek naar strategieën voor de preventie en 
behandeling in vroegtijdige AD patiënten. Bovendien draagt deze studie bij aan het 
ontwikkelen van meer en betere therapieën en diagnostiek voor het zeer vroege 
stadium van AD. Hypertensie is namelijk goed te behandelen wat een mogelijke 
kans biedt ter preventie van AD. Verhoogde bloedwaarden van angiotensine II 
(AngII) zijn een belangrijke oorzaak van hypertensie. Angll heeft schadelijke 
effecten op de endotheelfunctie van bloedvaten en CBF, beide kunnen bijdragen 
tot de ontwikkeling van AD. Angll remmende middelen zijn daardoor potentiële 
kandidaten om AD risicofactoren bij hypertensieve patiënten te verlagen. Daarom 
hebben wij in hoofdstuk 3 het effect onderzocht van 2 maanden geïnduceerde 
hypertensie en daaropvolgend het effect van antihypertensiva op de SBP en CBF 
in 10 maanden oude wild-type (WT) C57BL/6J en AβPP/PS1 muizen. Hypertensie 
werd geïnduceerd met behulp van AngII-infusie via onderhuidse osmotische 
micropompen en als antihypertensiva werden dan wel eprosartan mesylaat (EM, 
0,35 mg / kg) of hydrochloorthiazide (HCT, 7,5 mg / kg) gebruikt na 1 maand van 
geïnduceerde hypertensie. SBP werd twee keer per maand gemeten via staart 
manchet plethysmografie. CBF werd gemeten met MRI met een “arteriële spin 
labeling”, bij deze methode wordt het bloed zelf als endogene tracer gebruikt. 
Chronische Angll-infusie veroorzaakte een verhoging van SBP zowel in AβPP/PS1 
als in WT-muizen. Deze verhoging van SBP ging gepaard met een CBF afname 
in de hippocampus en thalamus in de AβPP/PS1 muizen. De SBP in de AβPP/
PS1 muizen was hoger onder zowel hypertensieve en normotensieve condities 
in de WT muizen. Antihypertensiva waren niet effectief in het reduceren van 
AngII-geïnduceerde hoge bloeddruk tot normale waarden in AβPP/PS1 muizen, 
terwijl deze wel effectief de bloeddruk in WT-muizen verlaagden. Uit deze resultaten 
kunnen wij concluderen dat AngII-geïnduceerde verhoogde bloeddruk kan leiden 
tot een vermindering in CBF gecombineerd met een verlaagde gevoeligheid voor 
een bloeddrukverlagende behandeling in een transgeen AD-muismodel. Onze 
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bevindingen suggereren een verband tussen hypertensie op middelbare leeftijd 
en een verminderde CBF in een AD muismodel, vergelijkbaar met het al in AD 
patiënten gevonden verband. Zoals al in hoofdstuk 2 geconcludeerd, konden wij 
met deze studie bevestigen, dat dit translationele muismodel kan worden gebruikt 
om mogelijke preventie en behandelingsstrategieën voor AD te onderzoeken. 
In hoofdstuk 4 hebben wij ons verder verdiept in het effect van 2 maanden 
AngII-geïnduceerde hypertensie op SBP in WT en AβPP/PS1 muizen. Bovendien 
onderzochten wij ook het effect van de behandeling met de AngII-receptor blokker, 
EM, 1 maand na geïnduceerde hypertensie in WT en AβPP/PS1 muizen. In dit 
hoofdstuk zijn wij nu op EM als bloeddrukverlagend middel gefocust. Dit omdat wij 
in het onderzoek beschreven in hoofdstuk 3 hebben gevonden dat EM het minst 
effectief is als bloeddrukverlager in AβPP/PS1 muizen. AβPP/PS1 muizen hadden 
ook in deze studie een hogere SBP dan WT muizen. Na één maand onbehandelde 
hypertensie herstelde de behandeling met EM de SBP in alle muizen. Daarbij was 
de functionele connectiviteit verlaagd in hypertensieve AβPP/PS1 en WT muizen. 
Verder lieten 12 maanden oude AβPP/PS1 muizen ook weer een verlaagde CBF 
zien. De hypertensieve AD muizen waren slechter in het ruimtelijke leren in de 
Morris water maze (MWM). Bij deze gedragstest moesten de muizen aan de hand 
van visuele orientatiepunten een verstopt platform vinden in het ondoorzichtige 
water. AngII-geïnduceerde hypertensie verergerde in AD muizen de AD-achtige 
symptomen de CBF, functionele connectiviteit, en cognitie, en ook in gezonde 
WT muizen leed deze vorm van hypertensie tot een verminderde connectiviteit. 
Het was helaas niet mogelijk om aan te tonen dat door de AngII-geïnduceerde 
hypertensie de Aβ productie en neuroinflammatoire processen konden worden 
verbeterd. Onze bevindingen suggereren een verband tussen hoge bloeddruk op 
middelbare leeftijd, verminderde cerebrale hemodynamiek en connectiviteit bij 
dit muismodel voor AD. Daarbij verbeterde de behandeling met EM de CBF en 
ook de cerebrale connectiviteit. 
Onderzoek bevestigt dat levensstijl, zoals o.a. voeding, een belangrijke rol 
speelt bij het ontstaan en de progressie van AD. Het specifiek samengestelde 
dieet, Fortasyn, heeft een positief effect op de cognitieve gebreken in een AD 
muismodel. In de studie uit hoofdstuk 5 analyseerden we zoekstrategieën en 
ruimtelijk geheugen en inzicht van de 11 maanden oude AβPP/PS1 muizen in 
de MWM. Verder bestudeerden wij ook wat de invloed is van 9 maanden lang 
toedienen van het Fortasyn dieet versus een controle dieet op het ontwikkelen 
van zoekstrategieën in deze cognitieve gedragstest. Tijdens de vierde dag van de 
MWM, gebruikten AβPP/PS1 muizen op controle dieet vaker een willekeurige, 
niet-ruimtelijke zoekstrategie dan hun WT nestgenoten. AD muizen op Fortasyn 
dieet zwommen op een vaste afstand van de rand op zoek naar het platform, 
wat een compensatie strategie is. Dit gedrag vertoonden de AD muizen op het 
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Fortasyn dieet meer dan hun niet-transgene nestgenoten. Bij het verwijderen 
van het platform hadden de AβPP/PS1 muizen geen duidelijke voorkeur voor het 
voormalige platform. Zowel transgene als niet-transgene muizen op het Fortasyn 
dieet zwommen eerder naar de voormalige positie van het platform dan hun 
nestgenoten op controle dieet. Samenvattend, het Fortasyn dieet verbeterde in 
AβPP/PS1 muizen het zoekgedrag en -strategie en de effectiviteit om de verborgen 
platform in het MWM te vinden. 
Zoals al in de inleiding benoemd, is apoE4 een belangrijke genetische (vasculaire) 
risicofactor voor AD. In de studie beschreven in hoofdstuk 6 veronderstellen 
wij dat het Fortasyn dieet ook in apoE4 muizen pathologische veranderingen in 
AD kan tegengaan, zoals o.a. cerebrovasculaire schade. Daarnaast evalueerden 
we het dieet effect op de CBF, functionele connectiviteit, grijze en witte stof 
integriteit en veranderingen en postsynaptische dichtheid in verouderde apoE4 
muizen. 10-12 maanden oude apoE4 muizen toonden nog geen pathologische 
verschillen in vergelijking met WT muizen. Daarentegen, 16-18 maanden oude 
apoE4 muizen hadden verminderde CBF en toonden een verhoogd verlies van 
synapsen tegenover WT muizen. Met name het Fortasyn dieet was in staat de 
corticale CBF en het aantal synapsen te verhogen, en ook de witte stof integriteit 
en de functionele connectiviteit te verbeteren in zowel verouderde apoE4 en 
WT muizen. Met deze studie tonen wij aan dat beschermingsmechanismen op 
het gebied van vascularisatie en synaptogenese door het Fortasyn dieet in gang 
worden gezet en zelfs worden versterkt onafhankelijk van het apoE4 genotype. 
Met behulp van deze multidisciplinaire, translationele en geavanceerde MR 
neuroimaging aanpak beschreven in hoofdstuk 6, konden wij het positieve effect 
van een specifiek samengestelde dieet, zoals Fortasyn, in een muismodel van een 
vasculaire risicofactor, apoE4 bediscussiëren. 
Occlusie van de middelste hersenslagader (MCAo) is een van de meest 
voorkomende oorzaken van ischemische stroke bij mensen. Cerebrale ischemie 
leidt tot hersenbeschadigingen bestaande uit een onomkeerbaar beschadigde 
kerngebied (core) en een ischemisch grensgebied (penumbra). De penumbra 
bestaat uit hersenweefsel, dat nog te herstellen is. In de studie beschreven in 
hoofdstuk 7 onderzochten wij met behulp van een muismodel met een tijdelijke 
(30 min) occlusie van de middelste cerebrale slagader (tMCAo) het effect van 
Fortasyn als therapeutische aanpak op de neuroinflammatie en de verlaagde 
structurele en functionele connectiviteit, CBF en motoriek na een experimenteel 
geïnduceerd herseninfarct. In mannelijke volwassen C57BL/6J muizen werd 
de rechter middelste cerebrale slagader tijdelijk voor 30 min afgebonden met 
behulp van het intraluminale filament. Direct na het experimenteel geïnduceerde 
herseninfarct werden de muizen onderverdeeld in twee dieet groepen. De ene 
helft van de muizen kreeg het specifiek samengestelde Fortasyn dieet en de andere 
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groep muizen kreeg het controle dieet. Op verschillende tijdstippen na de tMCAo 
werden verschillende gedragstesten, MRI en PET scans uitgevoerd om het effect 
van de specifiek samengestelde Fortasyn dieet op de neuroinflammatoire respons, 
verlies van de cerebrale connectiviteit en de hieraan gekoppelde verslechtering 
van de motorische functie te onderzoeken na een geïnduceerd herseninfarct. 
Muizen op het specifieke samengestelde Fortasyn dieet toonden een verminderde 
neuroinflammatie, verbeterde functionele en structurele connectiviteit, hadden 
een verhoogde CBF, en lieten ook een verbeterde motorische functie na een 
experimentele herseninfarct zien. Uit deze bevindingen blijkt, dat deze specifiek 
samengestelde Fortasyn dieet als therapeutisch aanpak gunstige effecten op het 
structurele en functionele herstel na een herseninfarct heeft.
Slotopmerkingen
Het eerste doel van dit proefschrift was het ontrafelen van de effecten van 
vasculaire riscofactoren, zoals hoge bloeddruk, apoE4 en herseninfract op 
de neurodegeneratieve processen in de vroege fase van AD met behulp van 
verschillende muismodellen. In AD muizen is hypertensie reeds op jonge 
leeftijd gekoppeld aan cerebrovasculaire stoornissen leidend tot problemen van 
structurele en functionele connectiviteit vergezeld van een verminderde cognitie. 
Met name oudere AD muizen ontwikkelden een verhoogde SBP gelijktijdig met 
een aantal pathologische AD  symptomen, zoals verslechtering van de cerebrale 
hemodynamiek resulterend in een verminderde cognitie, structurele en 
functionele connectiviteit, verhoogde bewegingsactiviteit, en angst-gerelateerd 
gedrag zonder AngII-geïnduceerde hypertensie. Opmerkelijk was dat ook in 
oudere transgene apoE4 muizen een verminderde cerebrovasculaire circulatie, 
verlaagde corticale post-synaptische dichtheid, verstoorde witte en grijze stof 
integriteit, en een verlaagde functionele connectiviteit gedetecteerd werd. 
Kortom, de betrokkenheid van (vasculaire) risicofactoren, die genetisch en/ of 
experimenteel geïnduceerd waren in onze muismodellen, in neurodegeneratieve 
processen in de vroege fase van AD is aangetoond. Alle in dit proefschrift gebruikte 
muismodellen zijn diermodellen voor de asymptomatische fase van AD, middels 
hun (vasculaire) risicofactoren die het verloop van neurodegeneratieve processen 
in AD kunnen ontwikkelen en versnellen. Een ander doel van dit proefschrift was 
de mogelijke capaciteit van antihypertensiva en specifieke multi-nutriënt diëten 
als preventieve aanpak of behandeling tegen AD-symptomen en vasculaire 
risicofactoren van AD te onderzoeken. Naast hun bloedverlagende effect, 
toonden we aan dat antihypertensiva zoals EM een gunstig effect kunnen hebben 
op pathologische processen van AD, zoals het tegengaan van de verminderde 
CBF, en de verminderde structurele en functionele connectiviteit. Daarom is 
het belangrijk om effectievere bloeddrukverlagende behandelingen voor AD 
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patiënten te ontwikkelen en het bewustzijn van hoge bloeddruk als risicofactor 
voor AD te vergroten. Verder hebben we aangetoond dat een multimodale 
aanpak, waaronder geavanceerde MRI technieken, geschikt is voor het detecteren 
van veranderingen in hersenstructuur en functie door een dieet. Fortasyn 
gaf positieve effecten als preventieve aanpak, maar ook als therapeutische 
aanpak in pathologische veranderingen voor (vasculaire) risicofactoren voor 
AD-muismodellen. Toekomstig onderzoek kan zich richten op de verbetering van de 
compositie van multinutriënten diëten, die onder andere voedingscomponenten 
van het mediterrane dieet bevatten, om de klinische uitkomst na een beroerte te 
verbeteren en daarmee de ontwikkeling van dementie na een beroerte kan tegen 
gaan. Alle experimenten werden uitgevoerd in relatief jonge dieren. Daarom kunnen 
toekomstige studies zich beter richten op het effect van vasculaire risicofactoren 
en diëten in oudere muizen (>12 maanden leeftijd). In overeenstemming hiermee, 
hebben Toth en zijn collega’s aangetoond dat hypertensie bij oudere muizen 
een verminderde cerebrovasculaire autoregulatie, cerebromicrovasculaire 
schade en neuroinflammatie [254] kan veroorzaken. Ook in onze studie met een 
occlusie van de MCAo beschreven in hoofdstuk 7 hebben wij gebruik gemaakt 
van relatief jonge dieren om onze specifiek samengestelde dieet te testen tegen 
pathologische veranderingen veroorzaakt door een geïnduceerd herseninfarct. 
Bovendien werden er sekseverschillen voor apoE4 [511, 639], hypertensie [640], 
en ook voor herseninfarct [641] gevonden. Daarom is het van het grootste belang 
om sekseverschillen met betrekking tot elk van deze risicofactoren van AD te 
onderzoeken door het bestuderen van oudere vrouwelijke muizen. Vasculaire 
risicofactoren voor AD hebben een aantal negatieve effecten op de zeer vroege 
ontwikkeling van neurodegeneratieve processen, die betrokken zijn in AD. Maar 
door de behandeling van deze risicofactoren kunnen we de incidentie van AD 
mogelijk verlagen. Onze experimentele resultaten en ook epidemiologische data 
hebben aangetoond dat behandeling met alleen bloeddrukverlagende middelen 
of zogenaamde “single-component” diëten niet toereikend zijn om volledig 
onderliggende processen van pathologische processen tijdens de vroege fase van 
dementie te neutraliseren. Daarom moet toekomstig onderzoek zich richten op 
preventieve/ therapeutische behandelingen met behulp van gepersonaliseerde 
multinutriënt diëten gericht op (neuro)pathologische processen zoals 
neuroinflammatie, verlaagde CBF, cognitieve stoornissen, en andere klinische 
symptomen van dementie. Toekomstig onderzoek zou moeten focussen op een 
preventieve aanpak bestaand uit een mix van cognitieve en fysieke inspanning 
[642, 643], gecombineerd met een gepersonaliseerde multinutriënt dieet tijdens 
de vroege fase van AD. Deze preventieve behandelingen zullen moeten worden 
afgestemd voor elke individuele dementie patiënt om zo een optimale persoonlijke 
preventieve therapie te ontwikkelen en op die manier elk individuele genetische 
make-up te dekken.
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List of abbreviations
ACE  Angiotensin-converting enzyme 
AD  Alzheimer´s disease 
AngII  Angiotensin II
ApoE4  Apolipoprotein E ε4 allele 
ARA  Arachidonic acid
ARB  Angiotensin receptor blocker
ASL  Arterial spin labeling 
AT1  Angiotensin II receptor type 1 
AT2  Angiotensin II receptor type 2
AT-NPD1 Aspirin-triggered NPD1 
Aβ  Amyloid-β 
AβPP  Amyloid-β precursor protein 
AβPP/PS1 AβPPswe/PS1dE9 
BOLD  Blood oxygen level dependent 
BP  Blood pressure 
C21  Compound 21 
CA1  Cornu ammonis 1 
CA2  Cornu ammonis 2
CA3  Cornu ammonis 3
CAA  Cerebral amyloid angiopathy 
CADASIL Cerebral autosomal dominant arteriopathy with subcortical  
  infarcts and leukoencephalopathy
CBF  Cerebral blood flow 
CMI  Cortical microinfarct 
Cpu  Caudate putamen
CVD  Cerebrovascular disease 
DCX  Doublecortin
DG  Dentate gyrus 
DHA  Docosahexaenoic acid 
DTI  Diffusion tensor imaging
EIMI  European Institute for Molecular Imaging
EM  Eprosartan mesylate 
EPA  Eicosapentaenoic acid 
EPI  Echo planar imaging 
ET-1  Endothelin-1
FA  Fractional anisotropy
FAIR  Flow-sensitive alternating inversion recovery 
FC  Functional connectivity 
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GC-MS-SIM Gas-chromatography-mass-spectrometry-selected-ion-monitoring 
GE  Gradient echo 
GFAP   Glial fibrillary acidic protein
GLUT-1  Glucose transporter type 1 
GM  Grey matter 
GP  Globus Pallidus 
HCT  Hydrochlorothiazide
IBA-1  Ionized calcium-binding adapter molecule 1 
IML  Inner molecular layer 
LC-n3-FA Long-chain omega-3 polyunsaturated fatty acids
MANOVA Multivariate ANOVA 
MCAo  Occlusion of the middle cerebral artery 
MCI  Mild cognitive impairment 
MD  Mean diffusivity
MetS  Metabolic Syndrome 
MMSE  Mini-Mental State Examination
MRI  Magnetic Resonance Imaging
MWM  Morris water maze 
NE  North-East 
NFT  Neurofibrillary tangles 
NPD1  Neuroprotectin 1
OF  Open field
OML  Outer molecular layer 
ORT  Object recognition test 
OSCAR  Observational study on cognitive function and systolic blood  
  pressure reduction 
PBS  Phosphate buffered saline 
PET  Positron emission tomography 
Ppi  Prepulse inhibition 
PRIME  Preclinical Imaging Centre 
PROGRESS Perindopril Protection Against Recurrent Stroke Study
PSD  Postsynaptic density 
PSD-95   postsynaptic density-95
RAS  Renin-angiotensin system 
ROI  Regions of interest 
rsfMRI  Resting state fMRI 
Sal  Saline
SBP  Systolic blood pressure 
SHEP  Systolic Hypertension in the Elderly Program 
SHSRP  Stroke-prone spontaneously hypertensive rats 
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SLFF  Spontaneous low-frequency fluctuations 
SL  Stratum lucidum 
SPM  Statistical Parametric Mapping
SR  Stratum radiatum 
SYN  Synaptophysin
Syst-Eur Systolic Hypertension in Europe
T2DM  Type 2 diabetes mellitus 
TBI  Traumatic brain injury 
TI  Inversion time
tMCAo  Transient occlusion of the middle cerebral artery 
TR  Repetition time 
TSPO  Translocator protein 
UMP  Uridine monophosphate 
VaD  Vascular dementia 
VCI  Vascular cognitive impairment 
VOI  Volume of interest 
WM  White matter 
WMH  White matter hyperintensities 
WML  White matter lesions 
WT  Wild-type 
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unserer MWM Suchstrategien!
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Andor, zonder jou had ik vaak niet kunnen scannen. Maar jij was altijd bereikbaar 
(zelfs tijdens jouw papa-dagen) en kon voor mij altijd een oplossing verzinnen, 
waardoor ik nooit mijn MRI metingen moest laten uitvallen. Verder door jouw 
expertise was ik ook in staat nieuwe scantechnieken voor het stroke-project 
te introduceren. Bedankt voor alles, wat jij voor mij tot nu toe hebt gedaan en 
(hopelijk) nog gaat doen! Graag wil ik ook Sjaak danken, die ik altijd om benodigde 
software etc. kon vragen!
Vera, Dionne, Bas, Laura, Marianne en Lucas wil ik graag danken voor al jullie hulp 
en het klaarzetten voor alle practica!
Verder wil ik mij ook Bianca, Henk, Kitty, Iris, Karin, Wilma, Nicole, en Maikel 
danken. Zonder jullie hulp en het zorgen voor onze muizen zouden onze 
experimenten zeker niet zo succesvol zijn geweest!
Dank ook aan Jack, Annemieke, en Manon voor al jullie hulp!
Daarnaast wil ik natuurlijk ook alle andere collega’s van de afdeling Anatomie 
voor een leuke (nog voortdurende) tijd danken!
Tenslotte wil ik alle studenten, die aan alle (ook nog lopende) projecten hebben 
meegewerkt resp. meewerken, zonder jullie zouden zeker vele experimenten niet 
zijn doorgegaan. Daarom bedank ik mij aan Monica, Robert, Anja, Britt, Hasnae, 
Lieke, Josine, en Klara. Speciaal wil ik Laura danken, dat zij mijn eerste stagiair is 
geweest. Na een lange stage zijn wij ook goede vrienden geworden en door jouw 
inzet was het mogelijk, dat wij samen een review konden publiceren. Marloes, 
samen met jou, kon ik het eerste stroke-project hier in Nijmegen opstarten. De 
tijd in Münster en Nice was ook heel gezellig. Ik wens jou nu veel succes bij jouw 
stage in Cambridge!
Graag wil ik ook Prof. Dr. Frank-Erik de Leeuw bedanken, die samen met Amanda 
mij de mogelijkheid biedt, in het humane onderzoek als postdoc te kunnen 
doorgaan. 
Danken möchte natürlich auch meinen Freunden und meiner Familie! Edith, 
Erwin, Katja, Matthias, Jan-Bernd, und Sandra danke ich für eure Unterstützung! 
Jan-Bernd, ich bin sehr stolz auf dich, dass du jetzt auch studierst und dein 
Ding durchziehst, so wie du es möchtest! Auch meiner Oma Helga möchte ich 
danken, da du immer stolz auf mich warst und mit mir bei deinen Rommé-Damen 
angegeben hast!
Mein besonderer Dank gilt natürlich auch meinen Eltern. Mama und Papa, 
ohne euch würde ich hier jetzt nicht stehen. Von klein auf habt ihr mich immer 
unterstützt. Ich danke euch, dass ihr mich auf meinem bisherigen Lebensweg 
gefördert und gefordert habt. Dadurch habt ihr mir die Basis für meine persönliche 
und berufliche Entwicklung ermöglicht. Von der Grundschule zum Gymnasium, 
aber auch auf meinem Weg durch das Studium habt ihr mich immer begleitet und 
bei all meinen Problemen geholfen. Ihr hattet immer ein offenes Ohr für mich und 
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habt mir auch immer gut zugesprochen. Ihr seid in vielen Aspekten meine größten 
Vorbilder!
Zu guter Letzt, danke ich natürlich meiner wunderbaren Frau, Verena. Du hast 
immer an mich geglaubt und auch in allem unterstützt, egal wie lange ich noch in 
Nimwegen war oder noch Zuhause an meinen Sachen gesessen habe. Ich danke 
dir für die unermüdliche Unterstützung deinerseits, deine Liebe, deinen starken 
Rückhalt und deine Motivation. Ohne all diese Faktoren wäre diese Doktorarbeit 
sicher nicht so gelungen, wie sie nun ist. Wegen all dieser Dinge widme ich dir 
meine Doktorarbeit, ich liebe dich!
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Maximilian Wiesmann was born on May 29th in 1988 in Bocholt, Germany. After 
receiving his high school diploma (Abitur) in 2007, in first instance he was interested 
in studying veterinary medicine. But his fascination in biology helped him to choose 
for a Bachelor of Science (B.Sc.) in (medical) biology at the Radboud university 
Nijmegen. During his bachelor internship under the supervision of Professor Tamás 
Kozicz (Department of cellular animal physiology, Radboud university Nijmegen) 
he investigated the impact of chronic stress on the activity of urocortin 1 (Ucn1) 
neurons in the Edinger-Westphal-nucleus, which is involved in chronic stress and 
depression. His interest in translational research and the brain stimulated him 
to start a research Master of Science (M.Sc.) in medical biology at the Radboud 
university Nijmegen. During his first master internship (department of Anatomy, 
Radboud university medical center) he investigated the effects of docosahexaenoic 
acid (DHA) combination diets compared to control diet on spatial learning and 
memory, and cerebral hemodynamics in 10-12 month old male Alzheimer’s disease 
(AD) model mice versus their wild-type (WT) littermates. Combining the topics of 
his Bachelor and Master internship he addressed the question whether the mRNA 
levels of Ucn1 are decreased in the Edinger-Westphal-nucleus of AD patients due 
to the neuronal cell loss leading to altered mood and cognitive problems in AD 
patients. Finally, he accomplished his master degree in medical biology in 2007 
with cum laude. Directly after his M.Sc. he applied for a PhD position at the 
Radboud university medical center under the supervision of Dr. Amanda Kiliaan, 
Dr. Jurgen Claassen, and Professor Arend Heerschap. Being a cooperation between 
the three departments Anatomy, Geriatric Medicine, and Radiology and Nuclear 
Medicine, the objective of his PhD project, which is presented in this thesis, was to 
investigate the underlying pathological processes of major vascular risk factors and 
their accelerating effect during the very early development of neurodegenerative 
processes in AD using several mice models. Another aim of this PhD-project was to 
study the possible capacity of antihypertensives and specific multi-nutrient diets 
to serve as preventive or treatment against AD-like symptoms and vascular risk 
factors for AD. During this PhD-project he supervised several excellent bachelor 
and master students with their internship projects and theses. Additionally, he 
presented his research at multiple international conferences in oral/ poster 
sessions. As of June 2016, Maximilian works in the research group of Dr. Amanda 
Kiliaan as a postdoctoral research. Here, he elucidates the impact of stroke on the 
pathology of AD in male and female mice via a longitudinal approach. Furthermore, 
in collaboration with the departments Neurology (Professor Frank-Erik de Leeuw) 
and Anatomy (Dr. Amanda Kiliaan) he analyzes the role of small vessel disease in 
the development of white matter lesions in human post mortem brains using both 
high-field (7T) and ultrahigh-field MR systems (11.7T).
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Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and 
Behaviour established the Donders Graduate School for Cognitive Neuroscience 
(DGCN), which was officially recognised as a national graduate school in 2009. The 
Graduate School covers training at both Master’s and PhD level and provides an 
excellent educational context fully aligned with the research programme of the 
Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine 
and related disciplines. Selective admission and assessment centers guarantee 
the enrolment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD 
alumni show a continuation in academia with postdoc positions at top institutes 
worldwide, e.g. Stanford University, University of Oxford, University of Cambridge, 
UCL London, MPI Leipzig, Hanyang University in South Korea, NTNU Norway, 
University of Illinois, North Western University, Northeastern University in Boston, 
ETH Zürich, University of Vienna etc.. Positions outside academia spread among 
the following sectors: specialists in a medical environment, mainly in genetics, 
geriatrics, psychiatry and neurology. Specialists in a psychological environment, 
e.g. as specialist in neuropsychology, psychological diagnostics or therapy. Positions 
in higher education as coordinators or lecturers. A smaller percentage enters 
business as research consultants, analysts or head of research and development. 
Fewer graduates stay in a research environment as lab coordinators, technical 
support or policy advisors. Upcoming possibilities are positions in the IT sector and 
management position in pharmaceutical industry. In general, the PhDs graduates 
almost invariably continue with high-quality positions that play an important role 
in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please 
visit:
http://www.ru.nl/donders/graduate-school/donders-graduate/

